<SEC-DOCUMENT>0001654954-25-001431.txt : 20250213
<SEC-HEADER>0001654954-25-001431.hdr.sgml : 20250213
<ACCEPTANCE-DATETIME>20250213091409
ACCESSION NUMBER:		0001654954-25-001431
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250213
DATE AS OF CHANGE:		20250213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALATIN TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000911216
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				954078884
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15543
		FILM NUMBER:		25617569

	BUSINESS ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		609-495-2200

	MAIL ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERFILM INC
		DATE OF NAME CHANGE:	19930825
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptn_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ptn="http://ptn.com/20241231"><head><title>ptn_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-07-01to2024-12-31" id="ixv-8447">0000911216</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-07-01to2024-12-31" format="ixt:booleanfalse" id="ixv-8448">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2024-07-01to2024-12-31" id="ixv-8449">--06-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2024-07-01to2024-12-31" id="ixv-8450">Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2024-07-01to2024-12-31" id="ixv-8451">2025</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" unitRef="USDPShares" decimals="INF" id="ixv-8452">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-8453">10000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-8454">4030</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" unitRef="USDPShares" decimals="INF" id="ixv-8455">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-8456">300000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" unitRef="Shares" decimals="0" id="ixv-8457">23455846</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-8458">17926640</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-8459">4030</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-8460">4030</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-8461">4030</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8462">0</ix:nonFraction><ix:nonFraction name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8463">0</ix:nonFraction><ix:nonFraction name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8464">0</ix:nonFraction><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" unitRef="Shares" decimals="0" id="ixv-8465">4030</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_ptn_ContingentlyRedeemableWarrantsMember" unitRef="USD" decimals="0" id="ixv-8466">263400</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8467">40</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8468">0</ix:nonFraction><ix:nonFraction name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="0" id="ixv-8469">2358491</ix:nonFraction><ix:nonFraction name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8470">0</ix:nonFraction><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember" unitRef="Shares" decimals="0" id="ixv-8471">4030</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8472">40</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8473">0</ix:nonFraction><ix:nonFraction name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8474">0</ix:nonFraction><ix:nonFraction name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8475">0</ix:nonFraction><ix:nonFraction name="ptn:WarrantExercisesAmount" contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8476">0</ix:nonFraction><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8477">0</ix:nonFraction><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="Shares" decimals="0" id="ixv-8478">4030</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8479">40</ix:nonFraction><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" unitRef="Shares" decimals="0" id="ixv-8480">4030</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8481">40</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" unitRef="USD" decimals="0" id="ixv-8482">0</ix:nonFraction><ix:nonFraction name="ptn:WarrantExercisesShares" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="0" id="ixv-8483">3907679</ix:nonFraction><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-10-01to2024-12-31" unitRef="Shares" decimals="0" id="ixv-8484">13059777</ix:nonFraction><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2023-12-31" unitRef="Shares" decimals="0" id="ixv-8485">6595422</ix:nonFraction><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2023-07-01to2023-12-31" unitRef="Shares" decimals="0" id="ixv-8486">279700</ix:nonFraction><ix:nonFraction name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" contextRef="From2024-07-01to2024-12-31" unitRef="Shares" decimals="0" sign="-" format="ixt:numdotdecimal" id="ixv-8487">14338</ix:nonFraction><ix:nonFraction name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" contextRef="From2024-07-01to2024-12-31" unitRef="USD" decimals="0" id="ixv-8488">0</ix:nonFraction><ix:nonFraction name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" contextRef="From2024-07-01to2024-12-31" unitRef="USD" decimals="0" id="ixv-8489">0</ix:nonFraction><ix:nonFraction name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" contextRef="From2024-07-01to2024-12-31" unitRef="USD" decimals="0" id="ixv-8490">0</ix:nonFraction><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-10-04to2023-10-31" unitRef="USD" decimals="0" id="ixv-8491">9109117</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ptn-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="From2024-07-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-10_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-13_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-20_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-10-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-01-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-04to2023-10-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-10-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-07-01to2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberToZeroTwoFourSeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberTwoThousandTwentyFourSerisCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CumulativeFromInceptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_OneToThreeYearsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OneToThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_CurrentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_FourToFiveYearsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:FourToFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2017-11-01to2017-11-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-09-01to2017-09-06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-28_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="font-size:18pt"><strong>FORM <ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:DocumentType" id="ixv-9263">10-Q</ix:nonNumeric></strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="ixv-9264">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" id="ixv-9265">December 31, 2024</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">or</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="ixv-9266">&#9744;</ix:nonNumeric><strong>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from ___________ to __________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission file number: <strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityFileNumber" id="ixv-9267">001-15543</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_10qimg18.jpg" alt="ptn_10qimg18.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityRegistrantName" id="ixv-9268">PALATIN TECHNOLOGIES, INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="ixv-9269">Delaware</ix:nonNumeric></strong></p></td><td style="width:10%;"/><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityTaxIdentificationNumber" id="ixv-9270">95-4078884</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(State or other jurisdiction of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">incorporation or organization)</p></td><td/><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(I.R.S. Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Identification No.)</p></td></tr><tr style="height:15px"><td/><td/><td/></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityAddressAddressLine1" id="ixv-9271">4B Cedar Brook Drive</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityAddressCityOrTown" id="ixv-9272">Cranbury</ix:nonNumeric>, <ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="ixv-9273">New Jersey</ix:nonNumeric></strong></p></td><td/><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityAddressPostalZipCode" id="ixv-9274">08512</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Address of principal executive offices)</p></td><td/><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:CityAreaCode" id="ixv-9275">609</ix:nonNumeric>) <ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:LocalPhoneNumber" id="ixv-9276">495&#8209;2200</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trading Symbol</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Name of Each Exchange </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>on Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:Security12bTitle" id="ixv-9277">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:TradingSymbol" id="ixv-9278">PTN</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-9279">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityCurrentReportingStatus" id="ixv-9280">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T&#160; (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityInteractiveDataCurrent" id="ixv-9281">Yes</ix:nonNumeric>&#160;&#9746;&#160; &#160;&#160;&#160;No&#160;&#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer&#160;</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer&#160;</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="ixv-9282">Non-accelerated filer</ix:nonNumeric>&#160;&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="ixv-9283">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-9284">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="From2024-07-01to2024-12-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="ixv-9285">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate the number of shares outstanding of each of the registrant&#8217;s classes of common stock, as of the latest practicable date (February 12, 2025): <ix:nonFraction contextRef="AsOf2025-02-12" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-9286">26,005,846</ix:nonFraction></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC</strong>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="Toc1">Table of Contents</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Page</strong></p></td><td style="width:1%;"/></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a href="#p1">PART I &#8211; FINANCIAL INFORMATION</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#it1">Item 1. Financial Statements (Unaudited)</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#bs">Consolidated Balance Sheets as of December 31, 2024 and June 30, 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#so">Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2024 and 2023</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#sse">Consolidated Statements of Changes in Stockholders&#8217; Deficiency for the Three and Six Months Ended December 31, 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">3</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#sse1">Consolidated Statements of Changes in Stockholders&#8217; Deficiency for the Three and Six Months Ended December 31, 2023</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">4</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#cs">Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2024 and 2023</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">5</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#note">Notes to Consolidated Financial Statements</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">6</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#it2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">18</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#it3">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">22</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#it4">Item 4. Controls and Procedures</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">22</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a href="#p2">PART II &#8211; OTHER INFORMATION</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i1">Item 1. Legal Proceedings</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">23</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i1a">Item 1A. Risk Factors</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">23</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i3">Item 3. Defaults Upon Senior Securities</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i4">Item 4. Mine Safety Disclosures</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i5">Item 5. Other Information</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">24</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i6">Item 6. Exhibits</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">25</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#sign">Signatures</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">26</p></td><td/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">i</p></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Special Note Regarding Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;Palatin&#8221; mean Palatin Technologies, Inc. and its subsidiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Statements in this Quarterly Report, as well as oral statements that may be made by us or by our officers, directors, or employees acting on our behalf, that are not historical facts constitute &#8220;forward-looking statements,&#8221; which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The forward-looking statements in this Quarterly Report do not constitute guarantees of future performance. Investors are cautioned that statements that are not strictly historical facts contained in this Quarterly Report, including, without limitation, the following are forward looking statements:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">whether Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;), which acquired our product Vyleesi&#174; (the trade name for bremelanotide for treatment of hyperactive sexual desire disorder in premenopausal women) in December 2023, will have sufficient sales to generate significant milestone payments under our purchase agreement with Cosette;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the results of clinical trials with our late-stage products, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024 with topline results expected in the first quarter of calendar year 2025; PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed a first Phase 3 clinical trials with top line results announced from the Phase 3 clinical trial in the first quarter of calendar year 2024 and which has concluded a positive Type C meeting with the Food and Drug Administration (&#8220;FDA&#8221;) and can, depending on financial resources and product development priority, commence patient enrollment as early as the first half of calendar year 2025; and PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials in the third quarter of calendar year 2022 and is expected to report topline results in the first quarter of calendar year 2025;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">estimates of our expenses, future revenue and capital requirements;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to achieve profitability;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to advance product candidates into, and successfully complete, clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing or likelihood of regulatory filings and approvals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations regarding the clinical efficacy and utility of our melanocortin agonist product candidates for treatment of inflammatory and autoimmune related diseases and disorders, including ocular indications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to compete with other products and technologies treating the same or similar indications as our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the ability of our third-party collaborators to timely carry out their duties under their agreements with us;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to recognize the potential value of our licensing arrangements with third parties;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the potential to achieve revenues from the sale of our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to obtain adequate reimbursement from private insurers and other healthcare payers;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to maintain product liability insurance at a reasonable cost or in sufficient amounts, if at all;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">ii</p></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the performance and retention of our management team, senior staff professionals, other employees, and third-party contractors and consultants;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology in the United States and throughout the world;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our compliance with federal and state laws and regulations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing and costs associated with obtaining regulatory approval for our product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the impact of fluctuations in foreign exchange rates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the impact of any geopolitical instability, economic uncertainty, inflationary pressure, supply chain disruptions, financial markets volatility, or capital markets disruption resulting from the ongoing Russia-Ukraine and Israel-Hamas military conflicts, and any resulting effects on our revenue, financial condition, or results of operations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the impact of legislative or regulatory healthcare reforms in the United States;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to adapt to changes in global economic conditions as well as competing products and technologies; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to remain listed on the NYSE American stock exchange.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Such forward-looking statements involve risks, uncertainties and other factors that could cause our actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Our future operating results are subject to risks and uncertainties and are dependent upon many factors, including, without limitation, the risks identified under the caption &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report, and any of those made in our other reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Except as required by law, we do not intend, and undertake no obligation, to publicly update forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">iii</p></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="p1"><strong>PART I</strong> <strong>&#8211; FINANCIAL INFORMATION</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="it1">Item 1. Financial Statements.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="bs"><strong>PALATIN TECHNOLOGIES, INC</strong>.</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consolidated Balance Sheets</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, 2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>ASSETS</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current assets:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_289" contextRef="AsOf2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,416,604</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" contextRef="AsOf2024-06-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,527,396</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses and other current assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" contextRef="AsOf2024-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_296" contextRef="AsOf2024-06-30" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_299" contextRef="AsOf2024-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,669,717</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_298" contextRef="AsOf2024-06-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,769,668</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Property and equipment, net</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_301" contextRef="AsOf2024-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,741</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_300" contextRef="AsOf2024-06-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,361</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Right-of-use assets - operating leases</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_303" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">347,644</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_302" contextRef="AsOf2024-06-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527,321</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_304" contextRef="AsOf2024-06-30" name="us-gaap:OtherAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_305" contextRef="AsOf2024-12-31" name="us-gaap:OtherAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_307" contextRef="AsOf2024-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,310,018</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_306" contextRef="AsOf2024-06-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,742,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIENCY</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current liabilities:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" contextRef="AsOf2024-12-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,718,233</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_308" contextRef="AsOf2024-06-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,101,929</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_311" contextRef="AsOf2024-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,650,700</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" contextRef="AsOf2024-06-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,185,046</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Short-term operating lease liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,673</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_312" contextRef="AsOf2024-06-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,542</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Short-term finance lease liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_315" contextRef="AsOf2024-12-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_314" contextRef="AsOf2024-06-30" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,014</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other current liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" contextRef="AsOf2024-12-31" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">932,150</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_316" contextRef="AsOf2024-06-30" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,150</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_319" contextRef="AsOf2024-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,558,756</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_318" contextRef="AsOf2024-06-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,657,681</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Long-term operating lease liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_321" contextRef="AsOf2024-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,071</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_320" contextRef="AsOf2024-06-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,782</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other long-term liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_324" contextRef="AsOf2024-06-30" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,300</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_325" contextRef="AsOf2024-12-31" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,300</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_329" contextRef="AsOf2024-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,691,127</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_328" contextRef="AsOf2024-06-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,853,763</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Commitments and contingencies (Note 12)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stockholders&#8217; deficiency:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock of $<ix:nonFraction id="fid_348" contextRef="AsOf2024-12-31" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value &#8211; authorized <ix:nonFraction id="fid_350" contextRef="AsOf2024-12-31" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000,000</ix:nonFraction> shares: shares issued and outstanding designated as follows:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Series A Convertible: authorized <ix:nonFraction id="fid_351" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction> shares as of December 31, 2024: issued and outstanding <ix:nonFraction id="fid_362" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction> shares as of December 31, 2024 and June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_336" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_337" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock of $<ix:nonFraction id="fid_354" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value &#8211; authorized <ix:nonFraction id="fid_356" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">300,000,000</ix:nonFraction> shares:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">issued and outstanding <ix:nonFraction id="fid_359" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">23,455,846</ix:nonFraction> shares as of December 31, 2024 and <ix:nonFraction id="fid_358" contextRef="AsOf2024-06-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,926,640</ix:nonFraction> shares as of June 30, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_339" contextRef="AsOf2024-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,558</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_338" contextRef="AsOf2024-06-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,266</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_341" contextRef="AsOf2024-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,416,974</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_340" contextRef="AsOf2024-06-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,475,747</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_343" contextRef="AsOf2024-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">452,032,681</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_342" contextRef="AsOf2024-06-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">441,766,550</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total stockholders&#8217; deficiency</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_345" contextRef="AsOf2024-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,381,109</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_344" contextRef="AsOf2024-06-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">111,497</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total liabilities and stockholders&#8217; deficiency</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_347" contextRef="AsOf2024-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,310,018</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_346" contextRef="AsOf2024-06-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,742,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="so">PALATIN TECHNOLOGIES, INC.</span></strong></p></td></tr><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consolidated Statements of Operations</strong></p></td></tr><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended December 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">REVENUES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product revenue, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2346" contextRef="From2024-10-01to2024-12-31" name="ptn:ProductRevenueNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2362" contextRef="From2023-10-01to2023-12-31" name="ptn:ProductRevenueNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,034,113</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2010" contextRef="From2024-07-01to2024-12-31" name="ptn:ProductRevenueNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2011" contextRef="From2023-07-01to2023-12-31" name="ptn:ProductRevenueNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,140,090</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">OPERATING EXPENSES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cost of products sold</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2347" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ProductionCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2341" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ProductionCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,637</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2340" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProductionCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2363" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ProductionCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,637</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2348" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,429,479</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2364" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,554,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2013" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,173,233</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2014" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,568,830</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2349" contextRef="From2024-10-01to2024-12-31" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,681,844</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2365" contextRef="From2023-10-01to2023-12-31" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,032,613</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2015" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,702,775</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2016" contextRef="From2023-07-01to2023-12-31" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,232,857</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Gain on sale of Vyleesi</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2342" contextRef="From2024-07-01to2024-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,500,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2343" contextRef="From2023-07-01to2023-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,823,482</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2350" contextRef="From2024-10-01to2024-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,500,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2366" contextRef="From2023-10-01to2023-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,823,482</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2351" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,611,323</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2367" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">860,968</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2017" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,376,008</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2018" contextRef="From2023-07-01to2023-12-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,075,842</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Loss) Income from operations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2352" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,611,323</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2368" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,173,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2019" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,376,008</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2020" contextRef="From2023-07-01to2023-12-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,935,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">OTHER INCOME (EXPENSE)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Investment income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2353" contextRef="From2024-10-01to2024-12-31" name="us-gaap:InvestmentIncomeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,044</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2369" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InvestmentIncomeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,026</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2022" contextRef="From2024-07-01to2024-12-31" name="us-gaap:InvestmentIncomeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2023" contextRef="From2023-07-01to2023-12-31" name="us-gaap:InvestmentIncomeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,656</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Foreign currency transaction gain (loss)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2354" contextRef="From2024-10-01to2024-12-31" name="ptn:ForeignCurrencyTransactionLossGain" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2370" contextRef="From2023-10-01to2023-12-31" name="ptn:ForeignCurrencyTransactionLossGain" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">306,697</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2024" contextRef="From2024-07-01to2024-12-31" name="ptn:ForeignCurrencyTransactionLossGain" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2025" contextRef="From2023-07-01to2023-12-31" name="ptn:ForeignCurrencyTransactionLossGain" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">146,947</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2355" contextRef="From2024-10-01to2024-12-31" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,803</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2371" contextRef="From2023-10-01to2023-12-31" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,605</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2026" contextRef="From2024-07-01to2024-12-31" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,743</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2027" contextRef="From2023-07-01to2023-12-31" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,487</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Offering expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2356" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OtherExpenses" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2345" contextRef="From2023-07-01to2023-12-31" name="us-gaap:OtherExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,912</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2344" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OtherExpenses" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2372" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,912</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Change in fair value of warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2357" contextRef="From2024-10-01to2024-12-31" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2373" contextRef="From2023-10-01to2023-12-31" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,073,991</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2028" contextRef="From2024-07-01to2024-12-31" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2029" contextRef="From2023-07-01to2023-12-31" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,391,591</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total other income (expense), net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2358" contextRef="From2024-10-01to2024-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,841</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2374" contextRef="From2023-10-01to2023-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">9,017,179</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2030" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,877</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2031" contextRef="From2023-07-01to2023-12-31" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,114,281</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET LOSS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2359" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,442,482</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2375" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,844,034</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2032" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,266,131</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2033" contextRef="From2023-07-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,050,033</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Basic and diluted net loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2360" contextRef="From2024-10-01to2024-12-31" name="us-gaap:EarningsPerShareBasic" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.12</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2376" contextRef="From2023-10-01to2023-12-31" name="us-gaap:EarningsPerShareBasic" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.56</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2034" contextRef="From2024-07-01to2024-12-31" name="us-gaap:EarningsPerShareBasic" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.51</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2035" contextRef="From2023-07-01to2023-12-31" name="us-gaap:EarningsPerShareBasic" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.99</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2361" contextRef="From2024-10-01to2024-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,634,887</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2377" contextRef="From2023-10-01to2023-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,097,757</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2036" contextRef="From2024-07-01to2024-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,239,997</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2037" contextRef="From2023-07-01to2023-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,134,228</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="sse">PALATIN TECHNOLOGIES, INC.</span></strong></p></td></tr><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Deficiency</strong></p></td></tr><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three Months Ended December 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders' Deficiency</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Additional</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Paid-in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2462" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2463" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2557" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">19,548,167</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2558" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,481</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2568" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,709,073</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2573" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">449,590,199</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2578" contextRef="AsOf2024-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,685,605</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2685" contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember" name="ptn:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2690" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2693" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,955</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2694" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2697" contextRef="From2024-10-01to2024-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,955</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2688" contextRef="From2024-07-01to2024-12-31" name="ptn:SharesReleasedFromAbeyanceAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2676" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,907,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2677" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,077</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2681" contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,358,946</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2692" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2689" contextRef="From2024-07-01to2024-12-31" name="ptn:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,398,023</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2529" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2539" contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2554" contextRef="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2574" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,442,482</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2579" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,442,482</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2465" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2466" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2530" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">23,455,846</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2531" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2541" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,416,974</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2546" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">452,032,681</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2551" contextRef="AsOf2024-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,381,109</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Six Months Ended December 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders' Deficiency</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid-in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2462-c29bf2" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2463-c019e4" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2527" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,926,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2528" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2538" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">441,475,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2543" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">441,766,550</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2548" contextRef="AsOf2024-06-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">111,497</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2695" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2670" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">232,941</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2671" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,329</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2678" contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,649</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2647" contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2686" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">697,978</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2696" contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember" name="ptn:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2672" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">54,691</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2673" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">547</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2679" contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">98,935</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2646" contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember" name="ptn:SaleOfCommonStockNetOfCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2687" contextRef="From2024-07-01to2024-12-31" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">99,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Shares released from abeyance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_2648" contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2674" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:SharesReleasedFromAbeyanceShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,443,277</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2675" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:SharesReleasedFromAbeyanceAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,433</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2680" contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:SharesReleasedFromAbeyanceAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">14,433</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_2622" contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2621" contextRef="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="ptn:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2698" contextRef="From2024-10-01to2024-12-31" name="ptn:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2676-17e5ae" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,907,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2677-e0f6c2" contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember" name="ptn:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,077</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2681-cc6227" contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,358,946</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2624" contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2689-a139e4" contextRef="From2024-07-01to2024-12-31" name="ptn:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,398,023</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2559" contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2569" contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2544" contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,266,131</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2549" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,266,131</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2465-2e5694" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2466-e9dda5" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2530-de4bac" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">23,455,846</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2531-70dc8b" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2541-c4c114" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,416,974</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2546-b796b3" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">452,032,681</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2551-56ec46" contextRef="AsOf2024-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,381,109</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="sse1">PALATIN TECHNOLOGIES, INC.</span></strong></p></td></tr><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Deficiency</strong></p></td></tr><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three Months Ended December 31, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#ffffff;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders' (Deficiency) Equity</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contingently Redeemable Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid-in</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2473" contextRef="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2462-ae67e0" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2463-48981c" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2497" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,946,646</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2498" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,466</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2508" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,796,364</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2513" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">417,236,436</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2518" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,320,566</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Stock-based compensation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2654" contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2656" contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2660" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2661" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,971</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2644" contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2667" contextRef="From2023-10-01to2023-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,971</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Conversion of liability classified warrants upon warrant exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2655" contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2657" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2636" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,358,491</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2637" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,585</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2642" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,366,318</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2662" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2652" contextRef="From2023-07-01to2023-12-31" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,389,903</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Reclassification of contingently redeemable warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2629" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,700</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2659" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2643" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">159,700</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2663" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2653" contextRef="From2023-07-01to2023-12-31" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">159,700</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2464" contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2469" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2474" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2479" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2514" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,844,034</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2519" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,844,034</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance December 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2476" contextRef="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,100</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2465-595d5f" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2466-f9d0d5" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2470" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,305,137</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2471" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,051</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2481" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">413,552,953</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2486" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">425,080,470</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2491" contextRef="AsOf2023-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,384,426</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Six Months Ended December 31, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#ffffff;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders' (Deficiency) Equity</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contingently Redeemable Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional Paid-in Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance June 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2473-25680f" contextRef="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2462-e6ac26" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2463-ccf3a1" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2467" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">11,656,714</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2468" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,567</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2478" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">409,933,959</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2483" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">412,030,437</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2488" contextRef="AsOf2023-06-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,979,871</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Stock-based compensation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2625" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2665" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2630" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">98,372</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2631" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">984</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2639" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,323</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2669" contextRef="From2023-10-01to2023-12-31" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2649" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,307</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Withholding taxes related to restricted stock units</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2645" contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2599" contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2632" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">25,467</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2633" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">255</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2640" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">56,146</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2626" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2650" contextRef="From2023-07-01to2023-12-31" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">56,401</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Sale of common stock, net of costs</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2627" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:SaleOfCommonStockNetOfCostsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2664" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2634" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:SaleOfCommonStockNetOfCostsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,027</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2635" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:SaleOfCommonStockNetOfCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,170</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2641" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:SaleOfCommonStockNetOfCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">529,199</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2682" contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:ShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2651" contextRef="From2023-07-01to2023-12-31" name="ptn:SaleOfCommonStockNetOfCostsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,369</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Conversion of liability classified warrants upon warrant exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2628" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2666" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2636-1b1aba" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,358,491</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2637-a3ee06" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,585</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2642-a0f629" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,366,318</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2683" contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2652-7efcba" contextRef="From2023-07-01to2023-12-31" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,389,903</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Reclassification of contingently redeemable warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2629-56878c" contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,700</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2638" contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2668" contextRef="From2023-10-01to2023-12-31" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2643-0fd80f" contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">159,700</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2684" contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember" name="ptn:SharesReleasedFromAbeyanceAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2653-ff96a6" contextRef="From2023-07-01to2023-12-31" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">159,700</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2494" contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2499" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2504" contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2509" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2484" contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,050,033</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2489" contextRef="From2023-07-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,050,033</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance December 31, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2476-472c9b" contextRef="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,100</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2465-637b6b" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2466-07e801" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2470-0f9ffe" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,305,137</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2471-effd83" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,051</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2481-e7db77" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">413,552,953</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2486-ae5b00" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">425,080,470</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2491-3b22bd" contextRef="AsOf2023-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,384,426</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="cs">PALATIN TECHNOLOGIES, INC.</span></strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Consolidated Statements of Cash Flows</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2164" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,266,131</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2165" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,050,033</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2167" contextRef="From2024-07-01to2024-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2168" contextRef="From2023-07-01to2023-12-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,060</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Decrease in right-of-use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2169" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,677</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2170" contextRef="From2023-07-01to2023-12-31" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,098</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Unrealized foreign currency transaction loss (gain)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2171" contextRef="From2024-07-01to2024-12-31" name="ptn:UnrealizedForeignCurrencyTransactionLossGain" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2172" contextRef="From2023-07-01to2023-12-31" name="ptn:UnrealizedForeignCurrencyTransactionLossGain" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,947</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2173" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">697,978</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2174" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Change in fair value of liability classified warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2175" contextRef="From2024-07-01to2024-12-31" name="ptn:ChangeInFairValueOfLiabilityClassifiedWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2176" contextRef="From2023-07-01to2023-12-31" name="ptn:ChangeInFairValueOfLiabilityClassifiedWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,391,591</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Gain on sale of Vyleesi</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2379" contextRef="From2024-07-01to2024-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,500,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2381" contextRef="From2023-07-01to2023-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,823,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Changes in operating assets and liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2178" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2179" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">569,597</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Prepaid expenses and other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2180" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,841</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2181" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,047,164</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Inventories</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2182" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2183" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,154,355</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2184" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,616,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2185" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,710,051</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2186" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,534,346</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2187" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">896,812</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2188" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">186,580</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2189" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">176,913</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2382" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2383" contextRef="From2023-07-01to2023-12-31" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,012,197</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2190" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,863,319</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2191" contextRef="From2023-07-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,382,079</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Maturity of marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2193" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2194" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,992,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Proceeds from sale of Vyleesi</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2195" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2386" contextRef="From2023-07-01to2023-12-31" name="ptn:ProceedsFromSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2385" contextRef="From2024-07-01to2024-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2387" contextRef="From2023-07-01to2023-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,615</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2384" contextRef="From2024-07-01to2024-12-31" name="ptn:ProceedsFromSaleOfOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2196" contextRef="From2023-07-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,455,275</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Payment of withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2198" contextRef="From2024-07-01to2024-12-31" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2199" contextRef="From2023-07-01to2023-12-31" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,401</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Proceeds from the sale of common stock and warrants, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2200" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2201" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,531,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Payment of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2202" contextRef="From2024-07-01to2024-12-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,014</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2203" contextRef="From2023-07-01to2023-12-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,494</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Proceeds from exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2388" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,398,023</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2389" contextRef="From2023-07-01to2023-12-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2309" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,252,527</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2310" contextRef="From2023-07-01to2023-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,422,474</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2206" contextRef="From2024-07-01to2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,110,792</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2207" contextRef="From2023-07-01to2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,495,670</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, beginning of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2208" contextRef="AsOf2024-06-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,527,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2209" contextRef="AsOf2023-06-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,989,582</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2210" contextRef="AsOf2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,416,604</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2392" contextRef="AsOf2023-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,485,252</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL CASH FLOW INFORMATION:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2213" contextRef="From2024-07-01to2024-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,743</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2214" contextRef="From2023-07-01to2023-12-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,882</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Conversion of liability classified warrants upon warrant exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2390" contextRef="From2024-07-01to2024-12-31" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2391" contextRef="From2023-07-01to2023-12-31" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,389,903</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="note">PALATIN TECHNOLOGIES, INC.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1937" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="cont_68dba2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(1) ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nature of Business </em>- Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#8217;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women. As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;) on December 19, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results expected in the first quarter of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Business Risks and Liquidity &#8211; </em>The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of December 31, 2024 of $<ix:nonFraction id="fid_1444" contextRef="AsOf2024-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">452,032,681</ix:nonFraction> and a net loss for the three and six months ended December 31, 2024 of $<ix:nonFraction id="fid_2317" contextRef="From2024-10-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,442,482</ix:nonFraction> and $<ix:nonFraction id="fid_1445" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,266,131</ix:nonFraction>, respectively. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, the Company&#8217;s cash and cash equivalents were $<ix:nonFraction id="fid_1447" contextRef="AsOf2024-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,416,604</ix:nonFraction> and current liabilities were $<ix:nonFraction id="fid_1448" contextRef="AsOf2024-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,558,756</ix:nonFraction>. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#8217;s MC1r and MC4r programs, and development of other portfolio products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <em>Presentation of Financial Statements &#8212; Going Concern</em>, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#8217;s ability to meet its obligations for the next year.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_68dba2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on our available cash and cash equivalents as of December 31, 2024 and $<ix:nonFraction id="fid_2320" contextRef="AsOf2025-02-28_us-gaap_SubsequentEventMember" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,309,641</ix:nonFraction> received in February 2025, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company could be forced to make additional reductions in certain expenditures. This could include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company could be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company may receive contingent, sales-based milestone payments of up to $<ix:nonFraction id="fid_2162" contextRef="From2024-07-01to2024-12-31" name="ptn:SalesBasedMilestonePayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000,000</ix:nonFraction> on sales of Vyleesi by Cosette and its licensees.<em> </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Concentrations &#8211;</em> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1945" contextRef="From2024-07-01to2024-12-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and six months ended December 31, 2024, may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1938" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_bc6fe9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1953" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1954" contextRef="From2024-07-01to2024-12-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1955" contextRef="From2024-07-01to2024-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $<ix:nonFraction id="fid_282" contextRef="AsOf2024-12-31" name="ptn:MoneyMarketAccountsAndTreasuryBills" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,005,361</ix:nonFraction> and $<ix:nonFraction id="fid_2040" contextRef="AsOf2024-06-30" name="ptn:MoneyMarketAccountsAndTreasuryBills" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,089,113</ix:nonFraction> in a money market account at December 31, 2024 and June 30, 2024, respectively.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1957" contextRef="From2024-07-01to2024-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1958" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_bc6fe9" continuedAt="cont_89da68"><ix:nonNumeric id="fid_1961" contextRef="From2024-07-01to2024-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1962" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1963" contextRef="From2024-07-01to2024-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1989" contextRef="From2024-07-01to2024-12-31" name="ptn:RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" escape="true" continuedAt="cont_359796"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_89da68" continuedAt="cont_1e6423"><ix:continuation id="cont_359796"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gross product sales offset by product sales allowances for the three and six months ended December 31, 2024 and 2023 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1971" contextRef="From2024-07-01to2024-12-31" name="ptn:ScheduleOfSalesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2326" contextRef="From2024-10-01to2024-12-31_us-gaap_ProductMember" name="ptn:RevenuesGross" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2327" contextRef="From2023-10-01to2023-12-31_us-gaap_ProductMember" name="ptn:RevenuesGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,288,003</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" contextRef="From2024-07-01to2024-12-31_us-gaap_ProductMember" name="ptn:RevenuesGross" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2325" contextRef="From2023-07-01to2023-12-31_us-gaap_ProductMember" name="ptn:RevenuesGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,875,153</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2328" contextRef="From2024-10-01to2024-12-31_us-gaap_ProductMember" name="ptn:ProductSalesAllowancesAndAccruals" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2329" contextRef="From2023-10-01to2023-12-31_us-gaap_ProductMember" name="ptn:ProductSalesAllowancesAndAccruals" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,253,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_605" contextRef="From2024-07-01to2024-12-31_us-gaap_ProductMember" name="ptn:ProductSalesAllowancesAndAccruals" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2331" contextRef="From2023-07-01to2023-12-31_us-gaap_ProductMember" name="ptn:ProductSalesAllowancesAndAccruals" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,735,063</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2333" contextRef="From2024-10-01to2024-12-31_us-gaap_ProductMember" name="us-gaap:Revenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2330" contextRef="From2023-10-01to2023-12-31_us-gaap_ProductMember" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,034,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_264" contextRef="From2024-07-01to2024-12-31_us-gaap_ProductMember" name="us-gaap:Revenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2332" contextRef="From2023-07-01to2023-12-31_us-gaap_ProductMember" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,140,090</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1964" contextRef="From2024-07-01to2024-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1965" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1966" contextRef="From2024-07-01to2024-12-31" name="ptn:AccruedLiabilitiesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_1e6423"><ix:nonNumeric id="fid_1967" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1968" contextRef="From2024-07-01to2024-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1969" contextRef="From2024-07-01to2024-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended December 31, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and six months ended December 31, 2024 and 2023 were <ix:nonFraction id="fid_287" contextRef="From2024-07-01to2024-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,059,777</ix:nonFraction> and <ix:nonFraction id="fid_1415" contextRef="From2023-07-01to2023-12-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,595,422</ix:nonFraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are <ix:nonFraction id="fid_1416" contextRef="From2024-07-01to2024-12-31" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">279,700</ix:nonFraction> vested restricted stock units that had not been issued as of December 31, 2024, and 2023 due to a provision in the restricted stock unit agreements to delay delivery.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1970" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1939" contextRef="From2024-07-01to2024-12-31" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(4)</strong> <strong>New Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of the adoption on the consolidated financial statements and accompanying footnotes.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1940" contextRef="From2024-07-01to2024-12-31" name="ptn:AssetPurchaseAgreementTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(5) ASSET PURCHASE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#174;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the terms of the Purchase Agreement, the Company sold certain assets (the &#8220;Purchased Assets&#8221;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $<ix:nonFraction id="fid_1450" contextRef="From2024-07-01to2024-12-31" name="us-gaap:AccountsReceivablePurchase" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,000,000</ix:nonFraction>, consisting of an upfront purchase price of $<ix:nonFraction id="fid_1452" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SupplementalDeferredPurchasePrice" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,500,000</ix:nonFraction>, $<ix:nonFraction id="fid_1449" contextRef="From2024-07-01to2024-12-31" name="us-gaap:PaymentsForPurchaseOfOtherAssets1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction> payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $<ix:nonFraction id="fid_1451" contextRef="From2024-07-01to2024-12-31" name="ptn:PaymentsToSalesBasedMilestonePayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000,000</ix:nonFraction>. As of December 31, 2024, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#8220;Korea&#8221;) (see Note 8).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1988" contextRef="From2024-07-01to2024-12-31" name="ptn:ManufacturingSupplyAgreementsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#8220;Catalent&#8221;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#8220;Ypsomed&#8221;), to manufacture the auto-injector device (the &#8220;Ypsomed Agreement&#8221;); and Lonza Ltd. (&#8220;Lonza&#8221;), to manufacture the active pharmaceutical ingredient peptide (the &#8220;Lonza Agreement&#8221;).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1941" contextRef="From2024-07-01to2024-12-31" name="ptn:AgreementWithFosunTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun&#8221;) for exclusive rights to commercialize Vyleesi in China (the &#8220;Fosun License Agreement&#8221;). Under the terms of the Fosun License Agreement, the Company received $<ix:nonFraction id="fid_1618" contextRef="From2017-09-01to2017-09-06" name="us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction> in October 2017, which consisted of an upfront payment of $<ix:nonFraction id="fid_1619" contextRef="From2017-09-01to2017-09-06" name="us-gaap:PaymentsForRestructuring" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction> less $<ix:nonFraction id="fid_1626" contextRef="From2017-09-01to2017-09-06" name="ptn:UpfrontPaymentOfLess" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction> that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1942" contextRef="From2024-07-01to2024-12-31" name="ptn:AgreementWithKwangdongTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(8) AGREEMENT WITH KWANGDONG</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#8220;Kwangdong&#8221;) for exclusive rights to commercialize Vyleesi in Korea (the &#8220;Kwangdong License Agreement&#8221;). Under the terms of the Kwangdong License Agreement, the Company received $<ix:nonFraction id="fid_631" contextRef="From2017-11-01to2017-11-21" name="us-gaap:OfficersCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,500</ix:nonFraction> in December 2017, consisting of an upfront payment of $<ix:nonFraction id="fid_633" contextRef="From2017-11-01to2017-11-21" name="us-gaap:PaymentsForRestructuring" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction>, less $<ix:nonFraction id="fid_634" contextRef="From2017-11-01to2017-11-21" name="ptn:taxexpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,500</ix:nonFraction>, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $<ix:nonFraction id="fid_636" contextRef="From2017-11-01to2017-11-21" name="us-gaap:PaymentsToAcquireReceivables" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction> milestone payment based on the first commercial sale in Korea which has not occurred as of December 31, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1943" contextRef="From2024-07-01to2024-12-31" name="us-gaap:OtherCurrentAssetsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prepaid expenses<strong> </strong>and other current assets consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1972" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_637" contextRef="AsOf2024-12-31" name="ptn:PrepaidClinicalStudyCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,314</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_575" contextRef="AsOf2024-06-30" name="ptn:PrepaidClinicalStudyCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,926</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_638" contextRef="AsOf2024-12-31" name="ptn:PrepaidInsurancePremiums" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,744</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_577" contextRef="AsOf2024-06-30" name="ptn:PrepaidInsurancePremiums" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_640" contextRef="AsOf2024-12-31" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,055</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_581" contextRef="AsOf2024-06-30" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,249</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_641" contextRef="AsOf2024-12-31" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_583" contextRef="AsOf2024-06-30" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1944" contextRef="From2024-07-01to2024-12-31" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(10) FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#8217;s or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table provides the assets carried at fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1973" contextRef="From2024-07-01to2024-12-31" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Carrying Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Quoted prices in </p><p style="font-size:10pt;font-family:times new roman;margin:0px">active markets</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Level 1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Other quoted/observable inputs (Level 2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Significant unobservable inputs</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Level 3)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 31, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1460" contextRef="AsOf2024-12-31" name="ptn:CarryingValueDuringTheYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,005,361</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1471" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member" name="ptn:CarryingValueDuringTheYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,005,361</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1461" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member" name="ptn:CarryingValueDuringTheYear" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1466" contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member" name="ptn:CarryingValueDuringTheYear" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2042" contextRef="AsOf2024-06-30" name="ptn:CarryingValueDuringTheYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,089,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2041" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" name="ptn:CarryingValueDuringTheYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,089,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2043" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" name="ptn:CarryingValueDuringTheYear" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2044" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" name="ptn:CarryingValueDuringTheYear" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(11) ACCRUED EXPENSES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1948" contextRef="From2024-07-01to2024-12-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accrued expenses<strong> </strong>consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1981" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_661" contextRef="AsOf2024-12-31" name="ptn:CostClinicalStudy" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,153,170</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_660" contextRef="AsOf2024-06-30" name="ptn:CostClinicalStudy" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,509,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_663" contextRef="AsOf2024-12-31" name="ptn:OtherResearchRelatedExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,003</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_662" contextRef="AsOf2024-06-30" name="ptn:OtherResearchRelatedExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_665" contextRef="AsOf2024-12-31" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_664" contextRef="AsOf2024-06-30" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,215</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_667" contextRef="AsOf2024-12-31" name="ptn:PersonalCost" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_666" contextRef="AsOf2024-06-30" name="ptn:PersonalCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,694</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_669" contextRef="AsOf2024-12-31" name="ptn:AccruedSellingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_668" contextRef="AsOf2024-06-30" name="ptn:AccruedSellingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_671" contextRef="AsOf2024-12-31" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,403</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_670" contextRef="AsOf2024-06-30" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,883</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_673" contextRef="AsOf2024-12-31" name="ptn:TotaAcrruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,650,700</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_672" contextRef="AsOf2024-06-30" name="ptn:TotaAcrruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,185,046</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1949" contextRef="From2024-07-01to2024-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_21fd0f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(12) COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Inventory Purchases </em>- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#8220;Catalent Agreement&#8221;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of December 31, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1982" contextRef="From2024-07-01to2024-12-31" name="ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>4 - 5 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory purchase commitments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_865" contextRef="AsOf2024-12-31" name="us-gaap:AdvancesOnInventoryPurchases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,480,600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_866" contextRef="AsOf2024-12-31_ptn_CurrentMember" name="us-gaap:AdvancesOnInventoryPurchases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,448,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" contextRef="AsOf2024-12-31_ptn_OneToThreeYearsMember" name="us-gaap:AdvancesOnInventoryPurchases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,300</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2335" contextRef="AsOf2024-12-31_ptn_FourToFiveYearsMember" name="us-gaap:AdvancesOnInventoryPurchases" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_21fd0f"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, the Company has $<ix:nonFraction id="fid_870" contextRef="AsOf2024-12-31" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">932,150</ix:nonFraction> and $<ix:nonFraction id="fid_872" contextRef="AsOf2024-12-31" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,300</ix:nonFraction> accrued within other current and long-term liabilities, respectively, in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $<ix:nonFraction id="fid_869" contextRef="AsOf2024-06-30" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">944,150</ix:nonFraction> and $<ix:nonFraction id="fid_871" contextRef="AsOf2024-06-30" name="us-gaap:OtherLongTermDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,032,300</ix:nonFraction> was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Contingencies</em> - The Company accounts for litigation losses in accordance with ASC 450-20, <em>Loss Contingencies</em>. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#8217;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1950" contextRef="From2024-07-01to2024-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_6aa7db"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(13) STOCKHOLDERS&#8217; DEFICIENCY</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Series A Convertible Preferred Stock</em> &#8211; As of December 31, 2024, <ix:nonFraction id="fid_2704" contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,030</ix:nonFraction> shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $<ix:nonFraction id="fid_2710" contextRef="AsOf2024-12-31" name="us-gaap:CashAvailableForDistributions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction> divided by the Series A Conversion Price. As of December 31, 2024, the Series A Conversion Price was $<ix:nonFraction id="fid_2706" contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember" name="us-gaap:PreferredStockConvertibleConversionPrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">75.45</ix:nonFraction>, and each share of Series A Convertible Preferred Stock is convertible into approximately <ix:nonFraction id="fid_2707" contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember" name="us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.33</ix:nonFraction> shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $<ix:nonFraction id="fid_2708" contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember" name="us-gaap:CashAvailableForDistributions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction> per share, or $<ix:nonFraction id="fid_2705" contextRef="From2024-07-01to2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember" name="ptn:AggregateValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,000</ix:nonFraction> in the aggregate as of December 31, 2024. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $<ix:nonFraction id="fid_2709" contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember" name="ptn:CashAvailableForDistributionsAdditional" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100</ix:nonFraction> per share to holders of the Series A Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Financing Transactions &#8211; </em>On January 29, 2024, the Company entered into a securities purchase agreement (the &#8220;January 2024 Purchase Agreement&#8221;) to sell in a registered direct offering (the &#8220;January 2024 RD Offering&#8221;), <ix:nonNumeric id="fid_2703" contextRef="From2024-02-01to2024-02-29" name="ptn:DescriptionOfSecuritiesPurchaseAgreement">an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $<ix:nonFraction id="fid_2700" contextRef="AsOf2024-01-31" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.46</ix:nonFraction> per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#8220;2024 Placement Agent Warrants&#8221;) to purchase up to <ix:nonFraction id="fid_2716" contextRef="From2024-07-01to2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">91,575</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;January 2024 Placement Agent Warrant Shares&#8221;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $<ix:nonFraction id="fid_2717" contextRef="AsOf2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.825</ix:nonFraction> per share.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_6aa7db" continuedAt="cont_f74a09"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The gross proceeds from the January 2024 Offering totaled $<ix:nonFraction id="fid_2711" contextRef="From2024-07-01to2024-12-31" name="ptn:GrossProceeds" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,006</ix:nonFraction>, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $<ix:nonFraction id="fid_2699" contextRef="From2024-07-01to2024-12-31" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,224,056</ix:nonFraction>. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 20, 2023, the Company entered into a securities purchase agreement (the &#8220;October 2023 Purchase Agreement&#8221;) with a certain institutional investor, to sell in a registered direct offering (the &#8220;October 2023 RD Offering&#8221;), <ix:nonNumeric id="fid_2718" contextRef="From2023-10-01to2023-10-20" name="ptn:DescriptionOfSecuritiesPurchaseAgreement">an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $<ix:nonFraction id="fid_2701" contextRef="AsOf2023-10-20" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction> per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The October 2023 Pre-Funded Warrants had an exercise price of $<ix:nonFraction id="fid_2702" contextRef="AsOf2023-10-20" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase <ix:nonFraction id="fid_2719" contextRef="From2024-07-01to2024-12-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember" name="ptn:PurchaseOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,033,491</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $<ix:nonFraction id="fid_2712" contextRef="From2023-10-01to2023-10-20" name="us-gaap:CostsAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,573,948</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounted for in accordance ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of the Company, therefore the placement agent warrants are classified out of permanent equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 12, 2023, the Company entered into a new equity distribution agreement (the &#8220;2023 Equity Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may, from time to time, sell shares of the Company&#8217;s common stock at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. <ix:nonNumeric id="fid_2720" contextRef="From2023-04-01to2023-04-12" name="ptn:DescriptionOfSecuritiesPurchaseAgreement">The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission</ix:nonNumeric>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_f74a09" continuedAt="cont_2ab4bd"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proceeds raised under the 2023 Equity Distribution Agreement are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2105" contextRef="From2024-07-01to2024-12-31" name="ptn:ScheduleOfEquityDistributionAgreementTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Cumulative from inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Gross proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2395" contextRef="From2024-07-01to2024-12-31" name="ptn:EquityGrossProceedsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,027</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2394" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProceedsFromOtherEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,803</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2409" contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember" name="ptn:EquityGrossProceedsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">721,061</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2408" contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember" name="us-gaap:ProceedsFromOtherEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,744,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Fees</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2397" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ProceedsFromFeesReceived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,434</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2406" contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember" name="us-gaap:ProceedsFromFeesReceived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,336</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2399" contextRef="From2024-07-01to2024-12-31" name="ptn:EquityExpensesProceeds" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2404" contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember" name="ptn:EquityExpensesProceeds" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2400" contextRef="From2024-07-01to2024-12-31" name="ptn:EquityNetProceedsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,027</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2401" contextRef="From2024-07-01to2024-12-31" name="ptn:EquityNetProceedsProceeds" format="ixt:numdotdecimal" decimals="0" unitRef="USD">531,369</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2403" contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember" name="ptn:EquityNetProceedsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">721,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2402" contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember" name="ptn:EquityNetProceedsProceeds" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,565,406</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No proceeds were raised under the 2023 Equity Distribution Agreement during the three and six months ended December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock Warrants</em> &#8211; On December 13, 2024, the Company entered into a letter agreement (the &#8220;December 2024 Inducement Letter&#8221;) with a holder (the &#8220;December 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on June 24, 2024, with an initial exercise price of $<ix:nonFraction id="fid_2749" contextRef="AsOf2024-12-13_ptn_StockWarrantsMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction>, and October 24, 2023, with an initial exercise price of $2.12 (the &#8220;December 2024 Existing Warrants&#8221;). To induce the exercise of a portion of the December 2024 Existing Warrants by the December 2024 Exercising Holder, the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, <ix:nonNumeric id="fid_2751" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" name="ptn:DescriptionOfExistingHolderPurchaseOfWarrants">the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#8217;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase <ix:nonFraction id="fid_2750" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" name="ptn:PurchaseOfWarrantOfCommonStockSeriesA" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,907,679</ix:nonFraction> shares of common stock (the &#8220;Series C Warrants&#8221;) and Series D common stock purchase warrants to purchase <ix:nonFraction id="fid_2752" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" name="ptn:WarrantsToPurchaseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,953,839</ix:nonFraction> shares of common stock (the &#8220;Series D Warrants&#8221; and together with the Series C Warrants, the &#8220;December 2024 Inducement Warrants,&#8221; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#8220;December 2024 Inducement Warrant Shares&#8221;). The Company received aggregate gross proceeds of $<ix:nonFraction id="fid_2753" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,419,219</ix:nonFraction> from the exercise of the December 2024</ix:nonNumeric> Existing Warrants by the December 2024 Exercising Holder (the &#8220;December 2024 Warrant Inducement&#8221;). The incremental value of the December 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 20, 2024, the Company entered into a letter agreement (the &#8220;June 2024 Inducement Letter&#8221;) with a holder (the &#8220;June 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#8220;June 2024 Existing Warrants&#8221;). Pursuant to the June 2024 Inducement Letter, the June 2024 Exercising Holder agreed to exercise, for cash, June 2024 Existing Warrants to purchase, in the aggregate, <ix:nonFraction id="fid_2714" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" name="ptn:WarrantsToPurchaseShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,233,277</ix:nonFraction> shares of common stock in exchange for the Company&#8217;s agreement to <ix:nonNumeric id="fid_2723" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" name="ptn:DescriptionOfExistingHolderPurchaseOfWarrants">(i) lower the exercise price to $<ix:nonFraction id="fid_2721" contextRef="AsOf2024-06-20_ptn_StockWarrantsMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction> per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of <ix:nonFraction id="fid_2722" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" name="ptn:PurchaseOfWarrantOfCommonStockSeriesA" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,849,915</ix:nonFraction> warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $<ix:nonFraction id="fid_2715" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,078,561</ix:nonFraction> from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#8220;Warrant Inducement&#8221;)</ix:nonNumeric>. As part of the agreement, <ix:nonFraction id="fid_2724" contextRef="From2024-07-01to2024-12-31_ptn_StockWarrantsMember" name="ptn:ExercisingHolderReleasedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,443,277</ix:nonFraction> shares of common stock were held in abeyance on behalf of the June 2024 Exercising Holder. During the three months ended December 31, 2024, at the request of the June 2024 Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the June 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_2ab4bd" continuedAt="cont_31c98a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, the Company had outstanding warrants for shares of common stock as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2106" contextRef="From2024-07-01to2024-12-31" name="ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares of Common</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Latest Expiration</strong></p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 2022 Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2410" contextRef="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">66,666</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2413" contextRef="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.50</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2416" contextRef="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember" name="ptn:LatestTerminationDate">May 11, 2026</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2022 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2412" contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">90,909</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2415" contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.88</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2418" contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" name="ptn:LatestTerminationDate">October 31, 2027</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2023 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2423" contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">117,925</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2422" contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2421" contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" name="ptn:LatestTerminationDate">October 20, 2028</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Private Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2426" contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,831,503</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2425" contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.46</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2424" contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" name="ptn:LatestTerminationDate">February 1, 2028</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2429" contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">91,575</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2428" contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.83</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2427" contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" name="ptn:LatestTerminationDate">February 1, 2028</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 2024 Series B Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2432" contextRef="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,885,632</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2431" contextRef="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_2430" contextRef="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" name="ptn:LatestTerminationDate">June 24, 2029</ix:nonNumeric></p></td><td>*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series C Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2411" contextRef="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,907,679</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2414" contextRef="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.88</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2417" contextRef="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" name="ptn:LatestTerminationDate">December 17, 2029</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series D Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2420" contextRef="From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" name="ptn:SharesOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,953,839</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2419" contextRef="From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" name="ptn:ExercisePricePerShareWarrantsOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.88</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">**</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="12" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* <ix:nonFraction id="fid_2742" contextRef="From2024-07-01to2024-12-31" name="ptn:WarrantIssuanceShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,624,201</ix:nonFraction> shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="12" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">** <ix:nonFraction id="fid_2743" contextRef="From2024-07-01to2024-12-31" name="ptn:WarrantIssuance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,953,839</ix:nonFraction> shares expire on the five year anniversary following stockholder approval of the warrant issuance</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock Options &#8211;</em> For the three and six months ended December 31, 2024, the Company recorded stock-based compensation related to stock options of $<ix:nonFraction id="fid_2744" contextRef="From2024-10-01to2024-12-31" name="ptn:StockBasedCompensationToStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,673</ix:nonFraction> and $<ix:nonFraction id="fid_2725" contextRef="From2024-07-01to2024-12-31" name="ptn:StockBasedCompensationToStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,407</ix:nonFraction>, respectively. For the three and six months ended December 31, 2023, the Company recorded stock-based compensation related to stock options of $<ix:nonFraction id="fid_2745" contextRef="From2023-10-01to2023-12-31" name="ptn:StockBasedCompensationToStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,223</ix:nonFraction> and $<ix:nonFraction id="fid_2726" contextRef="From2023-07-01to2023-12-31" name="ptn:StockBasedCompensationToStockOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,540</ix:nonFraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of stock option activity is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2107" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Term in</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Intrinsic</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2433" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,263,440</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2436" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.11</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2444" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear">8.2</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2440" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2453" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,249,102</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2441" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.12</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2445" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">7.7</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2454" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">935,714</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2442" contextRef="From2024-07-01to2024-12-31" name="ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.76</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2446" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">6.1</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected to vest at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2455" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,313,387</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2443" contextRef="From2024-07-01to2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.82</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2447" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">8.9</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock options granted to the Company&#8217;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the outstanding options in the table above are <ix:nonFraction id="fid_2754" contextRef="From2024-07-01to2024-12-31" name="ptn:UnvestedPerformanceBasedStockOptionsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">418,945</ix:nonFraction> and <ix:nonFraction id="fid_2727" contextRef="From2023-07-01to2023-12-31" name="ptn:UnvestedPerformanceBasedStockOptionsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">88,911</ix:nonFraction> unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were <ix:nonFraction id="fid_2728" contextRef="From2020-07-01to2021-06-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">95,167</ix:nonFraction>, <ix:nonFraction id="fid_2729" contextRef="From2021-07-01to2022-06-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">60,566</ix:nonFraction>, <ix:nonFraction id="fid_2730" contextRef="From2022-07-01to2023-06-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">238,838</ix:nonFraction> and <ix:nonFraction id="fid_2731" contextRef="From2023-07-01to2024-06-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">264,945</ix:nonFraction>, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Restricted Stock Units &#8211; </em>For the three and six months ended December 31, 2024, the Company recorded stock-based compensation related to restricted stock units of $<ix:nonFraction id="fid_2746" contextRef="From2024-10-01to2024-12-31" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,281</ix:nonFraction> and $<ix:nonFraction id="fid_2732" contextRef="From2024-07-01to2024-12-31" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342,571</ix:nonFraction>, respectively. For the three and six months ended December 31, 2023, the Company recorded stock-based compensation related to restricted stock units of $<ix:nonFraction id="fid_2747" contextRef="From2023-10-01to2023-12-31" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,019</ix:nonFraction> and $<ix:nonFraction id="fid_2733" contextRef="From2023-07-01to2023-12-31" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,038</ix:nonFraction>, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong>&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_31c98a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of restricted stock unit activity is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2109" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2456" contextRef="AsOf2024-06-30" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,374,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2459" contextRef="From2024-07-01to2024-12-31" name="ptn:RestrictedStockVestedInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">232,941</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2461" contextRef="From2024-07-01to2024-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,726</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2460" contextRef="AsOf2024-12-31" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,139,313</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in outstanding restricted stock units in the table above are <ix:nonFraction id="fid_2734" contextRef="AsOf2024-12-31" name="ptn:NumberOfOutstandingSharesOfRestrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">279,700</ix:nonFraction> vested shares that have not been issued as of December 31, 2024, due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Time-based restricted stock units granted to the Company&#8217;s executive officers, other employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the outstanding restricted stock units in the table above are <ix:nonFraction id="fid_2735" contextRef="From2024-07-01to2024-12-31" name="ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">274,549</ix:nonFraction> and <ix:nonFraction id="fid_2736" contextRef="From2023-07-01to2023-12-31" name="ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">59,842</ix:nonFraction> unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were <ix:nonFraction id="fid_2738" contextRef="From2020-07-01to2021-06-30" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">22,343</ix:nonFraction>, <ix:nonFraction id="fid_2739" contextRef="From2021-07-01to2022-06-30" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,707</ix:nonFraction>, <ix:nonFraction id="fid_2740" contextRef="From2022-07-01to2023-06-30" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">152,432</ix:nonFraction> and <ix:nonFraction id="fid_2737" contextRef="From2023-07-01to2024-06-30" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">184,443</ix:nonFraction> restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the vesting of restricted share units during the six months ended December 31, 2024, the Company withheld <ix:nonFraction id="fid_2741" contextRef="From2024-07-01to2024-12-31" name="ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,691</ix:nonFraction> shares, with an aggregate value of $<ix:nonFraction id="fid_2748" contextRef="From2024-07-01to2024-12-31" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,482</ix:nonFraction>, in satisfaction of minimum tax withholding obligations.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2393" contextRef="From2024-07-01to2024-12-31" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(14) SUBSEQUENT EVENTS</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 10, 2025, the Company entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of <ix:nonFraction id="fid_2756" contextRef="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,688,000</ix:nonFraction> shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) at a purchase price of $<ix:nonFraction id="fid_2757" contextRef="AsOf2025-02-10_us-gaap_SubsequentEventMember" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction> per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company also agreed to issue to the same investor in a concurrent private placement warrants to purchase up to an aggregate of <ix:nonFraction id="fid_2758" contextRef="From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,688,000</ix:nonFraction> shares of common stock (the &#8220;Private Placement&#8221; and, together with the Registered Direct Offering, the &#8220;Offering&#8221;). The warrants being issued in the concurrent Private Placement will have an exercise price of $<ix:nonFraction id="fid_2759" contextRef="AsOf2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction> per share, will be exercisable beginning on the six-month anniversary of the date of issuance and will expire five and a half years from the date of issuance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The gross proceeds from the Offering totaled $<ix:nonFraction id="fid_2760" contextRef="From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,687,786</ix:nonFraction>. The Company intends to use the net proceeds from the Offering for general corporate purposes.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="it2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements filed as part of this report and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended June 30, 2024.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following discussion and analysis contain forward-looking statements within the meaning of the federal securities laws. You are urged to carefully review our description and examples of forward-looking statements included earlier in this Quarterly Report immediately prior to Part I, under the heading &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Forward-looking statements are subject to risk that could cause actual results to differ materially from those expressed in the forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and other factors that may affect our business and operating results, including those made in this Quarterly Report and our Annual Report on Form 10-K for the year ended June 30, 2024, as well as any of those made in our other reports filed with the SEC. You are cautioned not to place undue reliance on the forward-looking statements included herein, which speak only as of the date of this document. We do not intend, and undertake no obligation, to publish revised forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our significant accounting policies, which are described in the notes to our consolidated financial statements included in this report and in our Annual Report on Form 10-K for the year ended June 30, 2024, have not changed during the three and six months ended December 31, 2024. We believe that our accounting policies and estimates relating to the carrying value of inventory, revenue recognition, accrued expenses, purchase commitment liabilities, warrants and stock-based compensation are the most critical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor (&#8220;MCr&#8221;) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 and was being marketed in the United States by AMAG Pharmaceuticals, Inc. (&#8220;AMAG&#8221;) for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women pursuant to a license agreement between them for Vyleesi for North America, which was entered into on January 8, 2017 (the &#8220;AMAG License Agreement&#8221;). The AMAG License Agreement was terminated effective July 24, 2020, and we commenced marketing Vyleesi in North America. As disclosed in Note 5 to the Consolidated Financial Statements, effective December 19, 2023, Cosette acquired all rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our new product development activities focus on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which has completed Phase 2 in the fourth quarter of calendar year 2024, with topline results expected in the first quarter of calendar year 2025; and secondarily on ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed Phase 3 clinical trials and announced top line results from the first Phase 3 clinical trial in the first quarter of calendar year 2024; ulcerative colitis, including PL8177, an oral peptide formulation, which entered Phase 2 ulcerative colitis clinical trials in the third quarter of calendar year 2022 and is expected to report topline results in the first quarter of calendar year 2025. We are actively engaged in discussions with potential partners and licensees that have the financial and operational resources to progress our products for ocular conditions through development, approval and commercialization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pipeline Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following chart illustrates the status of our drug development programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_10qimg16.jpg" alt="ptn_10qimg16.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our Strategy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Key elements of our business strategy include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Maintaining a team to create, develop and commercialize MCr products addressing unmet medical needs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Entering into strategic alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale, and distribution of product candidates that we are developing;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Partially funding our product development programs with the cash flow generated from the sale of Vyleesi to Cosette and existing license agreements, as well as any future research, collaboration, or license agreements; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Completing development and seeking regulatory approval of certain of our other product candidates.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Corporate Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We were incorporated under the laws of the State of Delaware on November 21, 1986 and commenced operations in the biopharmaceutical area in 1996. Our corporate offices are located at 4B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, New Jersey 08512, and our telephone number is (609) 495-2200. We maintain an Internet site, where among other things, we make available free of charge on and through this website our Forms 3, 4 and 5, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) and Section 16 of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website and the information contained in it or connected to it are not incorporated into this Quarterly Report on Form 10-Q. The reference to our website is an inactive textual reference only.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (<em>www.sec.gov</em>).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Three and Six Months Ended December 31, 2024, Compared to the Three and Six Months Ended December 31, 2023:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenues &#8211;</em> For the six months ended December 31, 2024, we recognized $0 in product revenue, net of allowances. For the three and six months ended December 31, 2023, we recognized $2,034,113 and $4,140,090 in product revenue, net of allowances, respectively. The decrease in product revenue, net of allowances is a result of the sale to Cosette of worldwide rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cost of Products Sold &#8211; </em>Cost of products sold was $0 for the six months ended December 31, 2024 compared to $97,637 for the three and six months ended December 31, 2023. The decrease is a result of the sale to Cosette of worldwide rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development</em> &#8211; Research and development expenses were $3,429,479 and $9,173,233 for the three and six months ended December 31, 2024, respectively, compared to $5,554,200 and $10,568,830 for the three and six months ended December 31, 2023, respectively. The decrease was primarily related to a decrease in spending on our MCr programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development expenses related to our MCr other preclinical programs were $1,888,065 and $5,969,102 for the three and six months ended December 31, 2024, respectively compared to $3,828,383 and $7,287,971 for the three and six months ended December 31, 2023, respectively. The decrease was primarily related to a decrease in spending on our MCr programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The amounts of project spending above exclude general research and development spending, which was $1,662,717 and $3,204,131 for the three and six months ended December 31, 2024, respectively, compared to $1,725,817 and $3,280,859 for the three and six months ended December 31, 2023, respectively. The decrease is primarily attributable to a decrease in compensation-related expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cumulative spending from inception to December 31, 2024, was approximately $311,900,000 on our Vyleesi program and approximately $243,100,000 on all our other programs (which include PL3994, melanocortin receptor agonists, other discovery programs and terminated programs). Due to various risk factors described in our Annual Report on Form 10-K for the year ended June 30, 2024, under &#8220;Risk Factors,&#8221; including the difficulty in currently estimating the costs and timing of future Phase 1 clinical trials and larger-scale Phase 2 and Phase 3 clinical trials for any product under development, we cannot predict with reasonable certainty when, if ever, a program will advance to the next stage of development or be successfully completed, or when, if ever, related net cash inflows will be generated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Selling, General and Administrative</em> &#8211; Selling, general and administrative expenses, which consist mainly of compensation and related costs, were $1,681,844 and $3,702,775 for the three and six months ended December 31, 2024, respectively, compared to $3,032,613 and $6,232,857 for the three and six months ended December 31, 2023, respectively. The decrease is a result of the elimination of selling expenses relating to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Gain on Sale of Vyleesi</em> &#8211; For the three and six months ended December 31, 2024, the Company recorded a gain of $2,500,000 on the sale of Vyleesi as a result of the settlement of certain purchase commitments. For the three and six months ended December 31, 2024, the Company recorded a gain of $7,823,482 on the sale of worldwide rights to Vyleesi. The gain represents the upfront purchase price of $9,500,000 less the cost of net assets transferred to the purchaser.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Other Income (Expense) &#8211; </em>For the three and six months ended, December 31, 2024, total other income (expense), net was $168,841 and $109,877, respectively. For the three and six months ended December 31, 2023, other (expense) income was $(9,017,179) and $(8,114,281), respectively. The increase in other income (expense) for the three and six months ended December 31, 2024 compared to the three and six months ended December 31, 2023 was driven primarily by the change in fair values of the warrant liability, a decrease in offering expenses and foreign currency transaction gains.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, we have generally incurred net operating losses, primarily related to spending on our research and development programs. We have financed our net operating losses primarily through debt and equity financings and amounts received under collaborative and license agreements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our product candidates are at various stages of development and will require significant further research, development, and testing and some may never be successfully developed or commercialized. We may experience uncertainties, delays, difficulties, and expenses commonly experienced by early-stage biopharmaceutical companies, which may include unanticipated problems and additional costs relating to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the development and testing of products in animals and humans;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product approval or clearance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">regulatory compliance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">good manufacturing practices (&#8220;GMP&#8221;) compliance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">intellectual property rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product introduction;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">marketing, sales, and competition; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">obtaining sufficient capital.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Failure to enter into or successfully perform under collaboration agreements and obtain timely regulatory approval for our product candidates and indications would impact our ability to generate revenues and could make it more difficult to attract investment capital for funding our operations. Any of these possibilities could materially and adversely affect our operations and require us to curtail or cease certain programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended December 31, 2024, net cash used in operating activities was $11,863,319 compared to $16,382,079 for the six months ended December 31, 2023. The decrease was primarily related to a decrease in net loss during the period and working capital changes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended December 31, 2024, net cash provided by investing activities was $2,500,000, which consisted of proceeds from the sale of Vyleesi. During the six months ended December 31, 2023, net cash provided by investing activities was $12,455,275, which consisted of $9,500,000 of proceeds from the sale of Vyleesi and $2,992,890 proceeds from the maturity of marketable securities, offset by $37,615 used for the purchase of property and equipment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended December 31, 2024, net cash provided by financing activities was $3,252,527, which consisted of $3,398,023 of proceeds from the exercise of warrants, offset by $99,482 for payment of withholding taxes related to restricted stock units and $46,014 for payment of finance lease obligations. During the six months ended December 31, 2023, net cash provided by financing activities was $5,422,474, which consisted of proceeds from the sale of common stock of $5,531,266, proceeds from the exercise of warrants of $103, offset by $56,401 for payment of withholding taxes related to restricted stock units and $52,494 for payment of finance lease obligations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have incurred cumulative negative cash flows from operations since our inception, and have expended substantial funds to advance our planned product development efforts. Continued operations are dependent upon our ability to complete equity or debt financing activities and to enter into additional licensing or collaboration arrangements. As of December 31, 2024, our cash and cash equivalents were $3,416,604, and our current liabilities were $9,558,756.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our obligations include short-term lease obligations in an aggregate amount of $257,673 in current liabilities as of December 31, 2024, $100,071 in long-term lease liabilities, inventory purchase commitments in an aggregate amount of $1,964,450 which consists of $932,150 in current liabilities as of December 31, 2024, and $1,032,300 in other long-term liabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There have been no material changes outside the ordinary course of business to our contractual obligations and commitments, as disclosed in our Annual Report on Form 10-K for the year ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We intend to utilize existing capital resources for general corporate purposes and working capital requirements, including preclinical and clinical development of our MC1r and MC4r programs, and development of other portfolio products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of our sale of worldwide rights to Vyleesi pursuant to the Purchase Agreement, we currently do not have a recurring source of revenue. Based on our available cash and cash equivalents as of December 31, 2024, and $4,309,641 received in February 2025, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for one year from the date our consolidated financial statements are issued. We are evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm our business, results of operations, and future prospects. If we are not able to secure adequate additional funding in future periods, we would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. We may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If we are unable to raise capital when needed or enter into a strategic transaction, then we may be required to cease operations, which could cause our stockholders to lose all or part of their investment. Based on our current operating and development plans, we expect that our existing cash and cash equivalents as of the date of this filing will be sufficient to enable the Company to fund its operations into the second half of the calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will need additional funding to complete required clinical trials for our product candidates and development programs and, if those clinical trials are successful (which we cannot predict), to complete submission of required regulatory applications to the FDA. However, current economic conditions may negatively impact our operations, including possible effects on our financial condition, ability to access the capital markets on attractive terms or at all, liquidity, operations, suppliers, industry, and workforce. We will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2025 and beyond.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="it3">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not required to be provided by smaller reporting companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span class="atag" style="display: inline" id="it4"><strong>Item 4. Controls and Procedures</strong><strong>.</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective due to the previously-reported material weakness in our controls over financial reporting related to the accounting for complex financial instruments. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. GAAP. Accordingly, Company management believes that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the period presented. We will continue to improve these processes to ensure that the nuances of such significant or non-routine transactions are effectively evaluated in the context of the appropriate accounting standards. There were no other changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II &#8211; OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i1">Item 1. Legal Proceedings.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may be involved, from time to time, in various claims and legal proceedings arising in the ordinary course of our business. We are not currently a party to any claim or legal proceeding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i1a">Item 1A. Risk Factors.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs, and our management&#8217;s assumptions. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties facing our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Other than set forth below, there have been no material changes to our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are currently not in compliance with the continued listing standards of the NYSE American. Our failure to resume compliance with the continued listing standards or make continued progress toward compliance consistent with a plan of compliance that we submitted to NYSE Regulation may result in the delisting of our common stock.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are currently not in compliance with the continued listing standards of the NYSE American. If we fail to regain compliance with the NYSE American listing standards, our common stock could be de-listed from the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock is listed on the NYSE American, a national securities exchange, under the symbol &#8220;PTN&#8221;. As a result, we are subject to NYSE American&#8217;s listing standards, which generally mandate that we meet certain requirements relating to stockholders&#8217; equity, market capitalization, aggregate market value of publicly held shares and distribution requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 4, 2024, the Company received a letter from the staff of NYSE American LLC (the &#8220;NYSE American&#8221;) stating that the Company&#8217;s stockholders&#8217; equity as reported in its Annual Report on Form 10-K for the year ended June 30, 2024 was not in compliance with the NYSE American&#8217;s continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide. Section 1003(a)(iii) requires a listed company to have stockholders&#8217; equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 10, 2023, the Company received a notice from the staff of NYSE American that the Company was not in compliance with the NYSE American&#8217;s continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders&#8217; equity $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, and Section 1003(a)(ii) requires a listed company to have stockholders&#8217; equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company remains subject to the procedures and requirements of Section 1009 of the Company Guide, and previously submitted a plan (the &#8220;Plan&#8221;) of actions it has taken or will take to regain compliance with the continued listing standards by April 10, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The NYSE American accepted the Plan and granted a Plan period through April 10, 2025 to regain compliance with the continued listing standards, which now includes continued listing standards under Section 1003(a)(iii). The Company will be able to continue its listing during the Plan period and will be subject to periodic reviews including quarterly monitoring for compliance with the Plan until it has regained compliance. If the Company is not in compliance with the continued listing standards by that date or if the Company does not make progress consistent with the Plan during the plan period, the Exchange may commence delisting procedures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that the Company will be able to meet milestones set forth in the Plan between now and April 10, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we fail to regain compliance with the continued listing requirements of the NYSE American, the NYSE American may take steps to de-list our common stock. If the NYSE American de-lists our securities for trading on its exchange, we could face significant material adverse consequences, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a limited availability of market quotations for our securities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">reduced liquidity with respect to our securities;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a determination that our shares of common stock are &#8220;penny stock&#8221; which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a limited amount of news and analyst coverage for our company; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">a decreased ability to issue additional securities or obtain additional financing in the future.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Such a de-listing would likely have a negative effect on the price of our common stock and would impair our investors&#8217; ability to sell or purchase our common stock when investors wish to do so.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Shares of our common stock are considered to be covered securities because they are listed on the NYSE American. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed on the NYSE American, our common stock would not be deemed covered securities and we would be subject to regulation in each state in which we offer our securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i3">Item 3. Defaults Upon Senior Securities.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i4">Item 4. Mine Safety Disclosures.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i5">Item 5. Other Information.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i6">Item 6. Exhibits.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Exhibits filed or furnished with this report:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit Number</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filed Herewith</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Filing Date</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SEC File No.</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">3.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">Amended and Restated Bylaws of Palatin Technologies, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">September 17, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">3.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">Restated Certificate of Incorporation of Palatin Technologies, Inc., as amended.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">September 27, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">3.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Palatin Technologies, Inc., as amended.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">August 31, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/911216/000165495424014335/ptn_10q.htm">3.4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/911216/000165495424014335/ptn_10q.htm">Certificate of Decrease of Series A Convertible Preferred Stock.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">May 16, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex41.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex41.htm">Form of Series C Common Stock Purchase Warrant, dated December 17, 2024.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">December 16, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex42.htm">4.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex42.htm">Form of Series D Common Stock Purchase Warrant, dated December 17, 2024.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">December 16, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex101.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495424015560/ptn_ex101.htm">Inducement Letter, between Palatin Technologies, Inc. and the Holder (as defined therein), dated December 13, 2024.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">December 16, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex311.htm">31.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex311.htm">Certification of Chief Executive Officer.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex312.htm">31.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex312.htm">Certification of Chief Financial Officer.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex321.htm">32.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex322.htm">32.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a href="ptn_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">*</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">101.INS</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Inline XBRL Taxonomy Extension Instance Document (the instance document does not appear on the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">101.SCH</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Inline XBRL Taxonomy Extension Schema Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">101.CAL</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">101.DEF</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">101.LAB</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">101.PRE</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">104</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td/><td/><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><img src="ptn_10qimg17.jpg" alt="ptn_10qimg17.jpg"/>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc1">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline"><span id="sign" class="atag" style="display:inline">SIGNATURES</span></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:50%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:35%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Palatin Technologies, Inc.</strong></p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(Registrant)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">/s/ Carl Spana</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Date: February 13, 2025</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Carl Spana, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">President and</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Chief Executive Officer (Principal</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Executive Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">/s/ Stephen T. Wills</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Date: February 13, 2025</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Stephen T. Wills, CPA, MST</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Executive Vice President, Chief Financial Officer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">and Chief Operating Officer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">(Principal Financial and Accounting Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ptn_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;">Certification of Chief Executive Officer</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">I, Carl Spana, certify that:</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;" start="1" type="1"> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">I have reviewed this Quarterly Report on Form 10-Q of Palatin Technologies, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(c)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(d)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;" start="5" type="1"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</p></td></tr></table> <p style="MARGIN: 0px; text-align:left;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">Date: February 13, 2025</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px">/s/ Carl Spana</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Carl Spana, President and Chief Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ptn_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;">Certification of Chief Financial Officer</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">I, Stephen T. Wills, certify that:</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;" start="1" type="1"></p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">I have reviewed this Quarterly Report on Form 10-Q of Palatin Technologies, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="MARGIN: 0px; text-align:left;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(c)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(d)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;" start="5" type="1"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</p></td></tr></table> <p style="MARGIN: 0px; text-align:left;"> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">Date: February 13, 2025</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px">/s/ Stephen T. Wills</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Stephen T. Wills, Executive Vice President,</p> <p style="margin:0px">Chief Financial Officer and Chief Operating Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ptn_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;">Certification of Principal Executive Officer</p> <p style="MARGIN: 0px; text-align:center;">Pursuant to 18 U.S.C. Section 1350</p> <p style="MARGIN: 0px; text-align:center;">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">I, Carl Spana, President and Chief Executive Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the Quarterly Report on Form 10-Q for the period ended December 31, 2024 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">Dated: February 13, 2025</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"> <p style="margin:0px">/s/ Carl Spana</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="margin:0px">Carl Spana, President and Chief Executive Officer</p> <p style="margin:0px">(Principal Executive Officer) </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ptn_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: left; FONT: 10pt Times New Roman"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;">Certification of Principal Financial Officer</p> <p style="MARGIN: 0px; text-align:center;">Pursuant to 18 U.S.C. Section 1350</p> <p style="MARGIN: 0px; text-align:center;">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">I, Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the Quarterly Report on Form 10-Q for the period ended December 31, 2024 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;">Dated: February 13, 2025</p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="MARGIN: 0px; text-align:left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px">/s/ Stephen T. Wills</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Stephen T. Wills, Executive Vice President,</p> <p style="margin:0px">Chief Financial Officer and Chief Operating Officer</p> <p style="margin:0px">(Principal Financial Officer)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px; text-align:left;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ptn-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ptn="http://ptn.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ptn.com/20241231">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://ptn.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" id="ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited">
        <link:definition>000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>000007 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>000008 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/NewAccountingPronouncements" id="NewAccountingPronouncements">
        <link:definition>000010 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AssetPurchaseAgreement" id="AssetPurchaseAgreement">
        <link:definition>000011 - Disclosure - ASSET PURCHASE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" id="ManufacturingSupplyAgreementsForVyleesi">
        <link:definition>000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithFosun" id="AgreementWithFosun">
        <link:definition>000013 - Disclosure - AGREEMENT WITH FOSUN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithKwangdong" id="AgreementWithKwangdong">
        <link:definition>000014 - Disclosure - AGREEMENT WITH KWANGDONG</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>000016 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>000017 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiency" id="StockholdersDeficiency">
        <link:definition>000019 - Disclosure - STOCKHOLDERS DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>000025 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyTables" id="StockholdersDeficiencyTables">
        <link:definition>000027 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/OrganizationDetailsNarrative" id="OrganizationDetailsNarrative">
        <link:definition>000028 - Disclosure - ORGANIZATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" id="AssetPurchaseAgreementDetailsNarrative">
        <link:definition>000031 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" id="AgreementWithFosunDetailsNarrative">
        <link:definition>000032 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" id="AgreementWithKwangdongDetailsNarrative">
        <link:definition>000033 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>000034 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <link:definition>000036 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" id="StockholdersDeficiencyDetails">
        <link:definition>000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" id="StockholdersDeficiencyDetails1">
        <link:definition>000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" id="StockholdersDeficiencyDetails2">
        <link:definition>000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" id="StockholdersDeficiencyDetails3">
        <link:definition>000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" id="StockholdersDeficiencyDetailsNarrative">
        <link:definition>000043 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <element id="ptn_ProductRevenueNet" name="ProductRevenueNet" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ForeignCurrencyTransactionLossGain" name="ForeignCurrencyTransactionLossGain" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" name="WithholdingTaxesRelatedToRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" name="WithholdingTaxesRelatedToRestrictedStockUnitsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SaleOfCommonStockNetOfCostsShares" name="SaleOfCommonStockNetOfCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SaleOfCommonStockNetOfCostsAmount" name="SaleOfCommonStockNetOfCostsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" name="ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" name="ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ReclassificationOfContingentlyRedeemableWarrants" name="ReclassificationOfContingentlyRedeemableWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesReleasedFromAbeyanceShares" name="SharesReleasedFromAbeyanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesReleasedFromAbeyanceAmount" name="SharesReleasedFromAbeyanceAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnrealizedForeignCurrencyTransactionLossGain" name="UnrealizedForeignCurrencyTransactionLossGain" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" name="ChangeInFairValueOfLiabilityClassifiedWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ProceedsFromSaleOfOtherAssets" name="ProceedsFromSaleOfOtherAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" name="ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AssetPurchaseAgreementTextBlock" name="AssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ManufacturingSupplyAgreementsTextBlock" name="ManufacturingSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithFosunTextBlock" name="AgreementWithFosunTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithKwangdongTextBlock" name="AgreementWithKwangdongTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" name="RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedLiabilitiesPolicyTextBlock" name="AccruedLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfSalesTableTextBlock" name="ScheduleOfSalesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" name="ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" name="ScheduleOfEquityDistributionAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" name="ScheduleOfStockPurchaseWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SalesBasedMilestonePayments" name="SalesBasedMilestonePayments" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RevenuesGross" name="RevenuesGross" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ProductSalesAllowancesAndAccruals" name="ProductSalesAllowancesAndAccruals" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_MoneyMarketAccountsAndTreasuryBills" name="MoneyMarketAccountsAndTreasuryBills" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PaymentsToSalesBasedMilestonePayments" name="PaymentsToSalesBasedMilestonePayments" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UpfrontPaymentOfLess" name="UpfrontPaymentOfLess" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_taxexpenses" name="taxexpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PrepaidClinicalStudyCosts" name="PrepaidClinicalStudyCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PrepaidInsurancePremiums" name="PrepaidInsurancePremiums" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_CarryingValueDuringTheYear" name="CarryingValueDuringTheYear" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_CostClinicalStudy" name="CostClinicalStudy" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OtherResearchRelatedExpenses" name="OtherResearchRelatedExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PersonalCost" name="PersonalCost" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedSellingExpenses" name="AccruedSellingExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_TotaAcrruedLiabilities" name="TotaAcrruedLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityGrossProceedsShares" name="EquityGrossProceedsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityFeesShares" name="EquityFeesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityExpensesShares" name="EquityExpensesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityExpensesProceeds" name="EquityExpensesProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityNetProceedsShares" name="EquityNetProceedsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityNetProceedsProceeds" name="EquityNetProceedsProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesOfCommonStock" name="SharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ExercisePricePerShareWarrantsOutstanding" name="ExercisePricePerShareWarrantsOutstanding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_LatestTerminationDate" name="LatestTerminationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" name="shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RestrictedStockVestedInPeriod" name="RestrictedStockVestedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PurchaseOfWarrantShares" name="PurchaseOfWarrantShares" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" name="StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" name="NumberOfOutstandingSharesOfRestrictedStockUnits" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" name="UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" name="StockIssuedDuringPeriodValueRestrictedStockUnitshares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockBasedCompensationToStockOptions" name="StockBasedCompensationToStockOptions" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnvestedPerformanceBasedStockOptionsGranted" name="UnvestedPerformanceBasedStockOptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" name="WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_GrossProceeds" name="GrossProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantIssuanceShares" name="WarrantIssuanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantIssuance" name="WarrantIssuance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PurchaseOfWarrantOfCommonStockSeriesA" name="PurchaseOfWarrantOfCommonStockSeriesA" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfSecuritiesPurchaseAgreement" name="DescriptionOfSecuritiesPurchaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AggregateValue" name="AggregateValue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_CashAvailableForDistributionsAdditional" name="CashAvailableForDistributionsAdditional" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantsToPurchaseShares" name="WarrantsToPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" name="DescriptionOfExistingHolderPurchaseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ExercisingHolderReleasedShares" name="ExercisingHolderReleasedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OrganizationAbstract" name="OrganizationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AssetPurchaseAgreementAbstract" name="AssetPurchaseAgreementAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" name="ManufacturingSupplyAgreementsForVyleesiabstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithFosunAbstract" name="AgreementWithFosunAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithKwangdongAbstract" name="AgreementWithKwangdongAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" name="StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAConvertiblePreferredStocksMember" id="ptn_SeriesAConvertiblePreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CurrentMember" id="ptn_CurrentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OneToThreeYearsMember" id="ptn_OneToThreeYearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FourToFiveYearsMember" id="ptn_FourToFiveYearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DecemberToZeroTwoFourSeriesDWarrantsMember" id="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MayTwoThousandTwentyTwoWarrantsMember" id="ptn_MayTwoThousandTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" id="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" id="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoZeroTwoFourPrivateWarrantsMember" id="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" id="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwoThousandTwentyFourSerisBWarrantsMember" id="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwentyTwentyThreeEquityDistributionAgreementMember" id="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleSeriesAPreferredStocksMember" id="ptn_ConvertibleSeriesAPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CumulativeFromInceptionMember" id="ptn_CumulativeFromInceptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyFourPlacementAgentWarrantsMember" id="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ContingentlyRedeemableWarrantsMember" id="ptn_ContingentlyRedeemableWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DecemberTwoThousandTwentyFourSerisCWarrantsMember" id="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAConvertiblePreferredStockMember" id="ptn_SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockWarrantsMember" id="ptn_StockWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>ptn-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_d6eeed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_d6eeed" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_3b34b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_3b34b0" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_bc964a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_bc964a" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_f554a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_f554a3" xml:lang="en-US">Statement Class Of Stock Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="ptn_SeriesAConvertiblePreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesAConvertiblePreferredStocksMember" xlink:to="ptn_SeriesAConvertiblePreferredStocksMember_lbl_a9d981" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesAConvertiblePreferredStocksMember_lbl_a9d981" xml:lang="en-US">Series A Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_106dac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_106dac" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_0aab4d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_0aab4d" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_6d3c01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_6d3c01" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_8e4759" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_8e4759" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_663d98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_663d98" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_6" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_fba097" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_fba097" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_739e1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_739e1b" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl_2fbad2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl_2fbad2" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_080725" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_080725" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_10" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_466c9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_466c9e" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIENCY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_b305aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_b305aa" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_364e75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_364e75" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_354776" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_354776" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_207984" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_207984" xml:lang="en-US">Short-term operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_e9d33b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_e9d33b" xml:lang="en-US">Short-term finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl_bf088b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl_bf088b" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_2d4b75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_2d4b75" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_18" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_982d43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_982d43" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl_3e1470" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl_3e1470" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_d689ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_d689ee" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_21" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl_d12793" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl_d12793" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_cd149e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_cd149e" xml:lang="en-US">Stockholders' deficiency:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_6de795" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_6de795" xml:lang="en-US">Common stock of $0.01 par value - authorized 300,000,000 shares issued and outstanding 23,455,846 shares as of December 31, 2024 and 17,926,640 shares as of June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_a52256" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_a52256" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_a2716a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_a2716a" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_2c0e39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_2c0e39" xml:lang="en-US">Total stockholders' deficiency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_27" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_6f47d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_6f47d3" xml:lang="en-US">Total liabilities and stockholders' deficiency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_28" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_ba5073" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_ba5073" xml:lang="en-US">Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follow Series A Convertible: authorized 4,030 shares as of December 31, 2024: issued and outstanding 4,030 shares as of December 31, 2024 and June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_4262fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_4262fb" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_4d1b75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_4d1b75" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_e05e30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_e05e30" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_b3f28d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_b3f28d" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_fcfff8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_fcfff8" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_c47d62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_c47d62" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_08e73c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_08e73c" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_934a2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_934a2d" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_06c5eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_06c5eb" xml:lang="en-US">Consolidated Statements of Operations (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProductRevenueNet" xlink:label="ptn_ProductRevenueNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProductRevenueNet" xlink:to="ptn_ProductRevenueNet_lbl_a95d23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProductRevenueNet_lbl_a95d23" xml:lang="en-US">Product revenue, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl_cff644" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl_cff644" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_090805" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_090805" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="us-gaap_ProductionCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionCosts" xlink:to="us-gaap_ProductionCosts_lbl_229732" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionCosts_lbl_229732" xml:lang="en-US">Cost of products sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_112ebf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_112ebf" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_70ad39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_70ad39" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_dcfa0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_dcfa0d" xml:lang="en-US">Gain on sale of Vyleesi</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_8" xml:lang="en-US">[Gain (Loss) on Disposition of Other Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_fd85c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_fd85c9" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_9" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_2a68c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_2a68c6" xml:lang="en-US">(Loss) Income from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_10" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_983d9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_983d9b" xml:lang="en-US">OTHER (EXPENSE) INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl_4f9ab1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl_4f9ab1" xml:lang="en-US">Investment income</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ForeignCurrencyTransactionLossGain" xlink:label="ptn_ForeignCurrencyTransactionLossGain" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ForeignCurrencyTransactionLossGain" xlink:to="ptn_ForeignCurrencyTransactionLossGain_lbl_60b28b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ForeignCurrencyTransactionLossGain_lbl_60b28b" xml:lang="en-US">Foreign currency transaction (loss) gain</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_0d52e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_0d52e6" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_14" xml:lang="en-US">[Interest Expense, Operating and Nonoperating]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_4033b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherExpenses_lbl_4033b9" xml:lang="en-US">Offering expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl_15" xml:lang="en-US">[Other Expenses]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_b32b4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl_b32b4a" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_c04540" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_c04540" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_17" xml:lang="en-US">[Other Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_80beda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_80beda" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_18" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl_6a6da8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl_6a6da8" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_15e575" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl_15e575" xml:lang="en-US">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_164cd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_164cd7" xml:lang="en-US">Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_3ac259" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_3ac259" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_2fc253" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_2fc253" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_d57385" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_d57385" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_2f46bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_2f46bb" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ContingentlyRedeemableWarrantsMember" xlink:label="ptn_ContingentlyRedeemableWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ContingentlyRedeemableWarrantsMember" xlink:to="ptn_ContingentlyRedeemableWarrantsMember_lbl_a731da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ContingentlyRedeemableWarrantsMember_lbl_a731da" xml:lang="en-US">Contingently Redeemable Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="ptn_SeriesAConvertiblePreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesAConvertiblePreferredStockMember" xlink:to="ptn_SeriesAConvertiblePreferredStockMember_lbl_78e609" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesAConvertiblePreferredStockMember_lbl_78e609" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_5113b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_5113b3" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_7d2cc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_7d2cc6" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_7f745e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_7f745e" xml:lang="en-US">Stock-based compensation, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_b6dbe9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_b6dbe9" xml:lang="en-US">Stock-based compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares_lbl_9e20da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares_lbl_9e20da" xml:lang="en-US">Withholding taxes related to restricted stock units, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount_lbl_01f3b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount_lbl_01f3b9" xml:lang="en-US">Withholding taxes related to restricted stock units, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="ptn_SaleOfCommonStockNetOfCostsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SaleOfCommonStockNetOfCostsShares" xlink:to="ptn_SaleOfCommonStockNetOfCostsShares_lbl_41f91c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SaleOfCommonStockNetOfCostsShares_lbl_41f91c" xml:lang="en-US">Sale of common stock, net of costs, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="ptn_SaleOfCommonStockNetOfCostsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SaleOfCommonStockNetOfCostsAmount" xlink:to="ptn_SaleOfCommonStockNetOfCostsAmount_lbl_505621" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SaleOfCommonStockNetOfCostsAmount_lbl_505621" xml:lang="en-US">Sale of common stock, net of costs, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_lbl_6534c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_lbl_6534c0" xml:lang="en-US">Conversion of liability classified warrants upon warrant exercise, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_lbl_894af8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_lbl_894af8" xml:lang="en-US">Conversion of liability classified warrants upon warrant exercise, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:label="ptn_ReclassificationOfContingentlyRedeemableWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:to="ptn_ReclassificationOfContingentlyRedeemableWarrants_lbl_ba4c1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ReclassificationOfContingentlyRedeemableWarrants_lbl_ba4c1c" xml:lang="en-US">Reclassification of contingently redeemable warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_c6ddad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_c6ddad" xml:lang="en-US">Net Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="ptn_SharesReleasedFromAbeyanceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesReleasedFromAbeyanceShares" xlink:to="ptn_SharesReleasedFromAbeyanceShares_lbl_6c295a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesReleasedFromAbeyanceShares_lbl_6c295a" xml:lang="en-US">Shares released from abeyance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="ptn_SharesReleasedFromAbeyanceAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesReleasedFromAbeyanceAmount" xlink:to="ptn_SharesReleasedFromAbeyanceAmount_lbl_8428ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesReleasedFromAbeyanceAmount_lbl_8428ed" xml:lang="en-US">Shares released from abeyance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantExercisesShares" xlink:label="ptn_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantExercisesShares" xlink:to="ptn_WarrantExercisesShares_lbl_4b09da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantExercisesShares_lbl_4b09da" xml:lang="en-US">Warrant exercises, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantExercisesAmount" xlink:label="ptn_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantExercisesAmount" xlink:to="ptn_WarrantExercisesAmount_lbl_6b9c4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantExercisesAmount_lbl_6b9c4f" xml:lang="en-US">Warrant exercises, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_9131cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_9131cd" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_71df3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_71df3b" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_39dfd1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_39dfd1" xml:lang="en-US">Consolidated Statements of Cash Flows (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_ea9729" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_ea9729" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_115c9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_115c9f" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_d4ebec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_d4ebec" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_edb66e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_edb66e" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_cd1cb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_cd1cb8" xml:lang="en-US">Decrease in right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:label="ptn_UnrealizedForeignCurrencyTransactionLossGain" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:to="ptn_UnrealizedForeignCurrencyTransactionLossGain_lbl_3cb975" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnrealizedForeignCurrencyTransactionLossGain_lbl_3cb975" xml:lang="en-US">Unrealized foreign currency transaction loss (gain)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_a99ddf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_a99ddf" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:to="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl_ba02f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl_ba02f4" xml:lang="en-US">Change in fair value of liability classified warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_40b697" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_40b697" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_795016" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_795016" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_12" xml:lang="en-US">[Increase (Decrease) in Accounts Receivable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_c03c8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_c03c8c" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_13" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense and Other Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_b7c189" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_b7c189" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_14" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_b8a989" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_b8a989" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_2984eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_2984eb" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_16" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_b1cab9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_b1cab9" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_86d809" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_86d809" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f5c4b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f5c4b4" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_19" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_a7da90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_a7da90" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl_7eb850" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl_7eb850" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProceedsFromSaleOfOtherAssets" xlink:label="ptn_ProceedsFromSaleOfOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProceedsFromSaleOfOtherAssets" xlink:to="ptn_ProceedsFromSaleOfOtherAssets_lbl_d05076" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProceedsFromSaleOfOtherAssets_lbl_d05076" xml:lang="en-US">Proceeds from sale of Vyleesi</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_131fa1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_131fa1" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_23" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_fdb20a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_fdb20a" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_24" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_ca3394" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_ca3394" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_8e9fc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_8e9fc2" xml:lang="en-US">Payment of withholding taxes related to restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_26" xml:lang="en-US">[Payment, Tax Withholding, Share-Based Payment Arrangement]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_084554" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_084554" xml:lang="en-US">Proceeds from the sale of common stock and warrants, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_320175" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_320175" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_28" xml:lang="en-US">[Finance Lease, Principal Payments]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_21b875" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_21b875" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_5a451b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_5a451b" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_30" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_884dc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_884dc2" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_31" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_8e18f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_8e18f4" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_775bcd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_775bcd" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_098b97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_098b97" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_27d604" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_27d604" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_lbl_132f5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_lbl_132f5a" xml:lang="en-US">Conversion of liability classified warrants upon warrant exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OrganizationAbstract" xlink:label="ptn_OrganizationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OrganizationAbstract" xlink:to="ptn_OrganizationAbstract_lbl_a459bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OrganizationAbstract_lbl_a459bc" xml:lang="en-US">ORGANIZATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_fefed1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_fefed1" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_BasisOfPresentationAbstract" xlink:label="ptn_BasisOfPresentationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_BasisOfPresentationAbstract" xlink:to="ptn_BasisOfPresentationAbstract_lbl_592c39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_BasisOfPresentationAbstract_lbl_592c39" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_136f1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_136f1e" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_c28642" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_c28642" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_642ff5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_642ff5" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl_28a580" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl_28a580" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_c4c2c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_c4c2c6" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_2" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="ptn_AssetPurchaseAgreementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementAbstract" xlink:to="ptn_AssetPurchaseAgreementAbstract_lbl_3e2b26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AssetPurchaseAgreementAbstract_lbl_3e2b26" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementTextBlock" xlink:to="ptn_AssetPurchaseAgreementTextBlock_lbl_fbd530" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AssetPurchaseAgreementTextBlock_lbl_fbd530" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AssetPurchaseAgreementTextBlock" xlink:label="ptn_AssetPurchaseAgreementTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementTextBlock" xlink:to="ptn_AssetPurchaseAgreementTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AssetPurchaseAgreementTextBlock_lbl_2" xml:lang="en-US">[ASSET PURCHASE AGREEMENT]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:label="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:to="ptn_ManufacturingSupplyAgreementsForVyleesiabstract_lbl_7cb1de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ManufacturingSupplyAgreementsForVyleesiabstract_lbl_7cb1de" xml:lang="en-US">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsTextBlock" xlink:to="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_8f5d99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_8f5d99" xml:lang="en-US">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ManufacturingSupplyAgreementsTextBlock" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsTextBlock" xlink:to="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_2" xml:lang="en-US">[MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithFosunAbstract" xlink:label="ptn_AgreementWithFosunAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunAbstract" xlink:to="ptn_AgreementWithFosunAbstract_lbl_52b2da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithFosunAbstract_lbl_52b2da" xml:lang="en-US">AGREEMENT WITH FOSUN</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunTextBlock" xlink:to="ptn_AgreementWithFosunTextBlock_lbl_3a6ee2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AgreementWithFosunTextBlock_lbl_3a6ee2" xml:lang="en-US">AGREEMENT WITH FOSUN</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithFosunTextBlock" xlink:label="ptn_AgreementWithFosunTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunTextBlock" xlink:to="ptn_AgreementWithFosunTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithFosunTextBlock_lbl_2" xml:lang="en-US">[AGREEMENT WITH FOSUN]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="ptn_AgreementWithKwangdongAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongAbstract" xlink:to="ptn_AgreementWithKwangdongAbstract_lbl_8e641b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithKwangdongAbstract_lbl_8e641b" xml:lang="en-US">AGREEMENT WITH KWANGDONG</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongTextBlock" xlink:to="ptn_AgreementWithKwangdongTextBlock_lbl_b9fabe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AgreementWithKwangdongTextBlock_lbl_b9fabe" xml:lang="en-US">AGREEMENT WITH KWANGDONG</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithKwangdongTextBlock" xlink:label="ptn_AgreementWithKwangdongTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongTextBlock" xlink:to="ptn_AgreementWithKwangdongTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithKwangdongTextBlock_lbl_2" xml:lang="en-US">[AGREEMENT WITH KWANGDONG]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl_e60f82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl_e60f82" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl_df87bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl_df87bc" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl_2" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_4ce64a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_4ce64a" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_a38d31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_a38d31" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl_666fd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl_666fd0" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_5910d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_5910d9" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_2" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_50873a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_50873a" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_b0d69f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_b0d69f" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:to="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_lbl_64cab7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_lbl_64cab7" xml:lang="en-US">STOCKHOLDERS DEFICIENCY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_8be1ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_8be1ef" xml:lang="en-US">STOCKHOLDERS DEFICIENCY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_5135ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_5135ac" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_cb8caf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_cb8caf" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_03ee55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_03ee55" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_ef7f02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_ef7f02" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_3de171" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_3de171" xml:lang="en-US">Cash, Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_3600f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_3600f3" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_6b3405" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_6b3405" xml:lang="en-US">Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_36cb57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_36cb57" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_a0fbc1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_a0fbc1" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_ebd88e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_ebd88e" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" xlink:label="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" xlink:to="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_lbl_86b1ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_lbl_86b1ef" xml:lang="en-US">Revenue Recognition (Prior to the sale of Vyleesi)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_35cea3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_35cea3" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_c59b07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_c59b07" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AccruedLiabilitiesPolicyTextBlock" xlink:label="ptn_AccruedLiabilitiesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedLiabilitiesPolicyTextBlock" xlink:to="ptn_AccruedLiabilitiesPolicyTextBlock_lbl_3bf921" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedLiabilitiesPolicyTextBlock_lbl_3bf921" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_9e4f0f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_9e4f0f" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_6dff42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_6dff42" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_b09b69" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_b09b69" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_b2e5be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_b2e5be" xml:lang="en-US">Translation of foreign currencies</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfSalesTableTextBlock" xlink:label="ptn_ScheduleOfSalesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfSalesTableTextBlock" xlink:to="ptn_ScheduleOfSalesTableTextBlock_lbl_844305" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfSalesTableTextBlock_lbl_844305" xml:lang="en-US">Schedule of sales</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl_4d6153" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl_4d6153" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl_7818c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl_7818c1" xml:lang="en-US">Schedule of fair value asset measurement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_03392f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_03392f" xml:lang="en-US">Schdule of Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:label="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:to="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock_lbl_723ae3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock_lbl_723ae3" xml:lang="en-US">Schedule of inventory purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:label="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:to="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock_lbl_32b881" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock_lbl_32b881" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:label="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:to="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock_lbl_10f52f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock_lbl_10f52f" xml:lang="en-US">Outstanding Stock Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_d63b73" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_d63b73" xml:lang="en-US">Option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl_4abef2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl_4abef2" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_99817d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_99817d" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_7a6d37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_7a6d37" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_8955ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_8955ab" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_f5c8c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_f5c8c1" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SalesBasedMilestonePayments" xlink:label="ptn_SalesBasedMilestonePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SalesBasedMilestonePayments" xlink:to="ptn_SalesBasedMilestonePayments_lbl_7ed43a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SalesBasedMilestonePayments_lbl_7ed43a" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_bd68be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_bd68be" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_0502fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_0502fd" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl_3bebf3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl_3bebf3" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl_3863a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl_3863a7" xml:lang="en-US">Product Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RevenuesGross" xlink:label="ptn_RevenuesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RevenuesGross" xlink:to="ptn_RevenuesGross_lbl_1df39b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RevenuesGross_lbl_1df39b" xml:lang="en-US">Gross product sales</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="ptn_ProductSalesAllowancesAndAccruals" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProductSalesAllowancesAndAccruals" xlink:to="ptn_ProductSalesAllowancesAndAccruals_lbl_56f6ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProductSalesAllowancesAndAccruals_lbl_56f6ea" xml:lang="en-US">Product sales allowances and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_8421b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_8421b2" xml:lang="en-US">Net sales</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_19026e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_19026e" xml:lang="en-US">Potential number of common shares excluded from diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl_f045c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl_f045c0" xml:lang="en-US">Weighted average vested restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_MoneyMarketAccountsAndTreasuryBills" xlink:label="ptn_MoneyMarketAccountsAndTreasuryBills" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_MoneyMarketAccountsAndTreasuryBills" xlink:to="ptn_MoneyMarketAccountsAndTreasuryBills_lbl_81e6bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_MoneyMarketAccountsAndTreasuryBills_lbl_81e6bb" xml:lang="en-US">Money market account and treasury bills</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl_12ecb1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl_12ecb1" xml:lang="en-US">Payable the settlement of certain purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivablePurchase" xlink:label="us-gaap_AccountsReceivablePurchase" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivablePurchase" xlink:to="us-gaap_AccountsReceivablePurchase_lbl_b12c85" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivablePurchase_lbl_b12c85" xml:lang="en-US">Acounts receiveble</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PaymentsToSalesBasedMilestonePayments" xlink:to="ptn_PaymentsToSalesBasedMilestonePayments_lbl_f04cab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments_lbl_f04cab" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PaymentsToSalesBasedMilestonePayments" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PaymentsToSalesBasedMilestonePayments" xlink:to="ptn_PaymentsToSalesBasedMilestonePayments_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments_lbl_4" xml:lang="en-US">[Sales-based milestone payments]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl_0793c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl_0793c9" xml:lang="en-US">Upfront purchase price amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_lbl_f515e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_lbl_f515e5" xml:lang="en-US">Company License Agreement Recievables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl_46ca60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl_46ca60" xml:lang="en-US">Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UpfrontPaymentOfLess" xlink:label="ptn_UpfrontPaymentOfLess" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UpfrontPaymentOfLess" xlink:to="ptn_UpfrontPaymentOfLess_lbl_691118" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UpfrontPaymentOfLess_lbl_691118" xml:lang="en-US">Upfront payment of less</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl_713ed5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl_713ed5" xml:lang="en-US">Recievable under company agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl_c3b4cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl_c3b4cc" xml:lang="en-US">Upfront payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_taxexpenses" xlink:label="ptn_taxexpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_taxexpenses" xlink:to="ptn_taxexpenses_lbl_3af267" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_taxexpenses_lbl_3af267" xml:lang="en-US">Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="us-gaap_PaymentsToAcquireReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireReceivables" xlink:to="us-gaap_PaymentsToAcquireReceivables_lbl_abe6ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireReceivables_lbl_abe6ec" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PrepaidClinicalStudyCosts" xlink:label="ptn_PrepaidClinicalStudyCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrepaidClinicalStudyCosts" xlink:to="ptn_PrepaidClinicalStudyCosts_lbl_096b75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrepaidClinicalStudyCosts_lbl_096b75" xml:lang="en-US">Clinical / regulatory costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PrepaidInsurancePremiums" xlink:label="ptn_PrepaidInsurancePremiums" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrepaidInsurancePremiums" xlink:to="ptn_PrepaidInsurancePremiums_lbl_a097f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrepaidInsurancePremiums_lbl_a097f8" xml:lang="en-US">Insurance premiums</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl_733d08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl_733d08" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl_41a654" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl_41a654" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_b8de1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_b8de1e" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl_bbd8bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl_bbd8bd" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl_f150b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl_f150b9" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl_4e3360" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl_4e3360" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CarryingValueDuringTheYear" xlink:label="ptn_CarryingValueDuringTheYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CarryingValueDuringTheYear" xlink:to="ptn_CarryingValueDuringTheYear_lbl_20b479" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CarryingValueDuringTheYear_lbl_20b479" xml:lang="en-US">Carrying Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CostClinicalStudy" xlink:to="ptn_CostClinicalStudy_lbl_30703b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_CostClinicalStudy_lbl_30703b" xml:lang="en-US">Clinical / regulatory costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CostClinicalStudy" xlink:label="ptn_CostClinicalStudy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CostClinicalStudy" xlink:to="ptn_CostClinicalStudy_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CostClinicalStudy_lbl_2" xml:lang="en-US">[Clinical / regulatory costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OtherResearchRelatedExpenses" xlink:label="ptn_OtherResearchRelatedExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OtherResearchRelatedExpenses" xlink:to="ptn_OtherResearchRelatedExpenses_lbl_54985a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OtherResearchRelatedExpenses_lbl_54985a" xml:lang="en-US">Other research related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl_19b50d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl_19b50d" xml:lang="en-US">Professional services</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PersonalCost" xlink:label="ptn_PersonalCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PersonalCost" xlink:to="ptn_PersonalCost_lbl_f4f4bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PersonalCost_lbl_f4f4bf" xml:lang="en-US">Personal cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AccruedSellingExpenses" xlink:label="ptn_AccruedSellingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedSellingExpenses" xlink:to="ptn_AccruedSellingExpenses_lbl_f6bfee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedSellingExpenses_lbl_f6bfee" xml:lang="en-US">Selling expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_8c7a03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_8c7a03" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_7" xml:lang="en-US">[Other Accrued Liabilities, Current]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TotaAcrruedLiabilities" xlink:to="ptn_TotaAcrruedLiabilities_lbl_cf735a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_TotaAcrruedLiabilities_lbl_cf735a" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TotaAcrruedLiabilities" xlink:label="ptn_TotaAcrruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TotaAcrruedLiabilities" xlink:to="ptn_TotaAcrruedLiabilities_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TotaAcrruedLiabilities_lbl_8" xml:lang="en-US">[Total]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_bcbee7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_bcbee7" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CurrentMember" xlink:label="ptn_CurrentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CurrentMember" xlink:to="ptn_CurrentMember_lbl_550fd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CurrentMember_lbl_550fd6" xml:lang="en-US">Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OneToThreeYearsMember" xlink:label="ptn_OneToThreeYearsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OneToThreeYearsMember" xlink:to="ptn_OneToThreeYearsMember_lbl_eb2562" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OneToThreeYearsMember_lbl_eb2562" xml:lang="en-US">1 - 3 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_FourToFiveYearsMember" xlink:label="ptn_FourToFiveYearsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_FourToFiveYearsMember" xlink:to="ptn_FourToFiveYearsMember_lbl_1abfc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_FourToFiveYearsMember_lbl_1abfc4" xml:lang="en-US">4 - 5 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl_3ae126" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl_3ae126" xml:lang="en-US">Inventory purchase commitments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl_9a04ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl_9a04ed" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl_74d413" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLongTermDebt_lbl_74d413" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CumulativeFromInceptionMember" xlink:label="ptn_CumulativeFromInceptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CumulativeFromInceptionMember" xlink:to="ptn_CumulativeFromInceptionMember_lbl_ab8dd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CumulativeFromInceptionMember_lbl_ab8dd8" xml:lang="en-US">Cumulative From Inception</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityGrossProceedsShares" xlink:label="ptn_EquityGrossProceedsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityGrossProceedsShares" xlink:to="ptn_EquityGrossProceedsShares_lbl_2f02c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityGrossProceedsShares_lbl_2f02c9" xml:lang="en-US">Equity Gross proceeds, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl_f5ca00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl_f5ca00" xml:lang="en-US">Equity Gross proceeds, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityFeesShares" xlink:label="ptn_EquityFeesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityFeesShares" xlink:to="ptn_EquityFeesShares_lbl_e3d91a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityFeesShares_lbl_e3d91a" xml:lang="en-US">Equity Fees, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl_a0df1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl_a0df1d" xml:lang="en-US">Equity Fees, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl_5" xml:lang="en-US">[Proceeds from Fees Received]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityExpensesShares" xlink:label="ptn_EquityExpensesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesShares" xlink:to="ptn_EquityExpensesShares_lbl_1f215c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityExpensesShares_lbl_1f215c" xml:lang="en-US">Equity Expenses, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesProceeds" xlink:to="ptn_EquityExpensesProceeds_lbl_4ba19e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_EquityExpensesProceeds_lbl_4ba19e" xml:lang="en-US">Equity Expenses, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityExpensesProceeds" xlink:label="ptn_EquityExpensesProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesProceeds" xlink:to="ptn_EquityExpensesProceeds_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityExpensesProceeds_lbl_7" xml:lang="en-US">[Equity Expenses, Proceeds]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityNetProceedsShares" xlink:label="ptn_EquityNetProceedsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityNetProceedsShares" xlink:to="ptn_EquityNetProceedsShares_lbl_c298c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityNetProceedsShares_lbl_c298c9" xml:lang="en-US">Equity Net proceeds, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityNetProceedsProceeds" xlink:label="ptn_EquityNetProceedsProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityNetProceedsProceeds" xlink:to="ptn_EquityNetProceedsProceeds_lbl_6fd116" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityNetProceedsProceeds_lbl_6fd116" xml:lang="en-US">Equity Net proceeds, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:label="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:to="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember_lbl_bf54c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember_lbl_bf54c9" xml:lang="en-US">December 2024 Series D Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="ptn_MayTwoThousandTwentyTwoWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:to="ptn_MayTwoThousandTwentyTwoWarrantsMember_lbl_6d80a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_MayTwoThousandTwentyTwoWarrantsMember_lbl_6d80a9" xml:lang="en-US">May 2022 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:to="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_lbl_b33d35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_lbl_b33d35" xml:lang="en-US">October 2022 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:to="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember_lbl_36b4a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember_lbl_36b4a4" xml:lang="en-US">October 2023 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:to="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember_lbl_f3996f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember_lbl_f3996f" xml:lang="en-US">January 2024 Private Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:to="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_lbl_c552c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_lbl_c552c3" xml:lang="en-US">January 2024 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:to="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember_lbl_cc6b16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember_lbl_cc6b16" xml:lang="en-US">June 2024 Seris B Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:label="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:to="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember_lbl_9931cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember_lbl_9931cb" xml:lang="en-US">December 2024 Series C Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesOfCommonStock" xlink:label="ptn_SharesOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesOfCommonStock" xlink:to="ptn_SharesOfCommonStock_lbl_796095" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesOfCommonStock_lbl_796095" xml:lang="en-US">Shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="ptn_ExercisePricePerShareWarrantsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ExercisePricePerShareWarrantsOutstanding" xlink:to="ptn_ExercisePricePerShareWarrantsOutstanding_lbl_a38dc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ExercisePricePerShareWarrantsOutstanding_lbl_a38dc8" xml:lang="en-US">Exercise Price per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_LatestTerminationDate" xlink:label="ptn_LatestTerminationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_LatestTerminationDate" xlink:to="ptn_LatestTerminationDate_lbl_4b0be4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_LatestTerminationDate_lbl_4b0be4" xml:lang="en-US">Latest Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_lbl_8d6d54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_lbl_8d6d54" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_lbl_98ba52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_lbl_98ba52" xml:lang="en-US">Number of Options Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_60d1c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_60d1c2" xml:lang="en-US">Number of Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_4" xml:lang="en-US">[Number of Options Forfeited]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_1eb9b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_1eb9b7" xml:lang="en-US">Number of Options Exercied</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_5" xml:lang="en-US">[Number of Options Exercied]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_lbl_48819e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_lbl_48819e" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_lbl_3c6234" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_lbl_3c6234" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_lbl_49456f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_lbl_49456f" xml:lang="en-US">Number of Options Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_lbl_0e3f90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_lbl_0e3f90" xml:lang="en-US">Number of Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_lbl_059a46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_lbl_059a46" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_19517e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_19517e" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_85e36c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_85e36c" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_38c569" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_38c569" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_5579a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_5579a7" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_lbl_f60ffb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_lbl_f60ffb" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:to="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_lbl_39a73b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_lbl_39a73b" xml:lang="en-US">Weighted Average Exercise Price Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_lbl_c3db38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_lbl_c3db38" xml:lang="en-US">Weighted Average Exercise Price Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl_b4d4df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl_b4d4df" xml:lang="en-US">Weighted Average Remaining Term in Years Options outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_b0c540" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_b0c540" xml:lang="en-US">Weighted Average Remaining Term in Years Options outstanding at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_12f277" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_12f277" xml:lang="en-US">Weighted Average Remaining Term in Years Options exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl_d630b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl_d630b7" xml:lang="en-US">Weighted Average Remaining Term in Years Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_lbl_bb8df0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_lbl_bb8df0" xml:lang="en-US">Aggregate Intrinsic Value Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_lbl_ba2614" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_lbl_ba2614" xml:lang="en-US">Aggregate Intrinsic Value Options Expected to outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_lbl_328744" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_lbl_328744" xml:lang="en-US">Aggregate Intrinsic Value Options Exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_02e6ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_02e6ec" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_2" xml:lang="en-US">[Outstanding at beginning of year]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_730299" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_730299" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_1de316" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_1de316" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_4" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RestrictedStockVestedInPeriod" xlink:label="ptn_RestrictedStockVestedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RestrictedStockVestedInPeriod" xlink:to="ptn_RestrictedStockVestedInPeriod_lbl_fb5e44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RestrictedStockVestedInPeriod_lbl_fb5e44" xml:lang="en-US">Vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_7e8816" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_7e8816" xml:lang="en-US">Expirations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_ee7977" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_ee7977" xml:lang="en-US">Outstanding at ending of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_c87632" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_c87632" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_d4b59c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_d4b59c" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:to="ptn_TwentyTwentyThreeEquityDistributionAgreementMember_lbl_9589fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwentyTwentyThreeEquityDistributionAgreementMember_lbl_9589fa" xml:lang="en-US">2023 Equity Distribution Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="ptn_ConvertibleSeriesAPreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConvertibleSeriesAPreferredStocksMember" xlink:to="ptn_ConvertibleSeriesAPreferredStocksMember_lbl_2f9b59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConvertibleSeriesAPreferredStocksMember_lbl_2f9b59" xml:lang="en-US">Convertible Series A Preferred Stocks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:to="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember_lbl_58a7dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember_lbl_58a7dd" xml:lang="en-US">2024 Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockWarrantsMember" xlink:label="ptn_StockWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockWarrantsMember" xlink:to="ptn_StockWarrantsMember_lbl_e4b628" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockWarrantsMember_lbl_e4b628" xml:lang="en-US">Stock Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesOfCommonStock" xlink:to="ptn_SharesOfCommonStock_lbl_49d4e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_SharesOfCommonStock_lbl_49d4e4" xml:lang="en-US">Shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PurchaseOfWarrantShares" xlink:label="ptn_PurchaseOfWarrantShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PurchaseOfWarrantShares" xlink:to="ptn_PurchaseOfWarrantShares_lbl_7a6aee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PurchaseOfWarrantShares_lbl_7a6aee" xml:lang="en-US">Purchase of warrant shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:to="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_lbl_bbd60d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_lbl_bbd60d" xml:lang="en-US">Stock-based compensation related to restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:to="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits_lbl_940737" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits_lbl_940737" xml:lang="en-US">Number of outstanding shares of restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:to="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_lbl_9ddca8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_lbl_9ddca8" xml:lang="en-US">Unvested performance-based stock options granted estricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_lbl_ed93dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_lbl_ed93dd" xml:lang="en-US">Restricted stock units number of shares outstanding granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:to="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_5ee35d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_5ee35d" xml:lang="en-US">Withholding taxes related to restricted stock units, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:to="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_8" xml:lang="en-US">[Withholding taxes related to restricted stock units, shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockBasedCompensationToStockOptions" xlink:label="ptn_StockBasedCompensationToStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockBasedCompensationToStockOptions" xlink:to="ptn_StockBasedCompensationToStockOptions_lbl_51a95a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockBasedCompensationToStockOptions_lbl_51a95a" xml:lang="en-US">Stock-based compensation to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:to="ptn_UnvestedPerformanceBasedStockOptionsGranted_lbl_44d045" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGranted_lbl_44d045" xml:lang="en-US">Unvested performance-based stock options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_01f8f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_01f8f8" xml:lang="en-US">Number of shares outstanding granted</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun_lbl_92e29d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun_lbl_92e29d" xml:lang="en-US">Withholding taxes related to restricted stock units, value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_073a4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_073a4a" xml:lang="en-US">Fees and expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_GrossProceeds" xlink:label="ptn_GrossProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_GrossProceeds" xlink:to="ptn_GrossProceeds_lbl_772fbd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_GrossProceeds_lbl_772fbd" xml:lang="en-US">Gross proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_9c2320" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_9c2320" xml:lang="en-US">Exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl_bcedfd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl_bcedfd" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantIssuanceShares" xlink:label="ptn_WarrantIssuanceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantIssuanceShares" xlink:to="ptn_WarrantIssuanceShares_lbl_25779f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantIssuanceShares_lbl_25779f" xml:lang="en-US">Warrant issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantIssuance" xlink:label="ptn_WarrantIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantIssuance" xlink:to="ptn_WarrantIssuance_lbl_f837a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantIssuance_lbl_f837a6" xml:lang="en-US">Warrant issuance year five</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="ptn_PurchaseOfWarrantOfCommonStockSeriesA" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:to="ptn_PurchaseOfWarrantOfCommonStockSeriesA_lbl_c2e008" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PurchaseOfWarrantOfCommonStockSeriesA_lbl_c2e008" xml:lang="en-US">Purchase of warrant of common stock series A</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="ptn_DescriptionOfSecuritiesPurchaseAgreement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:to="ptn_DescriptionOfSecuritiesPurchaseAgreement_lbl_ecbb5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfSecuritiesPurchaseAgreement_lbl_ecbb5f" xml:lang="en-US">Description of securities purchase agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_297984" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_297984" xml:lang="en-US">Convertible preferred stock were outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AggregateValue" xlink:label="ptn_AggregateValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AggregateValue" xlink:to="ptn_AggregateValue_lbl_36f723" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AggregateValue_lbl_36f723" xml:lang="en-US">Aggregate value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl_e892fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl_e892fc" xml:lang="en-US">Conversion price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:to="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare_lbl_613d9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare_lbl_613d9b" xml:lang="en-US">Convertible shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="us-gaap_CashAvailableForDistributions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAvailableForDistributions" xlink:to="us-gaap_CashAvailableForDistributions_lbl_b62e24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAvailableForDistributions_lbl_b62e24" xml:lang="en-US">Distributable value of dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CashAvailableForDistributionsAdditional" xlink:label="ptn_CashAvailableForDistributionsAdditional" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CashAvailableForDistributionsAdditional" xlink:to="ptn_CashAvailableForDistributionsAdditional_lbl_583f3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CashAvailableForDistributionsAdditional_lbl_583f3a" xml:lang="en-US">Distributable value of dividend additional</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantsToPurchaseShares" xlink:label="ptn_WarrantsToPurchaseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantsToPurchaseShares" xlink:to="ptn_WarrantsToPurchaseShares_lbl_e1e033" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantsToPurchaseShares_lbl_e1e033" xml:lang="en-US">Warrants to purchase</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_10e73c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_10e73c" xml:lang="en-US">Gross proceeds from exercise of Existing Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:to="ptn_DescriptionOfExistingHolderPurchaseOfWarrants_lbl_79f301" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfExistingHolderPurchaseOfWarrants_lbl_79f301" xml:lang="en-US">Description of existing holder purchase of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="ptn_ExercisingHolderReleasedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ExercisingHolderReleasedShares" xlink:to="ptn_ExercisingHolderReleasedShares_lbl_f3744b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ExercisingHolderReleasedShares_lbl_f3744b" xml:lang="en-US">Exercising holder released shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_4da5bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_4da5bd" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl_d652a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl_d652a4" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_2a8562" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_2a8562" xml:lang="en-US">Common stock share purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_7146f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_7146f1" xml:lang="en-US">Purchase price per share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_da0c94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_da0c94" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_0e8dcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_0e8dcf" xml:lang="en-US">Gross proceeds from Offering</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ptn-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20241231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20241231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20241231.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20241231.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAccountingPronouncements" xlink:href="ptn-20241231.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20241231.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20241231.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20241231.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20241231.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20241231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20241231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20241231.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEvents" xlink:href="ptn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20241231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20241231.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20241231.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20241231.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20241231.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20241231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20241231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:href="ptn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Consolidated Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="loc_us-gaapProductionCosts" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProductionCosts" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProductRevenueNet" xlink:label="loc_ptnProductRevenueNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_ptnProductRevenueNet" xlink:type="arc" weight="1" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ForeignCurrencyTransactionLossGain" xlink:label="loc_ptnForeignCurrencyTransactionLossGain" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_ptnForeignCurrencyTransactionLossGain" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:label="loc_ptnUnrealizedForeignCurrencyTransactionLossGain" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ptnUnrealizedForeignCurrencyTransactionLossGain" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProceedsFromSaleOfOtherAssets" xlink:label="loc_ptnProceedsFromSaleOfOtherAssets" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ptnProceedsFromSaleOfOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="000008 - Disclosure - BASIS OF PRESENTATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAccountingPronouncements" xlink:title="000010 - Disclosure - New Accounting Pronouncements" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="000011 - Disclosure - ASSET PURCHASE AGREEMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="000013 - Disclosure - AGREEMENT WITH FOSUN" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="000014 - Disclosure - AGREEMENT WITH KWANGDONG" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="000016 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="000017 - Disclosure - ACCRUED EXPENSES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="000019 - Disclosure - STOCKHOLDERS DEFICIENCY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="000025 - Disclosure - ACCRUED EXPENSES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="000027 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="000028 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="000031 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="000032 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="000033 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="000034 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="000036 - Disclosure - ACCRUED EXPENSES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="000043 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:title="000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ptn-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20241231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20241231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20241231.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20241231.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAccountingPronouncements" xlink:href="ptn-20241231.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20241231.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20241231.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20241231.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20241231.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20241231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20241231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20241231.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEvents" xlink:href="ptn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20241231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20241231.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20241231.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20241231.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20241231.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20241231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20241231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:href="ptn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_b7d27b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0b34d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_b7d27b" xlink:to="loc_us-gaapStatementTable_0b34d6" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_46f1df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0b34d6" xlink:to="loc_us-gaapStatementLineItems_46f1df" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_e5c984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0b34d6" xlink:to="loc_us-gaapStatementClassOfStockAxis_e5c984" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_837f4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_e5c984" xlink:to="loc_us-gaapClassOfStockDomain_837f4f" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember_34adfd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_837f4f" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember_34adfd" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_04f24e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAssetsAbstract_04f24e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_f84a21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAssetsCurrentAbstract_f84a21" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0cdbd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0cdbd" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_4f3964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_4f3964" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_59aea6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAssetsCurrent_59aea6" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_685f3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_685f3a" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_d85feb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_d85feb" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_976c78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapOtherAssetsNoncurrent_976c78" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_5a514e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAssets_5a514e" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_ee21d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_ee21d7" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_a9f77f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_a9f77f" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_69d821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAccountsPayableCurrent_69d821" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_010521" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_010521" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_4c92bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_4c92bb" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_f63347" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_f63347" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_638130" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_638130" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_9093a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapLiabilitiesCurrent_9093a2" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_b7f1a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_b7f1a7" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_c6bbf9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapOtherLongTermDebt_c6bbf9" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_9412ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapLiabilities_9412ed" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_84159a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapCommitmentsAndContingencies_84159a" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_6ae908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapStockholdersEquityAbstract_6ae908" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_fd1c31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapCommonStockValue_fd1c31" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_df26c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapAdditionalPaidInCapital_df26c5" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_dbe9e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_dbe9e0" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_423ce8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapStockholdersEquity_423ce8" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_188f31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_188f31" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_35555f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_46f1df" xlink:to="loc_us-gaapPreferredStockValue_35555f" order="28" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_3512e9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1c9fc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_3512e9" xlink:to="loc_us-gaapStatementTable_1c9fc3" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9bf80b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1c9fc3" xlink:to="loc_us-gaapStatementLineItems_9bf80b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_c282a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1c9fc3" xlink:to="loc_us-gaapStatementClassOfStockAxis_c282a9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_b19c5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_c282a9" xlink:to="loc_us-gaapClassOfStockDomain_b19c5b" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember_8da2bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_b19c5b" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember_8da2bb" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_d5a067" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_d5a067" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_7eee4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_7eee4c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_8dfe35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_8dfe35" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_db685c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapCommonStockSharesAuthorized_db685c" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_6924a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapCommonStockSharesIssued_6924a5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2a7ece" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2a7ece" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_fcf5b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapPreferredStockSharesIssued_fcf5b9" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_2a9633" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9bf80b" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_2a9633" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Consolidated Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_ad3b5c" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProductRevenueNet" xlink:label="loc_ptnProductRevenueNet_c80b0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_ptnProductRevenueNet_c80b0b" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_744e99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapRevenuesAbstract_744e99" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_5a11b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_744e99" xlink:to="loc_us-gaapOperatingExpensesAbstract_5a11b6" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="loc_us-gaapProductionCosts_b353a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapProductionCosts_b353a4" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_0e2b55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_0e2b55" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_3b5336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_3b5336" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets_717b0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets_717b0b" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_a6d5e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapOperatingExpenses_a6d5e2" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_089378" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapOperatingIncomeLoss_089378" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet_dd5753" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" xlink:to="loc_us-gaapInvestmentIncomeNet_dd5753" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ForeignCurrencyTransactionLossGain" xlink:label="loc_ptnForeignCurrencyTransactionLossGain_266293" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" xlink:to="loc_ptnForeignCurrencyTransactionLossGain_266293" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_4a4629" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" xlink:to="loc_us-gaapInterestExpense_4a4629" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_0a4b54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" xlink:to="loc_us-gaapOtherExpenses_0a4b54" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_448832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_448832" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_447d3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_162af7" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_447d3a" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_62e68e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapNetIncomeLoss_62e68e" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_d17c73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapEarningsPerShareBasic_d17c73" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_f033e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_ad3b5c" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_f033e7" order="19" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_af34f8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ecdb08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_af34f8" xlink:to="loc_us-gaapStatementTable_ecdb08" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9747ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ecdb08" xlink:to="loc_us-gaapStatementLineItems_9747ea" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_eecd45" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ecdb08" xlink:to="loc_us-gaapStatementEquityComponentsAxis_eecd45" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_68931a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_eecd45" xlink:to="loc_us-gaapEquityComponentDomain_68931a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_9ca455" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_68931a" xlink:to="loc_us-gaapCommonStockMember_9ca455" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_92a652" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_68931a" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_92a652" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_1786a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_68931a" xlink:to="loc_us-gaapRetainedEarningsMember_1786a3" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ContingentlyRedeemableWarrantsMember" xlink:label="loc_ptnContingentlyRedeemableWarrantsMember_ed07bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_68931a" xlink:to="loc_ptnContingentlyRedeemableWarrantsMember_ed07bf" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStockMember_af7121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_68931a" xlink:to="loc_ptnSeriesAConvertiblePreferredStockMember_af7121" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_913190" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapSharesIssued_913190" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_ca8c68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapStockholdersEquity_ca8c68" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_89554d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_89554d" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_48eac7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapShareBasedCompensation_48eac7" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares_94d5e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares_94d5e6" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount_d71655" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount_d71655" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsShares_27e39e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsShares_27e39e" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsAmount_1b9595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsAmount_1b9595" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_294d64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_294d64" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_c1f4ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_c1f4ae" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:label="loc_ptnReclassificationOfContingentlyRedeemableWarrants_b0c906" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnReclassificationOfContingentlyRedeemableWarrants_b0c906" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_d60784" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapNetIncomeLoss_d60784" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="loc_ptnSharesReleasedFromAbeyanceShares_200f07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnSharesReleasedFromAbeyanceShares_200f07" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="loc_ptnSharesReleasedFromAbeyanceAmount_040568" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnSharesReleasedFromAbeyanceAmount_040568" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantExercisesShares" xlink:label="loc_ptnWarrantExercisesShares_24ac7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnWarrantExercisesShares_24ac7b" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantExercisesAmount" xlink:label="loc_ptnWarrantExercisesAmount_cd05ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_ptnWarrantExercisesAmount_cd05ce" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_b04875" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapSharesIssued_b04875" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_740cde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9747ea" xlink:to="loc_us-gaapStockholdersEquity_740cde" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d918a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d918a8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_c95829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d918a8" xlink:to="loc_us-gaapProfitLoss_c95829" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d918a8" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_f2ac32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_us-gaapDepreciationAndAmortization_f2ac32" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_4fdde2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_4fdde2" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnrealizedForeignCurrencyTransactionLossGain" xlink:label="loc_ptnUnrealizedForeignCurrencyTransactionLossGain_2f5ee4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_ptnUnrealizedForeignCurrencyTransactionLossGain_2f5ee4" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_c4fecd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_us-gaapShareBasedCompensation_c4fecd" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants_c9837d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants_c9837d" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets_0dbd26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets_0dbd26" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8802aa" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_d6ffe5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_d6ffe5" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_241a1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_241a1f" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_a04cc5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_a04cc5" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_e47ea7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_e47ea7" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_76a273" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_76a273" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_ffa76a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_ffa76a" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_65e832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_65e832" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_28bf75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_7f656f" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_28bf75" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_775d54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_775d54" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_ecc039" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_775d54" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_ecc039" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProceedsFromSaleOfOtherAssets" xlink:label="loc_ptnProceedsFromSaleOfOtherAssets_fbf15f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_775d54" xlink:to="loc_ptnProceedsFromSaleOfOtherAssets_fbf15f" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_7d2d79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_775d54" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_7d2d79" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_2966b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_775d54" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_2966b0" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_7d4deb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_7d4deb" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_e792cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_e792cb" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_20acdb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_20acdb" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_bca499" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" xlink:to="loc_us-gaapProceedsFromWarrantExercises_bca499" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_27ec1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_a2b1d8" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_27ec1a" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_cf40f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_cf40f4" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9efabb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9efabb" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed60e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed60e7" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_2444cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_8dff0e" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_2444cf" order="33" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_e5b2f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_2444cf" xlink:to="loc_us-gaapInterestPaidNet_e5b2f3" order="34" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_221cc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_2444cf" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_221cc3" order="35" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OrganizationAbstract" xlink:label="loc_ptnOrganizationAbstract_e29c4c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8042a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_e29c4c" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8042a6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="000008 - Disclosure - BASIS OF PRESENTATION">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_BasisOfPresentationAbstract" xlink:label="loc_ptnBasisOfPresentationAbstract_c3923a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_65f300" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnBasisOfPresentationAbstract_c3923a" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_65f300" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_7e1aee" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_08580a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_7e1aee" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_08580a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAccountingPronouncements" xlink:title="000010 - Disclosure - New Accounting Pronouncements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_3340c7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_190e08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_3340c7" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_190e08" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="000011 - Disclosure - ASSET PURCHASE AGREEMENT">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="loc_ptnAssetPurchaseAgreementAbstract_5d3ce9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AssetPurchaseAgreementTextBlock" xlink:label="loc_ptnAssetPurchaseAgreementTextBlock_1a32be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_5d3ce9" xlink:to="loc_ptnAssetPurchaseAgreementTextBlock_1a32be" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:label="loc_ptnManufacturingSupplyAgreementsForVyleesiabstract_32224e" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ManufacturingSupplyAgreementsTextBlock" xlink:label="loc_ptnManufacturingSupplyAgreementsTextBlock_1907c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnManufacturingSupplyAgreementsForVyleesiabstract_32224e" xlink:to="loc_ptnManufacturingSupplyAgreementsTextBlock_1907c9" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="000013 - Disclosure - AGREEMENT WITH FOSUN">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithFosunAbstract" xlink:label="loc_ptnAgreementWithFosunAbstract_f4f198" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithFosunTextBlock" xlink:label="loc_ptnAgreementWithFosunTextBlock_622c96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_f4f198" xlink:to="loc_ptnAgreementWithFosunTextBlock_622c96" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="000014 - Disclosure - AGREEMENT WITH KWANGDONG">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="loc_ptnAgreementWithKwangdongAbstract_4429be" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithKwangdongTextBlock" xlink:label="loc_ptnAgreementWithKwangdongTextBlock_ad88fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_4429be" xlink:to="loc_ptnAgreementWithKwangdongTextBlock_ad88fc" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_6e61f2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock_292f9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_6e61f2" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock_292f9a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="000016 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_8366ff" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_8e6979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_8366ff" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_8e6979" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="000017 - Disclosure - ACCRUED EXPENSES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_33b1a7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8eb28b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_33b1a7" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_8eb28b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="000018 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ae8f83" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_8caa3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_ae8f83" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_8caa3a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="000019 - Disclosure - STOCKHOLDERS DEFICIENCY">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_2f59ca" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_ed077d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_2f59ca" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_ed077d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_efc1fe" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_46a03c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_efc1fe" xlink:to="loc_us-gaapSubsequentEventsTextBlock_46a03c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_368291" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_7a736e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_7a736e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_699d9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapUseOfEstimates_699d9b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_6355f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_6355f0" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_be526a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_be526a" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_854c0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_854c0e" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_255ef9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_255ef9" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9980ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9980ec" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_e295ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_e295ae" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" xlink:label="loc_ptnRevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_ab761f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_ptnRevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_ab761f" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_fd3829" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_fd3829" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_684f75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_684f75" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_ptnAccruedLiabilitiesPolicyTextBlock_d043e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_ptnAccruedLiabilitiesPolicyTextBlock_d043e2" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_3f78ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_3f78ae" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_5e3d13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_5e3d13" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_3b316c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_3b316c" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6ffa5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_368291" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6ffa5f" order="16" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_a205f0" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfSalesTableTextBlock" xlink:label="loc_ptnScheduleOfSalesTableTextBlock_a08b7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_a205f0" xlink:to="loc_ptnScheduleOfSalesTableTextBlock_a08b7f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_6867ef" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock_1aba68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_6867ef" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock_1aba68" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_301fc5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_51db95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_301fc5" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_51db95" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="000025 - Disclosure - ACCRUED EXPENSES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_52e46f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f13429" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_52e46f" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f13429" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_0b81ca" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:label="loc_ptnScheduleOfInventoryPurchaseCommitmentsTableTextBlock_1385a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_0b81ca" xlink:to="loc_ptnScheduleOfInventoryPurchaseCommitmentsTableTextBlock_1385a9" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="000027 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_19298e" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:label="loc_ptnScheduleOfEquityDistributionAgreementTableTextBlock_56a2d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_19298e" xlink:to="loc_ptnScheduleOfEquityDistributionAgreementTableTextBlock_56a2d6" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:label="loc_ptnScheduleOfStockPurchaseWarrantsTableTextBlock_200e66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_19298e" xlink:to="loc_ptnScheduleOfStockPurchaseWarrantsTableTextBlock_200e66" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f74732" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_19298e" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f74732" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_387305" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_19298e" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_387305" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="000028 - Disclosure - ORGANIZATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OrganizationAbstract" xlink:label="loc_ptnOrganizationAbstract_dcd383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_8ee16f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_dcd383" xlink:to="loc_us-gaapStatementTable_8ee16f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_39c8a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8ee16f" xlink:to="loc_us-gaapStatementLineItems_39c8a4" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_602821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8ee16f" xlink:to="loc_us-gaapSubsequentEventTypeAxis_602821" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_36618b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_602821" xlink:to="loc_us-gaapSubsequentEventTypeDomain_36618b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_00125e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_36618b" xlink:to="loc_us-gaapSubsequentEventMember_00125e" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_c36c7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_39c8a4" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_c36c7b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_0326da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_dcd383" xlink:to="loc_us-gaapNetIncomeLoss_0326da" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SalesBasedMilestonePayments" xlink:label="loc_ptnSalesBasedMilestonePayments_2fc800" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_dcd383" xlink:to="loc_ptnSalesBasedMilestonePayments_2fc800" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c25174" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_dcd383" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c25174" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_d07d4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_dcd383" xlink:to="loc_us-gaapLiabilitiesCurrent_d07d4c" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_34f7dc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f6ad12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_34f7dc" xlink:to="loc_us-gaapStatementTable_f6ad12" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ea1c8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f6ad12" xlink:to="loc_us-gaapStatementLineItems_ea1c8e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_1945c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f6ad12" xlink:to="loc_srtProductOrServiceAxis_1945c0" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_693627" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_1945c0" xlink:to="loc_srtProductsAndServicesDomain_693627" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_5ad778" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_693627" xlink:to="loc_us-gaapProductMember_5ad778" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RevenuesGross" xlink:label="loc_ptnRevenuesGross_ce0e3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ea1c8e" xlink:to="loc_ptnRevenuesGross_ce0e3b" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="loc_ptnProductSalesAllowancesAndAccruals_f6eabe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ea1c8e" xlink:to="loc_ptnProductSalesAllowancesAndAccruals_f6eabe" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_ca421b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ea1c8e" xlink:to="loc_us-gaapRevenues_ca421b" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_b887ff" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47be70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b887ff" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47be70" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_4b7918" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b887ff" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_4b7918" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_MoneyMarketAccountsAndTreasuryBills" xlink:label="loc_ptnMoneyMarketAccountsAndTreasuryBills_740ea2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_b887ff" xlink:to="loc_ptnMoneyMarketAccountsAndTreasuryBills_740ea2" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="000031 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="loc_ptnAssetPurchaseAgreementAbstract_9467db" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="loc_us-gaapPaymentsForPurchaseOfOtherAssets1_0b0d4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_9467db" xlink:to="loc_us-gaapPaymentsForPurchaseOfOtherAssets1_0b0d4d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivablePurchase" xlink:label="loc_us-gaapAccountsReceivablePurchase_401c1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_9467db" xlink:to="loc_us-gaapAccountsReceivablePurchase_401c1c" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PaymentsToSalesBasedMilestonePayments" xlink:label="loc_ptnPaymentsToSalesBasedMilestonePayments_b5c582" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_9467db" xlink:to="loc_ptnPaymentsToSalesBasedMilestonePayments_b5c582" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice" xlink:label="loc_us-gaapSupplementalDeferredPurchasePrice_575bbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_9467db" xlink:to="loc_us-gaapSupplementalDeferredPurchasePrice_575bbe" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="000032 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithFosunAbstract" xlink:label="loc_ptnAgreementWithFosunAbstract_616c1e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_eb1776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_616c1e" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_eb1776" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaapPaymentsForRestructuring_f2a3da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_616c1e" xlink:to="loc_us-gaapPaymentsForRestructuring_f2a3da" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UpfrontPaymentOfLess" xlink:label="loc_ptnUpfrontPaymentOfLess_fa823a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_616c1e" xlink:to="loc_ptnUpfrontPaymentOfLess_fa823a" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="000033 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="loc_ptnAgreementWithKwangdongAbstract_5d1628" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_a1a032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_5d1628" xlink:to="loc_us-gaapOfficersCompensation_a1a032" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaapPaymentsForRestructuring_d157dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_5d1628" xlink:to="loc_us-gaapPaymentsForRestructuring_d157dc" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_taxexpenses" xlink:label="loc_ptntaxexpenses_5edae8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_5d1628" xlink:to="loc_ptntaxexpenses_5edae8" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="loc_us-gaapPaymentsToAcquireReceivables_1c1530" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_5d1628" xlink:to="loc_us-gaapPaymentsToAcquireReceivables_1c1530" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="000034 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_212496" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PrepaidClinicalStudyCosts" xlink:label="loc_ptnPrepaidClinicalStudyCosts_328836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_212496" xlink:to="loc_ptnPrepaidClinicalStudyCosts_328836" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PrepaidInsurancePremiums" xlink:label="loc_ptnPrepaidInsurancePremiums_0cffd4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_212496" xlink:to="loc_ptnPrepaidInsurancePremiums_0cffd4" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_ec80bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_212496" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_ec80bf" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets_ffc011" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_212496" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets_ffc011" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_1d2b16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_48d65a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_1d2b16" xlink:to="loc_us-gaapStatementTable_48d65a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ed7f97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_48d65a" xlink:to="loc_us-gaapStatementLineItems_ed7f97" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_92517c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_48d65a" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_92517c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_395735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_92517c" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_395735" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_4ea763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_395735" xlink:to="loc_us-gaapFairValueInputsLevel1Member_4ea763" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_b22929" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_395735" xlink:to="loc_us-gaapFairValueInputsLevel2Member_b22929" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_f0f4ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_395735" xlink:to="loc_us-gaapFairValueInputsLevel3Member_f0f4ad" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CarryingValueDuringTheYear" xlink:label="loc_ptnCarryingValueDuringTheYear_ce071e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ed7f97" xlink:to="loc_ptnCarryingValueDuringTheYear_ce071e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="000036 - Disclosure - ACCRUED EXPENSES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CostClinicalStudy" xlink:label="loc_ptnCostClinicalStudy_92624e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_ptnCostClinicalStudy_92624e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OtherResearchRelatedExpenses" xlink:label="loc_ptnOtherResearchRelatedExpenses_b577c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_ptnOtherResearchRelatedExpenses_b577c3" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent_5495e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent_5495e4" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PersonalCost" xlink:label="loc_ptnPersonalCost_66c1e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_ptnPersonalCost_66c1e8" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AccruedSellingExpenses" xlink:label="loc_ptnAccruedSellingExpenses_54954e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_ptnAccruedSellingExpenses_54954e" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_9def52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_9def52" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TotaAcrruedLiabilities" xlink:label="loc_ptnTotaAcrruedLiabilities_cc3102" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_7bae82" xlink:to="loc_ptnTotaAcrruedLiabilities_cc3102" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a643fb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_856755" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_a643fb" xlink:to="loc_us-gaapStatementTable_856755" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_a8a708" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_856755" xlink:to="loc_us-gaapStatementLineItems_a8a708" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_2f2242" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_856755" xlink:to="loc_us-gaapPlanNameAxis_2f2242" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_26d43b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_2f2242" xlink:to="loc_us-gaapPlanNameDomain_26d43b" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CurrentMember" xlink:label="loc_ptnCurrentMember_4dff54" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_26d43b" xlink:to="loc_ptnCurrentMember_4dff54" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OneToThreeYearsMember" xlink:label="loc_ptnOneToThreeYearsMember_160d47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_26d43b" xlink:to="loc_ptnOneToThreeYearsMember_160d47" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_FourToFiveYearsMember" xlink:label="loc_ptnFourToFiveYearsMember_02ee01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_26d43b" xlink:to="loc_ptnFourToFiveYearsMember_02ee01" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaapAdvancesOnInventoryPurchases_ae7253" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_a8a708" xlink:to="loc_us-gaapAdvancesOnInventoryPurchases_ae7253" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_84beb4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_184eca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_84beb4" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_184eca" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_e4f697" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_84beb4" xlink:to="loc_us-gaapOtherLongTermDebt_e4f697" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_dd9f55" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e63a13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_dd9f55" xlink:to="loc_us-gaapStatementTable_e63a13" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_bc17d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e63a13" xlink:to="loc_us-gaapStatementLineItems_bc17d6" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_e176f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e63a13" xlink:to="loc_us-gaapPlanNameAxis_e176f5" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_228955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_e176f5" xlink:to="loc_us-gaapPlanNameDomain_228955" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CumulativeFromInceptionMember" xlink:label="loc_ptnCumulativeFromInceptionMember_9c3608" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_228955" xlink:to="loc_ptnCumulativeFromInceptionMember_9c3608" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityGrossProceedsShares" xlink:label="loc_ptnEquityGrossProceedsShares_09bf34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_ptnEquityGrossProceedsShares_09bf34" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_a65c6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_us-gaapProceedsFromOtherEquity_a65c6b" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityFeesShares" xlink:label="loc_ptnEquityFeesShares_b0cdaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_ptnEquityFeesShares_b0cdaa" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_b4b921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_us-gaapProceedsFromFeesReceived_b4b921" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityExpensesShares" xlink:label="loc_ptnEquityExpensesShares_f9639c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_ptnEquityExpensesShares_f9639c" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityExpensesProceeds" xlink:label="loc_ptnEquityExpensesProceeds_d5a373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_ptnEquityExpensesProceeds_d5a373" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityNetProceedsShares" xlink:label="loc_ptnEquityNetProceedsShares_c796ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_ptnEquityNetProceedsShares_c796ee" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityNetProceedsProceeds" xlink:label="loc_ptnEquityNetProceedsProceeds_f117fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_bc17d6" xlink:to="loc_ptnEquityNetProceedsProceeds_f117fe" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_6b7e62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_454c30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_6b7e62" xlink:to="loc_us-gaapStatementTable_454c30" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d7a750" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_454c30" xlink:to="loc_us-gaapStatementLineItems_d7a750" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_0c831f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_454c30" xlink:to="loc_us-gaapPlanNameAxis_0c831f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_7449c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_0c831f" xlink:to="loc_us-gaapPlanNameDomain_7449c7" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:label="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember_58fda1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember_58fda1" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_ptnMayTwoThousandTwentyTwoWarrantsMember_ee5ce3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnMayTwoThousandTwentyTwoWarrantsMember_ee5ce3" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_296da7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_296da7" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember_0dc90d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember_0dc90d" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember_f273b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember_f273b4" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_75d435" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_75d435" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember_f27aae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember_f27aae" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:label="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember_496e93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7449c7" xlink:to="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember_496e93" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock_1daeaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d7a750" xlink:to="loc_ptnSharesOfCommonStock_1daeaf" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="loc_ptnExercisePricePerShareWarrantsOutstanding_62b60f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d7a750" xlink:to="loc_ptnExercisePricePerShareWarrantsOutstanding_62b60f" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_LatestTerminationDate" xlink:label="loc_ptnLatestTerminationDate_3518f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d7a750" xlink:to="loc_ptnLatestTerminationDate_3518f9" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_a0a910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_a0a910" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_06dd40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_06dd40" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_d762bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_d762bb" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_a3facc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_a3facc" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_7ecee3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_7ecee3" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_fdd187" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_fdd187" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_3c01c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_3c01c9" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_ff6c0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_ff6c0c" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_e97962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_e97962" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50f42d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50f42d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_afb589" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_afb589" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38cc07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38cc07" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0009c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0009c0" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_5839f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_5839f9" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="loc_ptnshareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_cd9836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnshareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_cd9836" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_5f9a52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_5f9a52" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_6010a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_6010a8" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a65dbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a65dbc" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_af8c23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_af8c23" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5ebb5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5ebb5d" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_52d9b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_52d9b6" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_caa763" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_caa763" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_526515" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_851fb8" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_526515" order="23" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_9c8ba3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_9c8ba3" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_390bd0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_390bd0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_5564f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_5564f7" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RestrictedStockVestedInPeriod" xlink:label="loc_ptnRestrictedStockVestedInPeriod_b8e773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" xlink:to="loc_ptnRestrictedStockVestedInPeriod_b8e773" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_5cb919" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_5cb919" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_00a4f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_532bac" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_00a4f2" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="000043 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_838aae" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_331ef8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_838aae" xlink:to="loc_us-gaapStatementTable_331ef8" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_daa6ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_331ef8" xlink:to="loc_us-gaapStatementLineItems_daa6ab" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_d55518" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_331ef8" xlink:to="loc_us-gaapAwardTypeAxis_d55518" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6f8fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_d55518" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6f8fc" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_7a0461" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_331ef8" xlink:to="loc_us-gaapStatementClassOfStockAxis_7a0461" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_be49df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_7a0461" xlink:to="loc_us-gaapClassOfStockDomain_be49df" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_b29268" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_331ef8" xlink:to="loc_us-gaapPlanNameAxis_b29268" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_7c67f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_b29268" xlink:to="loc_us-gaapPlanNameDomain_7c67f0" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_9fb9e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_331ef8" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_9fb9e6" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_15e11b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_9fb9e6" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_15e11b" order="60" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember_802d3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c6f8fc" xlink:to="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember_802d3a" order="61" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="loc_ptnConvertibleSeriesAPreferredStocksMember_d6d8da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_be49df" xlink:to="loc_ptnConvertibleSeriesAPreferredStocksMember_d6d8da" order="62" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember_ef76e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_7c67f0" xlink:to="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember_ef76e4" order="63" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockWarrantsMember" xlink:label="loc_ptnStockWarrantsMember_fd6e7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_15e11b" xlink:to="loc_ptnStockWarrantsMember_fd6e7f" order="64" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock_88a142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnSharesOfCommonStock_88a142" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PurchaseOfWarrantShares" xlink:label="loc_ptnPurchaseOfWarrantShares_756cd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnPurchaseOfWarrantShares_756cd5" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_c39e9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_c39e9c" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits_096317" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits_096317" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_dec238" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_dec238" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_20b3f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_20b3f0" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares_edceb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares_edceb8" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockBasedCompensationToStockOptions" xlink:label="loc_ptnStockBasedCompensationToStockOptions_5b1e11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnStockBasedCompensationToStockOptions_5b1e11" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGranted_566c6e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGranted_566c6e" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_287573" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_287573" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun_2f9a2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun_2f9a2f" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_eb77ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapCostsAndExpenses_eb77ad" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_GrossProceeds" xlink:label="loc_ptnGrossProceeds_7a3851" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnGrossProceeds_7a3851" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eed7e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eed7e4" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_37e676" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapSharesIssuedPricePerShare_37e676" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantIssuanceShares" xlink:label="loc_ptnWarrantIssuanceShares_e4d4ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnWarrantIssuanceShares_e4d4ea" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantIssuance" xlink:label="loc_ptnWarrantIssuance_c5f212" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnWarrantIssuance_c5f212" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA_77ea73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA_77ea73" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="loc_ptnDescriptionOfSecuritiesPurchaseAgreement_9c0eb5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnDescriptionOfSecuritiesPurchaseAgreement_9c0eb5" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_2f8bf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_2f8bf6" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AggregateValue" xlink:label="loc_ptnAggregateValue_c65451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnAggregateValue_c65451" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_bc23ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_bc23ea" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare_fe1956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare_fe1956" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaapCashAvailableForDistributions_fe8cbf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapCashAvailableForDistributions_fe8cbf" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CashAvailableForDistributionsAdditional" xlink:label="loc_ptnCashAvailableForDistributionsAdditional_74a41f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnCashAvailableForDistributionsAdditional_74a41f" order="25" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantsToPurchaseShares" xlink:label="loc_ptnWarrantsToPurchaseShares_1f5c1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnWarrantsToPurchaseShares_1f5c1c" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_53cc4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_us-gaapProceedsFromWarrantExercises_53cc4d" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants_8081f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants_8081f8" order="28" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="loc_ptnExercisingHolderReleasedShares_c3bc2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_daa6ab" xlink:to="loc_ptnExercisingHolderReleasedShares_c3bc2b" order="29" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:title="000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_a09321" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_25946f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_a09321" xlink:to="loc_us-gaapStatementTable_25946f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_ae81a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_25946f" xlink:to="loc_us-gaapStatementLineItems_ae81a7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_014d4f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_25946f" xlink:to="loc_us-gaapSubsequentEventTypeAxis_014d4f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_4363d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_014d4f" xlink:to="loc_us-gaapSubsequentEventTypeDomain_4363d2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_684141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_25946f" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_684141" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_11869c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_684141" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_11869c" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_e0e4f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_4363d2" xlink:to="loc_us-gaapSubsequentEventMember_e0e4f5" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_5979f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_11869c" xlink:to="loc_us-gaapPrivatePlacementMember_5979f5" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_f82ff5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ae81a7" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_f82ff5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_d9b21f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ae81a7" xlink:to="loc_us-gaapSaleOfStockPricePerShare_d9b21f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5daadb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ae81a7" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5daadb" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_f00daf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_ae81a7" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_f00daf" order="4" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ptn-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 02/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20241231.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20241231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20241231.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20241231.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20241231.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAccountingPronouncements" xlink:href="ptn-20241231.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20241231.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20241231.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20241231.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20241231.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20241231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20241231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20241231.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEvents" xlink:href="ptn-20241231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20241231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20241231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20241231.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20241231.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20241231.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20241231.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20241231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20241231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20241231.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:href="ptn-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrent" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLongTermDebt" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" order="28" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Consolidated Statements of Operations (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ContingentlyRedeemableWarrantsMember" xlink:label="loc_ptnContingentlyRedeemableWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ptnContingentlyRedeemableWarrantsMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStockMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:label="loc_ptnReclassificationOfContingentlyRedeemableWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnReclassificationOfContingentlyRedeemableWarrants" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="loc_ptnSharesReleasedFromAbeyanceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesReleasedFromAbeyanceShares" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="loc_ptnSharesReleasedFromAbeyanceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesReleasedFromAbeyanceAmount" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantExercisesShares" xlink:label="loc_ptnWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantExercisesShares" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantExercisesAmount" xlink:label="loc_ptnWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantExercisesAmount" order="16" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Consolidated Statements of Cash Flows (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="000008 - Disclosure - BASIS OF PRESENTATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAccountingPronouncements" xlink:title="000010 - Disclosure - New Accounting Pronouncements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="000011 - Disclosure - ASSET PURCHASE AGREEMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="000013 - Disclosure - AGREEMENT WITH FOSUN" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="000014 - Disclosure - AGREEMENT WITH KWANGDONG" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="000016 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="000017 - Disclosure - ACCRUED EXPENSES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="000018 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="000019 - Disclosure - STOCKHOLDERS DEFICIENCY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="000025 - Disclosure - ACCRUED EXPENSES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="000027 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="000028 - Disclosure - ORGANIZATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SalesBasedMilestonePayments" xlink:label="loc_ptnSalesBasedMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSalesBasedMilestonePayments" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_RevenuesGross" xlink:label="loc_ptnRevenuesGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnRevenuesGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="loc_ptnProductSalesAllowancesAndAccruals" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnProductSalesAllowancesAndAccruals" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="000031 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="000032 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="000033 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="000034 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" order="23" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CarryingValueDuringTheYear" xlink:label="loc_ptnCarryingValueDuringTheYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnCarryingValueDuringTheYear" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="000036 - Disclosure - ACCRUED EXPENSES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CurrentMember" xlink:label="loc_ptnCurrentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnCurrentMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OneToThreeYearsMember" xlink:label="loc_ptnOneToThreeYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOneToThreeYearsMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_FourToFiveYearsMember" xlink:label="loc_ptnFourToFiveYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnFourToFiveYearsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaapAdvancesOnInventoryPurchases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvancesOnInventoryPurchases" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CumulativeFromInceptionMember" xlink:label="loc_ptnCumulativeFromInceptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnCumulativeFromInceptionMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityGrossProceedsShares" xlink:label="loc_ptnEquityGrossProceedsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityGrossProceedsShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityFeesShares" xlink:label="loc_ptnEquityFeesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityFeesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityExpensesShares" xlink:label="loc_ptnEquityExpensesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityExpensesShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityExpensesProceeds" xlink:label="loc_ptnEquityExpensesProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityExpensesProceeds" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityNetProceedsShares" xlink:label="loc_ptnEquityNetProceedsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityNetProceedsShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_EquityNetProceedsProceeds" xlink:label="loc_ptnEquityNetProceedsProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityNetProceedsProceeds" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:label="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_ptnMayTwoThousandTwentyTwoWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnMayTwoThousandTwentyTwoWarrantsMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:label="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesOfCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="loc_ptnExercisePricePerShareWarrantsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnExercisePricePerShareWarrantsOutstanding" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_LatestTerminationDate" xlink:label="loc_ptnLatestTerminationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnLatestTerminationDate" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="000043 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="loc_ptnConvertibleSeriesAPreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnConvertibleSeriesAPreferredStocksMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockWarrantsMember" xlink:label="loc_ptnStockWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ptnStockWarrantsMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesOfCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PurchaseOfWarrantShares" xlink:label="loc_ptnPurchaseOfWarrantShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnPurchaseOfWarrantShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_StockBasedCompensationToStockOptions" xlink:label="loc_ptnStockBasedCompensationToStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockBasedCompensationToStockOptions" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGranted" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_GrossProceeds" xlink:label="loc_ptnGrossProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnGrossProceeds" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantIssuanceShares" xlink:label="loc_ptnWarrantIssuanceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantIssuanceShares" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantIssuance" xlink:label="loc_ptnWarrantIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantIssuance" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="loc_ptnDescriptionOfSecuritiesPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfSecuritiesPurchaseAgreement" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_AggregateValue" xlink:label="loc_ptnAggregateValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnAggregateValue" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaapCashAvailableForDistributions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAvailableForDistributions" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_CashAvailableForDistributionsAdditional" xlink:label="loc_ptnCashAvailableForDistributionsAdditional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnCashAvailableForDistributionsAdditional" order="25" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_WarrantsToPurchaseShares" xlink:label="loc_ptnWarrantsToPurchaseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantsToPurchaseShares" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" order="27" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants" order="28" />
    <link:loc xlink:type="locator" xlink:href="ptn-20241231.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="loc_ptnExercisingHolderReleasedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnExercisingHolderReleasedShares" order="29" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:title="000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="4" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ptn_10qimg17.jpg
<TEXT>
begin 644 ptn_10qimg17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !< FX# 2(  A$! Q$!_\0
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M#U%8NG^#?%6BZA:ZG9C2;F6*XU.-[6>601O;WEPD^[?L9O,0H%(P0XR21Q@
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M   RJ%Y9#\RLKJ<J"#T-7[BS\2MK%J8X-.NK"TV"W>YNI!(&QM>5E$9#-@D
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M84"L2V\$^(/M+S736"^9>Z;>OBXDE;-OCS!DH,YV_+C &<8&.0#KIO$VCKI
MU2#5+:6"02"%Q)E9&3.X<9/&UL\<8.>E5/#?B"\\1?#[1?%%KIJ"YU6P@O%M
M#/A$,B*VTR8Z#/7;GC@=JYFS\"^(-)UVUUBRN-/N)$DUF.2WD=XU\J^NUN5=
M6"GYT,:JPQALDY&,'I/"VBZMX5^&.@>'?+M+^_TRPM[*0-*T<4NQ%1B&V$]
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M"YCST!&[GC<M_#.K?VGI6H7MY8_:+)IY)4M+0PQ.9(P@VC<2,8R22Q/3@8H
MFA\66.J7<NG:"3=SMI<6J6UR8W:VECEW^40RCY@?+)XYZ=S6C9Z]'ML[/55%
MOK#P0/=6L&Z5;=Y,@ L!P"RN 3C.VN?\'^!;KPBVD*NJI=Q66@VFB2CR2AD-
MN7VR+\QV[O,.0<XP,&K6K>%[C4?%]GKD-PEA+:O"5N+962=XT9C)!(<[98G!
MQM8'9DLOS8*@#?$OBZZT/Q;HVA*UC;0:C8WET]Y>.52$P&$!3R/O>=USQM[U
M-HWC2WNO!.E>(M>L9M$N+RT-W)8R([R0JHRYQM#;0,')4'##(!.*B\3^![7Q
M3XHTS4-3:*?3;;3[W3KBQEB+"X2Y\K)W9^7;Y/H<[NHQ67+X*\1>?H&H-XFM
M;W5-&AN+ SZC8F5+RVE9"#(H=<3#R8OWBD!CO^4;@% -H^//"?VN.!=:C?S9
M((UE2-VAS. 8<R!=@#[AM).&) !R<5=_X2G0VNA;C4 ')F5"$8K*T.?-5&QA
MF7#949/RMQ\IQR7_  CFH:MKWB329F\G3'N-/9YGMRIF$*1LWE]$P2@4X^[S
MCG&+L/@.9/[,M9M4\VTT>_N]0L"8\2!ITF0)(<X*H+B0#&"<)GH=P!;L_B-X
M9U"]L8;"XN);:[MY;I+PVTD<'E(D;EP[* RXE0[AD=>>#716.J6NI(\EHTA1
M" V^)H^JA@?F R"&!R/Z&N4L_!.I6MCX5CBU:U>YT+2)=*=I+4M'.'CB7S F
M[CF%3M)(PQ'H:T/#/A9?#^EW^FI,%L+AAY%C"6\FS3RPI2+<254D%@HX7. .
M* )Y/''A6WMY[N?5DB@ALWU$R-&X5[9" \R<?.BY7++D ,IZ,";NEZYINM37
M<>GW#226<@CF5XGC9"5#+PP!(*L"".#7#7/PIFNO \'A6768\6'AZ[\.V-S]
MGRPBF1(Q)(,\LJ1(, @,<GC@#L]+T6?3]<U?5)KJ.1=06 ! A!C\M-IR<\YZ
M]L4 8VE^.(9KO7%UI8[*/3]<.BV[1*\AN&\J.120 <$^81C_ &>O.*NP^-M!
MNM2TNSLYI)UU&&ZG6=8V$<0MW6.8.2/E97<*0<$$'.,5FVO@.^MKZ_N#JD+?
M:_$:Z[M\AAL40I'Y6=W)^3.[WQCO5&+X8NL4<$VJAX6&M17"I$4+1:C<"=MI
MW95TP%!Z'DX!Q@ Z*7QSX8@W+-JGER1M"K1F&3?^^SY)"[<D.58*<8)! Y&*
M6S\:>&+R]BL;?4)#<27"VNR2VECV3-$)EC?<HV,8R& ;!/UK+L_"/B#^S-.M
M]4UC39KFQO+><36NG&W$T<3$_.-Y^=@<$@[0>0O.*E'@FZ76=2U#^THRM]K\
M&L[#"<H([:*#R\[N2?*#;NV<8XS0!#XH\?6>G^"?$>M:!)#=WNDZ7+J<44\;
MA)44/A@>-RDHPR#_ $SL>*/$?_"/P:8L5O\ :]0U>]BT^R@SM5I7!8LQ[*B(
M[GOA2!DD"N/NOA?K5]H.LZ;>^)HIY]6T.71Y[TV9\V1V9R+AOGP3ASE1@< +
MM'%=CXH\,_\ "2:;8>7<"RU/3+N._L;H1^8L4Z CE21N1E9T89!*L<$'! !-
M)J&H:7.\VM2V:Z8(5(N8PRMYQ<*(]A+9W%AMP22>,=,P-XQ\-1ND;:@1,]XU
M@(!!(91<+&93$4"[@WEC> 1RN",@BJVO^&=4\3:0+._U*"UN(+FVO;9K>$E%
MG@F29&<,<LI:, J"."><X(HR> YIO%-GXC:_CCN4UC^U[B-8CM?%@]FL:G((
M^5]Q8Y)(Q@#& #0'CK0&N;;RI9I+2XTV351=K YC6%&4'/&0?FY&,C'-3+XT
M\--8M?+?2>0$>9G-M*,1( 6EP5SY8W#Y_N\\&N?7X>ZC'906L>LVQ7^R+[2Y
MB;9OF\^0.KK\_&W!!!SG/45HR>$K^/4H=2LM2B2X?2!I-TLL3-&X4DQR*-W!
M4M)D?Q!N3P* -#3-:N+_ ,;ZSH_^CR6-I96=W;S19+/YQF!R<X(_=*01ZFLZ
MQ\3:IX@AUS4/#]K;/;Z;=3V4"W+,IO9825D^8?ZM=X9 <-G:6QC&9O"_@R+P
MIJ4IM+H-IRZ58:5;0,AWQI:B0!F?/S9$@[#&WJ<\&G^%+S1!K=GH.I1V]IJE
MU+>JLT6]K.67F4I@C<I?<X#=&9N2,  #]!\?>&_$>A6VK6=T\8DT^WU-H)$/
MF10S9\LD '.2KK\N>5(JW=^+/#=G>"TNM32&5O.V HV)&B4M*J'&&95!)49.
M%;CY3C&M_ASI6G7GA-M)NI[*S\/6OV$VX.X7D "F-9">I61$D!ZY!'1B##9^
M!]3LCK6GQZM9/IM_+>3V_F6.;J![DNSJTN_YD#R.1A5.-JYP,D Z"'Q)8W_A
MZ\U;16:XB@B9T>6&2-9"$#@C< 64@CYAD>]<WIGCZXU3X<1>+I-0TG38Y-"C
MU6=G22<:>TL8=/,56!=!\^<%3\G;/'71Z7<+X371&GC,HL_LIF"D*3LV[L9S
M[XS^-<U_P@+?\*8_X5VFH1K<?V$FB'4?L_4+#Y0D*;L^K;=W?K0!MR>+/#\>
MN-I+ZGMO([E+.1?)DVI,Z!T1FQM!92,9/.0!S4$GC+PS;VMU<3:H(X+:)IY)
M&C<+Y:OY;../F4,,$C('T(K/N?!-]<ZCJ5T=4A O=9LM5">0Q\L6Z0J8\[N2
MQASNXQNZ''.+/\-]>N?M8N_$EO-)=6,]C+</9MYLN^=9$D8^9C( V[0 /3:.
M* .W@\4:'<";R;XL\-U]A>'RG$HGV"39L(W$^60_3[OS=.:I+XNTF2X%PNL6
MXTW^SQ>[&MY!+M+[0^3QC/R[-N[/Y5BW_@75W\07>O:7K4-O?MK,>K6ZR6S/
M$@%DMI)#( X+!D#,&!4JQ7@@'-W5O">NZA+->P^(EMKZ73?L1GCMR/G\X2$@
M!LA" 4P#N .0V>: 'ZAXPC75O#-KI;1SQZGK$NDW?F(R20,EK/,>#C#9A4<C
MD-D=J/$GBVYT/Q;HV@J;&WAU&RO+M[R\<JD)@,("GD?>\[KGC;WJA:^ ;Z'4
M],NI-3M5CL-?DUI(8+5D!5[22W,7WST,I;=[8QSFKGB;P3:^)_%6F:EJ313:
M;;:?>Z=<6,L1;[0ESY63NS\NWR?0_>ZC% %G1?&EO=>#-*\1:]93:+/>V9NY
M+*5'>2%5&7.-H;: 0<E0<$9 )Q3CX\\)_:HX%UJ-_-D@B65(W:',X!AS(%V
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ME]'=6(ESY;NR20'</+;$K@AMX/R'J#N;<>"]0D\/SV,.K01W!UY=9BD>W8H
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M!@=R,<EAT6S^'MU;MI,<VK0R0:9K^H:RH6!E:1+I;H&(G=P5^UM\PZ[!P,\
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ME>7WV>2P%N=ZP>6Q,HDW<,K $Y&W!V]2#5BQ\.:M8VMS%_PE=Y++-&^)FMH
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M,/NE#R< Y7!.:JV_Q&TJ;4+Q?)N8K&#3["^CN9DV-,;N22.*(1L0P<O&%VD
M[FQQ4K> _*TO2+>Q\07ME?:3<2S6][''&6*RLQ>)T*E60[L= ?E4YR,U%JGP
MZL=8N]0NKK6K\27UG96[R+LWI-:3O/!<*=N ZR2$D$%3@ C&00#H=*UVSU2Z
MU*SMXYH;G3)A#=6\R89"R!U(QD,I5@05)'4=00,)OB)X?CMKJ62WU"-[2&UN
M9(6M2)1'<2-'$2G56W*048!UXRHR*V-.T4V5YJ5])<-/>Z@4\Z8*$P$3:JJ!
MT Y/4\L?I7+VGPLAM;8PMXAU"?=8V5@SR)&6<6L[31R,=OS2,SMO8_>SG@T
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M:#IJ#%0C&WF?]T>AWF,%A@<B-_3G1\=:UJFF_#>]UC3FDTV_1(77<JNT1:1
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MQPWU@NF7T8DRM[ K.P63())S++EA@D2-D],3S>#])G@UNU+721ZO=1WT[)(
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M(3B,'"O\RD'=_>9NE87BSQ--I?BBXAO[V;3M&TW1I-7GGM&!E/ER+GY2IW#
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MX!'))W'C@9FL/'6I:L?[-M]!CBUV&.[:YM9+K]TK6\HBPD@7+!V8%6VC ^\
M>*O:EX/C^Q:78:/&+2TMM8.JSYG<,69I'D*'D[FDD+8X')]<5>_X0_0]\$BV
MC0S6XG6.>*5TE(G;=,&<'+;V 8Y_B /4 T <W:_$>\UA#J&BZ# =*72;35WN
M;V_%NPBN(Y61=I0@,&C ;+ 8;()(Q1_PG6I7&NZ)86NGQ0+/K\VD732LPW*E
MA)=!T!4$9VJ/F&>O8YKH[CP3X;N;34+-].V6]_:16,T<4KQJ(8L^4J;2-FW<
M<%<$9Z\"HH_ _A^*]6Z6WN6N5OQJ:RO>3,PN!#Y)<$MQF/*D#@Y.1S0!B+\2
M';2K'7ET&9M)U6"V?3[OS %>6XFCBAB<$94MYJ-N4,  V>@W6/!5UJ5QXG^(
M%OJ$SR?9M:CBCB$[R)"AL+5MJ;ON@EF; P 6/UJT/AWX173M0TLZ;,UA?-N:
MW:\F:.W.X.# "^(,.%8>7MPR@C! K9T7PWIOA^XU&XT^.?SM2F6XNI)[B29I
M9%C6,,2Y./DC0<>E 'G/A?QAXDL/"&C02Z&VL37MA=SV,WVXM+=30DMY,FY?
MD+K]ULL,C#8XSZ%X=\16_B.T^WZ;MFTYHX9(K@-GS"Z!R,8XP&7\21QBJZ^&
M;?1;$_\ "-6=N;VVC=+**[F?RH0[!F4'#%%)'8'H!T&*TO#^CV^@Z)%I]O'#
M&=\D\ODIL1I9':21@.P+LQ_&@#C=/^(E]>7,/VC0X+:*]U:ZT:Q*73RO+/;2
M7(E9E$8VILMF8')))Q@8R<O6?$VJ7/B/1H=>M;G1-,.@:IJ-_9I=%9D>WFMU
M$BR1G/"LY7D9#_, 1@=G<^!_#5UH;Z-)9RI:F]?45,5S+%+%<O(TCRQR*P=&
M+.Y^4C[S#H2*FC\*Z)%>6MY]C,EQ:VLMG&\LK.3%*RM*K;B=Y8HI);))'6@#
M$O?&6M6=LMTWAEF6>>Q@MG:Y")*;F01D9*[@8R5+<8(8;23D5+9^+=7NKA(X
M_#8DDAN/L>H-!<[H[640^8S!V5=\8<JG #'=NVXJQ8> ?#.FZ3%I=G9W"64,
M\5Q#&]Y-((3$^^)4W,2B(P!"#"CIC%6X_">@_P#"276O1V\T5_=A3<"*YE2*
M5PNU9&B#;#(%  <KNPJ\\# !RVE_%":ZT2RUC4=%2S@U'3=.O[()=>86:\E$
M*1/\@VX=X_F&>&/ISLWOBS5;/4QH;:+'+K4D-U=6\$5P62>&$Q#=NVY0LTR+
M@CCDY(QFS_P@/A231UTG^S,V*:>FE+"97*K;(<H@YX*G!#?>! YXJ*?P#X;N
M(;&&:.^,MA(9(;P:E<+=98!6#3A_,8$!059B#M7C@8 '>)M::T\':;JE[I=W
M";J^TV*2T^UF":W>:ZAC 9XB0VQG&Y02K@%<D'FE%X\O6\066FRZ$D<-]JEY
MI,,ZW)8B6"*24,R[!A&6%QP20<<$'-=+J&@Z7J>GP:?>6H:V@DAECB5B@5X7
M62(\'^%D4CZ557POH:7=M="Q8S6M[+J,+&5SLGE1TD?KW61QCI\QP* .1\,_
M$35-:\(Z7=#2[>ZUF7P]!KUU;I,8UV2AMB)E3\S%)!SP-HR>:ZG_ (22&;PK
MI7B#3(_-M]5$#P_:&,1"2J&4[<%BV"/D ))_$U'!X%\,V=C9V=I8R006MJUC
M$$N) 1;-C,.=V2G PO;'&*T-2T#2]6MK&&\M3MTZ=+BU,3M$UO(JE04*D$?*
MS+[AB.AH XJ\^*%U:^')M>7PZ&@M=%?6KA&NMKJD;E9(U&SEL*2,XST.VNC7
MQ5)_PD][H+:>%O8Y+9K93*<7-O*"3-]WC;Y<H*\\H.1O%,7P#X772[G2_P"S
MY'LKFSDT^6%[F5@UO(Q9H^6R 2QZ=!P*M6NBW3^*FUO5(++-E"]GI\D6YI?)
M<HTAD9@,$F-1@9'&<\X !E>-KS4!XJ\%:+;R^78:MJ$\%XJRM&\B+9SR !EY
M7#*K9!!RHK$\.ZI)=7'A,67VVWB75M8L9(I]2FNC,8'GCW.[\L"T>X CY<@#
M@5Z!>:-I^I:EIFH7MN9+K2Y7FM'WD>4[1M&QP#@Y1V'.>IJC:^%-"L9;62UM
M'C:TN;B[AQ,_RRSLS3-UYW%W// W'&* .*M_B%-I/@FUOK70VFMK?P[)KCI<
M:D\LH2(C?'YCJ6=L'AF/)'.*Z6X\;3+XADTJWT>20QWMM9X=]KR+-$)//1<'
M,:Y*D^J2?W>;1\!^%VTMM+;37:R;3I-):)IY"#:O]^/[V>?7K[UGMX2U0^*+
MN_BO'MXY9(FAG@U&="B(BKM>WYCD/RGYB><\CCD NZYXL;1_$MKHOV'SS<Z7
M>ZDLOF;0OV<Q H1@_>\X<]MIXKG#\2+YY3+#H:-;QV>E7TS-=X81WLC1X4;.
M63:3U (]ZZ[6O#6EZ]=6]QJ5L[S6\<T"21S/$WE2@"1"5()5MJY'3*J>U1?\
M(/X9598UL7"2V]K:OB>3)BMF+P+G=GY69C[Y.<T <=KGBZ\U+7_!U]8R26ND
MIXGO-/F9)W5KC[/:WBR!T  *>9"Q )/W%/?C2O/B!JEKH]OJR^&)'L[QM.%K
M,]P(UD:[N%A\L\$AD\Q&)QM(;@Y%:?\ P@?AE=:35H[.=98[]M46-;J40K<O
M&T;R"/=L!97?=Q@EB2,DFI;7P#X7L=-&EP6,PLEGBN(H'O)G2W:*02QK$&8^
M6BNJL$7"C:!C  H 9KVM^(-+T#1[K[+8P:E=:A96EU$)FEBC$LRHX1]JENI
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M6\MJUY;V^N6T*N]VT?V6)K*T=RG]T N[X!&236S;^++I?'VH>%;R"WC$%O\
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M9>^&O#4 L?#\7A[3UTQGU&86XA&U'C+;&7T*X&,=,<8J>SL]/O/CGK.AS:?
M;"ST+3Q%$ 0H'VFZ^4C."/D7@C'% '2^$M6U35M5\6+J$Z/;V6J+;VL8B*-%
M&;2WEVMR<G,K9K \+^--8U!M.T6ZFM9-5U&XUIX[AX2(DAL[TP!-H?)8[X^_
M16SSC/;VNGV%I=7NIVMG%#=WLJ-<RHN#,RJ%#-ZG:JC/HH]!4,7A7PZ&,::1
M;QA9VU!2B[2D\F[S)%(Y4MELXQG<V>IH YR^\5ZM>?" ^*+*--+U*2W5F1OW
MRQ/Y@1PI^7<,YVMCD8..U9<.M:AH/C?Q$\:PS6MWXAL+*='+[@TUI NZ/G"
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M@  @\<BM75O&6N:#J"6M]'I=Y(D^GI-':M)NC2[O/LZEPW^KP""I^8R,KC"
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@ .BHJE9V5KI]I!864*P6UO&(XHTX"*HP /8"KM '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ptn_10qimg18.jpg
<TEXT>
begin 644 ptn_10qimg18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  ^ 0<# 2(  A$! Q$!_\0
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M<E PZ?0^GMTKPOXZ:/)HNE>&%L9CYL-U-)'*HP5(5,'ZY H56GB)*GRJ+?\
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)%00%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ptn_10qimg16.jpg
<TEXT>
begin 644 ptn_10qimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %# FL# 2(  A$! Q$!_\0
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MWN/#C#==6Z F1OE2%LCYSM.<_=VXRO7.:/;U']L7U"@K\T'\CHO^%JZE_P!
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MM2_Z!,/_ '\;_"O.J*/K=;^8G^Q<+_+^)Z)_PM;4O^@5#_W\;_"C_A:VI?\
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M^<@@]WZ?\%SIL.GK;ZXBW%I<22O=F&222Y5X]AW*\C('(QEE Z9&#4_5Z?\
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MXT)N%A%P2S1AMI8>P8@?C6+<?!5[C5%O&\2!/W[S[UM/WMN6>X;; ^_]V/\
M2.>#DQJ:T?"/P[NO"VO:&T+6YLM-L[M))8FDW7$TQA'*NS$#$.XX.,G@#FG]
M7I_RHKZ]B/YW]YK_ /"M?#?_ #SG_P"_[4?\*U\-_P#/.?\ [_-7;X(_AHI>
MPI_RHKZ]B/YW]YQ'_"MO#?\ SSG_ ._S4?\ "M?#?_/.?_O\U=O11["G_*@^
MO8C^=_></_PK;P]_SPF_\"&I/^%:^&\D>3<?^!#5W'S>M9.I,[R0V:L46;)D
M*G!VCL/J2/PI.A37V4$<;B).W._O9R3>!_!L;E&DDW X(%PQQ^52?\(3X._Y
MZ-_W_:NLCCCB01QH$4<  8 I:GV-/^5?<='UNO\ SR^\Y'_A"?!?_/23_O\
MM1_PA/@O_GI)_P!_VKKZ*/8T_P"5?<'UNO\ SR^\Y#_A"?!?_/23_O\ M2?\
M(3X,_P">DG_?]J["N<O?%NFV'B^U\-SPRB6>$RM<\>5$=K,J-SG<RQN1Q_#5
M+#P>T5]P?6Z_\\OO*/\ PA/@_P#YZ2?]_P!J/^$)\'_\])/^_P"U78O&WA>:
M%9EU,")K5KW>T+JH@!(\PDCA20<$]>U-TCQKH>O:^-)TEI;K-J;K[0L3"(8D
M*%"2.&!'>J^KQ_D7W$?6ZW\[^\J?\(3X-_YZ2?\ ?]J;_P (5X+_ .>C_P#?
MYJ?9_$+P]/IL^HWTC:;;Q71M3Y_+JP)'SJN3'TZ-C@BGZ;X]T&]N+:QN[J*R
MU"ZN)8(;8L6+[)7C4Y P-Q0XS1]67\B^X?UJM_._O(O^$)\&_P#/27_O^U._
MX0GP;_?D_P"_S4J^/-'BU?6+/4=UE%IUQ]G61HY&:4K&'D? 7A%##+9([G (
MS9O/&6BV_AC5-?M6DOK736*2^6I0,X;:55FP#@]2#@4OJL?Y%]P?6ZO\TOO*
MG_"$^"_^>LO_ '_:@^"?!>/]9)_W_:J]S\1M-M6OUN-/D\RQL?MSK'<1.)5]
M(CG$@[%EX!X-6;GQO9V6AZUJ%YIMQ!<:-)''=6A="P,FTH5<':5(<'/;!I_5
M%_*A_7*W\\OO#_A"?!G_ #TD_P"_[4?\(3X,_P">DG_?]JAL_B1HD]L+V\'V
M&T,'FJ6)DD<^8Z?*J*=RGRR0P/(["HI?B?H-O;:Q/-!<'^SW_=1QQ.6NH]D;
M[ERH .)1E2<@<T_JJ_E7W!];K?SR^\M_\(3X,_YZ2?\ ?]J/^$)\&?\ /23_
M +_M6D_BK2/[,UB^MVFN5T=':Z1(7#*RKN*#(&6QU';O3-/\7Z#J%Q96L=R\
M5U>(C)#+$RE69/,$9)& ^WG;G..>E+ZO'^5?<'URO_/+[RC_ ,(3X,_Y[2_]
M_FH_X0GP9_SVE_[_ #59A\8Z?(+NZ>UGBTV"Y:R2\(#">=7V%$C7+D[L@<<X
M-+_PG7A/R)KC^V(S##$DLD@C?:@<X0$X^\3QMZ^U'U:/\J^X7URO_/+[RM_P
MA/@S_GI)_P!_VI/^$)\%_P#/23_O^U0'XE>'VO5AM8;V\B>6UBCN8+=FC?S]
MVU@<=!M.>_IT-:(\;>';C0]8U;3+U=1BTB)I;A(/O8 )&,X!SM.#TXI?54OL
MK[@^N5_YY?>4?^$)\'_\])/^_P"U'_"$^#O[\G_?]J</B%X?M4F77F.B7,+(
MK0W#!\ATWJRE,@KMSD]L'-7+OQUX2L87FN]9CBB65H?,,;[69<[MIQA@N#DC
M(&.:?U9?R+[B?K=7^9_>4?\ A"?!_P#?E_[_ +4?\(3X/_OR_P#?]JN_\)YX
M3^VFS_M8>:)/*SY,FW=O$9^;;C&\A<YQDCUK/T_XE>&9]!34M3O%TR3 \RWE
M5BRY+@;?E&\?(W*Y'!]*?U5?R+[A_6JW\S^\F_X0GP7_ ,]9/^_[4G_"$^"?
M^>DG_?\ :MO3_$&DZL+S^R)FOVM"%D\I"%+%0P4,0%)((/![BN9@^)>ES;,Z
M7>+ME,5R<H5@_P!(^SAL@_.IDX!7/ )[5*PT7]E?<5];K?SR^\N_\(3X-_YZ
M2_\ ?]J3_A"?!G_/23_O^U5K[XB6.FVNK376CW:'2KM+2=0\9R74."I!P3AA
ME>H/6NX&" 1T(S2>'C'>*^X/K=;^>7WG(_\ "$^"_P#GI)_W_:C_ (0GP7_S
MTD_[_M77X%&!4^QI_P J^X?UJM_/+[SCO^$)\'_\])/^_P"U-_X0GP;_ ,]7
M'UN&%=G11[&G_*ON%]:K?SO[SF4^'?A611)&LSJ>0RW!(-=#X=\.Z;X?AFCT
M]'196#-OD+\XQWJ*,?8]1B:'Y8KAMDB#INP2& ]>,&NACW;#BM:=."=XQLSC
MQ&)K3CRSFVGW8GG/ZC\J/.?U'Y5Q'B#QU%H.MW6F2:?YS0)8NK><%,@N;AH3
MA<?P;=WOTXZU5MOBEX?O]$CU73[+4;I'OK6Q\KRE213<!3&^&;&TAP>N?:M=
M3D]T]!\Y_4?E1YS^H_*O-Y_B38WGA76=6\+V-SJ5SIPB*P2H8Q(DA(248RS)
M@,V -Y"GC.*BN?B=+'!<R6.DP:C'#I]EJ27%O<.\;PSNRO+M6,R*B!2WW22.
MPHU#W3TWSG]1^5'G/ZC\J\YL/B=;S:UJMK?Z1+:Z?8Z6VKQ7T;-(MU;J$)=!
MM&5._P"7!).TY"GBL^Z^,GA^.QN);>QOOM$(8^1=PF'S"H?(!&[D,F#GCD4:
MA[IZMYS^H_*CSG]1^5>5VGQDT%H[EM1LY[9X6;$, ,SE5:;<_0# 6!F/.?8\
M9U4^*'AVZL-:N[-;DC28O.<SPE%E3S6BW(1DD;T8=.U&H>Z=_P"<_J/RH\Y_
M4?E7!V_Q-\.76DZIJ44=_P"3IKQ)(K6^'D\V0Q1E!GD%U89R.E8]U\9O"<.G
M2WEK;ZG>[(]WEQP!27 !:++, '"G<>V!U)IZA[IZIYS^H_*CSG]1^5>:2?&3
MP?'+>1[=2D:SG>WEV69(#(KM(0<X(41OGOQT.1F*7XR>&[2&]NM0M;RRMK3S
M=QD5"[[)C$64!L$$J3C.[_9I:A[IZAYS^H_*CSG]1^5<):_$?1Y-'TW5+R&:
MWAU/4+BP@=<,@,;NH9W;:$#!,@'G)P,USB_'3P:TCR%;O[&%55=(]\KS%W4Q
MA%R" L9;<&.0>.:-0]T]>\Y_4?E1YS^H_*N(/Q%\/C1KW55COWCL[]=->$6^
M)FF8@+A"00#N!!;''/2L-OC)X=D^PR6=O<-'<R1K(+E#"\4;-#^\Q@Y&R=6Q
MG)Z4:A[IZGYLGJ/RH\V3U'Y5Y7)\;/"?]CQZE9V>K7:2Q/+$@MA%Y@5E!VEV
M 8X<-@$\=<5<O?BYX5L;JXM9(M1>:!W3;':[M_E^8)"OS=$,4@.<<KQD<T]0
M]T](\Y_4?E1YS^H_*O.(?BUX-NKZ2UM9+V8)>1V)F%N1#YCDJ#O8A0,J1S@Y
MQ@'(KT/H<4M1VB2>:_M^5'FO[?E4=%%Q\J)HY'9P"1BK&*IQ?ZQ:N52,IJS*
MLWWE^E>2:G#\0-+U34=<AO)7T^UGOKJ*U:,',:JC("Q<Y#A751M&TG-5/B]\
M5-<\ ^(=/T[2]/L+F*XM3,S7(?(.XC VL..*XF;XZ?$>WADFN/"-C;QQQB5F
MF@FCPA(4-RPR,D#CUKKAA:E2*E%:,UC&Z1WJZU\2I[ZZBM8[F66*W222,VD(
MBB\R$/A6."TRE@H4_*<<TZ34OBJM] MK8W,EM]DG.^X@@#.?WAB9@,!)1B,%
M<[26Z#FO-5_:.\8R2)''H>CN[G:JJLI+$]@-_-377[0GCJQDCCO/#NDV[RH)
M$61902I)&<;_ &/Y5K]1J]OQ'R,]0>+QU-J3O8W6K2QN(I;9M1MX$6$B"8-N
M"!<,9!&".1ALCVL:#>?$:Y\864FMPBQT>>W\]K7[*K^6S;CY;RJ?E9/D'<-S
MUZCR6U_:&\<WUPMO8^'-+NIFSMCABF=CCDX ;-,F_:+\:6T[P7&@:3#,APT<
MB2JRGT(+<4?4:O;\0Y&>C6J_$33KB*VTN&]AT]M2=I[R]@^T3S*=IPT?F$*O
MWQO0@'"G YS>M]4^)<3E;S2[B8RS&.(QPPX2/S8BCN<\$Q>;NZ@/P.U>51_M
M&>,IIDAAT'2))7;:J(DI9CZ !^32-^TAXO1F5]%T964X8%900??YZ7U&IV_$
M.1GKGAB;QY?:Y)-XBM;BWMHFNEAWA$^5ECV!MN ^&# -@5@6</Q$TW0H#X?M
M=2T]'6UCNQJ*F\F$P1_.ECC9R=A;RP>>>2 .M<#_ ,-)>+L_\@?1?RE_^+I/
M^&D?%W_0&T7\I/\ XNI^IU.P<C/69I/B%<7TP@2Y7R[J6..\:VC0)$QCP4C/
M8#?RQ;)&>.E6+?\ X3RZTOQE:ZM)*[B&6/38X;<1,?OA6252 Y9=A[$,3TZ#
MR6W_ &AO'-Y<I;6GAW2[B=_NQ113.S?0!LFF3?M&>-+>>2"XT'2(98SM>.1)
M593Z$%\BJ^HU>WXAR,]$6'QMI]M=7&BV.J6MC@FSM[@">Y3_ %(=/G9M@=A*
M06W;1SC'%:=O-\1IM=:WD^TV5FUT!,[6\!6&/>VT1-SO!C"[V8$ACQZ5Y+_P
MTEXN!P='T7/TE_\ BZ/^&DO%W_0(T7\I?_BZ/[/K=OQ#D9Z&DWQ66\DN8_MD
M'VBXA2X>>SCE$057W+%&C<Q;BHW_ 'B,<]Z]%\.+KG]E/)KT[27DEQ,P0HB"
M*/S&$:C;U&P*<G)Y_"OG<?M(>+B1C1]&.?19?_BZ/^&CO&'_ $!M&_[YE_\
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M\0R1GN#@U-;:#X;M="O-"A,HTV[1HGMS(Q5$;.53NHY->(G]I#QAC_D#:/\
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MRI4YXY^4D?0D4DOAGPW<>;Y_A[39?.;?)OM(SO;.<G(Y.:^<_P#AI#QA_P!
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M'@OI)()?.6.-%++&JR%MO7)&0,#!.>^*XROLC_A1WPT_Z ,G_@7+_P#%4?\
M"COAI_T 9/\ P+E_^*K>&94HJR3*56*/C>MF\_Y$[1O^OBZ_FE?5_P#PH[X:
M_P#0!D_\"Y?_ (JG2?![X>BWBLFT-G@A+/&C7,AVEL;N_? IO,Z;:T8>U1\@
M:;=+8ZQ8WTBLR6]Q',P7J0K X'OQ7=-\1[>ZO?,U'1XY[9-16:.$1KQ; R-Y
M9+$G<7<,><$CTKW[_A3/PV_Z%W_R8D_QH_X4S\-O^A=_\F)/\:SGCJ,]TP]I
M%G@'_"=Z2LXN%L'CF$D[2&VM8H5N/,A,:LWS,5*Y/ )!R3UXJS_PL#PWYR ^
M'3]G67SMGDPYW><&Z_[F5QTYKW;_ (4S\-O^A=_\F)/\:/\ A3/PV_Z%W_R8
MD_QI?7*79BYXG@5GXV\+P-<-<:+/(DEBEK'!Y,7EPD1E6 Y!(+8?<<D'(QWK
MC?$6IQZUXGU#5H8WCCNI?,59,;AP!SCZ5]7_ /"F?AM_T+O_ ),2?XT?\*9^
M&W_0N_\ DQ)_C3CCJ<7S),:J11\JZ1_R!_$7_7DG_I3#6-7V5!\'?AZL<\$>
MAO''<($D"W,@WJ&# 'GU4'\*;_PH[X:_] &3_P "Y?\ XJM5F=)7T8>UB?*7
MA?6X= U>:_FMOM(>SGMUC[%I$*C=R#MR><'-==#\1K.\M[5?$6GRWLT9,K/'
M'&-LIF9]RYYQM8#&1G'XU[__ ,*.^&G_ $ 9/_ N7_XJC_A1WPT_Z ,G_@7+
M_P#%5SSQM&;NTQ.I%G@W_"?^%?MC3KX=8#[3+/$!#&%CWQ[=Y4-\[!N0,C'/
M)[<S:>(-/3_A*?M'VB-=9@:*&.U@5(E8R*X9DW_*/EQ@9QD\^OT__P *.^&G
M_0!D_P# N7_XJC_A1WPT_P"@#)_X%R__ !52L9171A[2)\;UK^&/^1NTG_KY
M3^=?6/\ PH[X:?\ 0!D_\"Y?_BJ?#\&/A[8W$=Y;Z*\<\+!T;[5(<$=#UKH>
M94FK68_:Q/C:3_6R?[Q_G3[:407D$[ D1R*Y ZD @U]?GX,_#<DD^'>>O_'Q
M)_C2?\*9^&W_ $+O_DQ)_C2_M"GM9C]K$\(;XGQ75_J?V[3B^GW-P&AMEC4A
M8-TK,K;B<L6D!R#VXQ3)O''A1]-CM$\/S_+9&U8E(P['Y2H\S.<9!R<<@XP.
MM>]?\*9^&W_0N_\ DQ)_C1_PIGX;?]"[_P"3$G^-8_6Z/1,GGB?.MYXJT&_\
M?6.N3:?-;Z9:KQ;6<"PN<$LB,0^'4' )RI*C&!7):M>OJ6MWVH23-,]U.\S2
M.@0L6.<E02!],FOK?_A3/PV_Z%W_ ,F)/\:/^%,_#;_H7?\ R8D_QJHXRE'9
M,?M(GQV>AK:\3?\ (;3_ *\[3_TFCKZJ_P"%,_#;_H7?_)B3_&K$_P &/A[>
M2"XN-&D:38B9^TR#Y54*HZ]@ /PK5YC3O>S#VJ/C2N^TKXB2:5IVDZ?;V[)#
M:V4D%PP4%Y9/WQC(R<;5,N<8R>>M?17_  H[X:?] &3_ ,"Y?_BJ/^%'?#3_
M * ,G_@7+_\ %5G/'T9JTDQ.I%G@:>//"RP.1X>?SWO([HEX(G0%=NX@9&,X
M;Y>^<Y'2L?Q'XJT75-!33=+TLV>VY:9FDB5I7R[,&\T-D'# $;<?*.:^E/\
MA1WPT_Z ,G_@7+_\51_PH[X:?] &3_P+E_\ BJR6,HIWLP]I$^6?%6O6NN_V
M2MM',/L%I]F:2550R?.S<(I(7&[''7J:YVOLC_A1WPT_Z ,G_@7+_P#%4?\
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MA:+_ - 6P_\  9/\*L[K;_GJO_?S_P"O1NMO^>J_]_/_ *]:<\AE;^PM%_Z
MMA_X#)_A1_86B_\ 0%L/_ 9/\*L[K;_GJO\ W\_^O1NMO^>J_P#?S_Z]'/("
MM_86B_\ 0%L/_ 9/\*/["T7_ * MA_X#)_A5G=;?\]5_[^?_ %Z-UM_SU7_O
MY_\ 7HYV!'#I>FV[%K?3;6%CWCA53^@J^EI;;%_T>/I_=%5-UM_SU7_OY_\
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M02,+C/"@@$9)KN=-U#2]8M&NM-F-Q ',>\!U!(]-V,CW'%7_ "8_0_\ ?1H
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M.A.[(S[8KR3RT_N+^5?='B/PAX:\6V\4/B'28;[R<^4YRKQYZ[6&"/I7,?\
M"D_AO_T F_\  N7_ !KUL/BJ=.FHRCL=$:B2L?'WEI_<7\J/+3^XOY5]@_\
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MY5G2QLI&V>?_ +^&H\-_S\3_ /?PT^5C-7RH_P#GFOY4>5'_ ,\U_*LK#?\
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M"C[):_\ /K%_WP*5P*VV/_GH?^^Z-L?_ #T/_?=6?LEK_P ^L7_? H^R6O\
MS[1?]\"BX%;;'_ST/_?=-D6/RF_>'I_?JU]CM?\ GVB_[X%+]DM?^?:+_O@4
M[@96(_[_ /X_1B/^_P#^/UJ?8[7_ )]8O^^!1]CM?^?6+_O@4^8=S+Q'_?\
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M5P58^JFHH_#]TVLQ:6\L >2'SQ(AWJ!Y9D ..^!26!I_S_@-YQ57V/Q/2U\
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MS"I_7WBEG%:"O*-EZGJW_"H/A#_SS/\ X-7_ /BJ/^%0?"'_ )YG_P &K_\
MQ5>=0>%[^\T^QNK$+=->%L(B\1[<YW-T!P,X]".M6+;P3KTTBK)9^0"TB*3A
MB64,< #U*D U+H6WJ/\ KYE+.:SM:/XG>?\ "HOA#_SS/_@T?_XJM?P]X$^&
MWA?5!JFBB"&]4%4GEOC*T8/7;N)QGUKR<^$M3:WCDMX5D;:3(#(@ 8,XVH<_
M-]QORID?A74/[4T^QO/*M6OE9D8L'*A1DY Y'TK-X?F5G-E/-Z^SA^)](#4M
M-_BUQ,?]?2TG]I:1_P!!Q/\ P*7_ !KYU_X0[59XDNM/C2\LI(TECN!B,,&]
MFZ$8.1VQ38O!NO2+YC6/EQ*P#NS#Y/FVDXZ\8S]*7]GP_G,O[7K7^#\3Z,_M
M31_^@XG_ ($K_C1_:FC_ /0<3_P)7_&OG&3PAK"S.B6\3JK,-_F*ORC=\Y!.
M54A&()ZXIR^#=>;/^B0KAMOS3H,\@9'/()90#WW"E]0I_P X?VS6_D/HW^U-
M)_Z#B?\ @4O^-']I:3_T'$_\"E_QKYQ'@W7]D3MIZQ+(N\&614P,@<Y/'WE_
M.H?^$;OEU6PTV5H$GO,; &W&/YBOS =.0?RJ?J-/^<?]K5>L/Q/I;^UM'_Z#
ML?\ X%+_ (TUM2TK:=NN1Y[?Z4O^-?-T_AN:#Q$='::/(5G:=D*JJJI9SCOM
MP0<9Y&*;#X9O[U$FTU$N[>5@(GR(VD&X+NVDY W$ GIFG]3I_P _X"_MBK>W
M)^)](_VII_\ T'$_\"EI/[3T_P#Z#B?^!2U\Y_\ "(:WN4?9H"&4MO$Z%0-N
M[).>!CD4O_"&^(-\J#3PQB4NY612!@D$9!^]E3Q[57]GT_YQ_P!LU?Y3Z,_M
M/3_^@XG_ (%+1_:>G_\ 0<3_ ,"EKYSA\)ZC]OBM[J-(E:58CLD1FW$;L 9&
M2 02,\9J*7PSJ%OH\NJ7$:16ZQ"9#U\P%@N..A&X'FH^H4_YP_M6K:_+^)](
M?VGI_P#T'$_\"EH_M/3_ /H.)_X%+7S]<>!M206ZVDD=W+,N[R@OEL!L5LC/
MWA\P&1W!%4(_"^J2*K*EMYC-$JPF=?,)E!*<=L@9YI+ T]^<'FM9.W+^)](_
MVIIW_0<3_P "EH74M*VC.N1Y_P"OI?\ &OG)?!^O2)(\>GAT0H-ZR*5;< 1@
MYY'S#\Z=#X0U*1G$AMH0(Y75FF4JYC.&&0<#GC)XJWE]/^</[6JO['XGT;_:
MFD_]!M/_  *7_&C^U-*_Z#2?^!2_XU\YOX/U;RD,5KF0*?-21D7#AG7:O/S?
MZMORJNOAR\749[*Z\NWDM[?[3+R&VKQ@<=SD#\:A8&#^T2\WK+>'XGTK_:^D
M?]!E?_ E?\:/[7TC_H,K_P"!*_XU\Y7'@_5XYI1#:B2)68+N= Y +#)4$X^X
MP^HI!X+\0E(V_LX!9&V F1>N"?7V/XC%5]2I_P Q7]LU/Y3Z-_M;2?\ H-K_
M .!2_P"-']J:5_T'!_X%+_C7SBG@_5YC$+=;6<R1),-DZ\!RP4<XY.T\>U">
M#]>D5FCT\.BNJ!Q(I5BVW!!S@CYEY]Z7U"G_ #C_ +9J_P I]&-J6F@C9KL?
M_@4M']J:?_T'$_\  I:^:[[P[?Z=IIO[L6ZQ^8L85959FW+D$8ZC@_D:N7/@
MO68-2DL88HKHJ&*O&XP^W&X>Q&1P>:/J%/\ G%_;%7^7\3Z'_M/3_P#H.)_X
M%+2_VIIW_0<3_P "EKYWA\&ZU-Y@:")76(S*N]6W8VY!(/RD!PW/:J=AX:U?
M4[/[98V0E@\T0A]R@%L@<9[9(Y]Z/J%/^<G^UZRTY?Q/I/\ M/3_ /H.)_X%
M+1_:>G_]!Q/_  *6OG'_ (1/6ECFD-K$(XU5B_G)M8'&-IS\W4=*E/@WQ &D
M7^SURA5<>8N6+8QMYY^\OYT?4:?\X_[9K?R'T2=2TUAAM;C(/4?:EY_6K%KJ
MFE1P,J:A:A1Q@2K@?K7S:W@_5H4O)+R.*U6UA>7YG!,FT X4#D\,.>V:BC\+
MZI<0V\MO';RK/$LR;95!&XD*ISCYB5.!WP:KZA"WQA_;57;D_$]RU31? ^M:
MLVJ:E-:W%PT0A8FZPI0)*@&T''2:3\QZ"J6D^%_ .BZC:7UC=)OLQ'Y,<NH&
M2-'2+R5DVEL%Q'E=QYY->(P:+J%S:I>0VZF%S(%)8 GRUW/Q["K@\'ZZ6519
M1EV<(%\U-V=P7.,],L!GIS2>!IK>8+.:KV@>P-X)^&LFW<\)VJ$'_$P/0%R/
MXO\ IHWYUE7GP_\ ";:]HNL:/XB71YM,=20DR3><JMD+\Y.T_>&1G[Q[@&O,
M&\*ZRJLWV2,J%W*5E4B0;=V4Y^; Y..E1W7A_4+-8?.$'F37+6JQ)*K,)%P"
M#CCJP[T_J$'ISE/.*J5W#\3W9M)\+W5KXFM=4U2WOHO$4C?:@TRH?*\M8UB!
M!S@*O7KDFJEYX3^'=X65C:P*41 MK=>0$"1R1KM"$;?EFDZ=SGM7C4OA/6X0
M"UI&09%B7;,C;W+%0JX/)RK CM@TT^%]84H/LL;>8RI$5E0B8MT"'/S>^.E/
MZA3_ )R?[;J_R'JP^&_PM^Q?8F9&A5%1 U]GR]LAD##GKN8\G/4CI712:7X3
MDUW1]875MEQI$#6UHD=]MB6-@ P,8.ULA5ZC^$>E>%MX/UU)EA>R17>3RU!D
M7YCMW<>VWFL^^TQ[&*TE9TD2ZC,BE.@(8JR_@5JEET'HIBEGE2*O*%OF>V3>
M!_AK=W%Y<Z@MM?3WF_S);J\\ULL%7<I)^5@%4*PY '6HE\$^"X9X9K/6-ACN
MUN&$UYYX9!,9S$-S?(C3;7;'4J.U>%[5_NBC:O\ =%:?V6OY_P #'_6&7\GX
MGO%QX#^&=U=W5Y)Y(N;G_63)?%6/[QY."&X^:1OPP.@%,D\"_#%IV:'R;.)U
M,<EM:7AAAE1E161D4@$,(DW#OMY[UX5M7^Z*-J_W13_LI?S?@5_;LOY?Q/?M
M6\)_#G6-9FUB]^S?VA+'Y;317S1_W-K !L!E\I,,!D;142^$_!?]C?V2VOW+
MVXU(ZL'.I8D^T$YRS@Y<;OFPV<''H,>#;5_NBC:O]T4?V2OYOP*_MF7\OXGO
M4G@WX>M=+=1Z@\$RW2WBM%JC+M=6=P -V-H>21]O3<Q/6MS2+7PKHE_J6H6>
MI0M>:G(LEU/-=!VDV@A1R>  3@5\T[5_NBC:O]T4_P"RE_/^ ?VY+^3\3ZS_
M +:TG_H)VO\ W^7_ !H_MK2?^@G:_P#?Y?\ &ODS:O\ =%&U?[HH_LI?S_@1
M_;4OY?Q/K3^VM)_Z"EI_W^7_ !H_MK2?^@I:?]_E_P :^2]J_P!T4;5_NBC^
MRE_/^ _[;E_+^)]:?VUI/_03M?\ O\O^-']M:3_T$[7_ +_+_C7R7M7^Z*-J
M_P!T4?V4OY_P#^VY?R_B?7,6L:6T@5-1MF8]A*I/\ZO[O>OC5U7RV^4=#7UK
MII;^RK7_ *Y+_*O/Q.#]A;6]SU<)F;Q"=XVL>/\ Q7T?5]0\90366F75S&+-
M%+Q1%AG>_&1]:Y^P?QOI]JUM#H5RT1C**K67"L2OSD;?F;"@9.:^DY,[@/:O
M)=8^*RZ3JCW4]C"?#]OJ<^DR.LC&[9X8B\DJH!C8K#9@G)R#W%.GCG"FH.*:
M1-;)XU*TJJDTV<"P\?-MW6&HL5S@FUYY5E/./1V_.HH[?QU';-;C3]2=3NP\
MEN7=-PPVUR"5R!@X->G:Q\5M/TNUU&"32+N/5[1),6<TD9'F+ )@K,C'CYXU
M)&<,X%/L?BUI.H:G::3:Z+J=Q>7;1I 8A'LFW&4%P2^54>1*?F . #CD5K_:
M#_D1C_8D?YV>97*^.[N%X;C2[UXWC,;+]CP&!())^7KE0<]>*@ET_P 6M=6-
MQ!H5_;/8Q)'!Y<#?+MYW<CJ223]:^GMOM1M]J2Q[6T$)Y-%[R9\V1/X^@E\R
M'3+R/Y0H1;$!%P2<A=N <L3D<\FH(X/',5S#<)INH!XD$8'V8[6 7:-RXPQV
M\9.3BOIK;[4;?:C^T'_(A_V,G]IGS0%\=+''&NE7L:1;#$J66!$5)*E?E^4C
M)Z=C31#XW5G,>CW<0=F=ECLMJDLNUC@+W%?3.T>E&T>E+^T'_(@_L9?S,^9;
MR#QOJ%O);WFD7DT;D':UG]S"A?EX^7@ <>E0MI_C)IGF.DZ@7>V%H3]F/^J
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M;_AQOA_HFHR-H'VF"XR+.7S// <-<,-W[S <"9G&\9P6QWH ]#HHHI@%%%%
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M=_\ \+F@_P"@"_\ W^'^%'_"YH/^@"__ '^'^%<!_P (3XM_Z%^\_P"^*/\
MA"?%O_0OWG_?%'L<+Y?>'ML5Y_<=_P#\+F@_Z +_ /?X?X5(/C5"!_R WX_Z
M;C_"O//^$)\6_P#0OWG_ 'Q2_P#"$^+/^A?O/^^*CV.&\OO)^LXSL_N/11\;
M(,\Z"^/^NX_PKMO#/BJW\5Z<UYIL:(8VVR0RL0R'WP*\#_X0GQ=_T+]Y_P!\
M5ZY\+_#=YX9T^ZN-522*YO&7]R(V;8JYQD@=>37-BZ6'A3YJ;U]3TL!7Q52J
MHS3Y>MU8]%\N]_YYP_\ ?9_PH\N]_P"></\ WV?\*?\ ;H/[LO\ WZ;_  H^
MV0?W9?\ ORW^%>/J?4#/+O?^></_ 'V?\*/+O?\ GG#_ -]G_"G_ &R#^[+_
M -^6_P */MD']V7_ +\M_A1J!!);WKD?+"/^!'_"F?9+S^[#_P!]'_"K)U"W
M'7S1_P!LF_PI/[1M?63_ +]-_A3NP*_V6\](?^^C_A1]EO/2'_OH_P"%3_VC
M:^LG_?IO\*/[1M?63_OTW^%%V,@^RWGI#_WT?\*/LMYZ0_\ ?1_PJ?\ M&U]
M9/\ OTW^%']HVOK)_P!^F_PHNP*S07RC(CB?V#D']14]DXDA9@".<$'@@^E*
MU_ %^597/]WRV&?S%)IX;RY7< -(Y<@'.,]J+L#SOQG\1-%\+^)KK1[[P\^H
MN^G"XG>-T+21A9F52AY*#RWRW12X]:JS^+/A//.+R^L(4N[FWN-_FZ<XF(3<
M9HV&W=NX<D=_QK2\6:U9Z?KNL6C^&+74"^CHUU/,77SXVDD1(681LH7.X_,P
M/S' -<ZMYX%N/&&G6.I^$--@U:]N+FSN9XI-WEON*@JX +B1BPR=I&2#UQ0(
MZ/1]=^'>I:CJFD^'[6VEU#["LEU:PVYC,D012$)QC(5D&.HW"L.7QYX1@\#^
M'M2NO":)I-Y?2Z6UN5C9+!59Q+(P(^Y^[W'@'')%:*:E\/\ 0Y;G['X<EM$E
MWZ<\EK;A$EBBPDC###Y$^52V W3&:S+CQ!X+DT^PT6Q\$_:-++W#.MW (XHH
MVC;?+CYB_F!V&>IR<T 41\1OAAJ%E?7VHZ##'J!2[BCM)85:2[@7<V<@;567
M+$!O4UIW'B[X56%A>W<6D0RW*6;0?9XM/9GN8PKAXT.W#J/+D1F' VG)P*+K
M5OANDT<TG@B[<LD@62+3QAHR'1LX;E66)\ ]EZ#C-:\U3X6RWVHZ;#X/COY#
M<#[44MT\L$0RRK(3NSMVI(" ,Y)RO- '1^'?%'@2XM[>TT..SM;NUC+16>Q8
M&BD?(,8+8&]MI^H&[IBN<U7Q]X7TGPG#XTO/!?\ I'B2=K">(^7ON$0NN]G/
M#Q$+E6Z892< YJY#K?P]TY]?,>BWLZZTX:\C6W#I/$D)A+(,C$2I"X.<'@\'
M(J766^&]E;0^%+_PW]ML;''V>!+7S8@[J#Y29;.2C@[?NX./:@#9OI/!FBZ&
MVO:7I.FW<_V!;B"&':)9[=<,I7@L5!VG(!Z"L+5/$7PVATW1/$FI:*[2G3?[
M7M;:"T\XK'A>?E^0NN0!SQS6M?:]X+A\,Z5I]UI<XT>\A C@2$@6T:NJ8?#
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M=NR,,H(9R7 "CD\^AI /G^'.BW,:+/JFH2M#.)K<RQQ2"W =WV!6C*D;G/+
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MLL+Y?>>?[?%]G]Q[#X-\41^+M/FFAVVMQ P66%@6QGH0<\@UU7V*Y_Y^(_\
MO@_XUPGPY\,W'A.SN9M0C=KRZ(W+& 5C4=!G/)YKOO[0CS_Q[S_]\C_&O#KJ
M*J-0V/L<#*I*C%U%[W41;*Z5@WGQ<?[!_P :E\B\_P">T7_?!_QIHU%6.!:S
MY_W1_C3OMW_3I<?]\C_&L-3N#R+S_GM%_P!\'_&CR+S_ )[1?]\'_&E^W?\
M3I<?]\C_ !H^W?\ 3I<?]\C_ !I:@)Y%Y_SVB_[X/^-'D7G_ #VB_P"^#_C2
M_;O^G2X_[Y'^-'V[_ITN/^^1_C1J GD7G_/:+_O@_P"-(UO>,I7SHN?]@_XT
M[[=_TZ7'_?(_QI#?84DVEQ@?[(_QHU A^PW/_/>/_O@_XT?8;G_GO'_WP?\
M&G_VDG_/O/\ ]\C_ !H_M)/^?>?_ +Y'^-.[&,^PW/\ SWC_ .^#_C1]AN?^
M>\?_ 'P?\:?_ &DG_/O/_P!\C_&C^TD_Y]Y_^^1_C1=@,^PW/_/>/_O@_P"-
M'V&Y_P">\?\ WP?\:?\ VDG_ #[S_P#?(_QH_M)/^?>?_OD?XT78#/L-U_SW
MC_[X/^-2BWO  /.BX_V#_C2?VE'_ ,^T_P#WR/\ &GB^R,BTN/\ OD?XT:B$
M\B\_Y[1?]\'_ !H\B\_Y[1?]\'_&E^W?].EQ_P!\C_&C[=_TZ7'_ 'R/\:6H
M">1>?\]HO^^#_C1Y%Y_SVB_[X/\ C2_;O^G2X_[Y'^-'V[_ITN/^^1_C1J G
MD7G_ #VB_P"^#_C1Y%Y_SVB_[X/^-+]N_P"G2X_[Y'^-'V[_ *=+C_OD?XT:
M@1O:7;D9FB_[X/\ C3/L-U_SWC_[X/\ C4K:@%^]:W _X"/\:3^TH_\ GVG_
M .^1_C3U C^PW/\ SWC_ .^#_C1]AN?^>\?_ 'P?\:?_ &DG_/O/_P!\C_&C
M^TD_Y]Y_^^1_C1=C&?8;G_GO'_WP?\:/L-S_ ,]X_P#O@_XT_P#M)/\ GWG_
M .^1_C1_:2?\^\__ 'R/\:+L"%K6\ RLD3GT((S^-2V+>9"[;2K!MK*>H(ZB
MD;4/E.RUF+=L@ ?GFET\,L4GF??=R[8Z GL*-1E:?6-+M=0&GW&H0Q79C,PB
M=L'8 26^F%8_@:I:/XKT'79KJ'2KX7+6N/. 1U"9&1DL .G/T(-4O$'@^S\0
M7$UQ+>W%O)*L";HMN56-I-P&1T=971O8\<U8OO#-O?:9KM@]Q+''K#!VP 1%
MB-$  /!&(QD'KDCI3)-+^V-+^P&__M& VH8KYH?*YW^7_P"A_+]:M)/#)"LR
MS+Y;C*L3C/YUYS;?"+3[>_CNAK-T2L'DE%C5$'[[S<HHPJ#)QMP1WZT[4OA+
MI>HV$MK_ &Q?1*S1.F,;8RH(?@$9W\,>>"JD=*0'HX="2!(I(X(##(J-KBW6
M,R-<1JBD@L9  ".HS7(6_@.UM=<TJ]M)MD5M-/<70*X:[=FW1[B.NQB2"3FL
MR#X56,>IW-Y+K$MV;F\ENI(KFWBDCQ(NUE"D85L 8<<]?4TP.]2_LY(9+B*Z
MCDAC7<SH=PQC(((ZC'IFB+4+&=BL-Y%)MSDJ^0,'!!/0'/&.M<1%\+]/CL[:
MW_M2Y588/L["*-(UD00B- 5 P-I59!C^(57U'X1Z9?Z?<62ZI<6D<EP;A1!$
MD8!+[R'"XW\D\DYZ>@H ]&,T2[MTR#:=IRP&#Z'WJ,7EJU\]B+B,W21B5H=W
MS*A) 8CTR#7#7OPUM[WPOJV@'6)X(=2O!=L\4" ITRHSDG.,EB<Y_*FK\*]/
M6\N;EM6NB\TB,76-%D*!F9T=P,N'#LI)Y"X Z4 =^LL3 ;9D;)VC#@Y/I]:C
M^U6WFM%]H3>HR1NX'..O3.>W6N!L_A3I-O=7%Q<:I=74LEU)=QLT:+]G=GB;
M,>!\I B R,<,:>OPMT>2QAL[V\-Q#"K(BBUCC4Y615=@!AI!YF[?U)4&@#O)
MKJWM[>>XFG18[=&DE;=G8H&23Z<"LA/%FA/KEKH:Z@%U.X@%S';-&X8QD9W=
M, <C.3QTZUR7A_X>ZII=KXCM+N[L)%UJ^CFDGB#^<\ <EU=CW*_* .!DG/-=
M!XD\%V?B6ZN)I[^XM6FTY].VPA=JJTJ2;L'KS& 1T()!I =)/>6MO T\UPBQ
MJNXD'=QZX')'(IMQ?6=I;SW%U=PQ10(TDK,X^15&6)^@Y->36WP/M4U>\GN-
M:F%JT*QP"")4D5BIWY.,*F6.V-?E&%]!5NZ^"NGWEO8V\GB2^B@LY)Y%$<$2
MO)YF<EW W.V"06).X=:0'I,FK:9&;#S+^%!J#!;3+?Z\E2PV^OR@FD76-+?5
M&TM+^)[U0K-"IR0&!*D]N0#CUQ7!>(/A#I/B*^M+FXUF^M_LUC'8CR50/A(Y
M(PROC*9$I) X)"^E58_@CI*6 @&N7Z.L)1)(U4&-\-MD7.<%6;<!G&5';BF!
MZF98QG,J# R<L.!09(PNXRH%QG)88Q7EEK\$=!M]72^;5+V>,?92\$^'60PM
M&QSDX*N8\L,=68C&:C?X22_\(OJ6CQZG"LEYK4=\C2Q><EO:1R9CMPK##;5W
M8!&,L1TI@>GV^I:?=W%S;VU[#+-:R&&9%<9C<*&*D>N&4_C5@21L5"RH2WW<
M,#GZ5Y1)\$=+)L/+\2:HD5G)Y@0K&Q<^2D7+8S]U.><'-6(/@GX=MYHY(=2O
M8_*V^3Y:HAAQMW;"!\I;!R1_>-(#TBXU/3[$VIO+V&$74RV\.YQ^]D;@*/4U
MJ5X_HOP5TG1[_0[J+6+R9M*F691)&K>858L,%LE,Y.[;C=QQQ7L%)@9]VMZT
MH^SS0HFWHZ%CG\#7+OXJMVU>ZTTW22_8F,=W=BR<VMJ^S<5DE)VJ=I&?3(!Q
MFNQE^^/I7F.K?"31-2U"[NKC6K^VBN9YKF.W5XPD<\S*SMDKEP2@.QLKR>*
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M88AEB/4^@KD_^%P>'_\ H'WO_CO^-=5/#U9QYHQT."KBZ%*7)4DDSO=FH_\
M/Q;?]^V_QHV:C_S\6W_?MO\ &N"_X7!H'_0.O?\ QW_&C_A<&@?] Z]_\=_Q
MK7ZK6_E9S_7<-_,CO=FH_P#/Q;?]^V_QHV:C_P _%M_W[;_&N"_X7!H'_0.O
M?_'?\:/^%P:!_P! Z]_\=_QH^J5OY65_:F'_ )T=_&FI>:N+BVS_ -<F_P :
ML[-4_P"?FU_[]-_C7G*_&'05<-_9][Q_N_XU+_PN;0?^@?>_^._XU#PE?^4/
M[3H?SH]!V:I_S\VO_?IO\:-FJ?\ /S:_]^F_QKS[_A<V@_\ 0.O?_'?\:/\
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M8H(X0&54&1DR9.&SE<=ZV;2W^(UML OHKAS(()9KN2%F,9EF)E&T ?*ABPN
M3N.<XI+&3XF-X:G759H3J?\ : Q]C^SA_LO\7EER4SG&-X!QGO@T 9&I?"WQ
M'/HWA9-*UZULM6T"&Z6*ZVN5WS2+G QT\OS%Y[D4W0_A/J'A^TELXDT?5;8Z
M>UE;"]:4-9@/,0$(4\.)5WG@Y4_>&,:[6OQ$O+N1KJXB$4<SF-?.B4$$.!MV
M8RF"G#_-NR>F*DTN#XA64^G+=7C72B[1;R666W+2PC?N)(' Y4@*NX]"1UH
MQO#OPMUW2?&7AOQ)?7E@\FE6%K82P0;RKK%!)$75BH;.64A2=N-V1D*:R-<\
M"?$K18[^\T+5I[Z37;Y+K48M+E%K-&P,A^21NJE6C0D\_(O&,UU=O8^*?MDJ
M6ZR"*YNR)IVN?+$!2^>5I-A.65XBJC;G.,' I_ANQUNQUK1_[0M;F*X5;C[=
M<RWQN8[EMB@NO)$89]I"\< \#'(!FS>"?B;<27#KXYEMD=I'C1+F0DMB7RR?
ME^4*6B!1<JPC)ZMBBZ^'_CRX,\9\6 6[,)5BCNIH!Y@O/.&/+4;08\HQ^8DX
MZ#.?5_-C_P">B_G1YL?_ #T7\Z 'T4SS8_\ GHOYT>;'_P ]%_.F ^BF>;'_
M ,]%_.CS8_\ GHOYT /HIGFQ_P#/1?SH\V/_ )Z+^= 'BWQ4\*ZS=>(5UBQM
M9+NVDB6-A$-QC*^H]#7G?_"/Z[_T![S_ +\M_A7U1/)'\N)!W[U#YB_WOUKT
M:./G3@H6O8^8Q66TZ]:53F:N?+O_  C^N_\ 0'O/^_+?X4?\(_KO_0'O/^_+
M?X5]1>='_P ]/UH\Z/\ YZ?K73_:<_Y3E_LNG_,_N/EW_A']=_Z ]Y_WY;_"
MC_A']=_Z ]Y_WY;_  KZB\Z/_GI^M'G1_P#/3]:/[3G_ "C_ +(I?SO[CY=_
MX1[7O^@/>?\ ?EO\*/\ A'=>_P"@+>_]^&_PKZD29<K^\&/K4OG)_L_G6?\
M:D_Y2?['I_SO[CY6_P"$=U[_ * M[_WX;_"C_A'=>_Z M[_WX;_"OJOS$_O+
M^='F)_>7\Z?]I5/Y1_V+#^9_<?*G_".Z]_T!;W_OPW^%'_".Z]_T!;W_ +\-
M_A7U5YB>J_G1YB>J_G1_:D_Y0_L2'\S^X^5?^$=U[_H"WO\ WX;_  H_X1[7
MO^@->_\ ?AO\*^J_,3^\OYU'))'Y3?..GK1_:=3^4/[$A_,_N/EC_A']=_Z
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MW%M^_21E)ECB#'$F/E /'.X#I7I_G)_SU'_?5'GK_P ]A_WU0 B;7B1O+VY
M;:RX*_AV-/\ PIGFQ_\ /1?SH\V/_GHOYTP'!5'10/H*7CK@9]:9YL?_ #T7
M\Z/-C_YZ+^= #Z0!1]U0/H*;YL?_ #T7\Z/-C_YZ+^= #MJ\?*..G'2EZ8P,
M8IGFQ_\ /1?SH\V/_GHOYT )#!!;PB&"%(XQGY%&!SR:?M7&-JX],4WS8_\
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M^?\ Y]9O^^*/G_Y]9O\ OBM'[5;_ //Q%_WV*/M5O_S\1?\ ?8HYF!G?O/\
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M4?:K?_GXB_[[%',P,[Y_^?6;_OBCY_\ GUF_[XK1^U6__/Q%_P!]BC[5;_\
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M& _RL=ZD!L<'K6UJ7@OPOJD]K)>:/"&M9VN8Q"/*!D;!9F"XW9VKG.>E:_\
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M,/\ SR?\J/,/_/)_RH ?13/,/_/)_P J/,/_ #R?\J 'T4SS#_SR?\J/,/\
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MQ?\ >^\XS_A/_&'_ $')_P!/\*L67Q(\56MW'-<:D]W"#\\4F,,._(Z5U?\
MPIJ3_H/#_P !S_C5BR^#MO#>1RWFK_:H58%HEC*;_8G)K&5;#V>B^XZ:=#%J
M2U:^9ZG91V][807BM,JS1K( 9#D C-7OL4>/]=-C_KH:H127,,2Q1) $4!5
MW8 %6UFOBH/^C\_[U>&]SZF%U%<VY+]AC_Y[3_\ ?PT?88_^>T__ '\-1^;?
M?].__CU'FWW_ $[_ /CU3J62?88_^>T__?PT?88_^>T__?PU'YM]_P!._P#X
M]1YM]_T[_P#CU&H$GV&/_GM/_P!_#1]AC_Y[3_\ ?PU'YM]_T[_^/4>;??\
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M-?:#';!BJHS7+%,G8?F/EY PXZ \AO2NWW-_>-,=$DV^8H?:P9=PS@CH1[T
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M=K/?VMS- CS6[ZMY3D<I_I03C_@/'TXHHH [#:OI1M7THHJ@#:OI1M7THHH
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'J6BBI8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331274608512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PALATIN TECHNOLOGIES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000911216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,005,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4078884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">4B Cedar Brook Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">495&#8209;2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331363505280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,416,604<span></span>
</td>
<td class="nump">$ 9,527,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">253,113<span></span>
</td>
<td class="nump">242,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,669,717<span></span>
</td>
<td class="nump">9,769,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">235,741<span></span>
</td>
<td class="nump">388,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">347,644<span></span>
</td>
<td class="nump">527,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">56,916<span></span>
</td>
<td class="nump">56,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,310,018<span></span>
</td>
<td class="nump">10,742,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,718,233<span></span>
</td>
<td class="nump">4,101,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,650,700<span></span>
</td>
<td class="nump">4,185,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liabilities</a></td>
<td class="nump">257,673<span></span>
</td>
<td class="nump">380,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">932,150<span></span>
</td>
<td class="nump">944,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,558,756<span></span>
</td>
<td class="nump">9,657,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">100,071<span></span>
</td>
<td class="nump">163,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="nump">1,032,300<span></span>
</td>
<td class="nump">1,032,300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,691,127<span></span>
</td>
<td class="nump">10,853,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficiency:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.01 par value - authorized 300,000,000 shares issued and outstanding 23,455,846 shares as of December 31, 2024 and 17,926,640 shares as of June 30, 2024</a></td>
<td class="nump">234,558<span></span>
</td>
<td class="nump">179,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">445,416,974<span></span>
</td>
<td class="nump">441,475,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(452,032,681)<span></span>
</td>
<td class="num">(441,766,550)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficiency</a></td>
<td class="num">(6,381,109)<span></span>
</td>
<td class="num">(111,497)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficiency</a></td>
<td class="nump">4,310,018<span></span>
</td>
<td class="nump">10,742,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficiency:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follow Series A Convertible: authorized 4,030 shares as of December 31, 2024: issued and outstanding 4,030 shares as of December 31, 2024 and June 30, 2024</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331364092192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">23,455,846<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">23,455,846<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331272064368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProductRevenueNet', window );">Product revenue, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,034,113<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,140,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionCosts', window );">Cost of products sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,429,479<span></span>
</td>
<td class="nump">5,554,200<span></span>
</td>
<td class="nump">9,173,233<span></span>
</td>
<td class="nump">10,568,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,681,844<span></span>
</td>
<td class="nump">3,032,613<span></span>
</td>
<td class="nump">3,702,775<span></span>
</td>
<td class="nump">6,232,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on sale of Vyleesi</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">7,823,482<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">7,823,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,611,323<span></span>
</td>
<td class="nump">860,968<span></span>
</td>
<td class="nump">10,376,008<span></span>
</td>
<td class="nump">9,075,842<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) Income from operations</a></td>
<td class="num">(2,611,323)<span></span>
</td>
<td class="nump">1,173,145<span></span>
</td>
<td class="num">(10,376,008)<span></span>
</td>
<td class="num">(4,935,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER (EXPENSE) INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">29,044<span></span>
</td>
<td class="nump">62,026<span></span>
</td>
<td class="nump">107,620<span></span>
</td>
<td class="nump">133,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ForeignCurrencyTransactionLossGain', window );">Foreign currency transaction (loss) gain</a></td>
<td class="nump">143,600<span></span>
</td>
<td class="num">(306,697)<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="num">(146,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,803)<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
<td class="num">(9,743)<span></span>
</td>
<td class="num">(12,487)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Offering expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(696,912)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(696,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,073,991)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,391,591)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">168,841<span></span>
</td>
<td class="num">(9,017,179)<span></span>
</td>
<td class="nump">109,877<span></span>
</td>
<td class="num">(8,114,281)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (2,442,482)<span></span>
</td>
<td class="num">$ (7,844,034)<span></span>
</td>
<td class="num">$ (10,266,131)<span></span>
</td>
<td class="num">$ (13,050,033)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.99)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</a></td>
<td class="nump">20,634,887<span></span>
</td>
<td class="nump">14,097,757<span></span>
</td>
<td class="nump">20,239,997<span></span>
</td>
<td class="nump">13,134,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ForeignCurrencyTransactionLossGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ForeignCurrencyTransactionLossGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProductRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProductRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized production cost incurred during period for oil- and gas-producing activities. Includes cost incurred to operate and maintain well and related equipment and facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(a)(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331268921440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Contingently Redeemable Warrants</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,656,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2023</a></td>
<td class="num">$ (1,979,871)<span></span>
</td>
<td class="nump">$ 116,567<span></span>
</td>
<td class="nump">$ 409,933,959<span></span>
</td>
<td class="num">$ (412,030,437)<span></span>
</td>
<td class="nump">$ 263,400<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, Amount</a></td>
<td class="nump">940,307<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">939,323<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount', window );">Withholding taxes related to restricted stock units, Amount</a></td>
<td class="num">(56,401)<span></span>
</td>
<td class="num">$ (255)<span></span>
</td>
<td class="num">(56,146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsShares', window );">Sale of common stock, net of costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsAmount', window );">Sale of common stock, net of costs, Amount</a></td>
<td class="nump">531,369<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="nump">529,199<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares', window );">Conversion of liability classified warrants upon warrant exercise, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,358,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount', window );">Conversion of liability classified warrants upon warrant exercise, Amount</a></td>
<td class="nump">2,389,903<span></span>
</td>
<td class="nump">$ 23,585<span></span>
</td>
<td class="nump">2,366,318<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ReclassificationOfContingentlyRedeemableWarrants', window );">Reclassification of contingently redeemable warrants</a></td>
<td class="num">(159,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(159,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(13,050,033)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,050,033)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,305,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="num">(11,384,426)<span></span>
</td>
<td class="nump">$ 143,051<span></span>
</td>
<td class="nump">413,552,953<span></span>
</td>
<td class="num">(425,080,470)<span></span>
</td>
<td class="nump">423,100<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,946,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="num">(6,320,566)<span></span>
</td>
<td class="nump">$ 119,466<span></span>
</td>
<td class="nump">410,796,364<span></span>
</td>
<td class="num">(417,236,436)<span></span>
</td>
<td class="nump">263,400<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, Amount</a></td>
<td class="nump">549,971<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">549,971<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares', window );">Conversion of liability classified warrants upon warrant exercise, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,358,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount', window );">Conversion of liability classified warrants upon warrant exercise, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ReclassificationOfContingentlyRedeemableWarrants', window );">Reclassification of contingently redeemable warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(7,844,034)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,844,034)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,305,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="num">(11,384,426)<span></span>
</td>
<td class="nump">$ 143,051<span></span>
</td>
<td class="nump">413,552,953<span></span>
</td>
<td class="num">(425,080,470)<span></span>
</td>
<td class="nump">$ 423,100<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="num">(111,497)<span></span>
</td>
<td class="nump">$ 179,266<span></span>
</td>
<td class="nump">441,475,747<span></span>
</td>
<td class="num">(441,766,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, Amount</a></td>
<td class="nump">697,978<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">695,649<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount', window );">Withholding taxes related to restricted stock units, Amount</a></td>
<td class="num">(99,482)<span></span>
</td>
<td class="num">$ (547)<span></span>
</td>
<td class="num">(98,935)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(10,266,131)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,266,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesReleasedFromAbeyanceShares', window );">Shares released from abeyance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesReleasedFromAbeyanceAmount', window );">Shares released from abeyance, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 14,433<span></span>
</td>
<td class="num">(14,433)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesShares', window );">Warrant exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,907,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesAmount', window );">Warrant exercises, Amount</a></td>
<td class="nump">3,398,023<span></span>
</td>
<td class="nump">$ 39,077<span></span>
</td>
<td class="nump">3,358,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,455,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="num">(6,381,109)<span></span>
</td>
<td class="nump">$ 234,558<span></span>
</td>
<td class="nump">445,416,974<span></span>
</td>
<td class="num">(452,032,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,548,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2024</a></td>
<td class="num">(7,685,605)<span></span>
</td>
<td class="nump">$ 195,481<span></span>
</td>
<td class="nump">441,709,073<span></span>
</td>
<td class="num">(449,590,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation, Amount</a></td>
<td class="nump">348,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">348,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(2,442,482)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,442,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesShares', window );">Warrant exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,907,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesAmount', window );">Warrant exercises, Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,455,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="num">$ (6,381,109)<span></span>
</td>
<td class="nump">$ 234,558<span></span>
</td>
<td class="nump">$ 445,416,974<span></span>
</td>
<td class="num">$ (452,032,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ReclassificationOfContingentlyRedeemableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ReclassificationOfContingentlyRedeemableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SaleOfCommonStockNetOfCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SaleOfCommonStockNetOfCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SaleOfCommonStockNetOfCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SaleOfCommonStockNetOfCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesReleasedFromAbeyanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesReleasedFromAbeyanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesReleasedFromAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesReleasedFromAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331268871696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (10,266,131)<span></span>
</td>
<td class="num">$ (13,050,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">152,620<span></span>
</td>
<td class="nump">172,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Decrease in right-of-use asset</a></td>
<td class="nump">179,677<span></span>
</td>
<td class="nump">174,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnrealizedForeignCurrencyTransactionLossGain', window );">Unrealized foreign currency transaction loss (gain)</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">146,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">697,978<span></span>
</td>
<td class="nump">940,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ChangeInFairValueOfLiabilityClassifiedWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,391,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on sale of Vyleesi</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">7,823,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">569,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(10,841)<span></span>
</td>
<td class="nump">1,047,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,154,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,616,304<span></span>
</td>
<td class="num">(2,710,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(2,534,346)<span></span>
</td>
<td class="num">(896,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(186,580)<span></span>
</td>
<td class="num">(176,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,012,197)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,863,319)<span></span>
</td>
<td class="num">(16,382,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,992,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProceedsFromSaleOfOtherAssets', window );">Proceeds from sale of Vyleesi</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">12,455,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of withholding taxes related to restricted stock units</a></td>
<td class="num">(99,482)<span></span>
</td>
<td class="num">(56,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock and warrants, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,531,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(46,014)<span></span>
</td>
<td class="num">(52,494)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">3,398,023<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">3,252,527<span></span>
</td>
<td class="nump">5,422,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(6,110,792)<span></span>
</td>
<td class="nump">1,495,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">9,527,396<span></span>
</td>
<td class="nump">7,989,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
<td class="nump">3,416,604<span></span>
</td>
<td class="nump">9,485,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">9,743<span></span>
</td>
<td class="nump">10,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise', window );">Conversion of liability classified warrants upon warrant exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,389,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ChangeInFairValueOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ChangeInFairValueOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProceedsFromSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProceedsFromSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnrealizedForeignCurrencyTransactionLossGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnrealizedForeignCurrencyTransactionLossGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271725376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(1) ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nature of Business </em>- Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#8217;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women. As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;) on December 19, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results expected in the first quarter of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Business Risks and Liquidity &#8211; </em>The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of December 31, 2024 of $452,032,681 and a net loss for the three and six months ended December 31, 2024 of $2,442,482 and $10,266,131, respectively. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, the Company&#8217;s cash and cash equivalents were $3,416,604 and current liabilities were $9,558,756. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#8217;s MC1r and MC4r programs, and development of other portfolio products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company follows the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <em>Presentation of Financial Statements &#8212; Going Concern</em>, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#8217;s ability to meet its obligations for the next year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on our available cash and cash equivalents as of December 31, 2024 and $4,309,641 received in February 2025, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company could be forced to make additional reductions in certain expenditures. This could include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company could be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees.<em> </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Concentrations &#8211;</em> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275772032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_BasisOfPresentationAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and six months ended December 31, 2024, may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271716304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $3,005,361 and $9,089,113 in a money market account at December 31, 2024 and June 30, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gross product sales offset by product sales allowances for the three and six months ended December 31, 2024 and 2023 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,288,003</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,875,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,253,890</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,735,063</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,034,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,140,090</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended December 31, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and six months ended December 31, 2024 and 2023 were 13,059,777 and 6,595,422, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of December 31, 2024, and 2023 due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271560000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(4)</strong> <strong>New Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of the adoption on the consolidated financial statements and accompanying footnotes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275652048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementAbstract', window );"><strong>ASSET PURCHASE AGREEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementTextBlock', window );">ASSET PURCHASE AGREEMENT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(5) ASSET PURCHASE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#174;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the terms of the Purchase Agreement, the Company sold certain assets (the &#8220;Purchased Assets&#8221;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $171,000,000, consisting of an upfront purchase price of $9,500,000, $2,500,000 payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $159,000,000. As of December 31, 2024, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#8220;Korea&#8221;) (see Note 8).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331272005072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ManufacturingSupplyAgreementsForVyleesiabstract', window );"><strong>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ManufacturingSupplyAgreementsTextBlock', window );">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#8220;Catalent&#8221;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#8220;Ypsomed&#8221;), to manufacture the auto-injector device (the &#8220;Ypsomed Agreement&#8221;); and Lonza Ltd. (&#8220;Lonza&#8221;), to manufacture the active pharmaceutical ingredient peptide (the &#8220;Lonza Agreement&#8221;).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ManufacturingSupplyAgreementsForVyleesiabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ManufacturingSupplyAgreementsForVyleesiabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ManufacturingSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ManufacturingSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275857088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH FOSUN<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunAbstract', window );"><strong>AGREEMENT WITH FOSUN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunTextBlock', window );">AGREEMENT WITH FOSUN</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun&#8221;) for exclusive rights to commercialize Vyleesi in China (the &#8220;Fosun License Agreement&#8221;). Under the terms of the Fosun License Agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275807936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH KWANGDONG<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongAbstract', window );"><strong>AGREEMENT WITH KWANGDONG</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongTextBlock', window );">AGREEMENT WITH KWANGDONG</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(8) AGREEMENT WITH KWANGDONG</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#8220;Kwangdong&#8221;) for exclusive rights to commercialize Vyleesi in Korea (the &#8220;Kwangdong License Agreement&#8221;). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea which has not occurred as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331272025744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prepaid expenses<strong> </strong>and other current assets consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,314</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,744</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,097</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">124,055</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,249</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">253,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">242,272</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271789632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(10) FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#8217;s or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table provides the assets carried at fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Carrying Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Quoted prices in </p><p style="font-size:10pt;font-family:times new roman;margin:0px">active markets</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Level 1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Other quoted/observable inputs (Level 2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Significant unobservable inputs</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Level 3)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 31, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,005,361</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,005,361</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275783904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accrued expenses<strong> </strong>consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,153,170</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,509,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,003</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,484</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">284,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,771,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">324,640</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">351,485</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">75,403</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,650,700</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,185,046</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271711168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(12) COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Inventory Purchases </em>- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#8220;Catalent Agreement&#8221;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of December 31, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>4 - 5 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory purchase commitments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,480,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,448,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,032,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, the Company has $932,150 and $1,032,300 accrued within other current and long-term liabilities, respectively, in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $944,150 and $1,032,300 was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Contingencies</em> - The Company accounts for litigation losses in accordance with ASC 450-20, <em>Loss Contingencies</em>. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#8217;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275825088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS DEFICIENCY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(13) STOCKHOLDERS&#8217; DEFICIENCY</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Series A Convertible Preferred Stock</em> &#8211; As of December 31, 2024, 4,030 shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $100 divided by the Series A Conversion Price. As of December 31, 2024, the Series A Conversion Price was $75.45, and each share of Series A Convertible Preferred Stock is convertible into approximately 1.33 shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $100 per share, or $403,000 in the aggregate as of December 31, 2024. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $100 per share to holders of the Series A Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Financing Transactions &#8211; </em>On January 29, 2024, the Company entered into a securities purchase agreement (the &#8220;January 2024 Purchase Agreement&#8221;) to sell in a registered direct offering (the &#8220;January 2024 RD Offering&#8221;), an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $5.46 per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#8220;2024 Placement Agent Warrants&#8221;) to purchase up to 91,575 shares of the Company&#8217;s common stock (the &#8220;January 2024 Placement Agent Warrant Shares&#8221;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $6.825 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The gross proceeds from the January 2024 Offering totaled $10,000,006, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $9,224,056. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 20, 2023, the Company entered into a securities purchase agreement (the &#8220;October 2023 Purchase Agreement&#8221;) with a certain institutional investor, to sell in a registered direct offering (the &#8220;October 2023 RD Offering&#8221;), an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $2.12 per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The October 2023 Pre-Funded Warrants had an exercise price of $0.0001 per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase 1,033,491 shares of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $4,573,948.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounted for in accordance ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of the Company, therefore the placement agent warrants are classified out of permanent equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 12, 2023, the Company entered into a new equity distribution agreement (the &#8220;2023 Equity Distribution Agreement&#8221;) with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may, from time to time, sell shares of the Company&#8217;s common stock at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proceeds raised under the 2023 Equity Distribution Agreement are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Cumulative from inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Gross proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547,803</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,744,542</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Fees</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,434</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(126,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">531,369</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,565,406</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No proceeds were raised under the 2023 Equity Distribution Agreement during the three and six months ended December 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock Warrants</em> &#8211; On December 13, 2024, the Company entered into a letter agreement (the &#8220;December 2024 Inducement Letter&#8221;) with a holder (the &#8220;December 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on June 24, 2024, with an initial exercise price of $1.88, and October 24, 2023, with an initial exercise price of $2.12 (the &#8220;December 2024 Existing Warrants&#8221;). To induce the exercise of a portion of the December 2024 Existing Warrants by the December 2024 Exercising Holder, the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#8217;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#8220;Series C Warrants&#8221;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#8220;Series D Warrants&#8221; and together with the Series C Warrants, the &#8220;December 2024 Inducement Warrants,&#8221; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#8220;December 2024 Inducement Warrant Shares&#8221;). The Company received aggregate gross proceeds of $3,419,219 from the exercise of the December 2024 Existing Warrants by the December 2024 Exercising Holder (the &#8220;December 2024 Warrant Inducement&#8221;). The incremental value of the December 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 20, 2024, the Company entered into a letter agreement (the &#8220;June 2024 Inducement Letter&#8221;) with a holder (the &#8220;June 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#8220;June 2024 Existing Warrants&#8221;). Pursuant to the June 2024 Inducement Letter, the June 2024 Exercising Holder agreed to exercise, for cash, June 2024 Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company&#8217;s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#8220;Warrant Inducement&#8221;). As part of the agreement, 1,443,277 shares of common stock were held in abeyance on behalf of the June 2024 Exercising Holder. During the three months ended December 31, 2024, at the request of the June 2024 Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the June 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 31, 2024, the Company had outstanding warrants for shares of common stock as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares of Common</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Latest Expiration</strong></p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 2022 Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">66,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">12.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">May 11, 2026</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2022 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">90,909</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 31, 2027</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2023 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">117,925</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 20, 2028</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Private Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,831,503</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.46</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">91,575</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 2024 Series B Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,885,632</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June 24, 2029</p></td><td>*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series C Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,907,679</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 17, 2029</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series D Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,953,839</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">**</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="12" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="12" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock Options &#8211;</em> For the three and six months ended December 31, 2024, the Company recorded stock-based compensation related to stock options of $177,673 and $355,407, respectively. For the three and six months ended December 31, 2023, the Company recorded stock-based compensation related to stock options of $205,223 and $410,540, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of stock option activity is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Term in</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Intrinsic</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263,440</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,249,102</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6.12</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7.7</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">935,714</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10.76</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6.1</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected to vest at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,313,387</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.82</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.9</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock options granted to the Company&#8217;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the outstanding options in the table above are 418,945 and 88,911 unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were 95,167, 60,566, 238,838 and 264,945, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Restricted Stock Units &#8211; </em>For the three and six months ended December 31, 2024, the Company recorded stock-based compensation related to restricted stock units of $171,281 and $342,571, respectively. For the three and six months ended December 31, 2023, the Company recorded stock-based compensation related to restricted stock units of $185,019 and $370,038, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of restricted stock unit activity is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,374,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,941</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,726</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,139,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in outstanding restricted stock units in the table above are 279,700 vested shares that have not been issued as of December 31, 2024, due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Time-based restricted stock units granted to the Company&#8217;s executive officers, other employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the outstanding restricted stock units in the table above are 274,549 and 59,842 unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were 22,343, 40,707, 152,432 and 184,443 restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the vesting of restricted share units during the six months ended December 31, 2024, the Company withheld 54,691 shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271732944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(14) SUBSEQUENT EVENTS</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 10, 2025, the Company entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) at a purchase price of $1.00 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company also agreed to issue to the same investor in a concurrent private placement warrants to purchase up to an aggregate of 4,688,000 shares of common stock (the &#8220;Private Placement&#8221; and, together with the Registered Direct Offering, the &#8220;Offering&#8221;). The warrants being issued in the concurrent Private Placement will have an exercise price of $1.00 per share, will be exercisable beginning on the six-month anniversary of the date of issuance and will expire five and a half years from the date of issuance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The gross proceeds from the Offering totaled $4,687,786. The Company intends to use the net proceeds from the Offering for general corporate purposes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331276856144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $3,005,361 and $9,089,113 in a money market account at December 31, 2024 and June 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock', window );">Revenue Recognition (Prior to the sale of Vyleesi)</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gross product sales offset by product sales allowances for the three and six months ended December 31, 2024 and 2023 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,288,003</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,875,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,253,890</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,735,063</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,034,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,140,090</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended December 31, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and six months ended December 31, 2024 and 2023 were 13,059,777 and 6,595,422, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of December 31, 2024, and 2023 due to a provision in the restricted stock unit agreements to delay delivery.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of foreign currencies</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275654608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfSalesTableTextBlock', window );">Schedule of sales</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,288,003</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,875,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,253,890</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,735,063</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,034,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,140,090</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275548704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,314</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,744</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,097</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">124,055</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,249</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">253,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">242,272</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275811760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value asset measurement</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Carrying Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Quoted prices in </p><p style="font-size:10pt;font-family:times new roman;margin:0px">active markets</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Level 1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Other quoted/observable inputs (Level 2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Significant unobservable inputs</p><p style="font-size:10pt;font-family:times new roman;margin:0px">(Level 3)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 31, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,005,361</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,005,361</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271790416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schdule of Accrued Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,153,170</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,509,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,003</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,484</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">284,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,771,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">324,640</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">351,485</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">75,403</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,650,700</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,185,046</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271766048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock', window );">Schedule of inventory purchase commitments</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>4 - 5 Years</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory purchase commitments</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,480,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,448,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,032,300</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271735552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfEquityDistributionAgreementTableTextBlock', window );">Equity Distribution Agreement</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Cumulative from inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Gross proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547,803</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,744,542</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Fees</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,434</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(126,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">531,369</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,565,406</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock', window );">Outstanding Stock Purchase Warrants</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares of Common</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Latest Expiration</strong></p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 2022 Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">66,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">12.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">May 11, 2026</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2022 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">90,909</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 31, 2027</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2023 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">117,925</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 20, 2028</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Private Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,831,503</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">5.46</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Placement Agent Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">91,575</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.83</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 2024 Series B Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,885,632</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June 24, 2029</p></td><td>*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series C Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,907,679</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 17, 2029</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series D Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,953,839</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.88</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">**</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="12" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="12" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Term in</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Intrinsic</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263,440</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,249,102</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6.12</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7.7</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">935,714</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10.76</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6.1</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected to vest at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,313,387</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.82</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.9</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Units</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,374,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,941</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,726</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,139,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfEquityDistributionAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfEquityDistributionAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331273422144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,442,482)<span></span>
</td>
<td class="num">$ (7,844,034)<span></span>
</td>
<td class="num">$ (10,266,131)<span></span>
</td>
<td class="num">$ (13,050,033)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">3,416,604<span></span>
</td>
<td class="nump">$ 9,485,252<span></span>
</td>
<td class="nump">3,416,604<span></span>
</td>
<td class="nump">$ 9,485,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,527,396<span></span>
</td>
<td class="nump">$ 7,989,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,558,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,558,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,657,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (452,032,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (452,032,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (441,766,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,309,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275468192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Product Revenue [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RevenuesGross', window );">Gross product sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,288,003<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,875,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProductSalesAllowancesAndAccruals', window );">Product sales allowances and accruals</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,253,890)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,735,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,034,113<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,140,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProductSalesAllowancesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProductSalesAllowancesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RevenuesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RevenuesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331273593232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential number of common shares excluded from diluted EPS</a></td>
<td class="nump">13,059,777<span></span>
</td>
<td class="nump">6,595,422<span></span>
</td>
<td class="nump">13,059,777<span></span>
</td>
<td class="nump">6,595,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Weighted average vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_MoneyMarketAccountsAndTreasuryBills', window );">Money market account and treasury bills</a></td>
<td class="nump">$ 3,005,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,089,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_MoneyMarketAccountsAndTreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_MoneyMarketAccountsAndTreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271702224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementAbstract', window );"><strong>ASSET PURCHASE AGREEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Payable the settlement of certain purchase commitments</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivablePurchase', window );">Acounts receiveble</a></td>
<td class="nump">171,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PaymentsToSalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="nump">159,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Upfront purchase price amount</a></td>
<td class="nump">$ 9,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PaymentsToSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PaymentsToSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivablePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivablePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271979392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH FOSUN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunAbstract', window );"><strong>AGREEMENT WITH FOSUN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits', window );">Company License Agreement Recievables</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Upfront Payments</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UpfrontPaymentOfLess', window );">Upfront payment of less</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UpfrontPaymentOfLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UpfrontPaymentOfLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331272505648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH KWANGDONG (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongAbstract', window );"><strong>AGREEMENT WITH KWANGDONG</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Recievable under company agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Upfront payments</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_taxexpenses', window );">Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireReceivables', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_taxexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_taxexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of all receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331271805248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PrepaidClinicalStudyCosts', window );">Clinical / regulatory costs</a></td>
<td class="nump">$ 43,314<span></span>
</td>
<td class="nump">$ 23,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PrepaidInsurancePremiums', window );">Insurance premiums</a></td>
<td class="nump">85,744<span></span>
</td>
<td class="nump">71,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">124,055<span></span>
</td>
<td class="nump">147,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 253,113<span></span>
</td>
<td class="nump">$ 242,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PrepaidClinicalStudyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PrepaidClinicalStudyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PrepaidInsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PrepaidInsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331274924944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">$ 3,005,361<span></span>
</td>
<td class="nump">$ 9,089,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">3,005,361<span></span>
</td>
<td class="nump">9,089,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CarryingValueDuringTheYear', window );">Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_CarryingValueDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_CarryingValueDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275700064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CostClinicalStudy', window );">Clinical / regulatory costs</a></td>
<td class="nump">$ 1,153,170<span></span>
</td>
<td class="nump">$ 1,509,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OtherResearchRelatedExpenses', window );">Other research related expenses</a></td>
<td class="nump">36,003<span></span>
</td>
<td class="nump">65,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">61,484<span></span>
</td>
<td class="nump">284,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PersonalCost', window );">Personal cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,771,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedSellingExpenses', window );">Selling expenses</a></td>
<td class="nump">324,640<span></span>
</td>
<td class="nump">351,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">75,403<span></span>
</td>
<td class="nump">201,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_TotaAcrruedLiabilities', window );">Total</a></td>
<td class="nump">$ 1,650,700<span></span>
</td>
<td class="nump">$ 4,185,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedSellingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedSellingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_CostClinicalStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_CostClinicalStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OtherResearchRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OtherResearchRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PersonalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PersonalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_TotaAcrruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_TotaAcrruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331273532096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">$ 2,480,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_CurrentMember', window );">Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">1,448,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember', window );">1 - 3 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">1,032,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_FourToFiveYearsMember', window );">4 - 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_FourToFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_FourToFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331365781552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 932,150<span></span>
</td>
<td class="nump">$ 944,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="nump">$ 1,032,300<span></span>
</td>
<td class="nump">$ 1,032,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331272699024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityGrossProceedsShares', window );">Equity Gross proceeds, Shares | shares</a></td>
<td class="nump">217,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity Gross proceeds, Proceeds</a></td>
<td class="nump">$ 547,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Equity Fees, Proceeds</a></td>
<td class="num">(16,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityExpensesProceeds', window );">Equity Expenses, Proceeds</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsShares', window );">Equity Net proceeds, Shares | shares</a></td>
<td class="nump">217,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsProceeds', window );">Equity Net proceeds, Proceeds</a></td>
<td class="nump">$ 531,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember', window );">Cumulative From Inception</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityGrossProceedsShares', window );">Equity Gross proceeds, Shares | shares</a></td>
<td class="nump">721,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity Gross proceeds, Proceeds</a></td>
<td class="nump">$ 1,744,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Equity Fees, Proceeds</a></td>
<td class="num">(52,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityExpensesProceeds', window );">Equity Expenses, Proceeds</a></td>
<td class="num">$ (126,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsShares', window );">Equity Net proceeds, Shares | shares</a></td>
<td class="nump">721,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsProceeds', window );">Equity Net proceeds, Proceeds</a></td>
<td class="nump">$ 1,565,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityExpensesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityExpensesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityGrossProceedsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityGrossProceedsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityNetProceedsProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityNetProceedsProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityNetProceedsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityNetProceedsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331276684192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 1)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_DecemberToZeroTwoFourSeriesDWarrantsMember', window );">December 2024 Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,953,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 0.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember', window );">May 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">66,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">May 11, 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember', window );">October 2022 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">90,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 6.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">October 31, 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember', window );">October 2023 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">117,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">October 20, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember', window );">January 2024 Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,831,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">February 1, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember', window );">January 2024 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">91,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 6.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">February 1, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember', window );">June 2024 Seris B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,885,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">June 24, 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember', window );">December 2024 Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">3,907,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 0.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">December 17, 2029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ExercisePricePerShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ExercisePricePerShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_LatestTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_LatestTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_DecemberToZeroTwoFourSeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_DecemberToZeroTwoFourSeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331275620176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 2)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance', window );">Number of Options Outstanding, Beginning | shares</a></td>
<td class="nump">2,263,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01', window );">Number of Options Expired | shares</a></td>
<td class="num">(14,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance', window );">Number of Options Outstanding, Ending | shares</a></td>
<td class="nump">2,249,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A', window );">Number of Options Exercisable | shares</a></td>
<td class="nump">935,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance', window );">Number of Options Expected to vest | shares</a></td>
<td class="nump">1,313,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance', window );">Weighted Average Exercise Price Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 6.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired | $ / shares</a></td>
<td class="nump">4.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance', window );">Weighted Average Exercise Price Outstanding, Ending | $ / shares</a></td>
<td class="nump">6.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable | $ / shares</a></td>
<td class="nump">10.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice', window );">Weighted Average Exercise Price Options Expected to vest | $ / shares</a></td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Term in Years Options outstanding at beginning of year</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term in Years Options outstanding at end of year</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term in Years Options exercisable at end of year</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term in Years Options Expected to vest</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options Expected to vest | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options Expected to outstanding | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable', window );">Aggregate Intrinsic Value Options Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331272235184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">1,374,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,945<span></span>
</td>
<td class="nump">238,838<span></span>
</td>
<td class="nump">60,566<span></span>
</td>
<td class="nump">95,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RestrictedStockVestedInPeriod', window );">Vested</a></td>
<td class="num">(232,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expirations</a></td>
<td class="num">(2,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber', window );">Outstanding at ending of year</a></td>
<td class="nump">1,139,313<span></span>
</td>
<td class="nump">1,374,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RestrictedStockVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RestrictedStockVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331266083472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2024</div></th>
<th class="th"><div>Apr. 12, 2023</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Oct. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits', window );">Stock-based compensation related to restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,281<span></span>
</td>
<td class="nump">$ 185,019<span></span>
</td>
<td class="nump">$ 342,571<span></span>
</td>
<td class="nump">$ 370,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_NumberOfOutstandingSharesOfRestrictedStockUnits', window );">Number of outstanding shares of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits', window );">Unvested performance-based stock options granted estricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,549<span></span>
</td>
<td class="nump">59,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU', window );">Restricted stock units number of shares outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,443<span></span>
</td>
<td class="nump">152,432<span></span>
</td>
<td class="nump">40,707<span></span>
</td>
<td class="nump">22,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockBasedCompensationToStockOptions', window );">Stock-based compensation to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,673<span></span>
</td>
<td class="nump">$ 205,223<span></span>
</td>
<td class="nump">$ 355,407<span></span>
</td>
<td class="nump">$ 410,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnvestedPerformanceBasedStockOptionsGranted', window );">Unvested performance-based stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,945<span></span>
</td>
<td class="nump">88,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,945<span></span>
</td>
<td class="nump">238,838<span></span>
</td>
<td class="nump">60,566<span></span>
</td>
<td class="nump">95,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun', window );">Withholding taxes related to restricted stock units, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,109,117<span></span>
</td>
<td class="nump">$ 4,573,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,224,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantIssuanceShares', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,624,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantIssuance', window );">Warrant issuance year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,953,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfSecuritiesPurchaseAgreement', window );">Description of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAvailableForDistributions', window );">Distributable value of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from exercise of Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,398,023<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember', window );">Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PurchaseOfWarrantOfCommonStockSeriesA', window );">Purchase of warrant of common stock series A</a></td>
<td class="nump">3,907,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,849,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantsToPurchaseShares', window );">Warrants to purchase</a></td>
<td class="nump">1,953,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from exercise of Existing Warrants</a></td>
<td class="nump">$ 3,419,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,078,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfExistingHolderPurchaseOfWarrants', window );">Description of existing holder purchase of warrants</a></td>
<td class="text">the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#8217;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#8220;Series C Warrants&#8221;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#8220;Series D Warrants&#8221; and together with the Series C Warrants, the &#8220;December 2024 Inducement Warrants,&#8221; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#8220;December 2024 Inducement Warrant Shares&#8221;). The Company received aggregate gross proceeds of $3,419,219 from the exercise of the December 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#8220;Warrant Inducement&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisingHolderReleasedShares', window );">Exercising holder released shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember', window );">2024 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember', window );">Convertible Series A Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock were outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AggregateValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAvailableForDistributions', window );">Distributable value of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_CashAvailableForDistributionsAdditional', window );">Distributable value of dividend additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember', window );">2023 Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PurchaseOfWarrantShares', window );">Purchase of warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,033,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_CashAvailableForDistributionsAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_CashAvailableForDistributionsAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfExistingHolderPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfExistingHolderPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ExercisingHolderReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ExercisingHolderReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_NumberOfOutstandingSharesOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_NumberOfOutstandingSharesOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PurchaseOfWarrantOfCommonStockSeriesA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PurchaseOfWarrantOfCommonStockSeriesA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PurchaseOfWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PurchaseOfWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockBasedCompensationToStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockBasedCompensationToStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnvestedPerformanceBasedStockOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnvestedPerformanceBasedStockOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantIssuanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantIssuanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAvailableForDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAvailableForDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45331269722992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Oct. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share purchased</a></td>
<td class="nump">4,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from Offering</a></td>
<td class="nump">$ 4,687,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share purchased</a></td>
<td class="nump">4,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7(LRM1_UTR]R'U#H_"UU:JK?Z&F/Q2.T+(W5V=X8&&0JW_T57_<3T3 @K,>
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MZMAA4=2BS,ZCTFZ/^KU^]@V"L!4X4V@7>9F]@"30)_95D4B42BI0L&J?I80
MZ"N 6):UMW_Y38%-ZTFQ#YN0,- UMAA?%T>PH=/75RLGA=ZDK\2QC=,AL/VF
MH29O?^_1>,:+>?U.0D)Z9:XVCT:W9[?O/=[73_NU\[?D:D@LYT?D*MZ\U=C1
M;UZR?&'%/,DE2OD,AL*7 4RWV+RWV!PHL:P?S+\(I416?UUP-N5%!8#?9T*H
MUX-J@.W;H\%_4$L#!!0    ( ,))35KIEM!*:@H  *E-   8    >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULM5QM;]LX$OXK@N]PV 7J6GS16R\)T#J2;@^W
MBZ"YO7Y6;*81*DM924Z:?W^4K%@69T19*?NEC9/A,^0,A^+SB/3%<U%^JQZ$
MJ*WONRRO+A</=?WX8;6J-@]BEU3OBT>1R[_<%^4NJ>7'\NNJ>BQ%LFT;[;(5
MM6UWM4O2?'%UT?[NIKRZ*/9UEN;BIK2J_6Z7E"^?1%8\7R[(XO47G].O#W7S
MB]75Q6/R5=R*^L_'FU)^6AU1MNE.Y%5:Y%8I[B\7'\F'F#M-@];B?ZEXKDY^
MMIJAW!7%M^;#;]O+A=WT2&1B4S<0B?SO2:Q%EC5(LA]_=:"+H\^FX>G/K^A1
M.W@YF+ND$NLB^Y)NZX?+A;^PMN(^V6?UY^+Y7Z(;4-O!39%5[;_6<V=K+ZS-
MOJJ+7==8]F"7YH?_D^]=($X:$#;2@'8-Z+D-6-> *0VH-]* =PVXVF!L#$[7
MP%$:L+$NN5T#5VTPUB6O:^"UR3I$MTW-=5(G5Q=E\6R5C;5$:WYH\]NVEAE)
M\V8JWM:E_&LJV]57ZR*OBBS=)K786K>U_$_.L[JRBGMK_9#D7T5EI;G\0['Y
M]E!D6U%6UK6X3S>IR#<O5OC7/JU?K%_V>;+?IA+B5VMI_7E[;?WR]U\O5K7L
M7^-EM>GZ\NG0%SK2E_\6=9(AS=;Z9NMBMRNZ/B*MK_6M/VYEQV51))EUDZ3;
MY6^YM4X>4[PGX0369K/?[;,VEH<HU0A(-#6<O$YEX/,Z>[$^BZV0:\]=)JPO
M25DF,C4(8JQ'O!5E*O/XT9+03Z*LTP;N1I:\*,LVZR!P*SF+CE.)'J<2;=WP
M$3>?DBS)-^*=53TDI?27U-:_]_E[B]GO+&I3ADT(+6*S#'^H'I.-N%S(=;82
MY9-87/WC;\2U_XE-DP.8TX(U2_#3%2&NXWJ$7ZR>3F>$2:^A2;#()%@,X\%M
M9A]C,4@R.R:9G9?D9%?L\_JL)!\0W9-^+$G@!;Y'AGE90\-# I7T03-N!P%C
M@1,,+4/$,R=4!H$S!32"IM1EW+:'9C'F&X\H/T:4:R/:EM^R>9QNK4VQDWN,
M*FD6I-<ZPB*J19Q;-AQ,D\!G'E6";M)E:!(L,@D6&P(;S 3G.!.<-\Z$CVVQ
M83/!@<EKBER9W6L'3-O 5U=%!(H%K"GI04U!,Z5&HDF+6&<Q")U[#)VK#=V7
MM'YH]B?RP6G5R7?Y]"G%X3E<%_+'JB[33?.I:D)L[?.TKG3UI74VM[Y<,-@E
M=3A8U4SZ#$V"12;!8D-@@UGB'6>)9WZ6C->>!Q/KN-Q6GVH>? A1QU&RCV(1
M[BK%!\W4XINTB'46@[#ZQ[#Z^G4KD?M)21@VAXUX&[UW5BYY=/O+JHGB[6BM
M:;'GUIH/QD:)9U.UUDSZ#$V"12;!8D-@@TD1'"=%\,.38KRT I!'AQ'F*ON[
M=0 W;3+=2K(1+!J00-TK0C.UM"8M8IW%((K$[OFYK8WC@;.URH\,7)8F=VG6
M<.Y-EE15>I_*Y>JY8X;6_E%:=9\L\5V4F[02NMK3^YY;?!W:H/J8X_- 61&O
MC;H-C:)%1M%B4VC#R7,B[I"?/7G&:[3S/4RW'P2VLF-<=X:N,B_41R"*Y[J,
M^$JE(H9JJ4Z;Q%J38;Q[!83H)9#/XC6RFW;G?ECK3O2<LM=SGL?UG$\$4O<E
M<0)/I:-KQ%!=_L[%"J>Q(L0$@XJU4,/8]L(#T2L/?\A'QW^*"H\70\;(;,>V
M&9B,D,&#B$$T$*NS'4;3:+&V3\-P]:H"T<L*B!IW+3;O+4;&A1H]Y.S' 106
M")<Q(JKV<FW4;V@4+3**%B,Q&=?D2"\<$+UR@*ART\F&)'Q)"/,YIZY:,U ^
M.&12S2.$Y(0Y<KOEJ"H"YIU3Q_9MKF[@(@R6,@)7'=C-,7&.],("T2L+2!W=
MBD>]X*F'G%U'4$ @)."NJ[+#:Z-^0Z-HD5&T&(F)IHYZ?8#H!0*DCJ:3C5!W
MEU';<4$9027@D$@UC1"1$]L+7.9RM8P0YYQX<M_$F:N6$;1%)6ZDFZ-EU$L$
M9$(C>(.V22";=W@0@-<&G9WVD7X>5(C8@=5HTB36F@P#V--IHN?3/Y<':GW/
M7K @#1[A@2;=AD;1(J-HL2FTX8O97D2@/UU$&"]3"FF_2E,Z$UV%3J.$TR;1
MM$FL-1G&M^?95,^S3?$^.DE;U],FU],FX;1)-&T2:TV&H3PY1*"GT#J:1Q$J
MZ\D-J\VX&B4Z/>$FZ6YXMK]H&BS6=FD8K)X3TS/?QL\@>7K(V6<N(+L=(7E&
M_89&T2*C:#$2D_'-*>T9/3V3T<\@>13RS3&2UYE.DCP$<HSD8=['2![B'B5Y
MF-U8:'O^3,_DS_C1)8Z&5@LYNXX@QR5>0"7) ^N62;^A4;3(*%J,Q$131SVC
MIV<R>OP($YYLY"4^(80'ZD&+SM %>52SB!!83KCG>-Q3JPCQ+6T]UW4<4$5&
M638RF-%:ZSDVU7/LMYQWTD/.KC6$"#,:<+#2F?0:&D6+C*+%IM"&4Z(7!ZAY
M<8!"CNT&7N#Y:D%"<:!)MIIJ#,UQN?J2&+$#)6CT%;[6X3#<O91 ]5*"X<-2
M>F^SBQ.*!TN'NT [,.HU-(H6&46+3:$-S_OVV@'3:P>&#TTQ2+^70<!]Y;SI
MFD')0,X#<!080_,#IKQ;#A$[M6[U89B;-*W#829ZE8'I508=-6:0BB^)+?<=
MA(%3UO!UO+K'1-!4;GR^PT@_K-F1/5MT8+WHP/2BPT$9;2:V:!]"]V6QLY([
M\7+8*(X+IWK<N6L?0UZO<\ZH!Z:]T1L,1M$BHVBQ*;3AQ#BY[: 76"8FAF:9
MFWSKOV;(=0>9;:;F&CMJ .W":8^1?K"S4Z-S.(QWKW$PO<;Q1=&=M2=']5BS
MBP^*%2RP/==3]XI&W89&T2*C:+$IM.%DZ%49IE=ED,F@*3@H%C 6^+9Z?V'-
MX"F!)L]@B<7P'#\ 1[(10U!W1F419 !C===K(FSV*8=3;1'51/20L\L/JAR4
M<<?QP2D'HWY#HVB14;08B8GF!E^OP+#9IQRFDXV><O )L=4SV0P>'S@D4DTC
M<LJ!.YQ(%J^><L"<<X?:C+H^V&P:%4:0P8PI8*R7.YA>[I@X4H3'W^@U"095
M!1(XW"?PKJ71JQ)&T2*C:#$2$TVQ]6(+TXLM$T>*\&0C&HCG^HYK.VJQP1L0
MAT2J:82(C81LRP<?V$<BSCD/G, &=R8B_=AG9P .9O1R;2]?<+U\\19MD4/R
MSK@?J)>VUHB=RJ3/A JGH2+]0&=?=#U;H."]0,'?+E!P1"^@G%.H_/!I?0(!
M4_6)L_U%^D'-CNO9\@3OY0FNER=FL2(]UNS+X5"2P%F14;>A4;3(*%IL"FTX
M&7I)@NLEB5FLB$_+$'SZ0L0T2CAM$NG'-3L+9]^9X"??Q/!#=R;09[4><G:Y
M01%BA 49]1L:18N,HL5(3,8W9KQ7%_@/W9G DPVI]P@+0BQ1%H38C;$@S/D8
M"]*/?78&SKA8L3KY#JKF2\Q^3\JO:5Y9F;B7C>SWGL0H#]\+=OA0%X_MUU+=
M%75=[-H?'T2R%65C(/]^7Q3UZX?FFZZ.W\YV]7]02P,$%     @ PDE-6OAK
M$B>B!P  ^AX  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RMF7UOXC@0
MA[^*Q9U.N]*RQ'9>>RT22^D=TI;V2MO[VTU,\6V(.=O0]C[]V0E-@#AN5ZI6
MVI(P'G[CL>?QR^D3%S_DDE(%GE=Y(<]Z2Z76)X.!3)=T1>17OJ:%_F;!Q8HH
M_2@>!W(M*,G*1JM\@#PO'*P(*WK#T_+=M1B>\HW*64&O!9";U8J(EV\TYT]G
M/=A[?7'#'I?*O!@,3]?DD<ZINEM?"_TTJ+UD;$4+R7@!!%V<]4;P9(PCTZ"T
MN&?T2>Y]!B:4!\Y_F(=I=M;SC"*:TU09%T3_V=(QS7/C2>OX=^>T5_^F:;C_
M^=7[11F\#N:!2#KF^=\L4\NS7MP#&5V03:YN^-.?=!=08/RE/)?E_^"ILHW"
M'D@W4O'5KK%6L&)%]9<\[SIBKX'V8V^ =@W0<0._HP'>-<!EH)6R,JQSHLCP
M5/ G((RU]F8^E'U3MM;1L,*D<:Z$_I;I=FHXYH7D.<N(HAF8*_U'YTA)P!=@
M3.027.@\2_!I4Y!-QK3-9] '=_-S\.G7SZ<#I048-X-T]V/?JA]#'3\6@DM>
MJ*4$DR*CV6'[@19>JT>OZK\AI\-SFGX%&'X!R$.^1<_X_<VQ0PZN.Q.7_G!7
M9X[F?X*+[U=_S\'%S=4EN+J>W(QNI[,_P&A\.[V?WDXG\Q-;MU5N?;M;,Y-/
MY)JD]*RGIZJD8DM[P]]^@:'WNRWF#W)VT -^W0.^R_MPI@M/SJ6T!5FU#,N6
MIKILAWWHH3"$&)X.MOL1V"RQ%W@>QK7E@;R@EA<X$S3*_M%3JAKABNLRE/(B
M93D%Q4ZW>6L^IV;L;Z2>$ZP NF8*HECQ6!4=IAB5UC0&'YG&#W)VT$]AW4^A
M,XWG5#M-&:DJ;9$!LN)"L?_*%[;(*W?!7L9@@$+D'2768A8A+_3L68UJM=$;
M:E--,$E-KH0IVWV^Z.OD 2(E53:YD45'$D;1D5R;F>\EL5UN7,N-G7+O"JTV
M9__IP:4QK#E3Z$(O!"W2%Z $*22I"%>.QT^/&L764ANWQ/6AAO=QE[?-H!\F
M?F2/(:EC2)PQS!5/?_0-/S.0\I5>5,C.L9&T%(1)E$3QD="V6>)[V.L0"KT&
M<)Y3ZGA)BL=R;"P($V!+\@TU>,L9>6 Y4R\@S?5 80NF8WDB0F= 6>O7[G?V
M%1YWML4DP@D,$M@1Q1ZFH3.*/X@I1 60)"_5W[_DE$IFU0E;(I"NG>VA83&,
M8H3]&'6H18U:Y 9AV>?RJ'B:V2C+<O+:]UV%=.?^@RKI1WD[[(QF40"=Q!V.
MTI1O#'%T2:5L2QYR:HT9OSV\VB9!F 1)UQQIJ W=V+X6=$U8!NBSF<FT2A)7
M2RIV6;,*]BT5R(O]8YI;[*#G1S#T.V0W-(=." ZGQ5:CG L]C*P"@[=[M&W2
MAS#P<1!TB&L0"MT,K=.^)B^=.6\#$84PQ)Y_K+-MV$<1]+R@J[(T\(1N>FJ=
M8D.;W%MUMDG81P'VL1\>"[58QDD8PZZ:TE 3NK%Y51>2O(3]7@VQ2K;Q,0Z#
MN#4$;(91F,".M29L& G=D+PJ)]!;.MO<:RELF^B)!A'LFOBH@2-RPW'VGK6N
M339JDTY/G#C$&"9'\JVF(8Z1%R4=^ALL(OA3.Z[I['XR?\^."SEQ^[.$^2AO
MA[W0X!8Y"3:\)&HCS$I&+PQ61/R@RA0<(&EJ7G=E$+TY\"PF*$E0G'0LV%'#
M1.1FXK7@*:69! O!5^]9U* V^NR+&HMA<F1XJ+F!)'H#DAN1+HFAHY:Z%F:F
MZ"XWI*3_;MC:["JMRMOX:VFVD!1'(>Q@$&H B=R K*>WEKMEF9[B#R]ZEF^I
M?,\4;[.QH\O;AA#Y08"BK@ :B*+PI^;WQ70VFHW?,[^=</[I^?U!W@Y[H4$T
M<B/ZFKR8T67&W1-3RR7/,Y,^19ZI657FY>%=>9XAE6"I>9)F@P8V!;.OW9 %
MTTFRO_+?!6ZQ"T+?ZUAUH(;FR$WSPP*@05D7 ;V=7)F-3AF F5VO>[(OYF3&
M&DR;X*TAVC8) @Q1&'8$TD >N2&_EYL%*TB1TMWZA#_D[+'<%-LS8(&Z'WKP
M>.5GLPN0GW0LGG&#?NQ&_V$&Z#,5*9-E!ER;8-R&.<9)7)Z?'NBV&$*O8TF%
M&]YC]S:X+FB?=@N6SP>EK<K VZ4-MW>^& 7ZW_$)D,4P\!'RHZ[N;YB-W<R>
M36[!^61\,QG-)WK9 LI*-YJ=5Q\F?]U-[T??)[/;N55_&\S]$$*]H#J>P!9+
MZ"=!&'7@$.^==;L1WBGX"WB@CZPH3!H,*:E@/+-&84,UBG!RO*FP&$9)G 1=
M!Q6X83IV,]T1!#5;8*?\-K6Q#\.PM7FS&.I2:X9;A_R&[]A]GCV_N[[^/KG4
M@D??0<U*/9PNKFXN1[?3JYG]NN%##ZH_RMMA'S1+!.S>9Y?75.7IQ8(+71$4
M-1BTAMW>1">1WRI<ED-J+^X<:@W$L1OB8Z[77:*\_GSK]!%LUMIJ]U279FM(
M4>NJY!A]%A.$XR1I%>/!WBWBBHK'\G)5@O(4H[J2J]_6%[BC\MKRZ/TW>#*N
MKF$;-]6M\"41NC)(3<B%=NE]C70OB^JBM7I0?%W>53YPI?BJ_+BD)*/"&.CO
M%YRKUP?S _5U]_!_4$L#!!0    ( ,))35HR2/ZN 0D  !H5   8    >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&ULG5AI;]PX$OTK1$\PF $4]^&V<_@ VO8F
MD\4D,>+,++#?**G4S;5$*CS<Z?SZ?45*LMIQG,5^L%L'JUCUZM5!G6Z-O74;
M(B^^-K5V9Y.-]^WKZ=05&VJD.S M:;RIC&VDQZU=3UUK2991J*FGB]GL>-I(
MI2?GI_'9M3T_-<'72M.U%2XTC;2["ZK-]FPRG_0//JGUQO.#Z?EI*]=T0_ZO
M]MKB;CIH*55#VBFCA:7J;+*:O[Y8\OJXX&]%6S>Z%NQ);LPMW[PKSR8S-HAJ
M*CQKD/BYHTNJ:U8$,[YT.B?#EBPXONZUOXF^PY=<.KHT];]4Z3=GDY<345(E
M0^T_F>T?U/ESQ/H*4[OX7VS3VOGA1!3!>=-TPK"@43K]RJ\=#B.!E[,?""PZ
M@46T.VT4K;R27IZ?6K,5EE=#&U]$5Z,TC%.:@W+C+=XJR/GSCY_>KCZ\^_?J
M\[N/'TZG'AKY^;3HI"^2].('TL?BO=%^X\0_=$GEOOP4E@SF+'IS+A9/*KRB
MXD <SC.QF"V63^@['-P[C/H._T_WDO3R<6E.B->NE06=3<!X1_:.)N>__C(_
MGIT\8=MRL&WYE/:?VO:T]&_SW\58@_@@?; D3"4N@L-BY\1[JJ4VA;%>:?&)
M"FJ]L>)FYSPU!^+SAL2E:5JI=[_^\G(Q?W'B1&L55A2F:<@62M9X8,I0^$S\
MO:N)G(+W+Y8GF=A*)V2+MW=4BGPG/)3]=7!S(-X84PJI2W%EPUJL2G!6.6]E
MS,'?>*/%[.3-U2I>S4]^%S#MGT$3(CY_)5!EHBJ/ N.1^Y[]V>Q:D[)7./H:
M8%4)2^!KJ9RQ)=E![Q\W5U=CQ8@:E)A6!@>IK<'-@5@Y%BQJXV Z%GTPGL11
MAGV5Z_U-_A5? K:)_EUBM<>ZZXU$+2@H>%7(VF7BG09C^_V[58,)<!F,IB:'
MC?-7D=6'!^)CL$*C7O5[E72'XMA&=Z.?RBMRP +YSQ%!M53UCI4%%P.<LUL<
M6J]*R@0P,P#-BO>72RODVC#B,&VK_$9X9;]1*]-**=[^>?U\WJ])<(^A-CF0
M]3O(;E2Q$7A*# "\QLX+1HNCXZ@PB/"7("W>LQRP(%U**W:$?YR\_?:F9>:B
M?CO422?H:XMZG(!G596RL.,I34=[3!6($7 W/6A*KS-<HT>5T07N%,X$6T0
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M0% QTJBFK5,("X-.%'=(YH/-=2EXV'HT5GE7V[)AL.#L&[Q/R=F!@A1S/'3
MSG=[&<YX,R"1JK ,8PVOER7 X' ^X@(BT&LEC,JEVRN4G=4Y<4R*!'$C;_<T
MC7R$,C JAC5"B370'(N%ZA'H UC'RIV((1VFS%3B7'!1,*$+\Z&M'L>H+U?[
M1&OD+K7#V.,]M\5:[K)D'*49KP"<0#7K]X@<(":/9G X!? @-DJN&](6F^]*
M8K\[KU3>C0X6ZELJ,V #JF5<@-KM..4&XA<8OJ1V,L+U6/""[D.7.-=WB>V&
M-"9LXFK 1O,4R^W%_$AYC*)^/)26NE, UX78<,<\2VF6%A>2YW/V$\?VXG9C
M:N[;+,=G#<%S ;N)4;=K-8JMPF 6Q^\4H9\7CS26$<73#91A'0@1&H[ZV(&M
MJNNG"MF][8 '>8@-4DOJ9+@</$@J?HMQ> @>7H^X&%F#%ZY*H/+K<>^/?0 $
M4#XYTIT -']<84L1_G2ZZ7*;3VJ=7]H\EHRL,.\;3Z17-W%T-G=+]@B)M'B0
ML^E$TDV!HX'CZ<XUU/QX#2Y6*>\BZF"-"Q4ZK^(]$7^VN+>NWL5QNE!MC/&]
MK7TY34P=G;,VLJ[^EZ,19W77,+L@8D!"[<;9E]SSA%2C<.TY>5NY2W& YM"R
ME<_F1Z^RV6S&?PQIE./7W=E_? Z.YP\(8U1EH[EJQ5E ^[X!=1/F8Q]*IJ/O
M5:@'Z_A5+E8\[=.GJ^'I\.%OE;YWW2]/7PW?2[M6V*VF"J*S@Q='$V'3E[AT
M@P-H_/J5&^]-$R\WA!)O>0'>5P8S>7?#&PR?0\__"U!+ P04    " #"24U:
MZIK *P $  !H"0  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*56;4_;
M2!#^*R-7JD#BXL2A%$$2*5!ZY4YM.0)WGS?V.-YVO>ONK@GY]S>S:[M!H@BI
M7Q+O>N:99]X]VQK[W56('AYKI=T\J;QOSM+4Y176PHU,@YK>E,;6PM/1;E+7
M6!1%4*I5FHW')VDMI$X6LW!W8Q<STWHE-=Y8<&U="[N[0&6V\V22]!>W<E-Y
MOD@7LT9L<(7^OKFQ=$H'E$+6J)TT&BR6\V0Y.;LX9OD@\*_$K=M[!O9D;<QW
M/EP7\V3,A%!A[AE!T-\#7J)2#$0T?G28R6"2%?>?>_2/P7?R92T<7AKUGRQ\
M-4].$RBP%*WRMV;["3M_WC%>;I0+O["-LEF60-XZ;^I.F1C44L=_\=C%84_A
M=/P+A:Q3R +O:"BP_""\6,RLV8)E:4+CA^!JT"9R4G-25M[26TEZ?G&Q7%VO
MX.M'N+F]6EU]N5O>77_],DL]0;- FG<P%Q$F^P7,"7PVVE<.KG2!Q5/]E"@-
MO+*>UT7V(N 'S$<PG1Q!-LZ.7\";#GY. ][T=_V,,,?/PW"+G+E&Y#A/J <<
MV@=,%F_?3$[&YR^0/!Y('K^$_GJ2+\,<9(?P+!3<54A]D)NZ$7HG]09:+=I"
M>BP@-]H9)0O!AU)JH7,I%#A/%]2$WD$E'A#6B!K(]498DI,ZP-F"I)$JUU?A
MW&K/X(V5!-(H=+!!C58HM>/WV/BHZXG.O0[F5VS'@2EA6:.5N8"#MV].LVQ\
M?C]:C>#/Y?(FG"?GAT"CB+0]B=5[3*6.(RKTNBXB&[8@M?.V#4/ @3? W0R3
M\1__C& 9R!-7M3MBV1T4!K3QI).KMJ!@*<6<(LQ3_-(83Z((A72Y,JZE>J Q
M]:.5'!FRLT8(-:)#1(DSQUTA:3P7WA%<QX"81FJV069KH6DP\NO SN$KLD02
M7G!>B+DHOM$$B?<'K"I=2 Q!:_9%$=^\M9;O]F0/@QE9(#NB,4?G:%X'%THA
M;>]5",4HU!1=T!0,Z:-U846,-2NP1[ZRB"%F3CY"'0<%\J  :G.LUVB'5C\B
MIW<A!;UA246SYO 75!4\PON$/&\4'QL:^%W$6:QL*1(EY8C<W:&PH]_K E>9
M5A7,B'<@5S'I?&MU7#)#T;T>D./"=>18SR(53E=\0XM<1J9<_Y/WYPZ66K>$
M<8N-L1[(:E_1?P].LZ-=B/]J-<)TW(>WE KWFB-TUXJK0'J)D<W58UX)O0F&
M:^G"_NV[<75UV??A$6PKF5<]7?<:7T.VGC *%NEAVC55E[2?^0IQT=&9T7-#
M-MW;?C0[-F'',QL:0W$1#K?#9\0R;L^?XO$;Y+.P&QH7H+ DU?'H_;L$;-SK
M\>!-$W;IVGC:S.&QHC) RP+TGH="?V #P\?5XG]02P,$%     @ PDE-6A7;
MSFY>"@  71H  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6RU66MOVSH2
M_2N$[^*B!93$L9U'VR1 ZIOT!N@C2)J[V(^T1%N\E425I.)X?_V>&5*R[#A!
ML8O]T$;B8QZ',V>&\MG2V!\N5\J+I[*HW/D@][Y^?W#@TER5TNV;6E68F1M;
M2H]7NSAPM54RXTUE<3 :#H\/2JFKP<49C]W:BS/3^$)7ZM8*UY2EM*N/JC#+
M\\'AH!VXTXO<T\#!Q5DM%^I>^8?ZUN+MH).2Z5)53IM*6#4_'UP>OO\XH?6\
MX"^MEJ[W+,B3F3$_Z.4F.Q\,R2!5J-23!(D_CVJJBH($P8R?4>:@4TD;^\^M
M]&OV';[,I%-34_Q39SX_'YP.1*;FLBG\G5G^J:(_1R0O-87C_\4RK)V,!R)M
MG#=EW P+2EV%O_(IXM#;<#I\8<,H;ABQW4$16_F']/+BS)JEL+0:TNB!7>7=
M,$Y7="CWWF)68Y^_N'_X\N7R[E_BV[6XO_GT]>;Z9GKY];NXG$Z_/7S]?O/U
MD[C]]OEF>G-U?W;@H8]V':11]L<@>_2"[&/QQ50^=^*JRE2VN?\ =G;&CEIC
M/XY>%?B'2O?%^# 1H^%H\HJ\<>?\F.6-_R_.!]F3W;(IF=Z[6J;J?(!L<<H^
MJL'%[[\='@\_O&+YI+-\\IKT_]'R5V7OMOS-^*WX=:7BUNHJU76AG#!S,365
M,X7.)"?B@U,T>.6\1E9AQ52Z/.'_Q=7/1C_*0E7>B6NIK?A+%@TOO]:5A$A9
MB)O*>=N4O&9J5::]N-/N!W2"JJQ?"5EE+*BF->*FK"&('R'FLZD6>Y]!!)FX
M=$Y!Q&>%I';B>Z[$W;<'(6E4:"=TI3W4%2M18D4#14)ZD1KG$[',=9KCN:RM
MILT>F^-Z(4O3!%TT6I!T46@YTX4FV[*_D=20!3Z-D[5<!6=*F2G2@9F9PKSJ
M28 N+$H5^P$@52+JHG'P==5ISK0%U[&)9'[:6#(:9Q"6!4$8AP@ X,"IJ2(D
M]@4(3A!X.*!J$1:ZA+5O0.*:F5,_&^SOH^)S:YI%#L;OV>N5+<D7&DFEM2L2
M_"HTT:%=SL2I-^"_QKUE9Q"9.-9,O)%I:AN5O=T",PE^DYZF@E[K];]AZTP6
MB"(.J%?@X) 0Z@F5#W]WG)3FU691L5 J+@(Q*:D"[%$Z4:' &O.H[!8F >LY
M![/Z1:37YC>.8*35F^I*Y7.#F+*F?"UFA#<\K:0M-$R+!Z&0+WC4<*QQ:MX4
M.)2YHC#LS6X=;5-U^,91*RLW5Q9>+RO\R77=;FM _[8($< .1C.FR!\ZRZBH
M?65PI3.5G,'Y%"F-WH+VJ"=E4^0; @#1RER"T;JQ:<X6[%"U#[; A"$T7H!Z
MC6YW7!LH[/9A7UR&?8'3XJH-P;T((49B+JTH]:4+'K3YU@::0TAC2,%K/DF-
MU=CDNP7D\//$V6?N:M$#%()['BBJ#&/=&4)JUR:24696Z$5PH0MSAQ;$Y[2V
MS44^<;AX.!)EJ.B\UKF@NC4/8@T8FC2S!)<#H3W>' 4SK:9%@W8 #W"X0/@N
M$K%0"!GB3I@D,Z2YIOBFM&R%T\88^% 0LA 611!17V!*#.XG3_$N(TS@'EDM
M0@Y$W4[,#,R+\Q7A5.UU*5.;*A"(?P%5( K282:;Q]!=;^/#%92F12\-P^2^
MN%./JD(]NPLGPKB_0:TD,<%ZA^)'COVU*I1R^FVWA2,"A12XI#X>T93[0\JY
MFXIMLAG3"D]>WD\!2:U3<3P\WO2F%YFU-5D#GK51S3)7%3,!@.66G]FRBQ(H
M1DC"2J_=7!.AKKK,MQ3+*5F(+C8F1"N>,(OMK++[XE9MI/SOOYV.#D\^N+![
M[5^[ 8?Q@MPEX.[T$T'6,4>P_E&M6J[WVA>J+=LFC961?=V6AD8E'#'BHJT(
MY&7?_.^6*W4(@K9P@*V4R!JUS6Y\<%N.$<"=<Q%2SXG3XP#=>1*;IU[]XH8_
M$97B:OHH$4+4#!2X8]$\LN%V\V 96]0D$H(=%&:N%V>ML@<$)5;<DS%NDU@8
MF'8Y?'2UHG8,/4V=2P1*JB$Q5OQE;B"?0EFF:,1<B'2JY8$*0QUEO+GI(5!@
M@:QQ$D_<%<+_\1!%:[5E!86NS9X'KFNQ6&/ V1G;"-*JJ_@R5U0(,NW"^5%P
M[<$DXB\ Q/A"^L+*$G,JMJF90)6Q"S63Z0\7HV,64&JA#J#R:<K"&2KB?ZLT
M4K!O+&ZQ5+)=&XB\DCC::63C7*>2..*3-2BL]89,,Y\38\]66^-;SA+TZ,94
M8#6GGUJZ5G0!$[@^J7*&U&NO4+P,#V.P)-$WA)! ]QZ0DY3^]6US]SUDOSS+
MLEGN^FF76_\0>_@W24:GI\EP.([OI\GIR5%R>#3> K;G+-<):OR ,_:\&26C
MHW%R^FXHWM+K)#D9'R7#XS%>OZI-;:-D.)XDAX?C3OOA9)@,L747.3,SC3Y@
M;-$4TAN+OE=#F >AK]M!0D\]Q;K6-6',2S)\?, ](=U@!S2 \49 C4V,L9:,
M9NT<XIGBV\*!=?&PJ@A] Q>B7&.XO=U@/PI.9^%VHQJ3'-2N#;^%.*2QM5?4
M$@6IZ(3O";D]^NR!>#<K3G<"?P<(Z%2:@NT*C!?IK4=]8!#*:P0J>J',H,S'
M9B>&;@&,JG YI-:GH'J+$R9$PL5NJ0M4@ I;9JKO%[-^I/66\3=[ME!6[0Z\
M8G#T_ \@S1MD;$RD!B"Y9TCH&(@[L&!#-VULVQ=9=@> -KPBD+?YC7>XKB03
M/%;I<M98M^Y\J)N4Z'S9A Q+"Q/NN^'ZQ[[CN2CDS(062<@%DKILNQ2V!I=[
MS0EE55OQ=UED,Q=C:\L0N38S-%(^-$ XWR9M.^,73>UZNVA.[P80,H$_(B "
M(G@O"N)O>YI/))P01P17V77?P,>X7MFRL(ZE$7A169'6MY<AN(T01<JO-^V#
MZ-9J7Z""V,TB3"GA4<9F=&^CZQ+5,R'G/K8_KR7=KPF?'+TH/*7/*)FT8@7,
M-I/]6<CWM=_%-']%*U]X?S: BO(K7G9'N_V<*<H_73T:!!J)[Y]A'\PIQ^UE
MN,Z+JS8TF($//Z E,>F/O8]\NA0GF)5KBL:"FPJ-MA+?Y1-V$>M_YH(#$[ <
M=5#<Y^3)%9(.%H69,'2]43I_L62B^0+]9AG7"81H&I0XDM@V 5D6K@OM%:'Q
MW6TQTT5#3<75[3T@2F7CN#1DZ!J,6)H&O58N<?V9*?2HZ OT'N] -QJRLS9T
MRZ'+6=6P@9"Y:<)F0>KKRQK;?D;X[[H%]NYPG R/WB4G)R<\<9P<O3M*)J-1
M0FE:*_[:7JSH KZ^\'%OR!_*Z1J,PB87:LOLQH6E 2^RD\(K#2D?G:!6KVA/
MM[^=8W5T JN&0_&HN-NE&S2J+S?7%$.@1DINGZ-7S67@+$99.]>$VSFP?.9]
MLG8_EG%)A>E1\\\3:X)ZKJO/NW3$*-\K^A_XV!5?)BI7=(%!W_W0#HI8S(C2
M=GTO/NA]\D>57? /&\1DZ&C#U_]NM/OMY#+\9+!>'GYX^8*V5N-F5Z@YM@[W
M3XX&H5%M7[RI^0<$W)I1TODQ5VC;+2W _-P@&.,+*>A^4;KX#U!+ P04
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M"4W\;00J3.6<G!B?Q"KO]T4H2%S:LI)F(\@$<I0+98(5THB9]U")F]IE!>9
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MIB$^%OAK@1P;8'UA0;1YX0#=WQ_3?P%02P,$%     @ PDE-6D=.\ZHJ P
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M"XG&;Z#U7&NW-7R [LV=_@902P,$%     @ PDE-6KN/QPA^ P  P@<  !D
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M:JA[,1I8(+HMT3F*U^UD;KC2<]Z:N5ZL*$R ?M]RKHZ.2="OZO 74$L#!!0
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MT,Z2Y^*L=SXZN9B*?3+X2_,J[(Q)(ID[]U$FU_E9;RB$V' 6!4'AL^1+-D:
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M4 =7<;Z[&L@5A+1S-8?O)O4G]." 0)>-]V(VHGV:T =6/M 4X\-N_!1 W04
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MK+TCXX!VEO*-HL;F$]M^,,J5:6M3'Z.5+FP=48GO!,/Q7ZB2OKRI69[-$QD
MO"0G<=?5\"U,G*2\8Z46D+.EPKQ\FU$<LFWKO7WT=ZW?PDZ/ 5LTGLVL?LBI
MCJI>;+!GU@$I(G$&EB53%!@M$-P&.G_@^3U+]YCYW\Z'-YGT<-(@Z"P&1G(
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MA$,69XR/L(:2V\^4BJN<+Z+"%RZF'&H/<GY 01FG;8V:'&J]K>TMAOBAOOS
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MY&C8@/8+K=UNP@&&?RC+?P!02P,$%     @ PDE-6K5AEEI1"P  H2(  !D
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M)NEX#8B29U?**[1[:EA%BE$PE;X/LY6U<Z4_NH,MO]$^:M0/T%02V'K0_-5
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MKZX# W@W-3I'LKKMU!63JN];,U>#%KD.4.=KQN3>T0GZT1W]!5!+ P04
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M!@[(SOS=1(NZ-=Q::&/?-BS,>XG2)IC]C1#Z,+$%^A<X_@-02P,$%     @
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M5.W,KK2K_6""@6B2F+$=F/GW:R=IAD :!=5\@%S\/L>'\V*;>'+$Y"O=(<3
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MQWLT'3R,!O>#H#MZ0MT@>)R-G@:C!S1^_#H(!OTIN@I!X"3EU^@3&C,:YY%
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M0>KS!(8O%4R5?]&QBNW[%DH+I45>@V$'.>75$S_6/IP @*<=X-4 [S6@]QV
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M7JT<[J#!)]($P/N-@(]C/3$"S;\,T;]02P,$%     @ PDE-6N"<XYV7 @
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MZ3<+A G0^RO.U>O$M,7N%8S^ %!+ P04    " #"24U:0=VM27P"  "+"
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M-M^@\-/0?#&CPORB35Y;KULH7@G)D@*L%"0DS:_XJ3B'+8![#. 5 .]4@%\
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M>-[Z\HEDF>D>4R95+S+#I?I: *X+U/Z<,?DRT0VI_/Z(_@%02P,$%     @
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M;]C3Q>Y7>$GBQ5EH)TLZLF20;*'?UK1>#ZYNTE]=/XS#4T)+6:1G^)FI2SO
M]-__1AM5VALNB<+>?ZY?Y6,O30,[5-9!98-0/[@BS :5];=D'.$$G\Y5OR[T
MT@B'\0F7>W2,F"/\*Q%K6DO$8*65^#S1R41[++8=Q3?-R7++E3ZGFF:IOR1
MF +]?,6Y>NR8PZK[-LG_ E!+ P04    " #"24U:UE/T5F4"  #R!@  &0
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M65;L;BA94JYO4-=7C,GG SU!W6>>_@]02P,$%     @ PDE-6I:_#<;S P
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MA5!:A*+Q"M;&G\MG M ["B;]('$N/26O8BV#!IA#:3J49D!I)I1F06DVE.9
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MET11DO@1P/P*H@A#8#?B"*8 -&!(%#7GX,YY%*[/J7#S.]'D%U!+ P04
M" #"24U:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MQ]^7CY.=M_>.LX-_48M?4$L#!!0    ( ,))35HNTOC K@$  ,H:   3
M6T-O;G1E;G1?5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQG=(? 9>VUY9#7\!-
M-B0BB2W;4'C[.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&\>&'-I
M0;5RL3;4A)U<VUKY\&J7S*ATI9;$Q'@\8:EN/#5^Y%N-:#Y]HERM*S]XWH;/
MKM3-++)4N6CPN"]LO6:1,J8J4^7#/MLTV3>7T<$A#IU=C2M*XX:A(&)G'=J=
MGPT.?:\;LK;,:+!0UK^H.E2Q;<6<WU7DXGZ),QEUGI<I93I=UZ$E=L:2REQ!
MY.LJWHL.^YU]N&':/_G5_IU,GV&H7%AM7)B8I<OMCB-INT<F")'U9?\13XY!
M^NKS43OMC+)?>H?K_=!VU<W#L6ZY_HZ_SOBD?V$. 9)#@N1(0'+<@.28@.2X
M!<EQ!Y+C'B0''Z,$02$J1T$J1V$J1X$J1Z$J1\$J1^$J1P$K1R&K0"&K0"&K
M0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K1"&K1"&K1"&K1"&K1"&K1"&K1"&K
M1"&K1"&K1"%K@D+6!(6L"0I9$Q2R)O])UG>M5W_]=Z5=XUJ5S=&?=;^PYI]0
M2P$"% ,4    " #"24U:!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,))35J& ^II[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M ,))35J97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ PDE-6C-5=Z[1!0  OAX  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M ,))35K@BL#LV04  ,D8   8              " @10.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #"24U:#:%('? "  "@"@  &
M            @($C%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ PDE-6K#MZ T_!@  21H  !@              ("!21<  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( ,))35KIEM!*:@H  *E-
M   8              " @;X=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #"24U:^&L2)Z('  #Z'@  &               @(%>*
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ PDE-6C)(_JX!
M"0  &A4  !@              ("!-C   'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( ,))35KJFL K  0  &@)   8              "
M@6TY  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #"24U:
M%=O.;EX*  !=&@  &               @(&C/0  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ PDE-6K&*PG&D P  5P@  !D
M     ("!-T@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M" #"24U:1M1$F5X%  "+#   &0              @($23   >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( ,))35I'3O.J*@,  &H'   9
M              " @:=1  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!
M A0#%     @ PDE-6D(&@Q)J P  ?P<  !D              ("!"%4  'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #"24U:NX_'"'X#
M  #"!P  &0              @(&I6   >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+ 0(4 Q0    ( ,))35KQ>-XR?@(  +8%   9              "
M@5Y<  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ PDE-
M6L)!%]/= P  20D  !D              ("!$U\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #"24U:?)LC#IL"  "U!0  &0
M        @($G8P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( ,))35HL \H?W00  " +   9              " @?EE  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ PDE-6M<ONDUC#P  9S,
M !D              ("!#6L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #"24U:[/"TA,,#  "M"   &0              @(&G>@
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,))35JU899:
M40L  *$B   9              " @:%^  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ PDE-6G([9]R2 @  Q@4  !D
M ("!*8H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #"
M24U:9]^FG)<"  "-!0  &0              @('RC   >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( ,))35J/6'8NHP(  /T%   9
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M970R."YX;6Q02P$"% ,4    " #"24U:H[]\ ,H"   J"   &0
M    @('MH0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M ,))35H<ZNSD6 ,  #X,   9              " @>ZD  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ PDE-6N"<XYV7 @  6 8  !D
M             ("!?:@  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #"24U:+RH=NY$"   I!P  &0              @(%+JP  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,))35IT/85GN@(
M /0'   9              " @1.N  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ PDE-6G5=M-JK @  $0<  !D              ("!
M!+$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #"24U:
M0=VM27P"  "+"   &0              @('FLP  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( ,))35IEW%%HX (  *<(   9
M      " @9FV  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ PDE-6M93]%9E @  \@8  !D              ("!L+D  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #"24U: @@U_T("  "Z!0
M&0              @(%,O   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( ,))35JMN\VR%0,  ),*   9              " @<6^  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ PDE-6D1-U<EQ
M!   <Q8  !D              ("!$<(  'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #"24U:EK\-QO,#  "@#P  &0
M@(&YQ@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,))
M35H9"A1"1@,  #T/   9              " @>/*  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ PDE-6B"+C[9I$0  2,<  !D
M         ("!8,X  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    " #"24U:AN0PPAH#  #>#   &0              @($ X   >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,))35I)E!C3' ,  #02
M   -              "  5'C  !X;"]S='EL97,N>&UL4$L! A0#%     @
MPDE-6I>*NQS     $P(   L              ( !F.8  %]R96QS+RYR96QS
M4$L! A0#%     @ PDE-6C*BD:D !   J1T   \              ( !@><
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,))35I''&"YI $  )L:   :
M              "  :[K  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( ,))35HNTOC K@$  ,H:   3              "  8KM  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     T #0 (PX  &GO      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>241</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - ASSET PURCHASE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AssetPurchaseAgreement</Role>
      <ShortName>ASSET PURCHASE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi</Role>
      <ShortName>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - AGREEMENT WITH FOSUN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithFosun</Role>
      <ShortName>AGREEMENT WITH FOSUN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - AGREEMENT WITH KWANGDONG</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithKwangdong</Role>
      <ShortName>AGREEMENT WITH KWANGDONG</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - STOCKHOLDERS DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiency</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ptn.com/role/NewAccountingPronouncements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyTables</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiency</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - ORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/OrganizationDetailsNarrative</Role>
      <ShortName>ORGANIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/ORGANIZATION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative</Role>
      <ShortName>ASSET PURCHASE AGREEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AssetPurchaseAgreement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithFosunDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH FOSUN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AgreementWithFosun</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithKwangdongDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH KWANGDONG (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AgreementWithKwangdong</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AccruedExpensesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails1</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails2</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails3</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ptn-20241231.xsd</File>
    <File>ptn-20241231_cal.xml</File>
    <File>ptn-20241231_def.xml</File>
    <File>ptn-20241231_lab.xml</File>
    <File>ptn-20241231_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ptn_10q.htm">ptn_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ptn_10qimg16.jpg</File>
    <File>ptn_10qimg17.jpg</File>
    <File>ptn_10qimg18.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="387">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ptn_10q.htm": {
   "nsprefix": "ptn",
   "nsuri": "http://ptn.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "ptn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptn-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptn-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptn-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptn-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ptn_10q.htm"
     ]
    }
   },
   "keyStandard": 159,
   "keyCustom": 82,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 19,
   "hidden": {
    "total": 45,
    "http://fasb.org/us-gaap/2024": 28,
    "http://ptn.com/20241231": 12,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 107,
   "entityCount": 1,
   "segmentCount": 28,
   "elementCount": 335,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 387,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://ptn.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ptn.com/role/ConsolidatedBalanceSheets",
     "longName": "000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
     "longName": "000004 - Statement - Consolidated Statements of Operations (unaudited)",
     "shortName": "Consolidated Statements of Operations (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "ptn:ProductRevenueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "ptn:ProductRevenueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
     "longName": "000005 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)",
     "shortName": "Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "000006 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://ptn.com/role/ORGANIZATION",
     "longName": "000007 - Disclosure - ORGANIZATION",
     "shortName": "ORGANIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://ptn.com/role/BasisOfPresentation",
     "longName": "000008 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ptn.com/role/NewAccountingPronouncements",
     "longName": "000010 - Disclosure - New Accounting Pronouncements",
     "shortName": "New Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ptn.com/role/AssetPurchaseAgreement",
     "longName": "000011 - Disclosure - ASSET PURCHASE AGREEMENT",
     "shortName": "ASSET PURCHASE AGREEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi",
     "longName": "000012 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
     "shortName": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ManufacturingSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ManufacturingSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ptn.com/role/AgreementWithFosun",
     "longName": "000013 - Disclosure - AGREEMENT WITH FOSUN",
     "shortName": "AGREEMENT WITH FOSUN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:AgreementWithFosunTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:AgreementWithFosunTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ptn.com/role/AgreementWithKwangdong",
     "longName": "000014 - Disclosure - AGREEMENT WITH KWANGDONG",
     "shortName": "AGREEMENT WITH KWANGDONG",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:AgreementWithKwangdongTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:AgreementWithKwangdongTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "000015 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ptn.com/role/FairValueMeasurements",
     "longName": "000016 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ptn.com/role/AccruedExpenses",
     "longName": "000017 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ptn.com/role/CommitmentsAndContingencies",
     "longName": "000018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ptn.com/role/StockholdersDeficiency",
     "longName": "000019 - Disclosure - STOCKHOLDERS DEFICIENCY",
     "shortName": "STOCKHOLDERS DEFICIENCY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ptn.com/role/SubsequentEvents",
     "longName": "000020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ScheduleOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ScheduleOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ptn.com/role/FairValueMeasurementsTables",
     "longName": "000024 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ptn.com/role/AccruedExpensesTables",
     "longName": "000025 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesTables",
     "longName": "000026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ptn.com/role/StockholdersDeficiencyTables",
     "longName": "000027 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ptn.com/role/OrganizationDetailsNarrative",
     "longName": "000028 - Disclosure - ORGANIZATION (Details Narrative)",
     "shortName": "ORGANIZATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:SalesBasedMilestonePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31_us-gaap_ProductMember",
      "name": "ptn:RevenuesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfSalesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31_us-gaap_ProductMember",
      "name": "ptn:RevenuesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfSalesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative",
     "longName": "000031 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)",
     "shortName": "ASSET PURCHASE AGREEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AssetPurchaseAgreementTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ptn.com/role/AgreementWithFosunDetailsNarrative",
     "longName": "000032 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)",
     "shortName": "AGREEMENT WITH FOSUN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2017-09-01to2017-09-06",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithFosunTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-09-01to2017-09-06",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithFosunTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative",
     "longName": "000033 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)",
     "shortName": "AGREEMENT WITH KWANGDONG (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2017-11-01to2017-11-21",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithKwangdongTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-11-01to2017-11-21",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithKwangdongTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "000034 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ptn:PrepaidClinicalStudyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ptn:PrepaidClinicalStudyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ptn.com/role/FairValueMeasurementsDetails",
     "longName": "000035 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ptn:CarryingValueDuringTheYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ptn:CarryingValueDuringTheYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ptn.com/role/AccruedExpensesDetails",
     "longName": "000036 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ptn:CostClinicalStudy",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "ptn:CostClinicalStudy",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails",
     "longName": "000039 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:EquityGrossProceedsShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:EquityGrossProceedsShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails1",
     "longName": "000040 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember",
      "name": "ptn:SharesOfCommonStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember",
      "name": "ptn:SharesOfCommonStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails2",
     "longName": "000041 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails3",
     "longName": "000042 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2024-12-31",
      "name": "ptn:RestrictedStockVestedInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
     "longName": "000043 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-01to2024-12-31",
      "name": "ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://ptn.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000044 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-01-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesOther",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://ptn.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r464"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_AccountsReceivablePurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivablePurchase",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acounts receiveble",
        "documentation": "Amount of increase from purchase of accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ptn_AccruedLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ptn_AccruedSellingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AccruedSellingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r464",
      "r588"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r501",
      "r502",
      "r503",
      "r504",
      "r548",
      "r589"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvancesOnInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory purchase commitments",
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "ptn_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AggregateValue",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate value"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithFosunAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AgreementWithFosunAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AGREEMENT WITH FOSUN"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithFosunTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AgreementWithFosunTextBlock",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosun"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AGREEMENT WITH FOSUN",
        "label": "[AGREEMENT WITH FOSUN]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithKwangdongAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AgreementWithKwangdongAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AGREEMENT WITH KWANGDONG"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithKwangdongTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AgreementWithKwangdongTextBlock",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdong"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AGREEMENT WITH KWANGDONG",
        "label": "[AGREEMENT WITH KWANGDONG]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential number of common shares excluded from diluted EPS",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ptn_AssetPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AssetPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSET PURCHASE AGREEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AssetPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "AssetPurchaseAgreementTextBlock",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSET PURCHASE AGREEMENT",
        "label": "[ASSET PURCHASE AGREEMENT]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r80",
      "r96",
      "r119",
      "r150",
      "r154",
      "r160",
      "r161",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r266",
      "r270",
      "r299",
      "r335",
      "r404",
      "r451",
      "r452",
      "r464",
      "r480",
      "r518",
      "r519",
      "r553"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r101",
      "r119",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r266",
      "r270",
      "r299",
      "r464",
      "r518",
      "r519",
      "r553"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240"
     ]
    },
    "ptn_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ptn.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ptn_CarryingValueDuringTheYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "CarryingValueDuringTheYear",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashAvailableForDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAvailableForDistributions",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributable value of dividend",
        "documentation": "Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CashAvailableForDistributionsAdditional": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "CashAvailableForDistributionsAdditional",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributable value of dividend additional"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r56",
      "r116"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r56"
     ]
    },
    "ptn_ChangeInFairValueOfLiabilityClassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ChangeInFairValueOfLiabilityClassifiedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of liability classified warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97",
      "r98",
      "r99",
      "r119",
      "r141",
      "r142",
      "r144",
      "r146",
      "r152",
      "r153",
      "r167",
      "r177",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r189",
      "r190",
      "r193",
      "r196",
      "r202",
      "r299",
      "r366",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r392",
      "r413",
      "r430",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r487",
      "r499",
      "r505"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r73",
      "r336",
      "r391"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r175",
      "r176",
      "r441",
      "r514",
      "r515"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r474",
      "r475",
      "r476",
      "r477",
      "r501",
      "r502",
      "r504",
      "r548",
      "r587",
      "r589"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r392"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r392",
      "r410",
      "r589",
      "r590"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock of $0.01 par value - authorized 300,000,000 shares issued and outstanding 23,455,846 shares as of December 31, 2024 and 17,926,640 shares as of June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r338",
      "r464"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r83"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r446"
     ]
    },
    "ptn_ContingentlyRedeemableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ContingentlyRedeemableWarrantsMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingently Redeemable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants upon warrant exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants upon warrant exercise, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants upon warrant exercise, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConvertibleSeriesAPreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ConvertibleSeriesAPreferredStocksMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series A Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CostClinicalStudy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "CostClinicalStudy",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Clinical / regulatory costs",
        "label": "[Clinical / regulatory costs]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CumulativeFromInceptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "CumulativeFromInceptionMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative From Inception"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "CurrentMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleLiquidationPreferencePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible shares",
        "documentation": "Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ptn_DecemberToZeroTwoFourSeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "DecemberToZeroTwoFourSeriesDWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Series D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "DecemberTwoThousandTwentyFourSerisCWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "ptn_DescriptionOfExistingHolderPurchaseOfWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "DescriptionOfExistingHolderPurchaseOfWarrants",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of existing holder purchase of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DescriptionOfSecuritiesPurchaseAgreement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "DescriptionOfSecuritiesPurchaseAgreement",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r141",
      "r144",
      "r145",
      "r146",
      "r149",
      "r261",
      "r264",
      "r282",
      "r283",
      "r332",
      "r346",
      "r448"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r148"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r90",
      "r105",
      "r106",
      "r107",
      "r120",
      "r121",
      "r122",
      "r126",
      "r133",
      "r135",
      "r137",
      "r151",
      "r168",
      "r171",
      "r173",
      "r204",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r281",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r310",
      "r318",
      "r345",
      "r354",
      "r355",
      "r356",
      "r372",
      "r430"
     ]
    },
    "ptn_EquityExpensesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "EquityExpensesProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity Expenses, Proceeds",
        "label": "[Equity Expenses, Proceeds]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityExpensesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "EquityExpensesShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Expenses, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityFeesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "EquityFeesShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Fees, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityGrossProceedsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "EquityGrossProceedsShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gross proceeds, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityNetProceedsProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "EquityNetProceedsProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Net proceeds, Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityNetProceedsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "EquityNetProceedsShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Net proceeds, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ExercisePricePerShareWarrantsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ExercisePricePerShareWarrantsOutstanding",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ExercisingHolderReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ExercisingHolderReleasedShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercising holder released shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value asset measurement",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r549",
      "r550",
      "r551"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Fair Value Hierarchy Level Axis",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r292",
      "r293",
      "r294",
      "r324",
      "r325",
      "r326",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r331",
      "r461",
      "r463"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r205",
      "r210",
      "r285",
      "r293",
      "r324",
      "r456",
      "r457",
      "r458",
      "r461"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r205",
      "r210",
      "r285",
      "r286",
      "r293",
      "r325",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r461"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r285",
      "r286",
      "r287",
      "r288",
      "r293",
      "r326",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r292",
      "r293",
      "r294",
      "r324",
      "r325",
      "r326",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r461",
      "r462"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligations",
        "label": "[Finance Lease, Principal Payments]",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r315"
     ]
    },
    "ptn_ForeignCurrencyTransactionLossGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ForeignCurrencyTransactionLossGain",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction (loss) gain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation of foreign currencies",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "ptn_FourToFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "FourToFiveYearsMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "4 - 5 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 5.0
      },
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of Vyleesi",
        "label": "[Gain (Loss) on Disposition of Other Assets]",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ptn_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "GrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r62"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r365"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "[Increase (Decrease) in Accounts Receivable]",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company License Agreement Recievables",
        "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r497"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "[Interest Expense, Operating and Nonoperating]",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r154",
      "r157",
      "r158",
      "r161",
      "r308",
      "r451",
      "r452"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r115"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r445",
      "r464"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ]
    },
    "ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "JanuaryTwoZeroTwoFourPrivateWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "JuneTwoThousandTwentyFourSerisBWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2024 Seris B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_LatestTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "LatestTerminationDate",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Termination Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r119",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r267",
      "r270",
      "r271",
      "r299",
      "r390",
      "r449",
      "r480",
      "r518",
      "r553",
      "r554"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' deficiency",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r74",
      "r340",
      "r464",
      "r500",
      "r512",
      "r552"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' DEFICIENCY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "verboseLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r94",
      "r119",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r267",
      "r270",
      "r271",
      "r299",
      "r464",
      "r518",
      "r553",
      "r554"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ManufacturingSupplyAgreementsForVyleesiabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ManufacturingSupplyAgreementsForVyleesiabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ManufacturingSupplyAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ManufacturingSupplyAgreementsTextBlock",
     "presentation": [
      "http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
        "label": "[MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ptn_MayTwoThousandTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "MayTwoThousandTwentyTwoWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_MoneyMarketAccountsAndTreasuryBills": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "MoneyMarketAccountsAndTreasuryBills",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market account and treasury bills"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r59"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net Loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r59",
      "r75",
      "r92",
      "r102",
      "r103",
      "r107",
      "r119",
      "r125",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r143",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r261",
      "r264",
      "r283",
      "r299",
      "r344",
      "r412",
      "r428",
      "r429",
      "r478",
      "r518"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://ptn.com/role/NewAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "New Accounting Pronouncements",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r91",
      "r123",
      "r124",
      "r127",
      "r128",
      "r138",
      "r139",
      "r165",
      "r169",
      "r170",
      "r259",
      "r260",
      "r262",
      "r264",
      "r277",
      "r280",
      "r317",
      "r319",
      "r320",
      "r328",
      "r329",
      "r330",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ]
    },
    "ptn_NumberOfOutstandingSharesOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "NumberOfOutstandingSharesOfRestrictedStockUnits",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of outstanding shares of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2022 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "OctoberTwoZeroTwoThreePlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2023 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recievable under company agreement",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ptn_OneToThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "OneToThreeYearsMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1 - 3 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) Income from operations",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r450",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in right-of-use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ptn_OrganizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "OrganizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/ORGANIZATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r70",
      "r362",
      "r363"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "[Other Accrued Liabilities, Current]",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Offering expenses",
        "label": "[Other Expenses]",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "verboseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r464"
     ]
    },
    "us-gaap_OtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities",
        "documentation": "Amount of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72",
      "r557"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "[Other Nonoperating Income (Expense)]",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER (EXPENSE) INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r513"
     ]
    },
    "ptn_OtherResearchRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "OtherResearchRelatedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other research related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForPurchaseOfOtherAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForPurchaseOfOtherAssets1",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable the settlement of certain purchase commitments",
        "documentation": "Amount of cash paid to purchase other assets as part of operating activities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative",
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payments",
        "verboseLabel": "Upfront payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r496"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of withholding taxes related to restricted stock units",
        "label": "[Payment, Tax Withholding, Share-Based Payment Arrangement]",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_PaymentsToAcquireReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireReceivables",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment receivable",
        "documentation": "The cash outflow for the purchase of all receivables."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ptn_PaymentsToSalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "PaymentsToSalesBasedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales-based milestone payments",
        "label": "[Sales-based milestone payments]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PersonalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "PersonalCost",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personal cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r189"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r392"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r189"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Convertible preferred stock were outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r392",
      "r410",
      "r589",
      "r590"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock of $0.01 par value - authorized 10,000,000 shares: shares issued and outstanding designated as follow Series A Convertible: authorized 4,030 shares as of December 31, 2024: issued and outstanding 4,030 shares as of December 31, 2024 and June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r337",
      "r464"
     ]
    },
    "ptn_PrepaidClinicalStudyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "PrepaidClinicalStudyCosts",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical / regulatory costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PrepaidInsurancePremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "PrepaidInsurancePremiums",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance premiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity Fees, Proceeds",
        "label": "[Proceeds from Fees Received]",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock and warrants, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gross proceeds, Proceeds",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ProceedsFromSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ProceedsFromSaleOfOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of Vyleesi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Gross proceeds from exercise of Existing Warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Revenue [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service Axis"
       }
      }
     },
     "auth_ref": [
      "r162",
      "r327",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r444",
      "r455",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r516",
      "r517",
      "r520",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ]
    },
    "ptn_ProductRevenueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ProductRevenueNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product revenue, net"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ProductSalesAllowancesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ProductSalesAllowancesAndAccruals",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product sales allowances and accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductionCosts",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of products sold",
        "documentation": "Amount of capitalized production cost incurred during period for oil- and gas-producing activities. Includes cost incurred to operate and maintain well and related equipment and facility."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "auth_ref": [
      "r162",
      "r327",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r444",
      "r455",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r516",
      "r517",
      "r520",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r102",
      "r103",
      "r112",
      "r119",
      "r125",
      "r133",
      "r136",
      "r137",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r261",
      "r264",
      "r265",
      "r268",
      "r269",
      "r283",
      "r299",
      "r333",
      "r343",
      "r371",
      "r412",
      "r428",
      "r429",
      "r459",
      "r460",
      "r479",
      "r493",
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r316",
      "r334",
      "r342",
      "r464"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r84",
      "r87",
      "r341"
     ]
    },
    "ptn_PurchaseOfWarrantOfCommonStockSeriesA": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "PurchaseOfWarrantOfCommonStockSeriesA",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of warrant of common stock series A"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PurchaseOfWarrantShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "PurchaseOfWarrantShares",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of warrant shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ReclassificationOfContingentlyRedeemableWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ReclassificationOfContingentlyRedeemableWarrants",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of contingently redeemable warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r442",
      "r451",
      "r555"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ptn_RestrictedStockVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "RestrictedStockVestedInPeriod",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r65",
      "r339",
      "r357",
      "r361",
      "r370",
      "r393",
      "r464"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r120",
      "r121",
      "r122",
      "r126",
      "r133",
      "r135",
      "r137",
      "r168",
      "r171",
      "r173",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264",
      "r272",
      "r274",
      "r275",
      "r278",
      "r281",
      "r309",
      "r310",
      "r354",
      "r356",
      "r372",
      "r589"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r443",
      "r447"
     ]
    },
    "ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition (Prior to the sale of Vyleesi)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net sales",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r108",
      "r119",
      "r150",
      "r155",
      "r156",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r299",
      "r333",
      "r451",
      "r518"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_RevenuesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "RevenuesGross",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross product sales"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SaleOfCommonStockNetOfCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SaleOfCommonStockNetOfCostsAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net of costs, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SaleOfCommonStockNetOfCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SaleOfCommonStockNetOfCostsShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net of costs, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SalesBasedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales-based milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schdule of Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfEquityDistributionAgreementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ScheduleOfEquityDistributionAgreementTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory purchase commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfSalesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ScheduleOfSalesTableTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ScheduleOfStockPurchaseWarrantsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ptn_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SeriesAConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SeriesAConvertiblePreferredStocksMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, Amount",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options outstanding at beginning of year",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year",
        "label": "[Outstanding at beginning of year]",
        "periodEndLabel": "Outstanding at ending of year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expirations",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures]",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Number of shares outstanding granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units number of shares outstanding granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Exercied",
        "label": "[Number of Options Exercied]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Forfeited",
        "label": "[Number of Options Forfeited]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Expected to outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r215",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options exercisable at end of year",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options outstanding at end of year",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options Expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SharesOfCommonStock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of Common Stock",
        "verboseLabel": "Shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesReleasedFromAbeyanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SharesReleasedFromAbeyanceAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares released from abeyance, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesReleasedFromAbeyanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "SharesReleasedFromAbeyanceShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares released from abeyance, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r117"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Class Of Stock Axis",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97",
      "r98",
      "r99",
      "r119",
      "r141",
      "r142",
      "r144",
      "r146",
      "r152",
      "r153",
      "r167",
      "r177",
      "r179",
      "r180",
      "r181",
      "r184",
      "r185",
      "r189",
      "r190",
      "r193",
      "r196",
      "r202",
      "r299",
      "r366",
      "r367",
      "r368",
      "r369",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r392",
      "r413",
      "r430",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r487",
      "r499",
      "r505"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r40",
      "r43",
      "r44",
      "r90",
      "r105",
      "r106",
      "r107",
      "r120",
      "r121",
      "r122",
      "r126",
      "r133",
      "r135",
      "r137",
      "r151",
      "r168",
      "r171",
      "r173",
      "r204",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r281",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r309",
      "r310",
      "r318",
      "r345",
      "r354",
      "r355",
      "r356",
      "r372",
      "r430"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/OrganizationDetailsNarrative",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r151",
      "r310",
      "r327",
      "r364",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r473"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/OrganizationDetailsNarrative",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r151",
      "r166",
      "r310",
      "r327",
      "r364",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r473"
     ]
    },
    "ptn_StockBasedCompensationToStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "StockBasedCompensationToStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation to stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock share purchased",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r40",
      "r65"
     ]
    },
    "ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockUnitshares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Withholding taxes related to restricted stock units, shares",
        "label": "[Withholding taxes related to restricted stock units, shares]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation related to restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_StockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "StockWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' deficiency",
        "label": "[Equity, Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r61",
      "r394",
      "r410",
      "r431",
      "r432",
      "r464",
      "r480",
      "r500",
      "r512",
      "r552",
      "r589"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' deficiency:"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS DEFICIENCY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS DEFICIENCY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r118",
      "r188",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r279",
      "r433",
      "r434",
      "r440"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r322"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r322"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r322"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://ptn.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r323"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalDeferredPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront purchase price amount",
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "ptn_TotaAcrruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "TotaAcrruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Total]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwentyTwentyThreeEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "TwentyTwentyThreeEquityDistributionAgreementMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "TwoThousandTwentyFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnrealizedForeignCurrencyTransactionLossGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "UnrealizedForeignCurrencyTransactionLossGain",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized foreign currency transaction loss (gain)"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnvestedPerformanceBasedStockOptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "UnvestedPerformanceBasedStockOptionsGranted",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested performance-based stock options granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested performance-based stock options granted estricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UpfrontPaymentOfLess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "UpfrontPaymentOfLess",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment of less"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r81",
      "r82",
      "r85",
      "r86"
     ]
    },
    "ptn_WarrantExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WarrantExercisesAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WarrantExercisesShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WarrantIssuance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issuance year five"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantIssuanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WarrantIssuanceShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantsToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WarrantsToPurchaseShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r146"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average vested restricted stock units",
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsAmoun",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, value"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_taxexpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20241231",
     "localname": "taxexpenses",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Expense"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(a)(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001654954-25-001431-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-001431-xbrl.zip
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M:.2+E\GWN@.E*M W>JHFC+9C6RVIN^UT/$- M_H]0%*VL4.BKQM2W;+D.\'
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M+F^H7(Z69VU4556$6#6B;(=20I(\A#(+OZ6X[_O>!X=^^B]02P,$%     @
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M<%_J6\&KLR]5(=C\<P3]X:W5Z_YNC;K]WAK6UMGX'\2+] +FA9%XC2O_QZ[
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MZ]]?5I[Q!$+H!O[GD_,W;T\,X-N!X_J+SR<Q/+6@[;HG!HPLW[&\P >?3]8
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M>=8#\$C]WU&95(G4.&<4Z[1O-E$Z1,Z4%\AZFZUB8LFML)%*&ZEX0W/.+?A
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M%_;.8..PYBW"1.N&YY<56V?XC%_[TZ\(XV3612\LH/OEV?(73K ]\I!'^$Z
M\)=?S<&7F^'@2P<HBX^0P>P5LNRQAL*3+GG,[\N8T9@V,OLW1N^W46\PZ4T,
M<W!C#*=?>V/C>C8>8V5((^]BH+BUW)"<I;Q'ZT8$ASE$_%1&?6OV40LU[V8]
MX[YG3F;CI.%VT1R2N_XS0]/05>8Q-,R.9[VM33LY,R&\$#4/L3*G70_O[_O3
MI+=CQJ^'9%KH#3J:$^A'.&A0JW/9='C]R]?AW4UO/#%N>K=XVAI<_][)!/P
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MC XFI<!N]I!ERTT\ETR5_!6G3Y)EDVQ;Y]6@ T.UE6KV<F9C_F[ 0[2-6>6
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M*;X ($B1 -Q['Z;'96>"#X '"2"12/S+OWU[W8$W&$9>X/_IN^&/@^\ ].W
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M(T9%WNM^AR&1W[V$T&5#V87A3UC_)Q\^8Z+ASRSP9X8S_)E_2GY]:VWA[CN
M)9\>;KBU6A3*2I1^DH3:K/![&'J!L_+3KW14T7*QLN [_?PFML*X59-7]157
MX#&(K5TKZ'E-Q:#O8+O6/NJI;F5D]6&[5LYI]@ ZK@)NW+2L-MWA7]VBGPH
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M_:>W%ZZ5V<(:F,.$R^1-0=(TUK# U7"&J@"DHW[YBPW=,H06AR/%/RN*=&1
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MF..!:LF^H0E9MF1Q<J:IO&;F TV416[0'OL*F3JQ_[D@0(]5!UOHJ#+BM79
M@*_<"W>K1W"[WN@.BV0VN:A6*L=N"SX8\5@.!U9E("*YXNE#\R1X2DB2)N1,
M\QA\LB+/YM2=(ZN.-$*P>?(P!:F3S)HYE@E$DH!8)A41H>&.WNZ K_V@)03
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MP:61SXX(6<83UO>\")]7;,G$"$QF6Q.B\&0PBIX.N:I[.J1U %7V>%V\>W^
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M[[&8;2]T)U>5A%C9@";RX"?$BV=\20[G6;)[>EHD 7GC1X<0;Y31OU^]PZN
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MOEH>/D.]#/PXM.SX8.UP*@O>(\B&8?P OH,^.Z<37T(? &G*XHDS<70&$WZ
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MOGJI/6Q> O7BC.!HH7L_?"KV3K8V;W@9JCO:-8A0!6G.4S_BWM&MBBF,;>5
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M0F5ZCP?.'5MG -.)L&7<7JEFA:KY7]RBG] OTU^A_^#KP?_Z_P!02P,$%
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M,[A:P4<Z*8^:<-%2%T!+*I2S$G-[";L*4P^N?D<PF4<^<9:JV?QK6W.1V!!
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MR8'HK"NS]%U@FI81O ??QG.O3AH1Y<I=<(<O^4E(K%(9I?([?^&;1C_JF5V
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MR%" &,ERR*R=<9RS'8]S<@,C@Z!FKASB=D*Y^,6W^V+QA>_:Y>,<=X*+GI?
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M<:V*[54A>'^XWKNW 4Z/8]M:$XQJJK#SM!O_\U-+%ML?95D4$_G1QX'C(A1
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M<YP3]_UE5@'3&-4HT4(\+P%82@I@]!;!?3OVW+FC&!"#D0GF $%8 [^8WH@
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MV]8+/_TYSF8HISIJWQ"M/_P6I22*@M@LS,YX%@/F!JE4!^[Y04I5A&:KG&=
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M==;^N6+V."<Q)W&)5\Q)?*K3ZNHJ_YTAY8C!.V,)T<:Z@(EZ;,ME %X'05^
M.&,7=2T=[)=85NT:D^4<I;A2''\V?A2:WURE9 LP^=@ "Y+6MP#IS&H&5YS7
M"N?UV?":R_7Y\+JP<EWHS"M61N^I^WNW_[7[O!:?0=C[Y]-EGIS.)SW^TCG1
M.=$YT3G13[X/G>:FQJ-CZ[[F(8=\)Y9/!/C.^JL:I\=KEND]R4VM7=D\\IMT
MGCM879 V)M9$R;/?II!-/>LJ)/Q30/<^64EQ_R^!S[$[WIK"4]M])>GT;..
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M1#UVH#8>@OW[]N K1U?)T75\<!''@-=TZ*$=F^_0),O .NIT'ATR(H[#3B0
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MPVO;K:V-+>35@K20EX2FJ@J-1HK]L*0WM$J EJW:Z APD"10..T4RH8WD"\
MGLOG+O!.:N7FWY:V&)L:R!]:NY W?Z[:R$=H9[6I"?D!M=O91T$8XM9W *^/
MQ#%L/8@O9-8$=5'81Q;:]=TWZL\*.)6&;/J>5\E"9YFUYI4%1>8M 0LR\A$
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M+'G(.W%NW)DH+0Y6KIHXM_-33<UT!M8^12^XIN+8S0>[Z;?55!==.7 Y< \
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M[C!J%Z.M;Q6$)GD +[E?'N/G@++S*>#FP'Z:\Y)9KE\I)ZODBO-X'H_G%6K
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MF_2ONX"2-7@O_(2=D,I_AG\CD\APA50A@2,&\,\[E-.P1L14A/N8NK$,Q8$
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M:4\H(( ;\T&D/>>CS,"= O@Y)T'2-II;\EQ^4$:,^$*=AT?H)?U):8BK@)!
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MGS)VHE8-1N'80&4X$$;_Z"#P[:-Q<Q4R)1V3@Y*CW0!U(D+M(J*F(1:UZ5K
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MUAPZ*' 5.V4K,H?+2462D1=17,M,]Z"1<YZ#>8(>H&OXN(<J3+^\8F8%B(.
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M?+\Z__;9NOY^>?GE'ZF3X!K6NK+^_H\O9V?7YP?E,<@G@.;Z,2DF@RD/9.&
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MX^W*B]%9O\ #2'R1U%3]*?3MY5 SP]2F*G<VRHQVX+$0NG#=O/PLG:2%$;R
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M\%OK93HMX4KI6?@H5\(30#N3+9B^G<YZ8I]B 7?"8Q5^)!YYAHH/\H%&XI2
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MT3-7(DH\K@&^ #&CG0&XL5^?MVAM!ST D)-Q_15RIDGVNAQU7=%=D'@3E+*
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M\!&]5BEGNGN<!X1)0I$%:$<8TP"610Y>_:Z_7'_\:.X;+$-X23 'NQ)^]1#
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MO,V$G@EWSU#"<9TCX*SD>.BE]#BLS>:%LC7NW+FR0\I"!RY;$U/@4V!JJ2A
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MIYG-RJ20>.B[T1WV3S)BF]>R[T2S_=[Y@(\UN^\G'^BM^JN>0JRS'YS'99T
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M7?QE8Z#T!<814-Y+#R+KSBZ^D";MN%$F]<BC-$7I5>/494JR2M+DNU"Y)TT
M9%+N:(2D%P6R4WW :50V[XCE932&*X.;L]6K":XJPU\0,L,'Y+-=FN>'3Z*Y
M56A-KW1\?(!X"W*)M VFD7%J BCQ%7@8?Y2 P"H8:MC*R62F+E_^4F( /C=M
M>N3!O7)T")(S*YP&XBB%+9TD2GP3[4DT/*F_3(!.1<$57Z$QC5>XH>'&SG$[
MI>L9#M/\30(8&;%X^D$ZR<Z0L8L996%LY)0Q1-4$&6$S,H3XC@T&B;U%$_3Y
M([S,EE]2&/!L#< I;ZK6*YFWL"\Y<(<>CFO6X;B7Z*N'Q,,#ZXJ2P?1!:,Y2
M5G&X(,!6RDX=9,>N&JM;*'P,S11;565:*%O\8&<V"+K.S.7)U:25R>UF8X*>
M#O9)FO_T\>38^DOPP'6'BH\A(PAP5HXQN(0S@-FSQ.+<*43:,EH]Q>VP45<Z
MS Z?3K4C_7+;U,(<.KCD/BP7V.U.;Y 11>ZT%K)D D8*[-J6HI7J(\PM10F>
M6X2TNPG.8'BTM7U"TIUD*F&"5@&1@[)ZQCQ4'I>X-L<EY8Q?I;S<ZQ'&YMKI
M8>$ZW-3+%M^)<NTF%0#LMY/!K:F+); I%Z;'1N(1;O @S!E5Q,&Y)9(#.[%S
M^TXM"08[R-#'GP&&.#?DG>5._O>=&[??_7J.PPW;Q]C$#X 7IW4!\(&G_OW1
M&-A]0LK_5T(J"TN<CW6NR@'5B'P+XHPZ-!*98$$T YK1$[S9U)$9\P>"46MB
M4B?%0L*H#ONMPT F;%]BO&."")2BR?_?WK4_IXTDX7]%Y;NK<K8P(!Z.G;W-
M%;&=A#K'YHQSV?WI2L!@M!$2JT>P__N;[NEY2( ?Q+R$]JIVSS9H-#/=/3W]
M^#[Z;]D0'%WTM.,+""%=_E'G3H8%), B^,2B=X+.&K#J9R.7#:V+>W[=0GV[
M1DA8$:H1?].$@/2WDJ Z)2LK;**Z,&)<3W+C*-T5(3ZY(Q.U(R*DQX82!#0%
M5GJ#]+IVW3FRFX=,-!#:S8'XJ60XUQ#\HO]+A00(T"#9,15%MN'\XWD@[_$(
M%+[<6F0#%\^;MD@E@$N@>14'B<(CF !I?9!$WL.1>'$V,%!7N9^(BTSQ3S4$
M3-DXM[1],+)Q,;(3*P;NH>C\X7[(O?%-U^=*D>C$BHQ7X2V(:IS2?A>7-N\A
M<B.QFVR,W6O@#4# !^\TN!IJA>8&6G!-^-1%40J$4?K0O(P9*Y1AY#C]U&IU
MRD@PC_BBT(<OKTE:Z"7M>*3._65XU160K$4=S]CCZ2&9(]XSU9Y0(VM4RLQ.
M^P[/\AE4W8$08AJ5 D\S;@[W;( "5E9;@7!AOUYFO1'@(A'HB( - !"^9E,9
M'],'/!I^M *MEW%)%PZM&0K2.D]PT_ ^ )Y!VH?%:Q.^)'%*S""4Q^^B T5@
M3.)/D5Z9-2"!=A&85KB9(-F+!5O(4Y\2J>1QP2/&(E#5QST3'ICD(A1LW489
M&DZ/T#SPCPX&5A0XLN=^AZG'P>RW2B][W^(&OJ8;>"T?-_!=<C\T9=QR%X))
M[>!]IW5S:[7;"A7A^O;SQ8W5OOIX??.E==N^OLJCM[_L!<JF^Y-=MB[YY=X3
M;BX#;8UR>2WZIF+%KO\C\'Z R1;Y'/XL]&WX?_%HEAW6?#%=:@[V<(DF>HFX
ME7<C2B(LR%*;*0V5^@&?32?9'/2I1?2#.R X(%+.9(;+R<5L24EUI*BVRI8)
M3)9+,;W5UPT#&W\0]!/IY0H4_!3L/0'O@P,XY7[2D1<$W\EQDMZI<DUZ\@JC
M8GZ8EY"!*X)O@ZL5X(AP[S)6MX\_F?3K,)"22']5)=$0P)][BJ5,/@]_ I=Z
M&.D2*>UNH\%^^RNX_U$RGE!EY"WZI9E,*NC/70)]OS$3#NF\T2G2]B!57>7H
M #\O*J6Q"$0G@1Y9+U6JI8&"KV7KCR"!\B:12^*G-:&Z^5"Q(OQO' 4?FQYH
MB Y4VC#D06:OB4D%NL,8<LMSV>3['4PQ3_=DN0^5\:3!#<TZ'6 2L]HEB\Q
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MX"9N$HE^& P3S<;TI"5./X ^'HE^$!U!P?MEZ$A,;#AN=% %"K(Q+#5T^FF
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MYS7KP+NT^OT@\<W7V.!AO)$HZWZ'X8\WO?P5&G,4C[WW_P=02P,$%     @
MPDE-6C'X R(.UP  6.H  !    !P=&Y?,3!Q:6UG,38N:G!GG'H'5%/;UFX0
MZ;UW@E*E]PX1D28BHM*;]":]UR (*%($I LH($6:2"_2>^]()_1B(*$&".0%
MC^?><\Y[[[_WO9V1C+''6GO.^7USSF_-/490/U#+ -('RFK*  P,#,!S] >
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MCTPL#O0BP%1^9B:EF%JYW^R>BP*$E12"1_@%+A!+$!4DGX;ZU<LX%&"I"P7
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M8HH-"71K8E?&WC)L+@_3UE4][3ND\11Z911RH\O0Q>*=S\9U>OS_G9[7(+(
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M_OE-VZ;O;-==KO>K,34(*Q0A4'[53X_'I)6$]%HEL5X[80?:71J4&_77K*(
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M7DV,F@$EU[WD>7%)*S<&HM/R3OGNKBOJ>+HG@7(_%QQS;7/%1U5'U2MC%U
MWXR8%5, F0D4!<"7@>1? BS1 U@=&/$%!%$)$$7W$V$6@@9=3U2:N^_]A?Q5
M,_%0  **NSB608QZ)6D:@Z0A% >I5M9TK+(Y7]!/!KWO0+S\I,3>H/11A5%+
MD5"=?%;E/3X\%?N@V\=*!0!1G0]4*PM" <*88.-7P<+@9:-FI#80EM-$#Q[!
MUD02H,LQ\O-QGUR*OVJ69!:#/KA-*W<7>\P[O%LCOF-.\+&4&IF+PLU2)O>1
M*,9GL("[-;7Q8XXF/55M2EQI/GPK; ^,'PB'[]RTMSB+Q7A3]@FM0']'H8+D
MV@]O/L)(0 %NK*./Q,)+O[=;Z SZ>'U>%2!LA]@VET.J(E=\;(#F,1,TU4D:
M<WH-A&;N,5*<-ST*FB%F"!/@M\#T]K*4),DUX78*FFB]^%2I81RZ5?G)O:6_
MP\CY1\*>)0DG6PO846R4N'<:R)= ZGZ:CS,3;+.%F$I91%-^ZRJZY?C=3?EN
M2ZO4?N0JS\]8A-82$6@+D_,*ZUK-M/Z9GT6Z1*XBMCYM\]CH7>O#J_M0AJLF
M_N8TW4FTX*/C0 '^%4B^&LP?LE43V5LI[G.+%YYCU..5U+5W";O3.)3NH,P\
M"62QJU&W*-9;4BWN=79E'* IQ&]9]H<;CP>HU-1_/Q1C8I:")FCIY[Q2;C3$
M9/6U+.=T]2;T;64=^WYQ13G<[GQ. SXPUX3G_/6F>#,F1VZ<Q([:!P?)Z?=@
MB)^Z=35%34;5L<0\S$FVYZ']X*'0DSK9&PJ]<CY%(-A768E-%GDFD(U^ #3S
MH=3")O;NU88NDU29%[I41&!S5V%+R)0$I.W?[NP"W9*M^7TRL6Q6G0E:IHE<
MLX=OJYDGE;>N=:ZWW;?2(U9@J0:Z]N*P,NU&PZGSF:M6 A5UPB5B9 H#.O6%
M:EUP),]_L947Q  >:4 !$LC!T<"_W4FN%G8>LG5]40)R;P,/<. TE[Z<5^_;
M]29/G@%Q@IB+W5N9P^'=+B_9"-Q9%C^% GR/'X/QG?]18D7:J6.ZHQ%5;PZ2
MPXYK/8A,',Y*FL:8A_P]8\OM2 L6>F3<?%L'/4>0RA6--56F9'8'BX-TPA7=
MC!8O\JP#^S-=JX*[E%T1T\UH$8M!V*%UFPX$XS>]XOY'A>C*PBNM]\8I"JE]
M))"<5U07%H^:F)[+C_/",0C-+):8%]85 WXRO!,6&N:L$;%;(9(#0>Y<J,RR
M&EMC1])"GS][H]=32I< [I,W>FY#)WM^"?I/BO"D_+VN,O,89]=Q&23VC*$R
MZ_P,/2?I_3/,+)+6V(AJ";)%PZTR1MA7#^<J51<5Q:EZ9BNU(OW8V0[$K.;Q
M-W C.$-^5@MKC>(KF\KM.LQ"0*BI:58HB*B7#>&=V0R'<R+&P&VI"$<4X-[^
MU4.U*]'FRCM0:Y #11O#2H"N[GG67.7*>>!@BZUCDMBMYPL\PM4K;IVY."PG
MJY2]C:X0E7&+2DV2X8,9!AUV5N+N=6[9@4TZ'$[&T"CBJGW3_Z$$+([KY2@X
M,SF':C*Y1YR1@1:E&OF#SGD&9=13+KS\+NJWA4@B'KO@]<7GT%+UVD^7%3IX
MS[Y*$!WVE!D8D[[)J[?)KL 2*.RP"T8\!1$U;QFC +UO0%VQ?[O[(MFG-2-T
MH9K%E!E>W:B! MRJ1 '*9#0O.6*:OORMY.T[4 !L>>9%57Y^43MZC=>I%P]#
MU[7Q<\J> Y \NBGCWW^VS^:L/MBO+'L=;V?@E9 _-_=-T<&*C8:0DB9)<XFV
MI[=K4GB3MG>S))#J/Z57?QBH;#_V\%&N_K+=ZC !+[%*1-:P?\_>&Y_;'EA>
M>RR6%I+.R4WN<6/E2)65$IIG(T\UQHXJ;*K7\ZSCV>U,^0<8!HG>N;20U0"Y
M-IK>_\^27YPD'.E=06)'L9Y%Y3!5OW_R8$Y%\ (K?R9-3?MQ[V&%2Z2JD5,W
MDU_:IL-_%D:I:-HBMFZH>< G](O!;1.T?5-O8)]T5]FW-80,[-C1O$*:M9(,
M_6/4<Z_"@K,L +\,;<,&4G-)T'PFQ(F8[!;)JQ<\*4 <?)=10B3DZ^EOGYRF
M!<[G=2V.+4JQ\B3J_1#-21A)Q H\3#LU_1_RFNUS+D:5FR(=9Q/Z(^#>R-$6
M2^55[_>FUX9Y6:+C#\C5'"-2C$CQZ 8^W)%L$Q#;R.5BN\6NL"KG:FKV]U+_
MVYV88+=6V*SF8^W;L;$\6UDS*,#5?4UJ%  M#Y71WG\O94]Y.IA-.%(D;_''
M5AIXQG%OR-I4*-V[/R87WJDL 'Q4(J^7/Y+Z3 /(ZO.TB]J/^"U5R4+E:;R"
M/]-Z?9@VZ5</_M;#K%1=NR>XG#A1.K-(A9'GXTW#CF8^-6Z!GRP;A90VS/76
MGJC(%T<X QQETT[+$%K-A"THP+O_VW%;Q!Z9,WE=Z2"-55,"-49X9[8&S>RG
M5$LSR@=:"Q8$Y1&W%.ZI=;/$Q=C[@U[3Z\1^8>!:SCQ4J:FM4D46\R.>1P6W
MB MV*3;:+(FAVS:GB>XOY]RO Q?TEPDI?]H6>GU X-BLHM\6VEXTC4(FXW$=
M!YX8EA3?3\4SZMT0(?=E@%<&S),K.\@+,!ID4<W83YLZ),W*B<O);V"'BVQ^
M":;SBTTL_[!&Q1FUFI7]?YXGLOXZ3[C%6LO[9(&:8X]2/69N.?)%;73RKCB\
M)H>8:=L)Y_#FAA-G":U1;MD/U:V:XJMY%LS.; ^[WDPZ5& :>*Q"$3#W@#LN
MA$Q5-BXA7FADNA&,UE*'_ZOD:QW/ZGY/^9ZK&;U5]NV?_?O/T(KR+YXD6^M6
MO8%_ISKYYV+!/_MS]GV#X$FYO$1V4\__W+KYET7J%20.%*M^_WEF 579>9FA
M&]-9*3#N/\F/RDD)_X!<\7\%[0NXZL[)?VM8^[)(\SK@3=-0\($>4@X%,&9#
M 48=31VG,VU!>$@2R*7?DMZ81WC(WH\$QO 597Q5%M@C:?HCV>FPF [E*B7V
M'UVY[S-&*9L# GGZ/)W#%RDFRO8]&(8IC-AJ#N:7%/(NL\G8R(ULAA(IHX?C
M&HEF\.G*H3MCE_"C,@&X<SO#$@5B%*GBO((]KE9!O:Q"(9*#NWFW)8( !> ;
MEIP7AREKN-/%O%V^>DG\2?YC#;F1L=%<+U'[PFRK9%Q&1MK=XA3%5%HS%UR
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M*7(.EZ;DH2J>?>G?2<3&6Z[$H'*HDA1-:>:CI,-::,V9E(?C53/E*/KX;6U
M;[A%5"WA*AW$[XAE0C<M,2;+3.SR>.WQW#VO7E;Q>Q]6G9D.[G8;3?-\#I I
M'T,J8%<P;6;(-4*Y<:IB@\W)OBY$M\9,LK^$CB?HIK?4\TIK3R:]_V97YNHC
M1B)'DJ+C,D,4WL-:+4>R>I>>:"6+I#M/K:#WRWV^;+V9'SSDV8JOSEP;V$(
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M-S(V*K&6*I^Y^M;=I2=]3D5G('MV]89WQ_->_'Y)ED/*;A#_H5)GXS*#N0I
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MTA)TBXM[BROKYWP3)6JY0])=UQ(G_0;?=U )"(&*!"*)Z];&/_!-:V.EG-
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MA7 ;W%<3<R!+H$!7_]BP?%SE!QP%DY$/F!QEZJ2(J]82WR8/>FB$*2R)VS[
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M=G0@=GLLUM4@N,V8I?CSFARSX'6XGN3!!QSKDKB/[D<.L-8[ &E"#YQ3IH\
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MBW1&,*AWHWRX%SS><&O!9_']L\>;S7A.+K*$ZP)?JM0/O>285*_- GPHI9>
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M'VCY\;^#%$@D6;B?K-)J/@A-,WGG2Z95$;6OUERE QSJ,+CXF?5W!&I#YZV
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M/D/VH[3]U(P".,(@0E&#?MY.,8:A!1+#6'%2C".A]OW-LI_;;(U-QVT!S%J
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M-D7SLQAJ( W8DJ0!PP;DX@:T<T/1TUU^^%*Q\JYZ_"_U7! 0%/E=4#YAFF-
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M./2CH,5=XVE])RDD!(T8P4[WIJV^R"Z@O99DI;1RU$YJ2=J*\WWZ.-1]'%H
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MN]N03R"T.\07*PONEL*1F+Y7W^NV&Z@Y?+?E,#_IL[?N*9B*E:EDY\XX:'R
M*WJ>N@-QW'[D&7$_@[)APSVS!![#%HT)51GJOC'</@S):E/]T9M8I\9'?W*7
M%<?Q&,4_E6:9?Q&?'\DV;/7H[8'R/VFU*+8\R#5Z,*!],PY<\MA );G1^7Z#
M&UL\71IO!%'3*-*RD(*A]*==E\)<>PIF.AB2\-K4]Q/17@E%99I_<=&IK[2J
M?K7I:.X[X+=YS_\%DA"P'4%-L-!YCH=XEN77$/F#QQGR*W/^IS]$_*/?Q:R
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MP!1SUE:)"J.OKOZ<!$R+[4T8_AH#DPH#_7%G]J-5($]T\<*&:8(ZJ/3T=X
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MN='-K794)X:#VHO\*XWU)PE<6IEF,].[9;AW6.;^7)42(]@IWI3WKH8+-A
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M:5IA"5/W.W6N>"MHA57'-R39[!?0Q'8B>?C\J>S:JZ>0-7FDR+F#;(.QO6/
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M8F(\426Q<\A$KU ZESM4&6Y*XKC4J-;ZXL.J$7(O\[9"-&+()<0V$CHY_5*
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M&&#H+\#BS.PZ1;HJ0-6C64ESTY=WC\'85@C4B3E"J*FM^3$2@"0SLLW<,Q<
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M(63(//[V49&#AR/3$L?@W25U"6^1KE99=475V D&WSUA6 8&.%\M5&WVSUH
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MD)S$)!GY]O8GG'!R.*O:?H]GIEQ?3V,;(U].;B93(S+YA R54G"YQDXQD\T
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MR0<D=JV;7Q)K%YK=U:Z;9VDMKI^H_P!G7SR2!&C/D*_F ;B<[GC C(Y4Y#=
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M\8CBC3@(JC  ]@*NT ?_V5!+ P04    " #"24U:,+O*HE8/   U$   $
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MF1=$[P:@  !B!?TCX#\%8F)F865CYSC!"68XX$\!3"!F9B;&_1D C-5(QCK
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M9'RR\**514'^#B^T4"K*1^N&;IM(I <L_EUUT?1&=G4;N.F&^W#%VT^T0)*
MM+FQ98C%.N55M<4ETU[4Q*J. PEL0/0I?>-!>?VM+Z2\"2X=<V7Z,&8I_2JS
MHD*#[;>_<"^C=#%]1D39XV Z,#,Z-5)[/+I;53&6(M?I%>9,!Z1D(:>-G?H\
M\1^[@]_5.5[OD$Z]]E[\$2C=\W,8HI<[W%OY@YOI^-#6-:?<0#(O8M 0BH4F
M0HGR27ZKZ6G^=\4]9#Q#-0F)"2U!Y7/K%.A,R+147UMHYPF;=)4BK0^7-Y^\
MKB)W]<Y 8WV\)28EV_(<2ER-&AI5LIA3&DN==1-:I,:OH6+I@%@#![KK&%LV
M^Y&K3G!^&R2C%_=(<R2)4N^.:OU473D:+]=CJBE8@U>OY.@TK;;624?-@#LN
M&HMX77"%Z#"?+1C!J-XP(6UV_(S.,9^"Z\0H\NA5!V ;YJA)L'/L4!_4L<#D
M3]H9*SK 49.QDT;>3:8#5R$!\>?'4BWLMC6G&C]YZ^N;S1X^#R ?Z>/)X067
MFX]L1.X_,FAA,5,Y N2^KC2T:!/ "+Y0S_%NP=H!2.N$J\WMJR>%9/Q!NED]
MU%"G=K:]ZYCA6WJ[GI-T(/X:'1!T,* #.%7J3-%TU_2O/9\YJ3#IOL\KVAT8
M_A;-Q50S6J^)!Z&IH>MADV6"S=IM8P1 C-C%&> 2 R-5D<0?T:54BY$'KH*-
M.QV^K_S$.7JV;>Z88='A4U.Z8)(S=E$9;+_9'''7]72Z5)3[ V@83].Q,4^X
M@F7*%8H/:79T_XR])ZSW'D(H]/TUHFM,T$ODD$:G3>+!B=9&30L5A5>IV?#N
MY-%'.E,9M!'LSG516KL$S;75?CSY,N8;<OEV?YY-D6YU>V>/A9P1O-Y(P/8/
M5@&KJ[\-LI(K&;W\=,%2\ H9LMR\FI3ZN3N=;:85$LD:/NRYJ&,T'ZF,M$M7
M^:+I5CQZ\C0=:&CE6?,JXKELX'Q8HBEPO)@P@D;GZ59(MCW-%\X_&7YH<M1%
MF:KM4@OXHZZ[8_2#BXL6BSBAS9Z4$X\V7P@."P);JQ=$.32!W.F ^"9YRI"8
M0X@+;AP-13HVT0'CS*VZE\/?[M,!Q>':K;70;:>F%%@YCX>)\ZJYF>/H2O2N
MVR^<!KEZ877J9R >?O#<):"W";IPG637O=9P2298Y/I!AK+H&Y0<Z!BQIM")
MMB*A"&Q5SN?W!,;FM405B[[ZT0X'HOZPO77][&USFR?9?YN+J'J;BN/GWZ0M
M,-*)#C0JWQW??1__2].Q7YISL8D]XUFO>$RC8INB1Y34E%XM6JCTNU<.<ZX2
MTZ'&B/+!R]D7$:PR^[@7+?S$U6XL'SZ[I:D@<#R+#HRIB\8XUOY=CFV9>[6-
M= A%=N9IQNZZ[[X4'+W3Z'P[35DZQ,UG!2?*J;8TBQZ/;+@V44&*<SYPPT:-
MO*<#"U9855':+-M6J^JP63<Q<JK'A:B4U*R;OS U'E^,<0U;>@J_/[N3W='C
MYS#78$)-3V"$YII>=3"4NWTIA^Q&ZR#2@36INE0+,UYT^<;!KN2U[*0Q2H$'
MBHCKT54B.;UI):G:-F3/#/Z=:%XG4[BJC0  N/"&!6P2ESR.Z30BS(&IF@GF
MM=^^@6<'?04%AD!49NP'.WR?U$=^^"#$YD'&".?A40<-,A9U(;2TFZ9&.EOY
MW6/,*3(#H:]J$J>?0BT.GB5G&,&&_ /*B^\UU$VW?9)4<OM\X=E:.Z^:J#(O
M^N)$@W: 4*Z8N$N% @B_N Q0:\E3ZD<ZY,=X5.)V\>#2</'@76!O)W\%,; "
MC7^(Z4PF^S&27$N/J(*BR;<,=!!Q7<HS&IN=FT>MRC9(^;D _OB[;4J(&Z<%
MJ)Z%/S?&7DC,>MT,0EGU9EMF6O]2HS'*IC%1^5]EL_(@8QUY!1W!^'12YY&4
M+3J +\(50A*L\_IQQ,*UOASBXJ]S.,X\=ZK'$5PBA+N8;"%&'=3 #V L$31#
MG"W)MA6UT,[AF;?;'1;LJ_8(2O!):D^^$Z6^.'>2QDO&=(MSO2-!4Q0?M$RJ
MNT7T8'3AQ)IIJWCILE4:J[6^,6_FRM9H>)W'S"7_G$+4?MSHXB1:R+O:OLGK
MI91O=Q'3#X<%AQUM\W#9+@R?<E*;^#KL_66/I3@376TSK *M2"\U0%./B7:F
MSTO1=VWGH[3DS:=.9L%BOKX.[)">J.'FDIZ,RM#$#^&Y"GYNJN8BXA\M^@!J
M)BUH9!+6%'):X]N9/=M1.M!Q8:?_9='(^R,$YE,AHTN9VF1$S1N<*W&;FM1L
M=QS610=><9+29B)H1A? M'8L'3!2CU!FQ-J2[1AF<PAZ#-CRT[BNW%:E<46Y
M\9(V:7!:.1UPDJ #HY5V;8)TH$]P1&]SD YH5.B)MR^E;6#WQGB.1? 1"TCJ
M,W-V6LOP+T\A8DX9'5@>V]-"1(='%E02@X_,V^)]+OB@?*2R-86YBL]+-5TX
MMVU)YB?=<)*U3#=%7RI_JR"W]'!($'&0<1EE1;8KCAK6V[F^@J3\.4P'ZJ;,
M2:(?]J-TB%64A\^3]A7[/'Q-*.67&"@%B72@^N90D99U3I<L[C!K*/.;2[T6
M)BW#Q(^88LZ51#(-\^G?\#_-!Y>8JIFF [W%T+W/F"RT$X9P?(,GX:"=FVK$
M?Y:6&\G[3DGEYLTG:\/C6M9K45G[D:4#+CS' <AE8ZG,<NL49 A*_4WQ9&R<
M#3+8X7620LK*_VPPY:^)^7>/#H@T7^RP%68)O]>"ZJ$#3(%._J;*+9KG1U'#
MGY?E5WX8TM:6=8O2//=G%,QN5A@XC@0K\6>>&=<!F]1_P8.19".T=RF^IO5A
MXL\IMY7D&ZD1E;M*[%833_R^I$+G/TWB$>^\' K'K>HDG<4QJ'V[.=PO7(#[
M_><2Z>KHBW>;W%@"]>P;O% U$_568RMM/Y!N!EFIJ07Y][E3XUN"OXR4P0FI
MP15I=^W6MHS\?U#J7RRV1,Z_QXB'.JZ%"(U-&[N:MGS-5'4)Z.'Y@M?1*C)A
MU$[N=8JBM5J?"]/5NHL=OD7"4HVJIH@""WFA<?^_L,K*AD+=]HYYJXFXW>?;
MSGTX27<T>4)5XF[LHXA%=8=.7>%Z(B;^82!84,70/1[= ZBEF"KVGNE3'[-:
M-]MIO+ +^5X%6:'!R$XNBXA3Z_;SD[+CR@US?RER5"&YA .PAMBA5ID;5L)F
ML([I)RI^(2;/T5?)#JC%S6,5BK?_JD6^A:V-.Z^IS-.0@)$8?"X=X$0Q6J77
MM03D$15#KMBC6E<BJFRL+-N2^P1+9:H#!O9XX@]@O=%2Q()*PK'!/DNS$)]C
M?V%)+KN4ALSNL!8EW*YH=M;0RPM2=9[O?*9Q$DP^^I&>/-[(35:N4L,P(R)U
MUAG%.*6M'YH,)6)O>];/?-,:_)(L\GRY_^'#@A9BU.M6I?P?+V0O(Y_-; R/
M".1]G:=)4[7QY,<EMV\Y;5C?NE#5<X<D<<_T1M/JII-KOFMS5([WO1HG;\*M
M6'$PJZ4JQ?:)G-ROSQ_U6P4[!F=J!T(7.]^2ASLU=<4+=J[!5Q_<5_043OC"
M/7(LCP*3@_6XR :]7;7?KPP&^QXJJ)9Q=17 H?9KE.K3A!RUPS#EDNU?)]U\
MG!.A\WJLLV3^KM37L\Y]H:G:PROP: L'L3N1"F^W3*DV&[E:&LNRP=VS/C]W
M$%"JZ"C:KT:_6GUIQIM0FJ/:)?+V.4_S+?'%-Y&Z61M^)LO=M:O:-DI162K'
M,ZP>,/Q9B+!VV4_KS#S3UL11(PC+[^X#2I_^#U!+ P04    " #"24U:VV4\
MU*4&  !2(@  #0   '!T;E]E>#,Q,2YH=&WM6MMN&S<0_17615H'D&PICH%"
M4@38L9,*2.)$U4/>"FIWI"7,76Y)KB[]^I[AKBS95F)=[+0H[ ?!6@Z'0_+,
MF4.N.HE/=;>3D(R[':^\IF[NLS]I=M)L'J&M<UP^[/Q4KU^8J$@I\R*R)#W%
MHG J&XO+B_=G_8_2>;+U>K=S7/H:FG@NG)]K>G/P]NK#5;\E?FZ$O[887'X=
MU,\^]-Y_:@E-(]\6[ZX^#5JBV<B]&*B4G/A$4]$WJ<P.NIU\X>?C6?]]#WT:
M^:PM/,U\76HUSEI6C1/?AJ7SUF3C[N77WWOGO8$X:1XU.\?5P\YQWA4/^PKQ
M''1_R88N;V_8)\*BD$6OMV2]&JE(>F4R84;B;:)H)"YG%!5>34A<C=!*]@EC
MJ?KT:N*MM%K\D<M,UD04 IL+GTC?>O+1826M?W/0/!!^GA/_L\6 HN/E4-/"
M>FAL#&2Y7$9 6ZO1OMMC9#+?"M#Q 3H9H&,9.NVIBGV"IL:+ ZR UKF,8_AX
M<] (H]C%$ DQ@%K-TWP6&N)%0^G@]8OVK?A3:<<J:S78>KDZR)1X?><)+WXD
M=16T-_FW_36/UOK:QD5/)!)0LS11-$66^D0Y\:7 CI#5<]&GW%@O@,]WQJ;(
MN?H71NIGJ8':3 PH2C*CS5B1JXE>%ATM9X</^_V%VV*9UIN6NZNR&"G5.MFN
M[SW31XUWEZUXM?]NGDN'/<1NI7-QG9FIIGA,M7)3;;F5L6'4&_ R,D%B#V4V
M%T7F;<%)!*8.I(T]EB+%-ZND%B,9X9$5)E7(&U/:W3/(*"+GI)VS22JO">.N
M^'1X%B,8#*EY87D,-HB41:6 68;NB 3Y*Z:)BA+A"OY8]I^2I<H)3R!53J-Z
M<%69*I]@@BZG* 3(?G.$9F),$PN(11G.5Y?A&:8[8^SD"6%*8J0R ($QM=SX
M&C *<S3;E7:5C4!)9?%46:2+&#X!KI5=K@&8BFDL!S88U@QWK9>XK2#C[@R-
MU(@5.ZZQ1:%A + :("H,YT(\D72)&&DS=0LD6QHKZ >)@20_+.-&E+450+I%
M,/>B?<;DSH!ZO3\F![<V\%=7X:W20DPRII1C85-[0EH*\ $<% L0;+,@QV)$
MN83-V2P%P3+)\O=8N4@;5Z ?4Z\UNL11;DU$,1X[<0C8Q 0<EMBXG$6)S,8D
MSL!J_4+#HGDBZ\W30WH9NC9/X_);^56QL,Q*_+)_P=2W NL29AS+Q@.-;@TT
MPD \S[M@AP6KB-9M0."#I=F66OIIE>Y_3B[^]@/EXJ%\N7>:7)"##6 3BO/#
MF*ZQ;HADX3;OP@5\2,!G-5(I"4R!)2W H1/E C/#BK+@A\\I2TY?K0N6@DX=
M+S3!$K2UJF9PHP*_(Q9GM(K#4=450Z=B!2D#LU*WA#J5L9_"L98([.""\ @L
M;APA'!Q_@Q+.):]HH247'TPJA+#4).A1*IQ588;_AL2&J _H3_%S/=@9I8?#
MQT;ZQMQZ#_";L_+&N$>N3%3,<);.9('0I$,JL(1FC$L;+Q"'#%!RJ+3R<Y8I
MZX;E[ O@#+B[N8U8I\3**C>K)I07-@?N79!5400N#0$$,3ZF#&I) _YHH9RS
MBDUPT"@ACNQ3.0K-,\AW!WFT/\@O)U(7@?,8 30:00VK"?;.K5&U$$4;L'?Y
M=;W$#6A&1S"O*X7TT!3^VV-O4E_DC37Q*6'T\.%/#!?GCY"@5*X!XFFS\V=
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M@:J^\^."G4+?%Z/A-Q_=?P!02P,$%     @ PDE-6HO!VD7 !@  +",   T
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M*W_!E3[FQZH_L[2S5\LWDIYB73RQ[R_AI]NFC]<_/&'A(<W_!5!+ P04
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MJCMAXGRCVF.49\RB)]#.GGA.SI]-'7W\,7KV ]D]]>F_4$L! A0#%     @
MPDE-6I]V:;P0$@  GL8  !               ( !     '!T;BTR,#(T,3(S
M,2YX<V102P$"% ,4    " #"24U:_-TB3-,.  #UJ0  %
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M2P$"% ,4    " #"24U:Q5[BJYKH   OS0L "P              @ &KNP
M<'1N7S$P<2YH=&U02P$"% ,4    " #"24U:,?@#(@[7  !8Z@  $
M        @ %NI $ <'1N7S$P<6EM9S$V+FIP9U!+ 0(4 Q0    ( ,))35JR
MJFWW.WX   I_   0              "  :I[ @!P=&Y?,3!Q:6UG,3<N:G!G
M4$L! A0#%     @ PDE-6C"[RJ)6#P  -1   !               ( !$_H"
M '!T;E\Q,'%I;6<Q."YJ<&=02P$"% ,4    " #"24U:VV4\U*4&  !2(@
M#0              @ &7"0, <'1N7V5X,S$Q+FAT;5!+ 0(4 Q0    ( ,))
M35J+P=I%P 8  "PC   -              "  6<0 P!P=&Y?97@S,3(N:'1M
M4$L! A0#%     @ PDE-6LMDI-P# P  IP<   T              ( !4A<#
M '!T;E]E>#,R,2YH=&U02P$"% ,4    " #"24U:3B.MI"@#  !)"   #0
M            @ & &@, <'1N7V5X,S(R+FAT;5!+!08     #0 - "4#  #3
%'0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>ptn_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptn="http://ptn.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptn-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-07-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-10_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-12</endDate>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2024-12-01to2024-12-13_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-13_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-13</instant>
        </period>
    </context>
    <context id="From2024-06-01to2024-06-20_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-20_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-10-20</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-10-04to2023-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-20</endDate>
        </period>
    </context>
    <context id="From2022-07-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberToZeroTwoFourSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberTwoThousandTwentyFourSerisCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CumulativeFromInceptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_OneToThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OneToThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_FourToFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:FourToFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2017-11-01to2017-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-21</endDate>
        </period>
    </context>
    <context id="From2017-09-01to2017-09-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-06</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-28_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-02-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-07-01to2024-12-31" id="ixv-8447">0000911216</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-07-01to2024-12-31" id="ixv-8448">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-07-01to2024-12-31" id="ixv-8449">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-07-01to2024-12-31" id="ixv-8450">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2024-07-01to2024-12-31" id="ixv-8451">2025</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="ixv-8452"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-8453"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-8454"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="ixv-8455"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-8456"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="ixv-8457"
      unitRef="Shares">23455846</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-8458"
      unitRef="Shares">17926640</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-8459"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-8460"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-8461"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8462"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8463"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8464"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8465"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="ixv-8466"
      unitRef="USD">263400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8467"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8468"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-8469"
      unitRef="Shares">2358491</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8470"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8471"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8472"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8473"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8474"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8475"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8476"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8477"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8478"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8479"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8480"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8481"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="ixv-8482"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:WarrantExercisesShares
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="ixv-8483"
      unitRef="Shares">3907679</ptn:WarrantExercisesShares>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="ixv-8484"
      unitRef="Shares">13059777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="ixv-8485"
      unitRef="Shares">6595422</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="ixv-8486"
      unitRef="Shares">279700</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="ixv-8487"
      unitRef="Shares">-14338</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="ixv-8488"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="ixv-8489"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="ixv-8490"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-04to2023-10-31"
      decimals="0"
      id="ixv-8491"
      unitRef="USD">9109117</us-gaap:CostsAndExpenses>
    <dei:DocumentType contextRef="From2024-07-01to2024-12-31" id="ixv-9263">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-07-01to2024-12-31" id="ixv-9264">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-07-01to2024-12-31" id="ixv-9265">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-07-01to2024-12-31" id="ixv-9266">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-07-01to2024-12-31" id="ixv-9267">001-15543</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-07-01to2024-12-31" id="ixv-9268">PALATIN TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-07-01to2024-12-31" id="ixv-9269">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-07-01to2024-12-31" id="ixv-9270">95-4078884</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-07-01to2024-12-31" id="ixv-9271">4B Cedar Brook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-07-01to2024-12-31" id="ixv-9272">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-07-01to2024-12-31" id="ixv-9273">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-07-01to2024-12-31" id="ixv-9274">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-07-01to2024-12-31" id="ixv-9275">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-07-01to2024-12-31" id="ixv-9276">495&#x2011;2200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-07-01to2024-12-31" id="ixv-9277">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-07-01to2024-12-31" id="ixv-9278">PTN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-07-01to2024-12-31" id="ixv-9279">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-07-01to2024-12-31" id="ixv-9280">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-07-01to2024-12-31" id="ixv-9281">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-07-01to2024-12-31" id="ixv-9282">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-07-01to2024-12-31" id="ixv-9283">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-07-01to2024-12-31" id="ixv-9284">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-07-01to2024-12-31" id="ixv-9285">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-02-12"
      decimals="INF"
      id="ixv-9286"
      unitRef="Shares">26005846</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_289"
      unitRef="USD">3416604</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_288"
      unitRef="USD">9527396</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_297"
      unitRef="USD">253113</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_296"
      unitRef="USD">242272</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_299"
      unitRef="USD">3669717</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_298"
      unitRef="USD">9769668</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_301"
      unitRef="USD">235741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_300"
      unitRef="USD">388361</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_303"
      unitRef="USD">347644</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_302"
      unitRef="USD">527321</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_304"
      unitRef="USD">56916</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_305"
      unitRef="USD">56916</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_307"
      unitRef="USD">4310018</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_306"
      unitRef="USD">10742266</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_309"
      unitRef="USD">6718233</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_308"
      unitRef="USD">4101929</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_311"
      unitRef="USD">1650700</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_310"
      unitRef="USD">4185046</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_313"
      unitRef="USD">257673</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_312"
      unitRef="USD">380542</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_315"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_314"
      unitRef="USD">46014</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_317"
      unitRef="USD">932150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_316"
      unitRef="USD">944150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_319"
      unitRef="USD">9558756</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_318"
      unitRef="USD">9657681</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_321"
      unitRef="USD">100071</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_320"
      unitRef="USD">163782</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_324"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_325"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_329"
      unitRef="USD">10691127</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_328"
      unitRef="USD">10853763</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="fid_348"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_350"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_351"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_362"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_336"
      unitRef="USD">40</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_337"
      unitRef="USD">40</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="fid_354"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_356"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_359"
      unitRef="Shares">23455846</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_358"
      unitRef="Shares">17926640</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_339"
      unitRef="USD">234558</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_338"
      unitRef="USD">179266</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_341"
      unitRef="USD">445416974</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_340"
      unitRef="USD">441475747</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_343"
      unitRef="USD">-452032681</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_342"
      unitRef="USD">-441766550</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_345"
      unitRef="USD">-6381109</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_344"
      unitRef="USD">-111497</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_347"
      unitRef="USD">4310018</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_346"
      unitRef="USD">10742266</us-gaap:LiabilitiesAndStockholdersEquity>
    <ptn:ProductRevenueNet
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2346"
      unitRef="USD">0</ptn:ProductRevenueNet>
    <ptn:ProductRevenueNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2362"
      unitRef="USD">2034113</ptn:ProductRevenueNet>
    <ptn:ProductRevenueNet
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2010"
      unitRef="USD">0</ptn:ProductRevenueNet>
    <ptn:ProductRevenueNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2011"
      unitRef="USD">4140090</ptn:ProductRevenueNet>
    <us-gaap:ProductionCosts
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2347"
      unitRef="USD">0</us-gaap:ProductionCosts>
    <us-gaap:ProductionCosts
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2341"
      unitRef="USD">97637</us-gaap:ProductionCosts>
    <us-gaap:ProductionCosts
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2340"
      unitRef="USD">0</us-gaap:ProductionCosts>
    <us-gaap:ProductionCosts
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2363"
      unitRef="USD">97637</us-gaap:ProductionCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2348"
      unitRef="USD">3429479</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2364"
      unitRef="USD">5554200</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2013"
      unitRef="USD">9173233</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2014"
      unitRef="USD">10568830</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2349"
      unitRef="USD">1681844</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2365"
      unitRef="USD">3032613</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2015"
      unitRef="USD">3702775</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2016"
      unitRef="USD">6232857</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2342"
      unitRef="USD">-2500000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2343"
      unitRef="USD">-7823482</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2350"
      unitRef="USD">-2500000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2366"
      unitRef="USD">-7823482</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:OperatingExpenses
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2351"
      unitRef="USD">2611323</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2367"
      unitRef="USD">860968</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2017"
      unitRef="USD">10376008</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2018"
      unitRef="USD">9075842</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2352"
      unitRef="USD">-2611323</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2368"
      unitRef="USD">1173145</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2019"
      unitRef="USD">-10376008</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2020"
      unitRef="USD">-4935752</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2353"
      unitRef="USD">29044</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2369"
      unitRef="USD">62026</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2022"
      unitRef="USD">107620</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2023"
      unitRef="USD">133656</us-gaap:InvestmentIncomeNet>
    <ptn:ForeignCurrencyTransactionLossGain
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2354"
      unitRef="USD">143600</ptn:ForeignCurrencyTransactionLossGain>
    <ptn:ForeignCurrencyTransactionLossGain
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2370"
      unitRef="USD">-306697</ptn:ForeignCurrencyTransactionLossGain>
    <ptn:ForeignCurrencyTransactionLossGain
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2024"
      unitRef="USD">12000</ptn:ForeignCurrencyTransactionLossGain>
    <ptn:ForeignCurrencyTransactionLossGain
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2025"
      unitRef="USD">-146947</ptn:ForeignCurrencyTransactionLossGain>
    <us-gaap:InterestExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2355"
      unitRef="USD">3803</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2371"
      unitRef="USD">1605</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2026"
      unitRef="USD">9743</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2027"
      unitRef="USD">12487</us-gaap:InterestExpense>
    <us-gaap:OtherExpenses
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2356"
      unitRef="USD">0</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2345"
      unitRef="USD">696912</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2344"
      unitRef="USD">0</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2372"
      unitRef="USD">696912</us-gaap:OtherExpenses>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2357"
      unitRef="USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2373"
      unitRef="USD">-8073991</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2028"
      unitRef="USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2029"
      unitRef="USD">-7391591</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2358"
      unitRef="USD">168841</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2374"
      unitRef="USD">-9017179</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2030"
      unitRef="USD">109877</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2031"
      unitRef="USD">-8114281</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2359"
      unitRef="USD">-2442482</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2375"
      unitRef="USD">-7844034</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2032"
      unitRef="USD">-10266131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2033"
      unitRef="USD">-13050033</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-10-01to2024-12-31"
      decimals="INF"
      id="fid_2360"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-10-01to2023-12-31"
      decimals="INF"
      id="fid_2376"
      unitRef="USDPShares">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-01to2024-12-31"
      decimals="INF"
      id="fid_2034"
      unitRef="USDPShares">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-01to2023-12-31"
      decimals="INF"
      id="fid_2035"
      unitRef="USDPShares">-0.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2361"
      unitRef="Shares">20634887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2377"
      unitRef="Shares">14097757</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2036"
      unitRef="Shares">20239997</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2037"
      unitRef="Shares">13134228</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2462"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2463"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2557"
      unitRef="Shares">19548167</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2558"
      unitRef="USD">195481</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2568"
      unitRef="USD">441709073</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2573"
      unitRef="USD">-449590199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2578"
      unitRef="USD">-7685605</us-gaap:StockholdersEquity>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2685"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2690"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2693"
      unitRef="USD">348955</us-gaap:ShareBasedCompensation>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2694"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2697"
      unitRef="USD">348955</us-gaap:ShareBasedCompensation>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2688"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:WarrantExercisesShares
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2676"
      unitRef="Shares">3907679</ptn:WarrantExercisesShares>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2677"
      unitRef="USD">39077</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2681"
      unitRef="USD">3358946</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2692"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2689"
      unitRef="USD">3398023</ptn:WarrantExercisesAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2529"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2539"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2554"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2574"
      unitRef="USD">-2442482</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2579"
      unitRef="USD">-2442482</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2465"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2466"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2530"
      unitRef="Shares">23455846</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2531"
      unitRef="USD">234558</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2541"
      unitRef="USD">445416974</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2546"
      unitRef="USD">-452032681</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2551"
      unitRef="USD">-6381109</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2462-c29bf2"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2463-c019e4"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2527"
      unitRef="Shares">17926640</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2528"
      unitRef="USD">179266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2538"
      unitRef="USD">441475747</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2543"
      unitRef="USD">-441766550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2548"
      unitRef="USD">-111497</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2695"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2670"
      unitRef="Shares">232941</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2671"
      unitRef="USD">2329</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2678"
      unitRef="USD">695649</us-gaap:ShareBasedCompensation>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2647"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2686"
      unitRef="USD">697978</us-gaap:ShareBasedCompensation>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-10-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2696"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2672"
      unitRef="Shares">-54691</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2673"
      unitRef="USD">-547</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2679"
      unitRef="USD">-98935</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2646"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2687"
      unitRef="USD">-99482</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2648"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:SharesReleasedFromAbeyanceShares
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2674"
      unitRef="Shares">1443277</ptn:SharesReleasedFromAbeyanceShares>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2675"
      unitRef="USD">14433</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2680"
      unitRef="USD">-14433</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2622"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-10-01to2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2621"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2698"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesShares
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2676-17e5ae"
      unitRef="Shares">3907679</ptn:WarrantExercisesShares>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2677-e0f6c2"
      unitRef="USD">39077</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2681-cc6227"
      unitRef="USD">3358946</ptn:WarrantExercisesAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2624"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2689-a139e4"
      unitRef="USD">3398023</ptn:WarrantExercisesAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2559"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2569"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2544"
      unitRef="USD">-10266131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2549"
      unitRef="USD">-10266131</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2465-2e5694"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2466-e9dda5"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2530-de4bac"
      unitRef="Shares">23455846</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2531-70dc8b"
      unitRef="USD">234558</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2541-c4c114"
      unitRef="USD">445416974</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2546-b796b3"
      unitRef="USD">-452032681</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2551-56ec46"
      unitRef="USD">-6381109</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2473"
      unitRef="USD">263400</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2462-ae67e0"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2463-48981c"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2497"
      unitRef="Shares">11946646</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2498"
      unitRef="USD">119466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2508"
      unitRef="USD">410796364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2513"
      unitRef="USD">-417236436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2518"
      unitRef="USD">-6320566</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2654"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2656"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2660"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2661"
      unitRef="USD">549971</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2644"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2667"
      unitRef="USD">549971</us-gaap:ShareBasedCompensation>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2655"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2657"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2636"
      unitRef="Shares">2358491</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2637"
      unitRef="USD">23585</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2642"
      unitRef="USD">2366318</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2662"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2652"
      unitRef="USD">2389903</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2629"
      unitRef="USD">159700</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2659"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2643"
      unitRef="USD">-159700</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2663"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2653"
      unitRef="USD">-159700</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2464"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2469"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2474"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2479"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2514"
      unitRef="USD">-7844034</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2519"
      unitRef="USD">-7844034</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2476"
      unitRef="USD">423100</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2465-595d5f"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2466-f9d0d5"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2470"
      unitRef="Shares">14305137</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2471"
      unitRef="USD">143051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2481"
      unitRef="USD">413552953</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2486"
      unitRef="USD">-425080470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_2491"
      unitRef="USD">-11384426</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2473-25680f"
      unitRef="USD">263400</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2462-e6ac26"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2463-ccf3a1"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2467"
      unitRef="Shares">11656714</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2468"
      unitRef="USD">116567</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2478"
      unitRef="USD">409933959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2483"
      unitRef="USD">-412030437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_2488"
      unitRef="USD">-1979871</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2625"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2665"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2630"
      unitRef="Shares">98372</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2631"
      unitRef="USD">984</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2639"
      unitRef="USD">939323</us-gaap:ShareBasedCompensation>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2669"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2649"
      unitRef="USD">940307</us-gaap:ShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2645"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2599"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2632"
      unitRef="Shares">-25467</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2633"
      unitRef="USD">-255</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2640"
      unitRef="USD">-56146</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2626"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2650"
      unitRef="USD">-56401</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2627"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2664"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:SaleOfCommonStockNetOfCostsShares
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2634"
      unitRef="Shares">217027</ptn:SaleOfCommonStockNetOfCostsShares>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2635"
      unitRef="USD">2170</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2641"
      unitRef="USD">529199</ptn:SaleOfCommonStockNetOfCostsAmount>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2682"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2651"
      unitRef="USD">531369</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2628"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2666"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2636-1b1aba"
      unitRef="Shares">2358491</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2637-a3ee06"
      unitRef="USD">23585</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2642-a0f629"
      unitRef="USD">2366318</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2683"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2652-7efcba"
      unitRef="USD">2389903</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2629-56878c"
      unitRef="USD">159700</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2638"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2668"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2643-0fd80f"
      unitRef="USD">-159700</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2684"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2653-ff96a6"
      unitRef="USD">-159700</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2494"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2499"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2504"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2509"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2484"
      unitRef="USD">-13050033</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2489"
      unitRef="USD">-13050033</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_2476-472c9b"
      unitRef="USD">423100</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2465-637b6b"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2466-07e801"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2470-0f9ffe"
      unitRef="Shares">14305137</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2471-effd83"
      unitRef="USD">143051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2481-e7db77"
      unitRef="USD">413552953</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2486-ae5b00"
      unitRef="USD">-425080470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_2491-3b22bd"
      unitRef="USD">-11384426</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2164"
      unitRef="USD">-10266131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2165"
      unitRef="USD">-13050033</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2167"
      unitRef="USD">152620</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2168"
      unitRef="USD">172060</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2169"
      unitRef="USD">179677</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2170"
      unitRef="USD">174098</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <ptn:UnrealizedForeignCurrencyTransactionLossGain
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2171"
      unitRef="USD">-12000</ptn:UnrealizedForeignCurrencyTransactionLossGain>
    <ptn:UnrealizedForeignCurrencyTransactionLossGain
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2172"
      unitRef="USD">146947</ptn:UnrealizedForeignCurrencyTransactionLossGain>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2173"
      unitRef="USD">697978</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2174"
      unitRef="USD">940307</us-gaap:ShareBasedCompensation>
    <ptn:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2175"
      unitRef="USD">0</ptn:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <ptn:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2176"
      unitRef="USD">7391591</ptn:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2379"
      unitRef="USD">-2500000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2381"
      unitRef="USD">-7823482</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2178"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2179"
      unitRef="USD">-569597</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2180"
      unitRef="USD">10841</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2181"
      unitRef="USD">-1047164</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2182"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2183"
      unitRef="USD">1154355</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2184"
      unitRef="USD">2616304</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2185"
      unitRef="USD">-2710051</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2186"
      unitRef="USD">-2534346</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2187"
      unitRef="USD">-896812</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2188"
      unitRef="USD">-186580</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2189"
      unitRef="USD">-176913</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2382"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2383"
      unitRef="USD">-1012197</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2190"
      unitRef="USD">-11863319</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2191"
      unitRef="USD">-16382079</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2193"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2194"
      unitRef="USD">2992890</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2195"
      unitRef="USD">2500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ptn:ProceedsFromSaleOfOtherAssets
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2386"
      unitRef="USD">9500000</ptn:ProceedsFromSaleOfOtherAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2385"
      unitRef="USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2387"
      unitRef="USD">37615</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ptn:ProceedsFromSaleOfOtherAssets
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2384"
      unitRef="USD">2500000</ptn:ProceedsFromSaleOfOtherAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2196"
      unitRef="USD">12455275</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2198"
      unitRef="USD">99482</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2199"
      unitRef="USD">56401</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2200"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2201"
      unitRef="USD">5531266</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2202"
      unitRef="USD">46014</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2203"
      unitRef="USD">52494</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2388"
      unitRef="USD">3398023</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2389"
      unitRef="USD">103</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2309"
      unitRef="USD">3252527</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2310"
      unitRef="USD">5422474</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2206"
      unitRef="USD">-6110792</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2207"
      unitRef="USD">1495670</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2208"
      unitRef="USD">9527396</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_2209"
      unitRef="USD">7989582</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2210"
      unitRef="USD">3416604</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_2392"
      unitRef="USD">9485252</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2213"
      unitRef="USD">9743</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2214"
      unitRef="USD">10882</us-gaap:InterestPaidNet>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2390"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2391"
      unitRef="USD">2389903</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1937">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(1) ORGANIZATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Nature of Business &lt;/em&gt;- Palatin Technologies, Inc. (&#x201c;Palatin&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#x2019;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Melanocortin Receptor System.&lt;/em&gt; The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s prior commercial product, Vyleesi&#xae;, was approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#x201c;HSDD&#x201d;) in premenopausal women. As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#x201c;Cosette&#x201d;) on December 19, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results expected in the first quarter of calendar year 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Business Risks and Liquidity &#x2013; &lt;/em&gt;The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of December 31, 2024 of $452,032,681 and a net loss for the three and six months ended December 31, 2024 of $2,442,482 and $10,266,131, respectively. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2024, the Company&#x2019;s cash and cash equivalents were $3,416,604 and current liabilities were $9,558,756. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#x2019;s MC1r and MC4r programs, and development of other portfolio products.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company follows the provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;em&gt;Presentation of Financial Statements &#x2014; Going Concern&lt;/em&gt;, which requires management to assess the Company&#x2019;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#x2019;s ability to meet its obligations for the next year.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Based on our available cash and cash equivalents as of December 31, 2024 and $4,309,641 received in February 2025, management has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#x2019;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company could be forced to make additional reductions in certain expenditures. This could include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company could be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of calendar year 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees.&lt;em&gt; &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Concentrations &#x2013;&lt;/em&gt; Concentrations in the Company&#x2019;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1444"
      unitRef="USD">-452032681</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2317"
      unitRef="USD">-2442482</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_1445"
      unitRef="USD">-10266131</us-gaap:NetIncomeLoss>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1447"
      unitRef="USD">3416604</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1448"
      unitRef="USD">9558756</us-gaap:LiabilitiesCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-02-28_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2320"
      unitRef="USD">4309641</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ptn:SalesBasedMilestonePayments
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2162"
      unitRef="USD">159000000</ptn:SalesBasedMilestonePayments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1945">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(2) BASIS OF PRESENTATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and six months ended December 31, 2024, may not necessarily be indicative of the results of operations expected for the full fiscal year.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1938">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cash, Cash Equivalents&lt;/em&gt; &#x2013; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $3,005,361 and $9,089,113 in a money market account at December 31, 2024 and June 30, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt; &#x2013; The Company&#x2019;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Credit Risk&lt;/em&gt; &#x2013; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Impairment of Long-Lived Assets&lt;/em&gt; &#x2013; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#x2019;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#x2019;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition (Prior to the sale of Vyleesi)&lt;/em&gt; &#x2013; The Company recognized product revenues in accordance with FASB ASC Topic 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#x2019;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Gross product sales offset by product sales allowances for the three and six months ended December 31, 2024 and 2023 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,288,003&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,875,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,253,890&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,735,063&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,034,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,140,090&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition &#x2014;&lt;/em&gt;&#x2013; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accrued Expenses &#x2013;&lt;/em&gt; Third parties perform a significant portion of the Company&#x2019;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation &#x2013; &lt;/em&gt;The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Net Loss per Common Share &lt;/em&gt;&#x2013;&lt;em&gt; &lt;/em&gt;Basic and diluted loss per common share (&#x201c;EPS&#x201d;) are calculated in accordance with the provisions of FASB ASC Topic 260, &lt;em&gt;Earnings per Share&lt;/em&gt;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For the three months ended December 31, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and six months ended December 31, 2024 and 2023 were 13,059,777 and 6,595,422, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of December 31, 2024, and 2023 due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Translation of foreign currencies &lt;/em&gt;&#x2013; Transactions denominated in currencies other than the Company&#x2019;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1953">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-07-01to2024-12-31" id="fid_1954">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1955">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Cash, Cash Equivalents&lt;/em&gt; &#x2013; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $3,005,361 and $9,089,113 in a money market account at December 31, 2024 and June 30, 2024, respectively.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ptn:MoneyMarketAccountsAndTreasuryBills
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_282"
      unitRef="USD">3005361</ptn:MoneyMarketAccountsAndTreasuryBills>
    <ptn:MoneyMarketAccountsAndTreasuryBills
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2040"
      unitRef="USD">9089113</ptn:MoneyMarketAccountsAndTreasuryBills>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-07-01to2024-12-31" id="fid_1957">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt; &#x2013; The Company&#x2019;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-07-01to2024-12-31" id="fid_1958">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Credit Risk&lt;/em&gt; &#x2013; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1961">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1962">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Impairment of Long-Lived Assets&lt;/em&gt; &#x2013; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1963">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#x2019;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#x2019;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ptn:RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock contextRef="From2024-07-01to2024-12-31" id="fid_1989">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition (Prior to the sale of Vyleesi)&lt;/em&gt; &#x2013; The Company recognized product revenues in accordance with FASB ASC Topic 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#x2019;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Gross product sales offset by product sales allowances for the three and six months ended December 31, 2024 and 2023 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,288,003&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,875,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,253,890&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,735,063&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,034,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,140,090&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock>
    <ptn:ScheduleOfSalesTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1971">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,288,003&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,875,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,253,890&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,735,063&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,034,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,140,090&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfSalesTableTextBlock>
    <ptn:RevenuesGross
      contextRef="From2024-10-01to2024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2326"
      unitRef="USD">0</ptn:RevenuesGross>
    <ptn:RevenuesGross
      contextRef="From2023-10-01to2023-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2327"
      unitRef="USD">4288003</ptn:RevenuesGross>
    <ptn:RevenuesGross
      contextRef="From2024-07-01to2024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_12"
      unitRef="USD">0</ptn:RevenuesGross>
    <ptn:RevenuesGross
      contextRef="From2023-07-01to2023-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2325"
      unitRef="USD">8875153</ptn:RevenuesGross>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2024-10-01to2024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2328"
      unitRef="USD">0</ptn:ProductSalesAllowancesAndAccruals>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2023-10-01to2023-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2329"
      unitRef="USD">-2253890</ptn:ProductSalesAllowancesAndAccruals>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2024-07-01to2024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_605"
      unitRef="USD">0</ptn:ProductSalesAllowancesAndAccruals>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2023-07-01to2023-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2331"
      unitRef="USD">-4735063</ptn:ProductSalesAllowancesAndAccruals>
    <us-gaap:Revenues
      contextRef="From2024-10-01to2024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2333"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-10-01to2023-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2330"
      unitRef="USD">2034113</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-01to2024-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_264"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-01to2023-12-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2332"
      unitRef="USD">4140090</us-gaap:Revenues>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1964">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition &#x2014;&lt;/em&gt;&#x2013; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-07-01to2024-12-31" id="fid_1965">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ptn:AccruedLiabilitiesPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1966">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Accrued Expenses &#x2013;&lt;/em&gt; Third parties perform a significant portion of the Company&#x2019;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.&lt;/p&gt;</ptn:AccruedLiabilitiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-07-01to2024-12-31" id="fid_1967">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation &#x2013; &lt;/em&gt;The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1968">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1969">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Net Loss per Common Share &lt;/em&gt;&#x2013;&lt;em&gt; &lt;/em&gt;Basic and diluted loss per common share (&#x201c;EPS&#x201d;) are calculated in accordance with the provisions of FASB ASC Topic 260, &lt;em&gt;Earnings per Share&lt;/em&gt;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;For the three months ended December 31, 2024 and 2023, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and six months ended December 31, 2024 and 2023 were 13,059,777 and 6,595,422, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of December 31, 2024, and 2023 due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_287"
      unitRef="Shares">13059777</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_1415"
      unitRef="Shares">6595422</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_1416"
      unitRef="Shares">279700</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1970">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Translation of foreign currencies &lt;/em&gt;&#x2013; Transactions denominated in currencies other than the Company&#x2019;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1939">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(4)&lt;/strong&gt; &lt;strong&gt;New Accounting Pronouncements&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of the adoption on the consolidated financial statements and accompanying footnotes.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <ptn:AssetPurchaseAgreementTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1940">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(5) ASSET PURCHASE AGREEMENT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#xae;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Under the terms of the Purchase Agreement, the Company sold certain assets (the &#x201c;Purchased Assets&#x201d;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $171,000,000, consisting of an upfront purchase price of $9,500,000, $2,500,000 payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $159,000,000. As of December 31, 2024, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#x201c;Korea&#x201d;) (see Note 8).&lt;/p&gt;</ptn:AssetPurchaseAgreementTextBlock>
    <us-gaap:AccountsReceivablePurchase
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_1450"
      unitRef="USD">171000000</us-gaap:AccountsReceivablePurchase>
    <us-gaap:SupplementalDeferredPurchasePrice
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_1452"
      unitRef="USD">9500000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:PaymentsForPurchaseOfOtherAssets1
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_1449"
      unitRef="USD">2500000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
    <ptn:PaymentsToSalesBasedMilestonePayments
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_1451"
      unitRef="USD">159000000</ptn:PaymentsToSalesBasedMilestonePayments>
    <ptn:ManufacturingSupplyAgreementsTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1988">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#x201c;Catalent&#x201d;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#x201c;Ypsomed&#x201d;), to manufacture the auto-injector device (the &#x201c;Ypsomed Agreement&#x201d;); and Lonza Ltd. (&#x201c;Lonza&#x201d;), to manufacture the active pharmaceutical ingredient peptide (the &#x201c;Lonza Agreement&#x201d;).&lt;/p&gt;</ptn:ManufacturingSupplyAgreementsTextBlock>
    <ptn:AgreementWithFosunTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1941">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(7) AGREEMENT WITH FOSUN&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun&#x201d;) for exclusive rights to commercialize Vyleesi in China (the &#x201c;Fosun License Agreement&#x201d;). Under the terms of the Fosun License Agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.&lt;/p&gt;</ptn:AgreementWithFosunTextBlock>
    <us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1618"
      unitRef="USD">4500000</us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits>
    <us-gaap:PaymentsForRestructuring
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1619"
      unitRef="USD">5000000</us-gaap:PaymentsForRestructuring>
    <ptn:UpfrontPaymentOfLess
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1626"
      unitRef="USD">500000</ptn:UpfrontPaymentOfLess>
    <ptn:AgreementWithKwangdongTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1942">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(8) AGREEMENT WITH KWANGDONG&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#x201c;Kwangdong&#x201d;) for exclusive rights to commercialize Vyleesi in Korea (the &#x201c;Kwangdong License Agreement&#x201d;). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea which has not occurred as of December 31, 2024.&lt;/p&gt;</ptn:AgreementWithKwangdongTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_631"
      unitRef="USD">417500</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRestructuring
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_633"
      unitRef="USD">500000</us-gaap:PaymentsForRestructuring>
    <ptn:taxexpenses
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_634"
      unitRef="USD">82500</ptn:taxexpenses>
    <us-gaap:PaymentsToAcquireReceivables
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_636"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1943">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Prepaid expenses&lt;strong&gt; &lt;/strong&gt;and other current assets consist of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;43,314&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,926&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,744&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,097&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;124,055&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,249&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;253,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;242,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1972">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;43,314&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,926&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,744&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,097&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;124,055&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,249&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;253,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;242,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ptn:PrepaidClinicalStudyCosts
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_637"
      unitRef="USD">43314</ptn:PrepaidClinicalStudyCosts>
    <ptn:PrepaidClinicalStudyCosts
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_575"
      unitRef="USD">23926</ptn:PrepaidClinicalStudyCosts>
    <ptn:PrepaidInsurancePremiums
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_638"
      unitRef="USD">85744</ptn:PrepaidInsurancePremiums>
    <ptn:PrepaidInsurancePremiums
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_577"
      unitRef="USD">71097</ptn:PrepaidInsurancePremiums>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_640"
      unitRef="USD">124055</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_581"
      unitRef="USD">147249</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_641"
      unitRef="USD">253113</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_583"
      unitRef="USD">242272</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1944">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(10) FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#x2019;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#x2019;s or liability&#x2019;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table provides the assets carried at fair value:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Carrying Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Quoted prices in &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;active markets&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Other quoted/observable inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Significant unobservable inputs&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 31, 2024:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,005,361&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,005,361&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 30, 2024:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1973">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Carrying Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Quoted prices in &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;active markets&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Other quoted/observable inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Significant unobservable inputs&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 31, 2024:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,005,361&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,005,361&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 30, 2024:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_1460"
      unitRef="USD">3005361</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="fid_1471"
      unitRef="USD">3005361</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="fid_1461"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="fid_1466"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2042"
      unitRef="USD">9089113</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="fid_2041"
      unitRef="USD">9089113</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="fid_2043"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <ptn:CarryingValueDuringTheYear
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="fid_2044"
      unitRef="USD">0</ptn:CarryingValueDuringTheYear>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1948">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Accrued expenses&lt;strong&gt; &lt;/strong&gt;consist of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,153,170&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,509,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;36,003&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,972&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Professional Services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;61,484&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;284,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,771,694&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Selling expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;324,640&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;351,485&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;75,403&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;201,883&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,650,700&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,185,046&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1981">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,153,170&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,509,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;36,003&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,972&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Professional Services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;61,484&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;284,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,771,694&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Selling expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;324,640&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;351,485&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;75,403&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;201,883&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,650,700&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,185,046&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptn:CostClinicalStudy
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_661"
      unitRef="USD">1153170</ptn:CostClinicalStudy>
    <ptn:CostClinicalStudy
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_660"
      unitRef="USD">1509797</ptn:CostClinicalStudy>
    <ptn:OtherResearchRelatedExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_663"
      unitRef="USD">36003</ptn:OtherResearchRelatedExpenses>
    <ptn:OtherResearchRelatedExpenses
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_662"
      unitRef="USD">65972</ptn:OtherResearchRelatedExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_665"
      unitRef="USD">61484</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_664"
      unitRef="USD">284215</us-gaap:AccruedProfessionalFeesCurrent>
    <ptn:PersonalCost
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_667"
      unitRef="USD">0</ptn:PersonalCost>
    <ptn:PersonalCost
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_666"
      unitRef="USD">1771694</ptn:PersonalCost>
    <ptn:AccruedSellingExpenses
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_669"
      unitRef="USD">324640</ptn:AccruedSellingExpenses>
    <ptn:AccruedSellingExpenses
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_668"
      unitRef="USD">351485</ptn:AccruedSellingExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_671"
      unitRef="USD">75403</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_670"
      unitRef="USD">201883</us-gaap:OtherAccruedLiabilitiesCurrent>
    <ptn:TotaAcrruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_673"
      unitRef="USD">1650700</ptn:TotaAcrruedLiabilities>
    <ptn:TotaAcrruedLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_672"
      unitRef="USD">4185046</ptn:TotaAcrruedLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1949">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(12) COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Inventory Purchases &lt;/em&gt;- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#x201c;Catalent Agreement&#x201d;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of December 31, 2024:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Current&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;1 - 3 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;4 - 5 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Inventory purchase commitments&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,480,600&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,448,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,032,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2024, the Company has $932,150 and $1,032,300 accrued within other current and long-term liabilities, respectively, in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $944,150 and $1,032,300 was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Contingencies&lt;/em&gt; - The Company accounts for litigation losses in accordance with ASC 450-20, &lt;em&gt;Loss Contingencies&lt;/em&gt;. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#x2019;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1982">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Current&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;1 - 3 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;4 - 5 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;Inventory purchase commitments&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,480,600&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,448,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,032,300&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_865"
      unitRef="USD">2480600</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-12-31_ptn_CurrentMember"
      decimals="0"
      id="fid_866"
      unitRef="USD">1448300</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-12-31_ptn_OneToThreeYearsMember"
      decimals="0"
      id="fid_867"
      unitRef="USD">1032300</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2024-12-31_ptn_FourToFiveYearsMember"
      decimals="0"
      id="fid_2335"
      unitRef="USD">0</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_870"
      unitRef="USD">932150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_872"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_869"
      unitRef="USD">944150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_871"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_1950">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(13) STOCKHOLDERS&#x2019; DEFICIENCY&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Series A Convertible Preferred Stock&lt;/em&gt; &#x2013; As of December 31, 2024, 4,030 shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $100 divided by the Series A Conversion Price. As of December 31, 2024, the Series A Conversion Price was $75.45, and each share of Series A Convertible Preferred Stock is convertible into approximately 1.33 shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $100 per share, or $403,000 in the aggregate as of December 31, 2024. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $100 per share to holders of the Series A Convertible Preferred Stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Financing Transactions &#x2013; &lt;/em&gt;On January 29, 2024, the Company entered into a securities purchase agreement (the &#x201c;January 2024 Purchase Agreement&#x201d;) to sell in a registered direct offering (the &#x201c;January 2024 RD Offering&#x201d;), an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#x201c;January 2024 Private Warrants&#x201d;) to purchase up to 1,831,503 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;Private Offering&#x201d; and together with the January 2024 RD Offering, the &#x201c;January 2024 Offering&#x201d;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $5.46 per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#x201c;2024 Placement Agent Warrants&#x201d;) to purchase up to 91,575 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Placement Agent Warrant Shares&#x201d;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $6.825 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The gross proceeds from the January 2024 Offering totaled $10,000,006, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $9,224,056. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 20, 2023, the Company entered into a securities purchase agreement (the &#x201c;October 2023 Purchase Agreement&#x201d;) with a certain institutional investor, to sell in a registered direct offering (the &#x201c;October 2023 RD Offering&#x201d;), an aggregate of (i) 1,325,000 shares of common stock (the &#x201c;October 2023 Shares&#x201d;), of the Company and (ii) pre-funded warrants (the &#x201c;October 2023 Pre-Funded Warrants&#x201d;) to purchase up to 1,033,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Pre-Funded Warrant Shares&#x201d;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#x201c;October 2023 Private Warrants&#x201d;) to purchase up to 2,358,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;October 2023 Private Offering&#x201d; and together with the October 2023 RD Offering, the &#x201c;October 2023 Offering&#x201d;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $2.12 per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The October 2023 Pre-Funded Warrants had an exercise price of $0.0001 per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase 1,033,491 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $4,573,948.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounted for in accordance ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of the Company, therefore the placement agent warrants are classified out of permanent equity.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 12, 2023, the Company entered into a new equity distribution agreement (the &#x201c;2023 Equity Distribution Agreement&#x201d;) with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;), pursuant to which the Company may, from time to time, sell shares of the Company&#x2019;s common stock at market prices by methods deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#x2019;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Proceeds raised under the 2023 Equity Distribution Agreement are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Cumulative from inception&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Gross proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;547,803&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,744,542&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Fees&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,434&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,336&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Expenses&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(126,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Net proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;531,369&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,565,406&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;No proceeds were raised under the 2023 Equity Distribution Agreement during the three and six months ended December 31, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock Warrants&lt;/em&gt; &#x2013; On December 13, 2024, the Company entered into a letter agreement (the &#x201c;December 2024 Inducement Letter&#x201d;) with a holder (the &#x201c;December 2024 Exercising Holder&#x201d;) of outstanding common stock purchase warrants that the Company issued on June 24, 2024, with an initial exercise price of $1.88, and October 24, 2023, with an initial exercise price of $2.12 (the &#x201c;December 2024 Existing Warrants&#x201d;). To induce the exercise of a portion of the December 2024 Existing Warrants by the December 2024 Exercising Holder, the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#x2019;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#x201c;Series C Warrants&#x201d;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#x201c;Series D Warrants&#x201d; and together with the Series C Warrants, the &#x201c;December 2024 Inducement Warrants,&#x201d; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#x201c;December 2024 Inducement Warrant Shares&#x201d;). The Company received aggregate gross proceeds of $3,419,219 from the exercise of the December 2024 Existing Warrants by the December 2024 Exercising Holder (the &#x201c;December 2024 Warrant Inducement&#x201d;). The incremental value of the December 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 20, 2024, the Company entered into a letter agreement (the &#x201c;June 2024 Inducement Letter&#x201d;) with a holder (the &#x201c;June 2024 Exercising Holder&#x201d;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#x201c;June 2024 Existing Warrants&#x201d;). Pursuant to the June 2024 Inducement Letter, the June 2024 Exercising Holder agreed to exercise, for cash, June 2024 Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company&#x2019;s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#x201c;June 2024 Series A Warrants&#x201d;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#x201c;June 2024 Series B Warrants&#x201d; and together with the June 2024 Series A Warrants, the &#x201c;June 2024 Inducement Warrants&#x201d;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#x201c;Warrant Inducement&#x201d;). As part of the agreement, 1,443,277 shares of common stock were held in abeyance on behalf of the June 2024 Exercising Holder. During the three months ended December 31, 2024, at the request of the June 2024 Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the June 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of December 31, 2024, the Company had outstanding warrants for shares of common stock as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares of Common&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Exercise Price per&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Latest Expiration&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Stock&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;May 2022 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;66,666&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;12.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;May 11, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2022 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;90,909&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2023 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;117,925&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 20, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Private Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,831,503&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;5.46&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;91,575&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6.83&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 2024 Series B Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,885,632&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;*&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series C Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3,907,679&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 17, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series D Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,953,839&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;**&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="12" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="12" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Stock Options &#x2013;&lt;/em&gt; For the three and six months ended December 31, 2024, the Company recorded stock-based compensation related to stock options of $177,673 and $355,407, respectively. For the three and six months ended December 31, 2023, the Company recorded stock-based compensation related to stock options of $205,223 and $410,540, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of stock option activity is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Term in&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Intrinsic&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,263,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.11&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,338&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,249,102&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.12&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7.7&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;935,714&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10.76&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.1&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected to vest at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,313,387&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2.82&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8.9&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Stock options granted to the Company&#x2019;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Included in the outstanding options in the table above are 418,945 and 88,911 unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were 95,167, 60,566, 238,838 and 264,945, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Restricted Stock Units &#x2013; &lt;/em&gt;For the three and six months ended December 31, 2024, the Company recorded stock-based compensation related to restricted stock units of $171,281 and $342,571, respectively. For the three and six months ended December 31, 2023, the Company recorded stock-based compensation related to restricted stock units of $185,019 and $370,038, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of restricted stock unit activity is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,374,980&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(232,941&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Expirations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,726&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,139,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Included in outstanding restricted stock units in the table above are 279,700 vested shares that have not been issued as of December 31, 2024, due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Time-based restricted stock units granted to the Company&#x2019;s executive officers, other employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Included in the outstanding restricted stock units in the table above are 274,549 and 59,842 unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were 22,343, 40,707, 152,432 and 184,443 restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In connection with the vesting of restricted share units during the six months ended December 31, 2024, the Company withheld 54,691 shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2704"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CashAvailableForDistributions
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2710"
      unitRef="USD">100</us-gaap:CashAvailableForDistributions>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_2706"
      unitRef="USDPShares">75.45</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare
      contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_2707"
      unitRef="USDPShares">1.33</us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare>
    <us-gaap:CashAvailableForDistributions
      contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2708"
      unitRef="USD">100</us-gaap:CashAvailableForDistributions>
    <ptn:AggregateValue
      contextRef="From2024-07-01to2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2705"
      unitRef="USD">403000</ptn:AggregateValue>
    <ptn:CashAvailableForDistributionsAdditional
      contextRef="AsOf2024-12-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2709"
      unitRef="USD">100</ptn:CashAvailableForDistributionsAdditional>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2024-02-01to2024-02-29" id="fid_2703">an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#x201c;January 2024 Private Warrants&#x201d;) to purchase up to 1,831,503 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;Private Offering&#x201d; and together with the January 2024 RD Offering, the &#x201c;January 2024 Offering&#x201d;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="fid_2700"
      unitRef="USDPShares">5.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2716"
      unitRef="Shares">91575</ptn:SharesOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2717"
      unitRef="USDPShares">6.825</us-gaap:SharesIssuedPricePerShare>
    <ptn:GrossProceeds
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2711"
      unitRef="USD">10000006</ptn:GrossProceeds>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2699"
      unitRef="USD">9224056</us-gaap:CostsAndExpenses>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2023-10-01to2023-10-20" id="fid_2718">an aggregate of (i) 1,325,000 shares of common stock (the &#x201c;October 2023 Shares&#x201d;), of the Company and (ii) pre-funded warrants (the &#x201c;October 2023 Pre-Funded Warrants&#x201d;) to purchase up to 1,033,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Pre-Funded Warrant Shares&#x201d;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#x201c;October 2023 Private Warrants&#x201d;) to purchase up to 2,358,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;October 2023 Private Offering&#x201d; and together with the October 2023 RD Offering, the &#x201c;October 2023 Offering&#x201d;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-20"
      decimals="INF"
      id="fid_2701"
      unitRef="USDPShares">2.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-10-20"
      decimals="INF"
      id="fid_2702"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <ptn:PurchaseOfWarrantShares
      contextRef="From2024-07-01to2024-12-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"
      decimals="0"
      id="fid_2719"
      unitRef="USD">1033491</ptn:PurchaseOfWarrantShares>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-01to2023-10-20"
      decimals="0"
      id="fid_2712"
      unitRef="USD">4573948</us-gaap:CostsAndExpenses>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2023-04-01to2023-04-12" id="fid_2720">The 2023 Equity Distribution Agreement and related prospectus is limited to sales of up to an aggregate maximum $50.0 million of shares of the Company&#x2019;s common stock. The Company pays Canaccord 3.0% of the gross proceeds as a commission</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <ptn:ScheduleOfEquityDistributionAgreementTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_2105">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Cumulative from inception&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Gross proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;547,803&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,744,542&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Fees&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,434&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,336&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Expenses&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(126,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Net proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;531,369&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,565,406&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfEquityDistributionAgreementTableTextBlock>
    <ptn:EquityGrossProceedsShares
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2395"
      unitRef="Shares">217027</ptn:EquityGrossProceedsShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2394"
      unitRef="USD">547803</us-gaap:ProceedsFromOtherEquity>
    <ptn:EquityGrossProceedsShares
      contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2409"
      unitRef="Shares">721061</ptn:EquityGrossProceedsShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2408"
      unitRef="USD">1744542</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2397"
      unitRef="USD">16434</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2406"
      unitRef="USD">52336</us-gaap:ProceedsFromFeesReceived>
    <ptn:EquityExpensesProceeds
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2399"
      unitRef="USD">0</ptn:EquityExpensesProceeds>
    <ptn:EquityExpensesProceeds
      contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2404"
      unitRef="USD">126800</ptn:EquityExpensesProceeds>
    <ptn:EquityNetProceedsShares
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2400"
      unitRef="Shares">217027</ptn:EquityNetProceedsShares>
    <ptn:EquityNetProceedsProceeds
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2401"
      unitRef="USD">531369</ptn:EquityNetProceedsProceeds>
    <ptn:EquityNetProceedsShares
      contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2403"
      unitRef="Shares">721061</ptn:EquityNetProceedsShares>
    <ptn:EquityNetProceedsProceeds
      contextRef="From2024-07-01to2024-12-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2402"
      unitRef="USD">1565406</ptn:EquityNetProceedsProceeds>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-13_ptn_StockWarrantsMember"
      decimals="INF"
      id="fid_2749"
      unitRef="USDPShares">1.88</us-gaap:SharesIssuedPricePerShare>
    <ptn:DescriptionOfExistingHolderPurchaseOfWarrants
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      id="fid_2751">the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#x2019;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#x201c;Series C Warrants&#x201d;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#x201c;Series D Warrants&#x201d; and together with the Series C Warrants, the &#x201c;December 2024 Inducement Warrants,&#x201d; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#x201c;December 2024 Inducement Warrant Shares&#x201d;). The Company received aggregate gross proceeds of $3,419,219 from the exercise of the December 2024</ptn:DescriptionOfExistingHolderPurchaseOfWarrants>
    <ptn:PurchaseOfWarrantOfCommonStockSeriesA
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2750"
      unitRef="Shares">3907679</ptn:PurchaseOfWarrantOfCommonStockSeriesA>
    <ptn:WarrantsToPurchaseShares
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2752"
      unitRef="Shares">1953839</ptn:WarrantsToPurchaseShares>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2753"
      unitRef="USD">3419219</us-gaap:ProceedsFromWarrantExercises>
    <ptn:WarrantsToPurchaseShares
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2714"
      unitRef="Shares">3233277</ptn:WarrantsToPurchaseShares>
    <ptn:DescriptionOfExistingHolderPurchaseOfWarrants
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      id="fid_2723">(i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#x201c;June 2024 Series A Warrants&#x201d;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#x201c;June 2024 Series B Warrants&#x201d; and together with the June 2024 Series A Warrants, the &#x201c;June 2024 Inducement Warrants&#x201d;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#x201c;Warrant Inducement&#x201d;)</ptn:DescriptionOfExistingHolderPurchaseOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-20_ptn_StockWarrantsMember"
      decimals="INF"
      id="fid_2721"
      unitRef="USDPShares">1.88</us-gaap:SharesIssuedPricePerShare>
    <ptn:PurchaseOfWarrantOfCommonStockSeriesA
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2722"
      unitRef="Shares">4849915</ptn:PurchaseOfWarrantOfCommonStockSeriesA>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2715"
      unitRef="USD">6078561</us-gaap:ProceedsFromWarrantExercises>
    <ptn:ExercisingHolderReleasedShares
      contextRef="From2024-07-01to2024-12-31_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2724"
      unitRef="Shares">1443277</ptn:ExercisingHolderReleasedShares>
    <ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_2106">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares of Common&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Exercise Price per&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Latest Expiration&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Stock&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;May 2022 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;66,666&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;12.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;May 11, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2022 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;90,909&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2023 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;117,925&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 20, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Private Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,831,503&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;5.46&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;91,575&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6.83&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 2024 Series B Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,885,632&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;*&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series C Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3,907,679&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 17, 2029&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series D Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,953,839&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;**&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="12" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="12" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      decimals="0"
      id="fid_2410"
      unitRef="Shares">66666</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      id="fid_2413"
      unitRef="USDPShares">12.50</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      id="fid_2416">May 11, 2026</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      decimals="0"
      id="fid_2412"
      unitRef="Shares">90909</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      decimals="INF"
      id="fid_2415"
      unitRef="USDPShares">6.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      id="fid_2418">October 31, 2027</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2423"
      unitRef="Shares">117925</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2422"
      unitRef="USDPShares">2.65</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      id="fid_2421">October 20, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      decimals="0"
      id="fid_2426"
      unitRef="Shares">1831503</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      decimals="INF"
      id="fid_2425"
      unitRef="USDPShares">5.46</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      id="fid_2424">February 1, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2429"
      unitRef="Shares">91575</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2428"
      unitRef="USDPShares">6.83</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      id="fid_2427">February 1, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      decimals="0"
      id="fid_2432"
      unitRef="Shares">1885632</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      decimals="INF"
      id="fid_2431"
      unitRef="USDPShares">1.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      id="fid_2430">June 24, 2029</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"
      decimals="0"
      id="fid_2411"
      unitRef="Shares">3907679</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"
      decimals="INF"
      id="fid_2414"
      unitRef="USDPShares">0.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2024-12-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"
      id="fid_2417">December 17, 2029</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember"
      decimals="0"
      id="fid_2420"
      unitRef="Shares">1953839</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2024-12-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember"
      decimals="INF"
      id="fid_2419"
      unitRef="USDPShares">0.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:WarrantIssuanceShares
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2742"
      unitRef="Shares">1624201</ptn:WarrantIssuanceShares>
    <ptn:WarrantIssuance
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2743"
      unitRef="Shares">1953839</ptn:WarrantIssuance>
    <ptn:StockBasedCompensationToStockOptions
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2744"
      unitRef="USD">177673</ptn:StockBasedCompensationToStockOptions>
    <ptn:StockBasedCompensationToStockOptions
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2725"
      unitRef="USD">355407</ptn:StockBasedCompensationToStockOptions>
    <ptn:StockBasedCompensationToStockOptions
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2745"
      unitRef="USD">205223</ptn:StockBasedCompensationToStockOptions>
    <ptn:StockBasedCompensationToStockOptions
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2726"
      unitRef="USD">410540</ptn:StockBasedCompensationToStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_2107">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Remaining&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Term in&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Aggregate&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Intrinsic&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,263,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.11&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,338&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,249,102&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.12&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7.7&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;935,714&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10.76&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.1&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected to vest at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,313,387&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2.82&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8.9&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2433"
      unitRef="Shares">2263440</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance
      contextRef="From2024-07-01to2024-12-31"
      decimals="INF"
      id="fid_2436"
      unitRef="USDPShares">6.11</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2024-07-01to2024-12-31" id="fid_2444">P8Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-12-31"
      decimals="INF"
      id="fid_2440"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2453"
      unitRef="Shares">2249102</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance
      contextRef="From2024-07-01to2024-12-31"
      decimals="INF"
      id="fid_2441"
      unitRef="USDPShares">6.12</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-07-01to2024-12-31" id="fid_2445">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2454"
      unitRef="Shares">935714</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A>
    <ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice
      contextRef="From2024-07-01to2024-12-31"
      decimals="INF"
      id="fid_2442"
      unitRef="USDPShares">10.76</ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-07-01to2024-12-31" id="fid_2446">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2455"
      unitRef="Shares">1313387</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice
      contextRef="From2024-07-01to2024-12-31"
      decimals="INF"
      id="fid_2443"
      unitRef="USDPShares">2.82</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2024-07-01to2024-12-31" id="fid_2447">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <ptn:UnvestedPerformanceBasedStockOptionsGranted
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2754"
      unitRef="Shares">418945</ptn:UnvestedPerformanceBasedStockOptionsGranted>
    <ptn:UnvestedPerformanceBasedStockOptionsGranted
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2727"
      unitRef="Shares">88911</ptn:UnvestedPerformanceBasedStockOptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-07-01to2021-06-30"
      decimals="0"
      id="fid_2728"
      unitRef="Shares">95167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-07-01to2022-06-30"
      decimals="0"
      id="fid_2729"
      unitRef="Shares">60566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-07-01to2023-06-30"
      decimals="0"
      id="fid_2730"
      unitRef="Shares">238838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="fid_2731"
      unitRef="Shares">264945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2024-10-01to2024-12-31"
      decimals="0"
      id="fid_2746"
      unitRef="USD">171281</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2732"
      unitRef="USD">342571</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_2747"
      unitRef="USD">185019</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2733"
      unitRef="USD">370038</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_2109">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,374,980&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(232,941&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Expirations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,726&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,139,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2456"
      unitRef="Shares">1374980</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber>
    <ptn:RestrictedStockVestedInPeriod
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2459"
      unitRef="Shares">-232941</ptn:RestrictedStockVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2461"
      unitRef="Shares">2726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2460"
      unitRef="Shares">1139313</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber>
    <ptn:NumberOfOutstandingSharesOfRestrictedStockUnits
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2734"
      unitRef="Shares">279700</ptn:NumberOfOutstandingSharesOfRestrictedStockUnits>
    <ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2735"
      unitRef="Shares">274549</ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits>
    <ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits
      contextRef="From2023-07-01to2023-12-31"
      decimals="0"
      id="fid_2736"
      unitRef="Shares">59842</ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2020-07-01to2021-06-30"
      decimals="0"
      id="fid_2738"
      unitRef="Shares">22343</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2021-07-01to2022-06-30"
      decimals="0"
      id="fid_2739"
      unitRef="Shares">40707</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2022-07-01to2023-06-30"
      decimals="0"
      id="fid_2740"
      unitRef="Shares">152432</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="fid_2737"
      unitRef="Shares">184443</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2741"
      unitRef="Shares">54691</ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmoun
      contextRef="From2024-07-01to2024-12-31"
      decimals="0"
      id="fid_2748"
      unitRef="USD">99482</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmoun>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-07-01to2024-12-31" id="fid_2393">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(14) SUBSEQUENT EVENTS&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On February 10, 2025, the Company entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the &#x201c;Registered Direct Offering&#x201d;) at a purchase price of $1.00 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company also agreed to issue to the same investor in a concurrent private placement warrants to purchase up to an aggregate of 4,688,000 shares of common stock (the &#x201c;Private Placement&#x201d; and, together with the Registered Direct Offering, the &#x201c;Offering&#x201d;). The warrants being issued in the concurrent Private Placement will have an exercise price of $1.00 per share, will be exercisable beginning on the six-month anniversary of the date of issuance and will expire five and a half years from the date of issuance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The gross proceeds from the Offering totaled $4,687,786. The Company intends to use the net proceeds from the Offering for general corporate purposes.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2756"
      unitRef="Shares">4688000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-02-10_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_2757"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2758"
      unitRef="Shares">4688000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-10_us-gaap_PrivatePlacementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_2759"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-02-01to2025-02-10_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2760"
      unitRef="USD">4687786</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
